{"j.efsa.2005.102r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu50of84appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption8092%within24-30h(ca.80%biliary,remainderinurine)distributionhighestconcentrationsinliver,kidneys,bladderandgastrointestinaltractpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion84-100%within48h(mostlyviabile)metabolisminanimalsextensivelymetabolised(<10%ofadministereddoserecoveredasparentatlowdose).50metabolitesidentified.toxicologicallysignificantcompounds(animals,plantsandenvironment)fluoxastrobin.metabolite48isnotconsideredastoxicologicallyrelevant;metabolitesm34,m39,m40,m41,m57,m70,m72andm82arepresentinwheatbutnotinratmetabolism:notoxicitydataavailableconsideredastoxicologicallyrelevantacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5mg/lskinirritationnon-irritanteyeirritationslightbutnotclassifiableskinsensitization(testmethodusedandresult)non-sensitiser(magnussonandkligman)intestwithhec5725ofhighpurity(98.1%pure)andhec5725(93.6%).shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgainandincreasedserumalkalinephosphatase(criticaleffectsindogs)liver(maintargetorganindogs,miceandrats)kidney/urethra/bladderlesions(athighdoseinrats)lowestrelevantoralnoael/noel90-day,dog:3mg/kgbw/daybasedontwo90-daydogand90daytimepointin1-yeardogstudies1-year,dog:1.5mg/kgbw/d'", "j.efsa.2005.25r.pdf": "(a.s.andppp)http://www.efsa.eu.int36of58appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>95%(basedonurinaryandfaecalexcretion)distributionwidelydistributed(highestresiduesinblood,organsthatproduceorcontainsblood,excretoryorgansandovaries)potentialforaccumulationnoevidencerateandextentofexcretionmin.89%excretedwithin48hours,mainlyviaurinemetabolisminanimalsextensivevian-demethylationandringhydroxylation,mainmetabolite:3,4-dichlorophenylureatoxicologicallysignificantcompounds(animals,plantsandenvironment)parentandmetabolites(animals)parentanddcpmu,dcpu(plants)acutetoxicity(annexiia,point5.2)ratld50oral437mg/kgbw(oilasvehicle)r22ratld50dermal>5000mg/kgbwratlc50inhalation>7.1mg/l(dustexposure)>0.26mg/l(aerosolexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)notaskinsensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbloodsystem(haemolyticanaemia)lowestrelevantoralnoael/noel0.66mg/kgbw/day(6monthrat)r48/22lowestrelevantdermalnoael/noelnonoaelestablished.loael250mg/kgbw/day(90-dayrat)lowestrelevantinhalationnoael/noel0.0041mg/l(5x6hours/dayfor4or8weeks)r48/23genotoxicity(annexiia,point5.4)noevidence'", "j.efsa.2005.26r.pdf": "andppp)http://www.efsa.eu.int43of78appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:rapid:80%within24hoursat1mg/kgbwdistribution:widelydistributedafter7days:highestconcentrationsinwholeblood(0.1gequivalents/g)andinheart,liver,kidney,lungs,spleenandthegastro-intestinaltract(0.04to0.09gequivalents/g)potentialforaccumulation:noevidenceofaccumulationrateandextentofexcretion:initiallyrapid:80.5%within24hours(80%inurine):93%after7days(91%inurine):nosex-relateddifferencesintheexcretionpatternmetabolisminanimalsextensive:0-11%unchangedoxamylexcretedby24hours:oxamylhydrolysistoin-a2213followedbyglucuronideconjugation:othermetabolitesincludein-n0079,in-l2953,in-d2708,andin-kp532:extensiveincorporationoftissueradioactivityintoaminoacidstoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompound;themainmetabolites,in-a2213andin-d2708,aregeneratedinvivoandareconsideredtobeadequatelytestedinstudiesinvolvingdpx-d1410basedontheavailabledata.acutetoxicity(annexiia,point5.2)ratld50oral3.1mg/kgbw(malerat);r282.5mg/kgbw(femalerat)ratld50dermal5027mg/kgbw(malerabbit)>2000mg/kgbw(femalerabbit)ratlc50inhalation0.056mg/lair,noseonly;r26skinirritationnon-irritant(rabbit)eyeirritationtransientirritant(rabbit)skinsensitisation(testmethodusedandresult)42%oxamyltechnicalincyclohexanoneandwater:non-sensitizing(buehler)'", "j.efsa.2005.27r.pdf": "pendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid(maximumbloodconcentrationwithin0.5to1hrafteradministration)butlow(ca.10%absorptionacrossallstudies)distributionhighestlevelsinkidney,liverandtestespotentialforaccumulationnonerateandextentofexcretion>95%96hourspostadministration,mainlyinfaecesmetabolisminanimalsinallspeciestested,glufosinateammonium(ga)isprimarilymetabolisedthroughoxidativede-aminationanddecarboxylationtoproduce3-methylphosphinco-propionicacid(mpp).inaddition,gaisreversiblyacetylatedresultinginlowlevelsofn-acetyl-glufosinate(nag).toxicologicallysignificantcompounds(animals,plantsandenvironment)inplantsandanimals,ga,mppandnag.intheenvironment,ga.acutetoxicity(annexiia,point5.2)rat/mouseld50oral1510mg/kgbw(rat)r22416mg/kgbw(mouse)rat/rabbitld50dermal>4000mg/kgbw(rat)>2000mg/kgbw(rabbit,m)<2000mg/kgbw(rabbit,f)ratlc50inhalation1.26mg/lr20skinirritationnon-irritatingeyeirritationnon-irritatingskinsensitization(testmethodusedandresult)notasensitizingagent(buehlerandmaximizationtests)shorttermtoxicity(annexiia,point5.3)target/criticaleffectclinicalsigns(sedation,lateralrecumbency,hunchedposture,spasm,hyperactivityandlacrimation),inhibitionofglutaminesynthetaseactivitylowestrelevantoralnoael/noelnoael4.5mg/kgbw/dayr48/22(1yrdog)lowestrelevantdermalnoael/noel100mg/kgbw/day(rat)lowestrelevantinhalationnoael/noel0.012mg/l(rat)r48/23endpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.28r.pdf": "ndpointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int45of77appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandnearlycomplete(82%at48hrsaftersingleoraladministration),plasmacmaxat0.75-4hrsafterbothsinglelowandhighoraldoseadministrationdistributionwidelydistributed;highestconcentrationinadrenals,fat,kidneys,liver,skinandbloodpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandhigherthan90%at168hrs,mainlyviabile,otherwiseviafaeces,regardlessofdoselevelmetabolisminanimalsextensivelymetabolized,mainlythroughconjugation(75%oftheurineresidue),reductionofnitro-groups,n-dealkylation,hydroxylationandcyclizationreactions.numerousminorurinarymetabolites(<5%oftheurineresidueor<2%oftheinitialdose);fourfaecalidentifiedmetabolites(1-9%ofthedose).nospeciesdifferencetoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandmetabolites.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.252mg/l/4hoursheadonlyexposureskinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)sensitising(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweightgain,increasedalpha-1globulinandalbuminconcentrations(rat),anaemia(dog),increasedliverweight(rat,dog)lowestrelevantoralnoael/noel2.4mg/kgbw/day,1-yeardogstudylowestrelevantdermalnoael/noel1000mg/kgbw/day,21-dayrabbitlowestrelevantinhalationnoael/noel>0.09mg/kgbw/day(i.e.22.5g/l),21-dayratstudy(limittest)'", "j.efsa.2005.29r.pdf": "ndpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int38of76appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionover90%within48h,basedonurinaryandbiliaryexcretiondistributionwidelydistributed.highestresiduelevelsinliver,kidneyandthyroids(2448h)potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion6090%inurine,1236%infeceswithphenyl-ringlabelleda.s.within48h.about16%ofdichloro-fluoromethyl-labelleda.s.isexhaledwithin48h.metabolisminanimalsextensivelymetabolised(>90%).theparentismetabolisedtodmstinoneoftwoparallelpathways,followedbyhydroxylation,demethylationandconjugationreactions.intheotherpathwaythedichlorofluoromethylsidechainisconvertedinaseriesofunknownreactionstottca.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandmetabolites.ttcaisidentifiedasanantithyroidealmetabolite.releaseoffluoridecauseshyperostosis.theplantmetaboliteswak6550,wak6676andwak6698werenotrelevant.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>1.038mg/l(mmad16.8-19.8m,<7%3m)0.383mg/l(mmad3.81-3.95m,35-39%3m)0.160-0.200mg/l(mmad2.1-2.5m,64-74%3m)(splitclassificationandlabelling,seepoint5.10)skinirritationirritatingtoskinr38eyeirritationirritatingtoeyesr36skinsensitization(testmethodusedandresult)sensitizing(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,kidneys,thyroidslowestrelevantoralnoael/noel13-weekdog:1000ppm(33mg/kgbw/d)'", "j.efsa.2005.30r.pdf": "ndpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int30of46appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionestimatedtobe10%acrossthelungsdistributiondistributedthroughoutthebodypotentialforaccumulationlowpotentialforaccumulationrateandextentofexcretionmoderaterateofexcretionmetabolisminanimalsmetabolismevident,butmetabolitesnotelucidatedtoxicologicallysignificantcompounds(animals,plantsandenvironment)1-mcpacutetoxicity(annexiia,point5.2)ratld50oralnodatasubmittedratld50dermalnodatasubmittedratlc50inhalationlc50>2.5mg/lskinirritationnodatasubmittedeyeirritationnodatasubmittedskinsensitization(testmethodusedandresult)nodatasubmittedshorttermtoxicity(annexiia,point5.3)target/criticaleffectproteinuriaasindicatedbytheincreasedincidenceofhyalinedropletsintherenalcorticaltubularepitheliuminmales,andsplenichaemosiderosis,alsoinmales.lowestrelevantoralnoael/noelnodatasubmittedlowestrelevantdermalnoael/noelnodatasubmittedlowestrelevantinhalationnoael/noel68mg/kgbw(i.e;107ppm),3weekstudyinrat9mg/kgbw(i.e;23.5ppm),90-daystudyinrat'", "j.efsa.2005.32ar.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidabsorption(>80%basedonurinaryexcretionofphenyllabel)within24hdistributionwidelydistributed.smalldistributionintotissuespotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensivewithin48h,80-90%viatheurine,and10-20%viathefaeces.metabolisminanimalsmetabolisedviaoxidativedesulfurationofthep=sgrouptop=o,oxidationof4-methylgroup,andcleavageofp-o-arylandp-o-methyllinkages.themajormetaboliteinbothratsandmicewas3,5-dichloro-4-hydroxybenzoicacid.thismetabolitewasexcretedastheglycineconjugateinmiceandasthefreeforminrats.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratandmouseratld50dermal>5000mg/kgratlc50inhalation>3.32mg/lskinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)sensitizing(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweightgainandincreasedliverweights.decreasedcholinesteraseactivities(mouse),andincreasedplasmaalkalinephosphataseactivity(dog,rat).lowestrelevantoralnoael/noel6-monthdog:21mg/kgbw/day12-monthdog:11mg/kgbw/daylowestrelevantdermalnoael/noel21drabbit:1000mg/kgbw/daylowestrelevantinhalationnoael/noelnodatanotrequiredendpointidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.33ar.pdf": "appendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid;>98%.excretionmainlyinfaecesfollowingexcretioninbile.distributionwidelydistributed(highestlevelsfoundinskin&fur,liver,plasmaandadrenals)potentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapid;>98%,urinary(>10%)andbiliary(>80%)aftersinglelowdoseand>89%(multiplelowdose),within72hours;mainlyviafaeces(bile).nearly100%after168hoursafterrepeatdose.metabolisminanimalsextensivelymetabolizedinratsaftersingleandrepeatedlowdose(only<1.5%ofdoseasparentcompoundinfaeces)viahydroxylationatdifferentpositionsofthemoleculetoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandhydroxylatedmetabolites.themetabolitesrpa406341(plant,lowlevelsinrats)andrpa406203(soil)weredeterminedtobeofnon-toxicologicalrelevance.acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.61mg/l(4hours,noseonly)skinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)notsensitizing(m&ktest,buehlertest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbiochemicalchangesindicativeoflivereffectsinfemales.othertargetorgansaffectedatdoses>loaelweretheadrenals(rat;dog:corticalfattyvacuolationanddegenerationofzonareticularis)andeye(dog:cataractsathighdoselevel).lowestrelevantoralnoael/noel1-yrdog:2.5mg/kgbw/dlowestrelevantdermalnoael/noel21-drat:>1000mg/kgbw/dlowestrelevantinhalationnoael/noelnodatanotrequiredendpointidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.34ar.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption75%basedonradiolabelrecoveredinurine,tissues,cagewashandresidualcarcasswithin168hinmalesonly.higheroralabsorptioninfemales.distributionwidely;highestresiduesinfat,muscle,liver,bloodandkidneys.residueshigherinmalesthanfemales.potentialforaccumulationpotentialaccumulationinfat.eliminationwasslowfromovaries,pancreas,thymusandthyroid.rateandextentofexcretionurinary(24h):16-27%(m),77-87%(f)faecal(24h)7-9%(m),2-5%(f)totalexcretion(7d):66-85%(m),92-96%(f)metabolisminanimalsextensivelymetabolised,<0.3%remainingasparent.toxicologicallysignificantcompounds(animals,plantsandenvironment)clodinafop-propargyl(anditss-isomer)acutetoxicity(annexiia,point5.2)ratld50oral1392mg/kgbw(m)2271mg/kgbw(f)r22ratld50dermal>2000mg/kgbwratlc50inhalation>2.3mg/lair(4h)skinirritationnon-irritatingeyeirritationnon-irritatingskinsensitization(testmethodusedandresult)sensitising(optimisationstudy)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverandhaematologicalparameters(ratsanddogs).thymicatrophyobservedathighdoselevelslowestrelevantoralnoael/noel3.4mg/kgbw/day,1yeardoglowestrelevantdermalnoael/noel50mg/kgbw/day,4weeksratlowestrelevantinhalationnoael/noelnodatanotrequiredendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.43r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid-approximately35-50%oftheadministereddoseexcretedinurinewithin6hoursofdosing.extensive-resultssuggest80-90%absorption.distributionwidespread-highestlevelsmainlyinliverandkidneys.potentialforaccumulationnoevidenceofaccumulation.highestresiduelevelsintheliver.rateandextentofexcretionrapid-approximately60-70%ofthe14c-pyrimidinyl-pirimicarbexcretedinurinewithin24hoursofdosing,4-10%infaeces.approximately70%ofthe14c-carbamoyl-pirimicarbexcretedinexhaledairwithin24hoursofdosing,17%inurine,1-3%infaecesextensive-lowtissueresiduestogetherwithhightotalrecoveries.metabolisminanimalsextensive-noparentmaterialwasdetectedinexcretaorbile(17identifiedmetabolitesplusunknowns).toxicologicallysignificantcompounds(animals,plantsandenvironment)parent,r34836(desmethylpirimicarb),r34885(desmethylformamidopirimicarb)and35140.invitrodataindicatesthattheplantmetabolitesr34836andr34885arerapidlymetabolisedintermediatesintherat.theld50valuesforthecarbamatemetabolitesareinthesamerangeasforpirimicarbormoretoxicandtheyexhibitsignsofcholinergictoxicity.thus,theyareconsideredtobeoftoxicologicalrelevance.acutetoxicity(annexiia,point5.2)ratld50oral152and142mg/kgbwinmalest;r25andfemales,respectivelyratld50dermal>2000mg/kgbw.ratlc50inhalation0.95and0.86mg/linmalesandt;r23femalesrespectivelyskinirritationslightirritant(notclassified).eyeirritationslightirritant(notclassified).skinsensitization(testmethodusedandresult)positive(m&kmaximisationtestr43endpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.44r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionextensive(>80%)andrelativelyrapiddistributionnodataatcmaxbutlikelytobeextensivepotentialforaccumulationsomeresiduesinfatfollowinghighdoses,otherwise<2%ofradiolabelincarcassatday4rateandextentofexcretionextensive,primarilyinurine;ca70%excretionin12hsample.biliarycomponent(>10%).metabolisminanimalsextensivelymetabolisedwithnoparentfoundineitherurineorbile,primarilyviacleavageofphosphorus-pyrimidinebond(atleast20fractions).toxicologicallysignificantcompounds(animals,plantsandenvironment)parent,metabolitescontainingthepyrimidine-dialkylphosphorothioatestructure,andtheiroxonsacutetoxicity(annexiia,point5.2)ratld50oral1414mg/kgbwxn;r22ratld50dermal>2000mg/kgbwratlc50inhalation>4.7mg/l(4hours,noseonly)skinirritationslightlyirritating(noclassificationproposed)eyeirritationslightlyirritating(noclassificationproposed)skinsensitization(testmethodusedandresult)weakresponse(magnussonandkligmantest)-noclassificationproposedshorttermtoxicity(annexiia,point5.3)target/criticaleffectacetylcholinesteraseinhibitionidentifiedfrom7daysonwardsina2-yrdogstudy.lowestrelevantoralnoael/noel2.0mg/kgbw/day,2-yrdog(timepoint12month)0.5mg/kgbw/day,2-yrdog(timepoint12week)lowestrelevantdermalnoael/noelnoreliabledatalowestrelevantinhalationnoael/noelnodata,notrequiredendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2005.45r.pdf": "pendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionapproximately70%,basedonurinaryexcretiondistributionwidelydistributed,highestresiduesinblood,skin,liverandkidneyspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion92-95%within72hours,approximatelytwothirdofthedoseinurineandonethirdinfaecesmetabolisminanimalsmorethan50%ofresiduesinurineandfaeceswereunmetabolisedparentsubstance,5metabolitesidentifiedtoxicologicallysignificantcompounds(animals,plantsandenvironment)rimsulfuron.themetabolitesin-e9260andin-70941arenotconsideredtoxicologicallyrelevant.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.4mg/l(noseonly,4h)skinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)notaskinsensitiser(m&ktest*)*accordingtotheepco14meetingthestudywas\"notoptimal\"(25%concentrationduringinductionphase).however,torepeatthestudywasnotnecessaryshorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweightgain,liver,kidneylowestrelevantoralnoael/noeldog,combined90-dayand1-year:9.63mg/kgbw/dlowestrelevantdermalnoael/noelnostudiessubmittedlowestrelevantinhalationnoael/noelnostudiessubmitted,notrequiredgenotoxicity(annexiia,point5.4).....................................................................noevidenceofgenotoxicityendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciple", "j.efsa.2005.46r.pdf": "appendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption85-90%within5dat10mg/kgbwdistributionextensive:highestlevelsingut,liver,kidney,lung,fat,thyroid,pancreas,adrenals,ovaries,uteruspotentialforaccumulationverylittlepotentialforaccumulationat10mg/kgbwrateandextentofexcretion65-83%(mainlyinfaeces)within24hat10mg/kgbwmetabolisminanimalsextensive.45identifiedmetabolitesinrats.toxicologicallysignificantcompounds(animals,plantsandenvironment)dimoxystrobin.themetabolites505m08and505m09areconsideredastoxicologicallyrelevant.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation1.3mg/lr20skinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)non-sensitizer(magnussonandkligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectduodenal(mucosal)thickeninglowestrelevantoralnoael/noel3mg/kgbw/day,90-dayratlowestrelevantdermalnoael/noel>1000mg/kgbw/daylowestrelevantinhalationnoael/noelnodataavailablegenotoxicity(annexiia,point5.4).....................................................................nogenotoxicpotentialendpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.174r.pdf": "sionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int42of67appendix1.3:impactonhumanandanimalhealthmanyofthetoxicitystudieshavebeenconductedwithethephonbase250(aliquidconcentrateofc.70%ethephoninwater)butalldoselevelsquotedhererefertoethephon.absorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption78-84%basedonradiolabelrecoveredinurine,tissues,cagewash,expiredair/volatilesandresidualcarcasswithin120h.distributionwidely;highestresiduesinliver,bloodandkidneyat50mg/kgbodyweight.potentialforaccumulationnopotentialforaccumulationrateandextentofexcretionextensivelyexcreted-urinary:50-60%in120h;faecal4.0-6.5%in120h;andexhaled20%metabolisminanimalsextensivelymetabolisedtodisodiumsaltofethephon,andhepawasfoundinthelivertoxicologicallysignificantcompounds(animals,plantsandenvironment)ethephonandhepa(toxicologicallyrelevant)acutetoxicity(annexiia,point5.2)ratld50oral1564mg/kgbw;r22ratld50dermal983mg/kgbw;r21ratlc50inhalation3.26mg/lair/4h(wholebody);r20skinirritationcausesburns;r34eyeirritationnodataavailable,notconsiderednecessaryduetophandeffects(r34)ofsubstanceskinsensitization(testmethodusedandresult)evidenceofskinsensitizationinconclusiveduetocorrosiveproperties(llnaandmaximisationtest);r43?shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofcholinesterase(che)activityinerythrocyteslowestrelevantoralnoael/noel28-daymouse:22mg/kgbw/day1-yeardog:(27mg/kgbw/day)basedondecreasedbodyweightandspleenandthyroidweight(cheactivityinplasma,erythrocytesand'", "j.efsa.2006.50r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyandcompletelyabsorbeddistributionextensive,lowtissuelevels(<0.01%ofapplieddose)potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidlyexcretedunchangedviaurine(>80%in24h)metabolisminanimalsnonetoxicologicallysignificantcompounds(animals,plantsandenvironment)clopyralidacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbw(rabbit)ratlc50inhalation>1mg/l(highestattainableconcentration)skinirritationmildlyirritating,noclassificationproposedeyeirritationseverelyirritatingtoeyesr41skinsensitization(testmethodusedandresult)slightlysensitising,noclassificationproposedshorttermtoxicity(annexiia,point5.3)target/criticaleffecthaematologicaleffectsandincreaseinliverweightlowestrelevantoralnoael/noel100mg/kgbw/dayindogslowestrelevantdermalnoael/noel>1000mg/kgbw/daylowestrelevantinhalationnoael/noelnodata,notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotentialendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciple", "j.efsa.2006.51r.pdf": "pendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentof(oral)absorptionmorethan82%basedonurine(52-63%)andbile(39%)excretions.distributionwidelydistributed.potentialforaccumulationnopotentialforaccumulation.rateandextentofexcretionrapidlyexcreted(>80%)within24hours.metabolisminanimalsextensivelymetabolisedinrats(upto18urinary,bileandfaecalmetabolites).oxidationofthephenyland/orpyrimidylrings.sulfatationandexcretionasconjuguates.aminorpathwayisthefurtheroxidationoftheprimarymetabolites.3-8%oftheparentisexcretedinfaeces.metabolismquitesimilarinrat,goatandhen.toxicologicallysignificantcompounds(animals,plantsandenvironment)cyprodinilandcga249287(0.014%intherat),cga275535,noa422054andcga321915aresoiland/orplantmetabolites(allmetabolitesconsideredasnottoxicologicallyrelevant).acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.2mg/lskinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)sensitising(magnussonandkligmantest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweightreduction(rat,mouse,dog).minorliverchanges(hepatocellularhyperthrophyandnecrosisintherat)andincreasedweightofthyroidsandhyperthrophyoffollicularepitheliumintherat.lowestrelevantoralnoael/noel3.14mg/kgbw/day,90-dayratlowestrelevantdermalnoael/noel5mg/kgbw/day,ratlowestrelevantinhalationnoael/noelnodatanotnecessaryendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.52r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>88%(basedonurinaryandfaecalexcretion)distributionwidelydistributed(highestresiduesinblood,liver,kidney,thyroid,adrenal,heartanduterus)potentialforaccumulationnosignificantaccumulationrateandextentofexcretionmin.88%excretedwithin120hoursor168hours(lowandhighdoserespectively)viaurine.3-12%viafaeces.metabolisminanimalslimitedmetabolism.3%unidentifiedmetabolites.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundand3%unidentifiedmetabolites(animals)sumofdichlorprop-pandisomer(plants)acutetoxicity(annexiia,point5.2)ratld50oral567mg/kgbw(methylcelluloseasvehicle)r22ratld50dermal>4000mg/kgbwratlc50inhalation>7.4mg/lskinirritationnon-irritanteyeirritationsevereeyeirritantr41skinsensitization(testmethodusedandresult)notaskinsensitiser(magnussonandkligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney,liver,bloodsystem(dog,mouseandrat)lowestrelevantoralnoael/noel35mg/kgbw/day,3-months,ratlowestrelevantdermalnoael/noel1000mg/kgbw/day,highdose;21dayrabbitlowestrelevantinhalationnoael/noelnodatasubmitted.genotoxicity(annexiia,point5.4).....................................................................nogenotoxicpotentialendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.53r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>90%oralabsorption(basedonexcretioninbileandurine).distributionwidelydistributed(highestresiduesinraterythrocytesduetospecies-specificbindingtohaemoglobin).potentialforaccumulationnoevidenceforaccumulationpotential(bindingtorathaemoglobinbutnottohumanhaemoglobin).rateandextentofexcretionrapid,3547%inurine,4858%infaeces(lowdose);90%excretedby168h.metabolisminanimalsextensivelymetabolised(>40metabolites;only12%excretedasparentcompound),primarilyviaglutathioneconjugation.toxicologicallysignificantcompounds(animals,plantsandenvironment)dimethenamidandplantmetabolitesm23andm27.acutetoxicity(annexiia,point5.2)ratld50oral397mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation>4.99mg/l(4-h,nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)skinsensitiser(magnusson-kligmantest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(biochemicalandhistopathologicalchanges),decreasedbodyweightgain.lowestrelevantoralnoael/noel4.3mg/kgbw/day,90-daydog2mg/kgbw/day,1-yeardoglowestrelevantdermalnoael/noelr1190mg/kgbw/d(systemictoxicity),21-day,rabbitlowestrelevantinhalationnoael/noelnostudiessubmitted,notrequired.endpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincip", "j.efsa.2006.54r.pdf": "5appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensive(80100%)within24hoverthedoseraterangeof100to3000mg/kgbw.distributionwidespreaddistributionandconcentrationintissuesproportionaltodoseatlowerdoserates.tissueconcentrationsnotexceeding6%after168h.highestconcentrationfoundinfat,kidneys,skin,spleenandadrenalspotentialforaccumulationnonerateandextentofexcretionrapideliminationviaurine,faecesandexpiredair.exactproportionsmeasuredviaeacheliminationroutedependonpositiononradiolabelmetabolisminanimalsmetabolisedtoethanol,phosphites(phosphonicacid)andco2toxicologicallysignificantcompounds(animals,plantsandenvironment)fosetyl-alandphosphonicacidacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.11mg/l(4h)skinirritationnotirritanteyeirritationseverelyirritatingr41skinsensitization(testmethodusedandresult)notsensitizer(magnussonandkligmantest)shorttermtoxicity(annexiia,point5.3)target/criticaleffecturinarytract,changesinurinephysical/chemicalcompositionandsubsequentchronicirritation.lowestrelevantoralnoael/noel1270mg/kgbw/day,90daymaleratlowestrelevantdermalnoael/noel>1050mg/kgbw/day(highestdosetested)lowestrelevantinhalationnoael/noelnodata,notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2006.55r.pdf": "pendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid(cmaxca1hourat2mg/kgbw)andextensive(>70-90%)distributionextensive;highestconcentrationinerythrocytespotentialforaccumulationlow,withtheexceptionoferythrocytesrateandextentofexcretionrapid(mainlyin012hoursamples)andextensive;significantproportionasexhaledvolatiles(40%)metabolisminanimalsveryextensive,primaryexcretionasacetonitrileandco2;retainedradiolabelmaybeintheformofsimplecarboncompoundsincorporatedintobiomoleculestoxicologicallysignificantcompounds(animals,plantsandenvironment)thiodicarbandmethomylacutetoxicity(annexiia,point5.2)ratld50oral50mg/kgbwr23ratld50dermal>2000mg/kgbwratlc50inhalation0.66mg/lr25skinirritationnotirritanteyeirritationmild,transientirritant(noclassificationproposed)skinsensitization(testmethodusedandresult)positive(m&k);negativeinhumanpatchtestr43shorttermtoxicity(annexiia,point5.3)target/criticaleffectcholinesteraseinhibition,clinicalsigns(includingtremors)redcelleffects(mildmacrocyticanaemia)&associatedsplenicfindings,lowestrelevantoralnoael/noel5mg/kgbw/d(6-monthand1-yeardogstudies)lowestrelevantdermalnoael/noelnonoaelpossibletobedeterminedduetopoorqualityofthestudieslowestrelevantinhalationnoael/noelloael0.005mg/l,lowestdosetestedendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipl", "j.efsa.2006.56r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensive(75-94%in72hincl.humans)distributionmainlykidneyspotentialforaccumulationnone,exceptfollowingchronicadministrationatveryhighdoses(>50mg/kginratand20mg/kgindog)rateandextentofexcretionrapid(89-95%inurinewithin72hintherat);(>80%unchangedpminhumanurine).inthedog(specifically)atdoses>5mg/kg,excretionbecomesnon-linear.metabolisminanimals3,5,6-trichloro-2-pyridinolanditsglucuronideandsulphateconjugatesandpossibletriclopyrconjugates(1-2%inraturine;<1%inhumans)toxicologicallysignificantcompounds(animals,plantsandenvironment)triclopyr,and3,5,6-trichloro-2-pyridinol(tcp)acutetoxicity(annexiia,point5.2)ratld50oral630mgtriclopyracid/kgbw803mgtriclopyrbee7/kgbwr22ratld50dermal>2000mgtriclopyracid/kgbw(male&femalerat)>2000mgtriclopyrbee/kgbw(male&femalerat)ratlc50inhalation>4.8mgtriclopyrbee/lair(max.attainableconc)skinirritationtriclopyracid:non-irritant(rabbit)triclopyrbee:non-irritant(rabbit)eyeirritationtriclopyracid:irritant(rabbit)r36triclopyrbee:non-irritant(rabbit)skinsensitization(testmethodusedandresult)bothtriclopyrandbeesensitiser(modifiedbuehler)r437triclopyrbee:triclopyrbutoxyethylester", "j.efsa.2006.57r.pdf": "pendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionoral:atleast96%,irrespectiveofdoseandsex,basedonradiolabelrecoveredfromurine,cagewash,carcassandtissues168afteradministration.twenty-fourhoursafteradministrationabsorptionwasatleast91%,basedonradiolabelrecoveredfromurine.distributionbarelydetectableinfat(1and166mg/kgbwdosegroups)andkidneys(highdosegrouponly)168hafteradministration.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion91%in24h,ca.95%in168h;mostlyinurinemetabolisminanimalsextensivelymetabolised,mainlyhydrolysistotrinexapac(92%ofurinaryradiolabelafterlowdoseadministration)toxicologicallysignificantcompounds(animals,plantsandenvironment)trinexapac-ethyl,cga113745acutetoxicity(annexiia,point5.2)ratld50oral4210mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>5.3mg/lskinirritationnotirritatingeyeirritationnotirritatingskinsensitization(testmethodusedandresult)notsensitisingtoskin(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweight/decreaseofabsoluteandrelativeorganweightlowestrelevantoralnoael/noel1-yrdog:32mg/kgbw/day90-drat:34mg/kgbw/daylowestrelevantdermalnoael/noel1000mg/kgbw/d(highestdosetested)lowestrelevantinhalationnoael/noelnodatanotrequiredendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.58r.pdf": "appendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>88%within72hours(at10mg/kgbw)distributionwidelydistributed,withhighestlevelsingastrointestinaltractandliverpotentialforaccumulationlowrateandextentofexcretion67-79%(mainlyinfaecesviabile)with24hoursat10mg/kgbw.metabolisminanimalsextensive,mostlyconsistingofsubstitutionofringmethoxygroupswithhydroxylgroupsandsubsequentconjugationwithglucuronicacid.toxicologicallysignificantcompounds(animals,plantsandenvironment)metrafenoneacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.0mg/lskinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)non-sensitiser(magnussonandkligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectincreasedrelativeliverweightsandhistopathologicalfindingsintheliverlowestrelevantoralnoael/noel43mg/kgbw/daylowestrelevantdermalnoael/noelnodatanotrequiredlowestrelevantinhalationnoael/noelnodata-notrequiredgenotoxicity(annexiia,point5.4).....................................................................nogenotoxicpotentialendpointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.59r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandalmostcompleteabsorption(86100%inurineafter7daysafteraloworhighdose).distributionwelldistributedintoorgansandtissues.liver>>wholeblood>residualcarcassafterlowdosepotentialforaccumulationlimitedpotentialrateandextentofexcretionrapid;88-99.8%inurinewithin24hafteralowdosemetabolisminanimalsextensivelymetabolised.noparentrecoveredinurineofrats,mice,rabbitsanddogs.primarilyconjugatesofparent,fenitrothionandconjugatesand3-methyl-4-nitrophenolandconjugatestoxicologicallysignificantcompounds(animals,plantsandenvironment)parentandmetabolites.acutetoxicity(annexiia,point5.2)ratld50oral330mg/kgbw(male)or800mg/kgbw(female)infirststudy(10%tween80solvent)and1700(male)or1720(female)insecondstudy(undiluted).r22ratld50dermal890mg/kgbw(males)and1200mg/kgbw(female).r21ratlc50inhalation2.2mg/l.themaximumattainableconcentration.skinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)sensitizinginm&kmaximisationstudy.r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofcholinesteraseactivitylowestrelevantoralnoael/noel1.32mg/kgbw/dayin13-weekdietarystudyinratswithneuropathologicalassessments.lowestrelevantdermalnoael/noel3mg/kgbw/dayin21-daydermalstudyinrabbitslowestrelevantinhalationnoael/noelnotdetermined.notrelevantendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipl", "j.efsa.2006.60r.pdf": "ndpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int41of66appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid,8090%aftersingleandrepeatedoraldose(ratstudies)distributionhighestlevelsfoundinliverandkidneysandintestine+contentspotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapid,90%within24-48hours,mainlyviaurinemetabolisminanimalsextensivelymetabolized;fourdifferentmetabolicpathways:sulphateconjugation,oxidativedesulfation,oxidativedealkylationandhydrolysistoxicologicallysignificantcompounds(animals,plantsandenvironment)phosalone,metaboliteoxophosalone,impurityaef073749acutetoxicity(annexiia,point5.2)ratld50oral120mg/kgbwt,r25ratld50dermal1530mg/kgbwxn,r21ratlc50inhalation1.26mg/lxn,r20aerosol,nose-onlyexposureskinirritationmildlyirritating,noclassificationproposedeyeirritationslightlyirritating,noclassificationproposedskinsensitization(testmethodusedandresult)sensitizing(magnussonandkligman)xi,r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightandbodyweightgain;cholinesteraseinhibitionlowestrelevantoralnoael/noel52-weeksdog,0.9mg/kgbwlowestrelevantdermalnoael/noelnodatanotrequiredlowestrelevantinhalationnoael/noelnodatanotrequiredgenotoxicity(annexiia,point5.4).....................................................................nogenotoxicpotentialofrelevancetohumanriskassessment'", "j.efsa.2006.61r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidbutlimitedto81and72%(basedonurinaryexcretion)aftersingleandrepeatedoraldose(ratstudies)distributionwidelydistributed(highestlevelsfoundinadrenals,blood,liver,kidney,thyroid,ovariesandrenalfat)potentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapid,95%(singlelowdose)and>90%(multiplelowdose)resp.within24hours,mainlyviaurinemetabolisminanimalsextensivelymetabolized;majormetabolicpathwayoxidationonbothringsofthemoleculetoformphenolsandsubsequentlyconjugationtoxicologicallysignificantcompounds(animals,plantsandenvironment)pyrimethanilacutetoxicity(annexiia,point5.2)ratld50oral4149(),5971()mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>1.98mg/l(4hours,noseonly)(max.attainableconcentration)skinirritationnotirritatingeyeirritationnotirritatingskinsensitization(testmethodusedandresult)notsensitizing(m&ktest,buehlertest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(increasedorganweight,hepatocytehypertrophy),thyroid(follicularepithelialhypertrophy,pigmentdeposits),indogsdecreasedwaterintakelowestrelevantoralnoael/noel5.4mg/kgbw/day,90-dayratlowestrelevantdermalnoael/noelnodatanotrequiredlowestrelevantinhalationnoael/noelnodatanotrequiredendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.62r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyabsorbed,almostcompletewithin24hdistributionwidelydistributed,butnotincompactbonestructures,thespinalmarrowandthebrain,indicatingminimalabilitytocrosstheblood-brainbarrierpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretion40-80%wasexcretedrenallywithin4hoftreatment,after48h>96%wasexcreted.faecalexcretionwas1.5(i.v.)-3.7(oral)%.metabolisminanimalsfenamiphoswasmetabolisedtofenamiphos-phenols(methylthiometacresol-derivatives)indifferentstagesofoxidationatthesulphuratomandtheirrespectivesulphuricacidconjugates.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundanditsmetabolitesfenamiphos-sulfoxide(m01),fenamiphos-sulfone(m02),des-isopropylfenamiphos(m06),des-isopropylfenamiphos-sulfoxide(m07),anddes-isopropylfenamiphossulfone(m08).acutetoxicity(annexiia,point5.2)ratld50oral6.0-6.1mg/kgbw,r28ratld50dermal72-92mg/kgbw,r24ratlc50inhalation65-79g/l/4h(aerosol),r26skinirritationstudynotacceptable.notrequiredsincetheacutedermaltoxicityishighandnoskineffectswerefoundintworepeateddosedermalstudieseyeirritationirritating,r36skinsensitization(testmethodusedandresult)nonsensitiser(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionbraincheactivitylowestrelevantoralnoael/noel0.083mg/kgbw/day,1yearstudyindoglowestrelevantdermalnoael/noel2.5mg/kgbw/day,21-daydermalstudyinrabbitlowestrelevantinhalationnoael/noel3.5g/l,28daysinhalationstudyinratsendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipl", "j.efsa.2006.63r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionuptoabout90%absorbedwithin72h,basedonurinaryexcretiondata.distributionlessthan1.5%ofadministereddosedetectedintissuesandcarcassat72hafterdosing,mainlyinliverfollowedbyskin,fat,boneandgitract.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion>90%oftotaldoseexcretedwithin72h.76-88%oftotaldoseexcretedinurineand6-14%oftotaldoseexcretedinfeces.metabolisminanimalsmalathionismainlymetabolisedthroughhydrolysis.majormetabolitesaremalathiondicarboxylicacidandmalathionmonocarboxylicacid.toxicologicallysignificantcompounds(animals,plantsandenvironment)malathionandmalaoxonimpurities(especiallyisomalathion)mayincreasegenotoxicityofmalathion.isomalathionisanacetylcholinesteraseinhibitor,whichenhancesthetoxicityofmalathionacutetoxicity(annexiia,point5.2)ratld50oral1778mg/kgbw(0.44%isomalathion)r22ratld50dermal>2000mg/kgbw(0.43%isomalathion)ratlc50inhalation>5mg/lair/4h(0.43%isomalathion)skinirritationnon-irritant(0.43%isomalathion)eyeirritationnon-irritant(0.43%isomalathion)skinsensitization(testmethodusedandresult)sensitising(magnussonandkligmantest)(0.43%isomalathion)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectacetylcholinesteraseinhibition(enzymeactivityinbrain)lowestrelevantoralnoael/noel34.4mg/kgbw/d,90drat(0.03%isomalathion),lowestrelevantdermalnoael/noel300mg/kgbw/d,21drabbit(0.2%isomalathion),lowestrelevantinhalationnoael/noel90drat:0.45mg/l(0.03%isomalathion)endpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.64r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionoral:rapid(48h)andefficient(95-97%)distributionwidelydistributedupto72h,tendencyforretentioninadrenales,git,andliverpotentialforaccumulationnoevidencerateandextentofexcretionrapid,(67-80%within48h)forthelowdose;slowerfortherepeateddosing(65-82%within96h)orforthehighdose(67%within96h)mainlyinthefaeces,followingbiliaryexcretionmetabolisminanimalsextensivemetabolisation,mainlybyhydroxylationofcyclopentane-orbenzylringtoxicologicallysignificantcompounds(animals,plantsandenvironment)metconazoleacutetoxicity(annexiia,point5.2)ratld50oral595mg/kgbwr22mouseld50,oral410mg/kgbwrabbitld50dermal>2000mg/kgbwratlc50inhalation>5.6mg/lairskinirritationnotirritanteyeirritationnotirritantskinsensitisation(testmethodusedandresult)notsensitizingshorttermtoxicity(annexiia,point5.3)target/criticaleffectlivertoxicity(mouse,rat,dog)lowestrelevantoralnoael/noel6.4mg/kgbw/d(90drat:hepatocellularvacuolation)lowestrelevantdermalnoael/noelnotdeterminedlowestrelevantinhalationnoael/noelnotdeterminedendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniform", "j.efsa.2006.65r.pdf": "dpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int62of110appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensiveat4mg/kg(bloodtmax@ca5.5h,>80%absorbedbasedonurinaryandbiliaryexcretionandtissueconcentration),slowerathigherdoseleveldistributionwidelydistributedinthetissueswithpredominanceinfattytissues.potentialforaccumulationlogp=3.5-4;terminaleliminationhalf-livesofca183h(malerat)and245h(femalerat)fat:blood20:1athighdoseand~70-90:1atlowdose.rateandextentofexcretionafterlowdose:viafaeces:46-61%in7days;viaurine:<6-16%in7days;viabile:7-18%in72hours.metabolisminanimalsextensiveandrapid;majorresidueintissuesismb46136(sulphonederivative)toxicologicallysignificantcompounds(animals,plantsandenvironment)fipronilmb46136,mb45950andmb46513(metabolites)acutetoxicity(annexiia,point5.2)ratld50oral92mg/kgt,r25ratld50dermalrat:>2000mg/kgbwrabbit:354mg/kgt,r24ratlc50inhalation0.36mg/lt,r23skinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)notasensitiser(m&k,buehler)shorttermtoxicity(annexiia,point5.3)target/criticaleffectneurotoxicitywithclinicalsigns(allspeciestested),liverandthyroid(rats)lowestrelevantoralnoael/noeloverall0.35mg/kg/dayin90-dayratand90-day/1-yearstudyindogslowestrelevantdermalnoael/noel5mg/kgbw/day(21-drabbitstudy)lowestrelevantinhalationnoael/noelnotdetermined'", "j.efsa.2006.66r.pdf": "ppendix1listofendpointsappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyandextensivelyabsorbed:>80%basedoncomparisonofexcretionfollowingoralandintravenousdosing.maximumbloodconcentrationwithin1hour.distributionwidelydistributed:highestvaluesinorgansofexcretion,fat,adrenalsandthyroidpotentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidlyexcreted:~60%inurine,~10%infaecesand~15%inexpiredairwithin48hours.biliaryexcretionestimatedtobe~8%.metabolisminanimalscompletemetabolism.dealkylationfollowedbyhydroxylationandconjugation.hydrolysistoco2.toxicologicallysignificantcompounds(animals,plantsandenvironment)o-ethyl-s-methyl-s-propyl-phosphorodithioate(sme)o-ethyl-o-methyl-s-propyl-phosphorothioate(ome)o-ethyl-s-propyl-phosphorothioate(eppa/m1)acutetoxicity(annexiia,point5.2)ratld50oral47mg/kgbwt,r25ratld50dermal226mg/kgbwrabbitld507.9mg/kgbw(males)t+,r27ratlc50inhalation0.123mg/l(4hour,nose-only)t+,r26skinirritationnotassessedduetohightoxicityeyeirritationnotassessedduetohightoxicityskinsensitization(testmethodusedandresult)positive(m&kmaximisation)xi,r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionoferythrocyteandbraincholinesteraseactivity.lowestrelevantoralnoael/noel0.1mg/kgbw/d:rat28-day,rat90-dayoverallnoael0.1mg/kgbw/dinthedoglowestrelevantdermalnoael/noel0.1mg/kgbw/d:rabbit21-daylowestrelevantinhalationnoael/noelnodataavailableendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprinciples", "j.efsa.2006.68r.pdf": "ndpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int46of70appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandnearlycomplete>80%,168hoursfollowingsingleorallowadministrationat1mg/kgbwdistributionwidelydistributed;highestconcentrationinliver,fat,kidneysandlungspotentialforaccumulationnoevidencerateandextentofexcretionrapidandhigherthan90%at168hrs,mainlyviaurine(63-78%),secondaryviatheexpiredair(14co2)(11-17%),regardlessofsexorrouteormodeofadministrationmetabolisminanimalsextensivelymetabolized,viacleavageofthethio-(sec-butyl)oro-ethyl-groups,oxidationandmethylation.themajorityoftheidentifiedmetabolitesweredetectedinurine.toxicologicallyrelevantcompound(animalsandplants)parentcompound(cadusafos)thetoxicityoftheplantmetabolitehydroxyl-2-butanesulfonicacid,identifiedinbananapeel,notknown(notoxicologydataavailable)toxicologicallyrelevantcompounds(environment)parentcompound(cadusafos)acutetoxicity(annexiia,point5.2)ratld50oral30.1mg/kgbw,femalesr25ratld50dermal10.7mg/kgbw,femalesr27ratlc50inhalation0.026mg/lair,femalesr26skinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)nonsensitizer(buehler)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedrbccholinesteraseactivitylowestrelevantoralnoael/noel0.067mg/kgbw/day(90-day,rat)lowestrelevantdermalnoael/noelnodata-notrequiredlowestrelevantinhalationnoael/noelnodataavailable,justificationrequired'", "j.efsa.2006.69r.pdf": "ndpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int43of78appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyabsorbed(>96%at120hours)atsingle(lowandhighdose)andrepeateddosebasedonurinaryexcretionincludingacomparisonoforalvsi.v.dosing(rat)distributionreadilydistributedinbodytissues,withhighestlevelsintheliverpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion>92%urine(predominatelyduringthefirst24hours)about4%faeces(predominatelyduringthefirst24hours)metabolisminanimalsextensivelymetabolised.majorpathways:-cleavagefromtheaminonitrogenandremovalofn-methylcarbamateresultingin3`hydroxyformanilide-deformylationof3`hydroxyformanilideto3-aminophenolandacetylationoftheaminogrouptoxicologicallysignificantcompounds(animals,plantsandenvironment)formetanateacutetoxicity(annexiia,point5.2)ratld50oral14.8mg/kgbwr28ratld50dermal>2000mg/kgbwratlc50inhalation0.15mg/l(snoutonly)r26ratlc50inhalation0.29mg/l(wholebody)skinirritation(0.5g)notirritanteyeirritation(0.1mleg.to0.43mg)notirritantskinsensitization(testmethodusedandresult)sensitisingproperties(modifiedbuehlertest;9applications)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectcholinesteraseinhibition(rbc,plasmaandbrain)lowestrelevantoralnoael/noel0.4mg/kgbw(29dayand1yearstudyindogs)lowestrelevantdermalnoael/noel20mg/kgbw(21daystudyinrats)'", "j.efsa.2006.72r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu62of99appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandcomplete,basedonurinary,faecalandco2excretioninratandmouse,accounting>90%doseafter48hofsingleoraladministrationof1and50mg/kgand1and100mg/kg,respectively.inhalationroute:rat:>73-79%human:cis-isomer:72-80%andtransisomer:77-82%within15minaftercessationofexposure(basedonexpiredairconcentrations)distributionat48hourspost-dosing,practicallyeliminated.about6%ofthedoseremainedintissuesandcarcassofrat,inwhichhighestvalueswerefoundinnon-glandularstomach,glandularstomach,bladder,liverandkidneys.potentialforaccumulationnoevidenceofaccumulationinratsorhumansrateandextentofexcretionoraladministrationinrat(50mg/kg):93.5%eliminatedwithin48h,mainlyviaurine(61.3%),faeces(17.1%)andco2(15.1%).inhalationrouteinhuman:89-99%within24h.mainlyviaurine(cisisomer-75%,trans-isomer-25%)biphasicexcretion.half-lives:cis-isomer:phase1-4.2h;phase2-12.3h;trans-isomer:phase1-3.2h;phase2-17.1hmetabolisminanimalsextensivelymetabolised.themajorroutewasglutathione-conjugation.thehydrolysiswasasecondrouteaffordingdimercapturateandco2andtheminorroutewastheepoxidationofdcpordcp-glutathione.threemainmetabolites:dimercapturate,c-3-chloroallylalcoholandc-3-chloroacrylicacid.basedonindirectevidenceofmutagenesisstudy,epoxidescouldbeformed.toxicologicallysignificantcompounds(animals,plantsandenvironment)1,3dichloropropene.themetabolitesc-3-chloroallylalcoholandc-3-chloroacrylicacid.acutetoxicity(annexiia,point5.2)ratld50oral110mg/kgbwr25ratld50dermal333mg/kgbwr24'intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu63of99ratlc50inhalation2.70mg/l(whole-body,vapourexposure)r20skinirritationirritantr38eyeirritationirritantr36skinsensitization(testmethodusedandresult)sensitizer(buehlertest)r43respiratorysystemirritationirritantr37shorttermtoxicity(annexiia,point5.3)target/criticaleffectstomach(rat,hyperkeratosisandbasalcellshyperplasia),liver(miceandrat,hepatotoxicity),tongue(dog,mucosalinflammation),nasalcavity(ratandmice,inhalationexposure,hyperplasiaofrespiratoryepithelium)andurinarybladder(mice,females).hypochromicandmicrocyticanaemiaindogs.lowestrelevantoralnoael/noel5mg/kg/bw/day(rat,90days)2.5mg/kg/bw/day(dog,1year)lowestrelevantdermalnoael/noelnodata;nonerequiredlowestrelevantinhalationnoael/noel10ppm(0.046mg/l)i.e.9.72mg/kg/day(rat,13-weeks)genotoxicity(annexiia,point5.4).....................................................................somestudiesshowclearindicationsfordnafragmentationinvivo,however,negativeresultsaredemonstratedinmicronucleus,udsanddominantlethaltests.mut.cat3,r68longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectdepressionofinlifebodyweights(ratsandmice)basalcellhyperplasiaofthenon-glandularmucosaofstomach,fociofalteredcellsintheliver(rats).hyperplasiaoftheurinarybladder,hyperplasticchangesoftherespiratoryepithelium(mice).lowestrelevantnoael/noel2.5mg/kg/day(2-yeardietarystudyinrats)5ppm(4.43mg/kg/day)(2-yearinhalationstudyinmice)'", "j.efsa.2006.75r.pdf": "ndpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int45of72appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandalmostcomplete(84%within24h).tmax:0.5hr.distributionwidelydistributed.highestlevelsinwholeblood.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretionmainlyviaurine(70-80%at24h)butalsoviafaeces(5-10%at24h).biliaryexcretionnotmeasured.metabolisminanimalsinvolvedthiophosphorylhydrolysis,s-methylation,oxidationofthesulfurtothesulfoxideandtothesulfone(u6),hydrolysisofthephthalimideringtotherespectivephthalimideacid.toxicologicallysignificantcompounds(animals,plantsandenvironment)phosmetandphosmet-oxonacutetoxicity(annexiia,point5.2)ratld50oral113mg/kgbwt;r25ratld50dermal>1000mg/kgbwrabbitld50dermal>5000mg/kgbwratlc50inhalationlc50>0.152mg/lskinirritationnon-irritanteyeirritationmoderateirritantskinsensitization(testmethodusedandresult)non-sensitising(modifiedbuehlertest,10-induction)shorttermtoxicity(annexiia,point5.3)target/criticaleffectplasma,rbcandbrainacetylcholinesteraselowestrelevantoralnoael/noeloverallnoael:2mg/kgbw/day(90dayrat,28-daymouseanddog)lowestrelevantdermalnoael/noel22.5mg/kgbw/day(rat21-days,brainche)lowestrelevantinhalationnoael/noelnodata.notrequired'", "j.efsa.2006.76r.pdf": "pendix1listofendpointsendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.euappendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandalmostcomplete(rat:~90%at24hr;inurine,faecesandexpiredco2)(rabbit:97%at24hr,mainlyinurine)distributionwidelydistributedtoallorgans,crossingtheblood-brainbarrier.liver,kidneyandbonemarrowhadthehighestlevelsofradioactivity.potentialforaccumulationnopotentialforaccumulation.repeateddoseresultedinlongerplasmahalf-life(t1/2=28.4hr)rateandextentofexcretionrat:rapid,byurine(45-50%),faeces(21%)andexpiredco2(21%)at24h.rabbit:veryrapidbyurine(96%)at24hmetabolisminanimalsextensivelymetabolisedwithextensiveconjugation.(ratandrabbit)toxicologicallysignificantcompounds(animals,plantsandenvironment)trichlorfon,dichlorvosacutetoxicity(annexiia,point5.2)ratld50oral212mg/kgbwxn;r22ratld50dermal>5000mg/kgbwratlc50inhalationhighestconcentrationtested0.53mg/l.skinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)sensitiser(magnussonandkligmanstest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectdepressionofplasma,rbcandbraincheactivitiesandneurotoxicologicalsigns.targetorgans:kidneysandspleen(increasedweight)lowestrelevantoralnoael/noelnoadequatedataforbrainacheinrats.lackofsubchronicstudiesindogs(mostsensitive).lowestrelevantdermalnoael/noel100mg/kgbw/day(rabbits,3weeks)lowestrelevantinhalationnoael/noel0.013mg/l(3.43mg/", "j.efsa.2006.77r.pdf": "ppendix1listofendpointsendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.euappendix1.3:impactonhumanandanimalhealthnote:theoverallqualityofthedatabaseisnottocurrentstandards.absorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid,>80%basedonurineexcretiondistributionresidualcarcass(13%to26%),liver(3%to5%),andallothertissuecombined(1%to2%).potentialforaccumulationnotassessableduetoincorporationintobiomoleculesrateandextentofexcretionexpiredair(40%to58%),urine(11%to17%),andfaeces(4%to7%).themajorityoftheradioactivityinexpiredairandexcretawaseliminatedwithin24hoursafterdosing.metabolisminanimalsextensivebyhydrolysisanddemethylationtoxicologicallysignificantcompounds(animals,plantsandenvironment)dichlorvos.themetabolitesdesmethyldichlorvos,2,2-dichloroacetldehydeand2,2-dichloroaceticacidareconsideredastoxicologicallyrelevant.theimpuritychloralisconsideredastoxicologicallyrelevant,butnodataisavailable.acutetoxicity(annexiia,point5.2)ratld50oral80mg/kgbwr25ratld50dermal120mg/kgbwr24ratlc50inhalation0.083mg/lr26skinirritationnotassessedduetohightoxicityeyeirritationnotassessedduetohightoxicityskinsensitization(testmethodusedandresult)skinsensitiser(splitadjuvanttest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectnervoussystem/cholinesteraseinhibitionlowestrelevantoralnoael/noel0.5mg/kg/day,52wksoralstudy,doglowestrelevantdermalnoael/noelnogoodstudiesavailablelowestrelevantinhalationnoael/no", "j.efsa.2006.78r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu45of80appendix1.3:impactonhumanandanimalhealththenotifierswereaskedtoprovideinformationforthetestmaterialusedinthetoxicitystudies(i.e.propamocarborpropamocarbhydrochloride).informationhasbeensubmittedtothermsinmarch2006butnotpeerreviewed,thereforeitsstillmissingfromthebelowreportedtable.absorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid(7896%)within72hdistributionmainlyinorgansassociatedwithbiotransformation(liver,lung,kidney).theseweretheonlyoneswhichhadquantifiableamountsrecorded(<0.17mgequivalents/kgtissue).thehighesttransitoryconcentrationsofradiolabelweredetectedinliverandkidneysbetween0.75and3hourspost-dosing.terminalhalf-lifeforalltissueswas1126hpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidexcretion-91to94%within72hforldandhdrespectively.majorityviaurine(8892%in72h).genderindependentmetabolisminanimalsextensivelymetabolisedwithonlybetween1.1and11%excretedasunchangedpropamocarb-anioninthelowdoseanimalsandupto20%inhighdose.fourmajormetabolitesidentified:2-hydroxypropyl3-(dimethylamino)propylcarbamate,propyl[3-(methylamino)propyl]carbamate,propyl-3-(dimethylamino)propylcarbamate-n-oxideand3-(3-dimethylaminopropyl)-4-hydroxy-4-methyloxazolidin-2-onetoxicologicallysignificantcompounds(animals,plantsandenvironment)propamocarbhydrochloride,2-hydroxypropyl3-(dimethylamino)propylcarbamate,propyl[3-(methylamino)propyl]carbamate,propyl-3-(dimethylamino)propylcarbamate-n-oxideand3-(3-dimethylaminopropyl)-4-hydroxy-4-methyloxazolidin-2-oneacutetoxicity(annexiia,point5.2)ld50oralld50>2000mg/kgbwld50dermalld50>2000mg/kgbwlc50inhalationlc50>5.01mg/lskinirritationnon-irritanteyeirritationnon-irritant'", "j.efsa.2006.79r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu44of82appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidabsorption,cmaxinplasmaat0.5h.extensivelyabsorbedafteroraldose,84-90%distributionextensivelydistributedintoorgansandtissuespotentialforaccumulationnopotentialforaccumulationt1/2forelimination8h21h.rateandextentofexcretionrapideliminationmainlyinurine(84-90%)within48h.faeceswas5-10%metabolisminanimalsextensivelymetabolised.oxidationofthesulphidegroup,removalofthecarbamategroupwithformationofphenolmetabolitesandconjugationofphenolhydroxygroupwithsulphateandglucuronicacidtoxicologicallysignificantcompounds(animals,plantsandenvironment)methiocarbandmetabolites(sulfoxide,sulfone,phenol)acutetoxicity(annexiia,point5.2)ratld50oral19mg/kgbwbasedonweightofevidenceofpublisheddatawithrangeof13135mg/kgbw.submittedstudyshowed33mg/kgbw(males)and47mg/kgbw(females)r28ratld50dermal5000mg/kgbwratlc50inhalation585mg/m3inmalesand433mg/linfemalesr23skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)notsensitizing(buehlerandmagnussonandkligmanmethods)shorttermtoxicity(annexiia,point5.3)target/criticaleffectcholinesteraseinhibition,cholinergicsignsandreductioninbodyweightgainlowestrelevantoralnoael/noel1.3mg/kgbw/dayin90-daydogwithinvestigationofneurofunctionlowestrelevantdermalnoael/noel150mg/kgbwin21-daystudyinrabbitslowestrelevantinhalationnoael/noel6mg/m3in21-daystudyinrats'", "j.efsa.2006.80r.pdf": "ndpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.eu.int41of71appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyabsorbed,about91.5%within24hoursbasedonurine(rat,1or50mg/kgbw)distributionwidelydistributed,highestlevelsinthekidneyat7dayspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionmainlyviaurine:about91.5%within24hours.metabolisminanimalsextensivelymetabolised.2.9%ofunchangedcarbarylinurine.threemainmetabolicpathways:areneoxideformationwithhydrolysistodihydrodihydroxycarbarylandglucuronideconjugation;hydrolysistoform1-naphtholandconjugation;oxidationofn-methylmoiety(alkyloxidation)toxicologicallysignificantcompounds(animals,plantsandenvironment)carbarylacutetoxicity(annexiia,point5.2)ratld50oral614mg/kgbw,r22ratld50dermal>5000mg/kgbwratlc50inhalation2.4mg/lforfemales,r20skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)non-sensitising(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofbrainandredbloodcellcholinesteraseactivitylowestrelevantoralnoael/noel<3.73mg/kgbw/day,femaledogs(1year,diet)lowestrelevantdermalnoael/noel20mg/kgbw/day,rats(5days/week,4weeks)lowestrelevantinhalationnoael/noelnodata'", "j.efsa.2006.82r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu40of69appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandalmostcomplete(>90%basedonbiliaryandrenalexcretionwithin24hours)distributioninitiallywidelydistributed,highestresiduesintheliverpotentialforaccumulationlowpotentialforaccumulation(t1/2:60-68h)rateandextentofexcretionrapid5.5/13%viaurine,88/85%viafeces48hoursafterdosing(male/female)metabolisminanimalsextensivelymetabolisedbydemethylationofthedimethoxyphenylringandtoasmallerextendbyoxidationofthemorpholineringtoxicologicallysignificantcompounds(animals,plantsandenvironment)dimethomorphacutetoxicity(annexiia,point5.2)ratld50oral3900mg/kgbw(racemate)>5000mg/kgbw(z-isomer)4472mg/kgbw(e-isomer)ratld50dermal>2000mg/kgbwratlc50inhalation>4.24mg/l(4hr,whole-body,dust)skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)notsensitising(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver;testesandprostate(dogonly)lowestrelevantoralnoael/noel1yrdog:(5mg/kgbw/d)90ddog:(15mg/kgbw/d)90drat:(16mg/kgbw/d)lowestrelevantdermalnoael/noelnodata-notrequiredlowestrelevantinhalationnoael/noelnodata-notrequired'", "j.efsa.2006.83r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu44of73appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidaftergavageadministrationwithpeakeffectsseen0.5to3hourspostdosing.absorption>90%intheratandapproximately75%inthemonkey(urineandexpiredair,5mg/kgbw).distributionrat:widespread(highestlevelsinthegastro-intestinaltract,liver,blood,andskin).monkey:widespread(highestlevelsinfatandmuscle).potentialforaccumulationalthoughtheradioactivetissuesresiduesappeartobehighat168hours,(8-9%intherat&approximately5%inthemonkey),methomylisbrokendownintosmallcarboncompoundswhichjointhepoolofnaturallyoccurringcarboncompoundsandareincorporatedintothetissues.rateandextentofexcretionradiolabelwasrapidlyexcretedinexpiredairandurine(within24hoursofdosing(80%intheratand63%inthemonkey)andextensiveeliminationintheratat168hourspostdosing(approximately91%).inthemonkey,approximately75%eliminatedat168hourspostdosing.metabolisminanimalsthreemajorpathwayswereproposed:displacementofs-methylfromsyn-methomylbyglutathionefollowedbytransformationtothemercapturicacidderivative(18%ofthedose);conversionofmethomyltomethomyloxime(mhtaorin-x1177)andco2release;andisomerisationofsyn-methomyltoanti-methomyl(in-b1884),followedbyabeckmannrearrangementandformationofacetonitrile.toxicologicallysignificantcompounds(animals,plantsandenvironment)methomyl,inhuz57,(ing6520)acutetoxicity(annexiia,point5.2)ratld50oral30mg/kgbwt,r25ratld50dermal>2000mg/kgbwratlc50inhalation0.215mg/linmale&femalest+,r26skinirritationnon-irritant(notclassified)eyeirritationslight-irritant(notclassified)'", "j.efsa.2006.84r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu54of102appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyandextensivelyabsorbed,>90%within24hours(raturine,10mg/kgbw)distributionwidelyandevenlydistributed,highestconcentrationinliverpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyexcreted(90%inurinewithin24h)metabolisminanimalscleavagetodimethoatecarboxylicacid;oxidationtoomethoate(~5%).toxicologicallysignificantcompounds(animals,plantsandenvironment)parent,omethoate,o-desmethylomethoatecarboxylicacid,o-desmethylisodimethoateacutetoxicity(annexiia,point5.2)ratld50oral245mg/kgbw(r22)ratld50dermal>2000mg/kgbwratlc50inhalation1.68mg/l(4hours,wholebody);studywithamanufacturingconcentrate(r20)skinirritationminimalirritanteyeirritationmildirritantskinsensitization(testmethodusedandresult)noevidence(3-inductionbuehler),studyinsufficient(provisionalr43)shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionoferythrocyteandbraincholinesteraseactivitylowestrelevantoralnoael/noel0.18mg/kgbw/day(1yeardogstudy)lowestrelevantdermalnoael/noel5mg/kgbw/day(5-dayratstudywithaformulation)lowestrelevantinhalationnoael/noelnodatagenotoxicity(annexiia,point5.4).....................................................................positivesinvitro,negativeinvivo.weightofevidenceindicatesnosignificantgenotoxicpotential'", "j.efsa.2006.85r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu42of73appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>90%within24h(basedonamountinurine)(rat,11or104mg/kgbw)distributionwidelydistributedbutlowlevels;highestresiduesinrbc,fatandovariespotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion>90%after24h;mainlyviaurine(rat,11and104mg/kgbw)metabolisminanimalsextensivemetabolism.mainlybyhydrolyticandoxidativecleavageofthephosphorusesterbond.5identifiedmetabolites,2majoronesfoundinurine:g27550(m1)andgs31144(m2).conjugationtoglucuronidesleadingprobablyto6aqueoussolublemetabolites.toxicologicallysignificantcompounds(animals,plantsandenvironment)diazinonimpuritiestepp;o,s-tepp;s,s-tepp;diazoxonacutetoxicity(annexiia,point5.2)ratld50oral1139mg/kgbwxn,r22ratld50dermal>2000mg/kgbwratlc50inhalation>5.0mg/l/4hskinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)non-sensitiser(buehler)shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofrbcandbraincheinallspecieslowestrelevantoralnoael/noel90d&1ydog:0.02mg/kgbw/dlowestrelevantdermalnoael/noel21drabbit:5mg/kgbw/dlowestrelevantinhalationnoael/noel21drat:<0.00005mg/lgenotoxicity(annexiia,point5.4).nogenotoxicpotential'", "j.efsa.2006.86r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu62of96appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid,>90%inratsbasedonurineexcretion.distributionwidelydistributed,highestlevelinblood.potentialforaccumulationnopotentialforaccumulationinorgansrateandextentofexcretionalmostcompletein72hours,mainlyviatheurinemetabolisminanimalsmoderatelymetabolised(27-67%)byoxidation,hydrolysistoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompound,impurities/metabolites:demeton-s-methylsulphon(m01),demetonsmethyl(m02)plantmetabolites:m06andm07acutetoxicity(annexiia,point5.2)ratld50oral48mg/kgbwt,r25ratld50dermal112mg/kgbwt,r24ratlc50inhalation0.471mg/lt,r23skinirritationnonirritanteyeirritationirritantr36skinsensitization(testmethodusedandresult)skinsensitiser(m&k,buehler)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofbrainandbloodcholinesteraseactivitieslowestrelevantoralnoael/noeloverallnoael=0.1mg/kgbw/d(90-drat,1-ydog)noael14-dayrat:0.15mg/kgbw/dlowestrelevantdermalnoael/noel0.5mg/kgbw/d(21daysrabbit)lowestrelevantinhalationnoael/noel0.00066mg/l/d(21daysrat)m01:s-[2(ethylsulfonyl)ethyl]o,o-dimethylphoshorothioatem02:s-[2(ethylthio)ethyl]o,o-dimethylphoshorothioatem06:o-methyl-s-[2(ethylsulfinyl)ethyl]phoshorothioatem07:o-methyl-s-[2-(ethylsulfonyl)-ethyl]phoshorothioate'", "j.efsa.2006.87r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu59of96appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensiveinallspeciestested,includinghumans(>80%).distributionprimarilybloodandliverpotentialforaccumulationnonerateandextentofexcretionspeciesandsexdependent.inrats,excretionwasmainlyviaurineinfemalesandfaecesinmalesandfasterinfemalesthanmales.indogsexcretionwasmainlyviafaecescomparedwithurineformonkeysandhumans.metabolisminanimalslimitedtoesterhydrolysis/acidconjugation.toxicologicallysignificantcompounds(animals,plantsandenvironment)animalsandplants:haloxyfop(r)methylester,haloxyfop(r)andconjugatesofhaloxyfop(r)expressedashaloxyfop(r).environment:haloxyfop-rmethylester,haloxyfop-r,de-535pyridinol,de-535pyridinoneacutetoxicity(annexiia,point5.2)ratld50oral300mg/kgbwxn;r22ratld50dermal>2000mg/kgbwratlc50inhalationnodatanotrequiredskinirritationnonirritanteyeirritationirritatingtoeyes(haloxyfop-r)nonirritant(haloxyfop-rmethylester)xi;r41skinsensitization(testmethodusedandresult)non-sensitiser(buehlerandm&ktests)shorttermtoxicity(annexiia,point5.3)target/criticaleffectratandmice:liverandkidney,andrbc.dogandmonkey:liver,thyroid,kidney,serumcholesterol.lowestrelevantoralnoael/noel0.2mg/kgbw/day16-daystudyinrat0.2mg/kgbw/day,90-daystudiesindogandmonkeyeffectsat2mg/kgbw/day0.5mg/kgbw/day,oneyeardogstudy'", "j.efsa.2006.88r.pdf": "pointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu42of74appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandnearlycompletewithin36h,basedonexcretionviaurine(40,4%)andfaeces(51,8%)afteroralandi.v.application.distributionwidelydistributedwithhighestconcentrationsinliverandkidney(eliminationhalflivesinalltissuesrangedbetween18.4and33.6h)potentialforaccumulationnoevidenceforaccumulationaftersingleandrepeatoraladministration.rateandextentofexcretionrapid,mostlywithin24hviaurine(38%)andfaeces(52%)followingeitherintravenousororaldosing.metabolisminanimalsextensivelymetabolised(>97%);mainmetabolitesdesaminometribuzin(da),6-tert-butyl-4,5-dihydro-1,2,4-triazin-5-one-3-mercapturicacidandt-buoh-datoxicologicallysignificantcompounds(animals,plantsandenvironment)metribuzinanddk,dadk,u1andm17acutetoxicity(annexiia,point5.2)ratld50oral322mg/kgbw(r22)ratld50dermal>5000mg/kgbwratlc50inhalation2.045mg/l(dust)skinirritationnotirritatingeyeirritationnotirritatingskinsensitization(testmethodusedandresult)notsensitising(buehlerandm&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,kidney(chronicinflammation)(rats,rabbitsanddogs),thyroidgland(changesinhormonelevels),erythrocytes(dogs)lowestrelevantoralnoael/noeloverallnoael(rat,rabbit,dog):2mg/kgbw/d(r48/22?)lowestrelevantdermalnoael/noel21-d,rabbit(15applications):40mg/kgbw/dlowestrelevantinhalationnoael/noel21-d,rat(15applications):0.031mg/lair'", "j.efsa.2006.89r.pdf": "pointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu50of81appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrelativelyrapid,70-81%basedonlevelsinurinewithin144h(rats,6.7or40mg/kgbw)distributionlarge,highestlevelinexcretoryorgansandcarcasspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionextensivelyexcreted,70-80%inurines;13-26%infaeceswithin48hmetabolisminanimalsextensive;benfuracarbbreaksdowntocarbofuran,whichisfurtherhydroxylated/oxidatedinto3-ketofuran-7-phenol,3-hydroxycarbofuran,3-hydroxycarbofuran-7-phenol,carbofuranphenoltoxicologicallysignificantcompounds(animals,plantsandenvironment)benfuracarbandmetaboliteswiththecarbamatemoiety,suchascarbofuranacutetoxicity(annexiia,point5.2)ratld50oral205mg/kgbwxn;r22ratld50dermal>2000mg/kgbwratlc50inhalation0.344mg/lt;r23skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)non-sensitizer(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectclinicalsignsofneurotoxicity,inhibitionofacetylcholinesterase,thymusinvolution(dogs)lowestrelevantoralnoael/noeloverall:1mg/kgbw/d(13-week;6monthand12-24monthdog)lowestrelevantdermalnoael/noel5mg/kgbw/d(28day,rat)lowestrelevantinhalationnoael/noelnotrelevant'", "j.efsa.2006.90r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu60of88appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption83-92%(urineandair)within32hour(0.4mg/kgbw,rat)distributionlarge,highestresidueinliverpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion92%ofphenylpartwithin48hmainlyviaurine(89%)andfaeces(2.5%);carbamatemoietyexcretedwithin32hinairasco2metabolisminanimalsoxidationatc-3,generating3-oh-metabolites,furtheroxidation(3-ketocarbofuran)and/orexcretionasconjugateshydrolysisofcarbamatebondintoco2toxicologicallysignificantcompounds(animals,plantsandenvironment)carbofuranandmetaboliteswiththecarbamatemoietyacutetoxicity(annexiia,point5.2)ratld50oral7mg/kgbwt+;r28ratld50dermal1000-2000mg/kgbwxn;r21ratlc50inhalation0.05mg/lt+;r26skinirritationnon-irritanteyeirritationnon-irritant,butmortalityreported(rabbits)t;r39/41skinsensitization(testmethodusedandresult)non-sensitizer(buehlerandm&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffecttesticulardegeneration,clinicalsignsofneurotoxicityrelatedtoacheinhibition(ratanddogs)lowestrelevantoralnoael/noel0.1mg/kgbw/day,1-yeardogand60day,rat(publishedstudy)lowestrelevantdermalnoael/noel25mg/kgbw/day,21dayrabbitlowestrelevantinhalationnoael/noelnostudyavailable'", "j.efsa.2006.91r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu53of84appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionhighbioavailability(>70%)within24h(4and30mg/kgbwrat)distributionlarge,highestlevelinexcretoryorgansandcarcasspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandextensive(app.90%)within24hmainlyviaurine(63-77%)metabolisminanimalsextensivemetabolism(>80%):hydrolysisatc-7toform7-phenolandatn-stoformcarbofurananddibutylamine.7-phenolandcarbofuranareoxidizedatc-3generating3-oh-metabolites.dibutylamineisoxidizedtoco2andvolatiles.toxicologicallysignificantcompounds(animals,plantsandenvironment)carbosulfanandmetabolitescontainingthecarbamatemoiety(animalsandplants),dibutylamineacutetoxicity(annexiia,point5.2)ratld50oral138mg/kgbwt;r25(42.7mg/kgbw,rabbit))ratld50dermal3700mg/kgbwratlc50inhalation0.61mg/lt;r23skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)sensitising(buehler10induction)xi;r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectinhibitionofacetylcholinesterase(rat)lowestrelevantoralnoael/noel2mg/kgbw/day,90dayratlowestrelevantdermalnoael/noel5mg/kgbw/day,21dayrabbitlowestrelevantinhalationnoael/noel0.00015mg/l,28dayratgenotoxicity(annexiia,point5.4)notgenotoxicinvitroandinvivohowever,possibleimpactofimpurityremainaconcern'", "j.efsa.2007.103r.pdf": null, "j.efsa.2007.105r.pdf": "ointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu41of69appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid,butincompletetotalrateofabsorptionamountedtoatleast48%distributionwidelypotentialforaccumulationnegligiblerateandextentofexcretionrapid,onlynegligibleradioactivitywasfoundinthetissuesandorgans72hoursaftertheadministrationmetabolisminanimalscompletetoxicologicallysignificantcompounds(animals,plantsandenvironment)noneacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgratld50dermal>2000mg/kgratlc50inhalation>4.87mg/l(highestachievableconcentration)skinirritationnoneeyeirritationnoneskinsensitization(testmethodusedandresult)positiveinamagnusson&kligmanassayr43shorttermtoxicity(annexiia,point5.3)target/criticaleffectadrenalsandmetabolicdisturbance(reducedcholesterol)lowestrelevantoralnoael/noel3mg/kgbw/day(mouse)lowestrelevantdermalnoael/noel1000mg/kgbw/day(rat,notmostsensitivespecies)lowestrelevantinhalationnoael/noel5.0mgspiromesifen/m3/dayforfourweeks(rat)genotoxicity(annexiia,point5.4)..negativeinvitro(amestest,amammaliancellgenemutationassaywithv79cells,andacytogenetictestinv79cells)andinvivo(mousebonemarrowmicronucleustest)'", "j.efsa.2007.106r.pdf": "ointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu52of98appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionjau6476:rapidandnearlycomplete(peakplasmalevelslessthan1hafterdosing>90%ofdoseabsorbedwithin48hafterdosingjau6476-desthio(m04):rapidandnearlycomplete(peakplasmalevelsat1-1.5hafterdosing>90%ofdoseabsorbedwithin48hafterdosingdistributionjau6476:broaddistribution,butprimarilytoliverandkidneyjau6476-desthio(m04):limiteddistributiontoperipheraltissues;mainlytoliverandrenalcortex,intensiveenterohepaticre-circulationpotentialforaccumulationnonerateandextentofexcretionjau6476:theexcretionofradioactivityisalmostcompletewithin48hoursoforaladministrationapproximately90-100%oforallyadministereddoseswasexcretedwithurine,faeces,orbilewithin7daysoftreatment,jau6476-desthio(m04):between68and74%wasexcretedwiththefaecesandabout10%inurine.metabolisminanimalsjau6476:jau6476isextensivelymetabolisedto18metabolites,withthemajormetabolicreactionsbeingdesulfuration,oxidativehydroxylationofthephenylmoiety,andconjugationwithglucuronicacid.twomajormetabolitesformed,jau6476-desthio(m04)andjau6476-s-oro-glucuronides(m06orm07),andparentjau6476,eachaccountfor10%oftheadministereddose.1,2,4-triazole(m13),occursinurineatupto2.3%oftheadministereddose.jau6476-desthio(m04):metabolismproceedsviaoxidationreactionsonthephenylmoietyonlywithsubsequentglucuronidationandmethylationoftheoxidationproducts.thecyclopropylandtriazoleringstructuresofjau6476-desthioremainintact.'ointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu53of98toxicologicallysignificantcompounds(animals,plantsandenvironment)allmainmetabolitesidentifiedinplantswerealsodetectedintheratmetabolismstudy.forthefollowingminorcropmetabolites,furthertestswereconducted(acuteoraltoxicitytest,ames-test,andinsomecases90drepeatdose/teratostudies):jau6476-triazolinone(m03),jau6476--hydroxy-desthio(m18),jau6476--acetoxy-desthio(m19)jau6476-sulfonicacid(m02)andjau6476-benzylpropyldiol(m09).thetestsdidnotshowtheypossessedmoreserioustoxicologicalpotentialthantheparentcompound.acutetoxicity(annexiia,point5.2)jau6476:jau6476-desthio(m04):ratld50oral>6200mg/kg>2500mg/kgratld50dermal>2000mg/kg>5000mg/kgratlc50inhalation>4990mg/m>5077mg/m3(dust)skinirritationnon-irritantnon-irritanteyeirritationnon-irritantslightlyirritatingskinsensitization(testmethodusedandresult)non-sensitizer(pilot)skinsensitizer(largescale)r43non-sensitizershorttermtoxicity(annexiia,point5.3)jau6476:jau6476-desthio(m04):target/criticaleffectliver,kidneyliverlowestrelevantoralnoael/noel25mg/kgbw/day(dog)1.6mg/kgbw/day(dog)lowestrelevantdermalnoael/noel>1000mg/kgbw/day(rat)lowestrelevantinhalationnoael/noelnotrelevantnodermalstudysubmittedasthismaterialisametabolite.evaluationmeeting(24-26/04/2007):theimpurityjau6476-deschloro,showntobeaskinsensitizer,isincreasedabovethetriggervalueforclassificationinthetechnicalspecificationofthelargescaleproduction.intheabsenceofanewskinsensitizationtestforthenewtechnicalspecification,theclassificationr43isproposed.'", "j.efsa.2007.107r.pdf": "pointsidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu47of81appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid(<48h);efficient(89-97%)atlowdose,lessefficient(41-54%)athighdosedistributionwidelydistributedpotentialforaccumulationapparentaccumulationafterrepeatedadministration,mostprobablyduetorecruitmentofvalinerateandextentofexcretionrapid,within48h:73-81%(lowdose)and80-86%(highdose);means(48h):12%urine/cagewash,65%faeces;evidenceofbiliaryexcretion,enterohepaticcirculationmetabolisminanimalsextensive(lowdose)tolow(highdose)metabolisation;majormetaboliteb11(glucuronicacidconjugateofhydroxylatedderivative);limitedcleavageoftheamidebondofthevalyl-moietytoxicologicallysignificantcompounds(animals,plantsandenvironment)benthiavalicarb-isopropyl;impuritieskif-230i6,andi12(onlypilotandsometoxbatches)andmetabolitesm1m4andm5acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgb.w.ratld50dermal>2000mg/kgb.w.ratlc50inhalation>4.6mg/lairskinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethodusedandresult)maximisationtest,sensitiserxir43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:liver(weight,gt),rbc(anaemia);dog:liver/adrenal(weight),thymus(weight),rbc(anaemia)lowestrelevantoralnoael/noel14mg/kgb.w./d(90drat)lowestrelevantdermalnoael/noel300mg/kgb.w./dlowestrelevantinhalationnoael/noelnodata,notrequired'", "j.efsa.2007.108r.pdf": "pointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu38of82appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandnearlycomplete(>90%)oralabsorptioninratsdistributioninitiallywidely,highestconcentrationsafter72hinheartandadrenalspotentialforaccumulationlowrateandextentofexcretion85-90%viaurine,7-26%viafaeceswithin72h(biliaryexcretion37%inmales,12%infemales)metabolisminanimalsrapid,extensive,primarilybyoxidation,hydroxylationandconjugationtoglucoronideandsulfate,3majormetabolitesinurine(ofatleast9metabolites)toxicologicallyrelevantcompounds(animalsandplants)parentcompound,soilandplantmetabolitesbandb-1toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral2140mg/kgbw(females)10ratld50dermal>2000mg/kgbwratlc50inhalation>5.4mg/lair(4h,noseonly)skinirritationnotirritanteyeirritationnotirritantskinsensitisationnotsensitising(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweightgain(allspecies),liverinrodents(increasedorganweight,histologicalfindings,changesinclinicalchemistryparameters)relevantoralnoael21mg/kgbw/day(90-dayrat)99mg/kgbw/day(12-monthdog)relevantdermalnoael1000mg/kgbw/day(21-dayrabbit)relevantinhalationnoaelnotsubmitted,notnecessary10isomerreducedcompoundproducedsinceabout1985'", "j.efsa.2007.109r.pdf": "dpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu34of73appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyandextensivelyabsorbed(87-100%within48hbasedonurinaryexcretionandivstudy).peakbloodconcentrationswereseen4hoursafterdosing.distributionlowlevelsofresiduesinliver,kidneys,blood,hairandcarcass.potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionmajorityoftheexcretionwithin2days,closeto100%after7days(~70%inurineand~30%infaeces).metabolisminanimalsextensivelymetabolised(>95%)byoxidationreactionsandcleavagereactions.toxicologicallyrelevantcompounds(animalsandplants)clomazonetoxicologicallyrelevantcompounds(environment)clomazoneacutetoxicity(annexiia,point5.2)ratld50oral2077mg/kgbw(males)1369mg/kgbw(females)r22rabbitld50dermal>2000mg/kgbwratlc50inhalation4.85mg/lair/4hrr20(wholebody,combinedsexes)skinirritationnotirritatingeyeirritationnotirritatingskinsensitization(testmethodusedandresult)non-sensitiser(m&kandbuehlertest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(rats,dogsandmice),withincreasedweight,alterationsinhepatocytes,grosspathologicalfindingsandchangesinclinicalchemistryparameters.relevantoralnoael13.3mg/kgbw/day(12monthsdogstudy)relevantdermalnoael1000mg/kgbw/day(28dayratstudy)relevantinhalationnoaelnodata/notrequired'", "j.efsa.2007.110r.pdf": "ointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu43of85appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption80%basedonurinaryandbiliaryexcretionafterlowdoseratstudydistributionuniformlydistributed(highestresiduesfoundinliverkidneyandlungs)potentialforaccumulationnopotentialrateandextentofexcretion15%intheurineandabout70%inthefaeceswithin24hours.theexcretionwasmainlyviathebile.metabolisminanimalsnoparentcompoundinurine,approx.10%parentinfaeces.inbileapprox.56%ofglucuronideconjugateofmetabolitesyn518577toxicologicallyrelevantcompounds(animalsandplants)fludioxoniltoxicologicallyrelevantcompounds(environment)fludioxonilacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.6mg/l(4h,noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver;rat,mice,dog(increasedweight,hepatocytehypertrophy,bileductproliferation)kidney;rat,mice(increasedweight,nephropathy)relevantoralnoael58.5mg/kgbw/day(90-daydog)64mg/kgbw/day(90-dayrat)relevantdermalnoael200mg/kgbw/day,females(3weeksrat)relevantinhalationnoaelnostudiessubmitted,notrequired'", "j.efsa.2007.111r.pdf": "dpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu37of81appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionfairlyrapidbutlimitedtoapproximately72%followingasinglelowdoseinrats(basedonexcretioninurine,cagewash,tissuesandcarcasses).distributionwidelydistributed(highestlevelsfoundinkidneys,liverandblood).elevatedlevelsinfatofhighdosefemalerats.potentialforaccumulationlowpotentialforaccumulation.rateandextentofexcretionfairlyrapid(>80%oflowdoseexcretedwithin48hrs).approximately68%and21%ofthesinglelowdosewasexcretedover5daysinurineandfaeces,respectively.metabolisminanimalsextensivelymetabolised.twomajorpathways:1.oxidationofthe-benzylcarbonandglycineconjugationoftheintermediatestoformhippuricacid.2.oxidationofthesulphurwithfurtheroxidationofintermediatestoformbenzylsulphonicacid.toxicologicallyrelevantcompounds(animals,plantsandenvironment)parentcompound.acutetoxicity(annexiia,point5.2)ratld50oral1820mg/kgbw(males)1958mg/kgbw(females)r22ratld50dermal>2000mg/kgbwforbothsexescombinedratlc50inhalation>4.72mg/l(maximumattainableconcentration,4hrs,wholebody).skinirritationnotirritating.eyeirritationnotirritating.skinsensitisationsensitising(locallymphnodeassay)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbwandbwgain(rat,dog)andreducedfoodconsumption(rat).targetorgansathigherdoses:liver(rat,dog),kidneys(rat,dog)andbonemarrow(dog).cholinergiceffects(rat).haematolyticanaemiaassociatedwithhistopathologicalchangesinspleen(dog).relevantoralnoael1mg/kgbw/day(13-weekrat)relevantdermalnoaelnodata-notrequired.'", "j.efsa.2007.117r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu39of70appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>80%basedonurinaryandbiliaryexcretion,andcarcassrecovery.distributionuniformlydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionalmostcompletelyeliminated(20%bile,54%urineand4%faeces)within24hmetabolisminanimalsextensivelymetabolisedtoseveralglucuronideandsulphateconjugates.toxicologicallyrelevantcompounds(animalsandplants)quinoclaminetoxicologicallyrelevantcompounds(environment)quinoclamineacutetoxicity(annexiia,point5.2)ratld50oral200<ld50<500mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation>0.79mg/l(4hrs,wholebody,highestattainableconcentration)skinirritationnon-irritanteyeirritationirritantr36skinsensitization(testmethodusedandresult)sensitizer(magnusson&kligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney,blood,spleen(haemosiderindepositionindicatedincreasedhaemopoiesis).r48/22?relevantoralnoael3mg/kgbw/day(90ddog)relevantdermalnoael100mg/kgbw/day(noel,28drat)relevantinhalationnoaelnostudysubmitted,notrequiredgenotoxicity(annexiia,point5.4)...notgenotoxic'", "j.efsa.2007.121r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu39of76appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(cmax<8hrs)andalmostcompletelyabsorbed(>90%)afterorallowdoseapplicationinrats,basedonurinaryandfaecal(assumedbiliary)excretionafteroralandi.v.applicationdistributionwidelydistributed,highestconcentrationsinkidneys,blood,fattytissuesandliver;totalamountafter7days:0.7-2%potentialforaccumulationnopotentialforaccumulationrateandextentofexcretion>75%excretedwithin48hours;malesgenerallyexcreteloweramountsofradioactivityviaurine(35-65%)thanviafaeces(43-54%)metabolisminanimalsextensivelymetabolisedviahydrolysisintofreeacidandconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>3150mg/kgbw(+)ratld50dermal>2000mg/kgbw(+)ratlc50inhalation>1.224mg/lair(+)(aerosol,4hours,noseonly,technicallyhighestadministrabledose)skinirritationslightlyirritating(classificationnotrequired)eyeirritationslightlyirritating(classificationnotrequired)skinsensitisationsensitizertotheskin(magnusson&kligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,kidneys(rat,mouse,toaweakerextentalsodog)relevantoralnoaelrat:overall2mg/kgbw/d(13wk+6mointerim)mouse:overall5.5mg/kgbw/d(13wk+12mointerim)dog:15.6mg/kgbw/d(13wk)relevantdermalnoael20mg/kgbw/d(rats,21appl.within30d)'", "j.efsa.2008.116r.pdf": "activesubstanceandtherepresentativeformulationendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu42of86appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandalmostcompleteenteralabsorption:>90%(basedonurinaryandassumedbiliaryexcretionwithin24h)distributionwidelydistributed;lowradioactivityresiduesmainlyinlung,heart,fat,skeletalmuscle,blood,plasma,spleen,liverpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidandmainlyviaurine(79.691.4%)metabolisminanimalspoorlymetabolized(>60%excretedasparent)majormetabolicpathway:o-demethylationofamidosulfuron;minorpathway:hydroxylationofparentandsulphateconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50intraperitoneal10002000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>1.8mg/lair(4hours,noseonly)(highesttechnicallyadministrabledose)skinirritationnotirritatingeyeirritationslightlyirritating(noclassificationrequired)skinsensitisationnotsensitising(m&k-test)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverandbodyweight(rat);clinicalchemistry(dog)relevantoralnoael215mg/kgbw/day(28-dayrat)792.1mg/kgbw/day(90-dayrat)144.1mg/kgbw/day(90-dayand1-yeardog)relevantdermalnoael>1000mg/kgbw/d(28-dayrat)relevantinhalationnoael>270mg/kgbw/d(28-dayrat,6h/d,5d/wk)(equivalentto1mg/lair)'", "j.efsa.2008.118r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu38of65appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(<1h)absorption,45%excretedviaurine,>80%whenbileisincluded(ratstudy)distributionwidelydistributed,highestconcentrationsinadrenalglandandthyroid.potentialforaccumulationnoevidence.rateandextentofexcretionexcretionwasrapidwith>80-90%excretionafter24hoursatlowdose,metabolisminanimalsextensivelymetabolised,initialstepviahydroxylation.toxicologicallyrelevantcompounds(animalsandplants)parentonlytoxicologicallyrelevantcompounds(environment)parentonlyacutetoxicity(annexiia,point5.2)ratld50oral>300-500mg/kgbwr22ratld50dermal>5000mg/kgbwratlc50inhalation>0.458mg/l(4hrs,noseonly,highestobtainableconc.skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationsensitising(m+k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectincreaseincidenceoffocalheartfibrosisandanincreaseinuterineweightindogs.relevantoralnoael0.72mg/kgbw/dayt;r48/25?xn;r48/22?relevantdermalnoael>250mg/kgbw(topdose)relevantinhalationnoaelnodataavailablenotrequired.genotoxicity(annexiia,point5.4)..clastogenicinvitro;negativeinvivo,noaneugenicitywasobserved.noconcernforhumanriskassessment.'", "j.efsa.2008.119r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu44of84appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption25%(basedonurinaryexcretionwithin48h)distributionlarge,highestlevelinexcretoryorganspotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion29.1-52.6%viaurine;63-46%viafaeceswithin48hformalesandfemalesrespectivelymetabolisminanimalsquantitativeestimationisnotpossible;nitro-reductionando-demethylationareinvolvedtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwmouseld50oralmale:1540mg/kgbwfemale:1780mg/kgbwxn;r22ratld50dermal>2000mg/kgbwratlc50inhalation>0.91mg/l(wholebody,dustexposure,4h,highestobtainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,bloodrelevantoralnoael1year,dogstudy:145mg/kgbw/dayrelevantdermalnoael28-dayrat:150mg/kgbw/dayrelevantinhalationnoaelnotrelevant-notrequiredgenotoxicity(annexiia,point5.4)..weightofevidencesuggestsnogenotoxicpotential'", "j.efsa.2008.120r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu42of91appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed,butonlytoalimitedextent:~40%,basedonurinaryandbiliaryexcretiondistributionwidelyanduniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive.predominantlyinthefaeces(63-73%),ofwhich15-18%viathebilewithin48h.23-28%intheurine.metabolisminanimalsexcretedlargely(69.5-86.3%)unchangedinthefaecesandurine.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>5.47mg/l(4h,wholebody)-skinirritationnon-irritant-eyeirritationslightirritant(noclassificationrequired)-skinsensitisationweaksensitiser(m&k):noclassificationrequired-shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweightandliver(increasedweightandclinicalchemistry)relevantoralnoael200mg/kgbw/d(dog28-day,90-dayand1-yearstudies)-relevantdermalnoaelnodata-notrequired-relevantinhalationnoaelnodata-notrequired-genotoxicity(annexiia,point5.4)nogenotoxicpotential-'", "j.efsa.2008.122r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu44of84appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption58%(males)/71%(females),basedonurinaryandbiliaryexcretionwithin48h.lowerabsorptionathighdoselevels.moderaterateofabsorption(max.bloodconcentrationtmax6h)distributionpreferentialdistributiontofat,residuesinfatincreasewithtimeover2.5-32hpotentialforaccumulationlongwholebodyeliminationhalf-life(50-60h).residuesinfatincreasewithtime.rateandextentofexcretionapproximately90%eliminationoverseveraldays(62-76%within48h,77-89%within72h,82-92%within96h),mainlyviafaeces(5%viaurine,40-50%inbilewithin48h).metabolisminanimalsextensivelymetabolised,predominantlybyhydroxylationofdifluorophenylring(withorwithoutconjugation).toxicologicallyrelevantcompounds(animalsandplants)diflufenicantoxicologicallyrelevantcompounds(environment)diflufenicanacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>5.12mg/l/4h(wholebody)-skinirritationnon-irritant-eyeirritationslightlyirritating(noclassificationproposed)-skinsensitisationnon-sensitiser(m&k)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgain,liver(hepatocytehypertrophy)relevantoralnoael13weekrat:19.47mg/kgbw/day1yeardog:100mg/kgbw/dayrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2008.124r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu42of84appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionoralabsorption>80%(excretionwithin48h,79%inurine,12%viabile).distributionwidelydistributedpotentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive>82%within48h,mainlyviaurine(77-86%)within24h.metabolisminanimalsextensivelymetabolised(>95%)mainmetabolite2-methyl-2-[4-(2-methyl-3-piperidin-1-yl-propyl)-phenyl]-propionicacid;oxidationreactionsandsulphateconjugation.toxicologicallyrelevantcompounds(animalsandplants)parentcompound,metabolitescga289267andcga289268toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral1452mg/kgbwr22ratld50dermal>4000mg/kgbw--ratlc50inhalation1.22mg/lair/4h(noseonly)r20skinirritationirritantr38eyeirritationirritantr41skinsensitisationsensitiser(maximization,buehler)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectlocalirritation,bodyweight,liver(hypertrophy),spinalchorddemyelination,cornealopacity.relevantoralnoael1yrdog2mg/kgbw/day13weekrat1.14mg/kgbw/dayrelevantdermalnoael21dayrabbit:nonoaelestablishedduetosevereirritation.relevantinhalationnoaelstudyinconclusiveforsystemictoxicity;localirritationofnoseandupperrespiratorytract.r37'", "j.efsa.2008.125r.pdf": "endpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu40of80appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionatleast28%,afterlowdose,48hafteradministration,basedonradiolabelrecoveredfromurine,bile,cagewashandcarcass(rat).atleast4.8%,afterhighdose,48hafteradministration,basedonradiolabelrecoveredfromurine,bile,cagewashandcarcass(rat).distribution24hoursaftersingleorallowdose(10mg/kgbw),highestconcentrationsgi-tractanditscontents;intermediateconcentrationswereinfat,kidneys,liver,lungs,lymphnodesandpancreas.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretionwithin24hca.75%oflowdoseexcretedandca.40%ofhighdose;within120hca.95%excreted,mainlyviafaeces(ca.87%afterlowdose).metabolisminanimalsextensivelymetabolised(noparentcompoundinurine,2%parentcompoundoftotalradiolabelinfaecesand2.5%oftotalradiolabelinbile).toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>0.84mg/l(aerosol,4hexposure,noseonly)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationsensitising(maximisationtest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectbloodrelevantoralnoael5mg/kgbw/day(1-year,dog)relevantdermalnoael200mg/kgbw/day(28-day,rat)relevantinhalationnoaelnodatano", "j.efsa.2008.126r.pdf": "activesubstanceandtherepresentativeformulationendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu31of63appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)inmammals(annexiia,point5.1)rateandextentoforalabsorption70%;basedonurinaryexcretionwithin24hdistributionuniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion>95%excretedwithin72hviaurine(70%)andfaeces(26%)metabolisminanimalsextensivelymetabolised;excretedasmetabolites(mainlym-4)inurineandasunchangedflutolanilinfaecestoxicologicallyrelevantcompounds(animalsandplants)flutolanilandmetabolites(m2andm4)toxicologicallyrelevantcompounds(environment)flutolanilacutetoxicity(annexiia,point5.2)ratld50oral>10,000mg/kgbwratld50dermal>5,000mg/kgbwratlc50inhalation>5.98mg/lair/4h(wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitizing(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectincreasedweightofliver(rat,dog)andthyroid/parathyroid(rat)andhistopathologicalalterationsinliver(dog)relevantoralnoael299mg/kgbw/d(90-drat)80mg/kgbw/d(90-ddog)680mg/kgbw/d(90-dmouse)relevantdermalnoael>1000mg/kgbw/day(21-drat)relevantinhalationnoaelnodataavailable-notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2008.127r.pdf": "tivesubstanceandtherepresentativeformulationendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu43of82appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(<48h)andincomplete(30%)basedonurinaryandcarcass/tissuelevels(20%)within7daysandbiliary(10%)excretionwithin24hdistributionwidelydistributed;slightpreferenceforfat,liver,kidney,bloodpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(77-91%)within48h,mainlyfaecal(73%),18%viaurine,10%viabilemetabolisminanimalsbenfluralinwassubjecttodi-dealkylationandreduction,andfurthermetabolisedintonumerouspolarcompounds,eachpresentat<1%ofthedose.parentcompoundpresentatabout35%.toxicologicallyrelevantcompounds(animalsandplants)benfluralintoxicologicallyrelevantcompounds(environment)benfluralinacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation2.16mg/lair<lc50<5mg/lair/4h(dust,noseonly)skinirritationirritant,basedontherepeateddermalstudiesr38eyeirritationirritantr36skinsensitisationsensitising(m&kandbuehlertest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneytubulepigmentation(),kidneyweightdecrease(rat);liverweightincrease(rat,dog);liver/spleenpigmentation(haemosiderosis?),(dog);rbceffects(rat,dog)relevantoralnoael90-dayrat:17mg/kgbw/day1-year&90-day,dog25mg/kgbw/dayrelevantdermalnoael21-day,rabbit:systemic:500mg/kgbw/day(increasedliverweight);local:<100mg/kgbw/day(skininflammation)'", "j.efsa.2008.128r.pdf": "ctivesubstanceandtherepresentativeformulationendpointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu40of77appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption40%basedonurinaryexcretionwithin24h(2.6%infemalesand5.4%inmales)andbiliaryexcretionwithin24h(38%infemalesand30%inmales).distributionhighestlevelsinurinarybladder,liverandadiposetissues.potentialforaccumulationnoevidenceforaccumulation;rateandextentofexcretionabout90%oftotaldoseeliminatedwithin48h.13-25%oftotaldoseexcretedinurineand60-76%oftotaldoseexcreted/eliminatedinfaeces.metabolisminanimalsextensivelymetabolised,phenylringhydroxylation,oxidationofthet-butylgroupsandthiadiazinringopening;conjugation.toxicologicallyrelevantcompounds(animalsandplants)nni-750andmetabolitestoxicologicallyrelevantcompounds(environment)nni-750acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>4.57mg/lair/4h(wholebody)-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationnon-sensitizer(llna)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(hepatotoxicity),thyroidrelevantoralnoael90-day,dog:10mg/kgbw/day2ydog:2mg/kgbw/day90-dayrat:13mg/kgbw/day-relevantdermalnoael24-day,rat:1000mg/kgbw/day-relevantinhalationnoaelnodata-notrequired-'", "j.efsa.2008.136r.pdf": "intsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu47of71appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapid(<48h)andalmostcomplete(88%)basedonurinaryandbileexcretion.distributionwidelydistributed;slightpreferenceforliver,kidney,adrenalesandbloodpotentialforaccumulationnonerateandextentofexcretionrapid,within48h:88-97%.metabolisminanimalsextensivephaseimetabolisation(hydroxylation)ofthetetrahydrofuraneanddichlorobenzenering,followedbyglucuronideorsulphateconjugation.glucuronideoraminoacidconjugationoftriazolering.noevidenceofphenyl-,thf-ortriazoleringdegradates(onlythfringopening).toxicologicallysignificantcompounds(animals,plantsandenvironment)bromuconazole,ta,taaand1,2,4-triazole.acutetoxicity(annexiia,point5.2)ratld50oral328()mg/kgb.w.(xn;r22)ratld50dermal>2000mg/kgb.w.ratlc50inhalation>5mg/lair(microniseddust,4h-noseonly)skinirritationnotirritanteyeirritationnotirritantskinsensitization(testmethod,result)maximisationtest,nosensitisationshorttermtoxicity(annexiia,point5.3)target/criticaleffect90d/1yrdog:liverweightincrease,increasedalkalinephosphataseandtransaminaseactivity,adrenalcorticalvacuolationlowestrelevantoralnoael/noel2.5mg/kgb.w./day(90-dayand1-yeardog)13.8mg/kgbw/day(90-day,rat)lowestrelevantdermalnoael/noel500mg/kgb.w./day(21-day,rat)lowestrelevantinhalationnoael/noelnotavailable,notrequiredgenotoxicity(annexiia,point5.4)in-vitro:negativebacterial,equivocalmammaliangenotoxicity;weakclastogenicity(cainchocellsandhumanlymphocytes)in-vivo:negativeinudsandbmmicronucleusoverall,nogenotoxicpotential.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectliver(rat,mouse)lowestrelevantnoael/noel0.88-1.09mg/kgb.w./day(2yr-rat)2.27mg/kgb.w./day(80weeksmouse)carcinogenicityhepatocellularcarcinoma(rat,mouse)and'", "j.efsa.2008.137r.pdf": "intidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu45of82appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:rapidbutlimited;35%absorbedbasedonexcretionratesinbileandurinedistribution:liver,fatandkidneyspotentialforaccumulation:noevidenceforaccumulationrateandextentofexcretion:rapid,mainlyviafeces(>84%within24h),alsoviaurine(24%)metabolisminanimalsalmostcompletelymetabolizedbyhydroxylation,followedbyconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundmetabolitetfaa(trifluoroaceticacid)toxicologicallyrelevantcompounds(environment)parentcompoundimpurity5(5-chloro-n-(3-chloro-5-trifluoromethyl-2-pyridyl)-,,-trifluoro-4,6-dinitro-o-toluidine)acutetoxicity(annexiia,point5.2)ratld50oral>4100mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.1mg/lair/4h(noseonly,dustaerosol)xn,r20skinirritationmildlyirritating(noclass.required)eyeirritationseverelyirritatingxi,r41skinsensitisationsensitising(m&k,buehler)xi,r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgain,histopathologicalchangesintheliver(rat,mouseanddog),histopathologicalchangesinthestomach(dog)relevantoralnoael1mg/kgbw/d(52-weekdog)4.1mg/kgbw/d(13-weekrat)relevantdermalnoaelloael10mg/kgbw/d(21-dayrat)xi,r38dermaleffects(acanthosis,dermatitis)atalldosesrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2008.138r.pdf": "intidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu45of80appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,about50%within48h,basedonurinaryandbiliaryexcretionandamountincarcassdistributionwide,highestresiduesinblood,liver,kidneys,spleen,lungandadrenalsafter168h;plasma:auc=15-22gh/g,t1/2=5-6hpotentialforaccumulationnopotentialforaccumulationintissue,butsloweliminationfrombloodrateandextentofexcretion>95%within168h(ca17%viaurineandca78%viafaeces)metabolisminanimalsextensivelymetabolisedwithatleast47metabolitesoccuring;mainpathways:openingoftheoxiranering,hydroxylationandconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolites(1,2,4-triazole,triazolealanin,triazoleaceticacid)toxicologicallyrelevantcompounds(environment)parentcompoundandmetabolites(1,2,4-triazole,triazolealanin,triazoleaceticacid)acutetoxicity(annexiia,point5.2)ratld50oral5000mg/kgbw(m)-ratld50dermal>2000mg/kgbw-ratlc50inhalation>5.3mg/lair(4h,noseonly,highestobtainableconcentration)-skinirritationnotirritant-eyeirritationnotirritant-skinsensitisationnotsensitising(m&ktest)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(increasedorganwt,clinicalchemistry,chronichepatitis);slightanaemiarelevantoralnoael1-yr,dog:1.6mg/kgbw/drelevantdermalnoael21-d,rat:400mg/kgbw/drelevantinhalationnoaelnodata,notnecessarygenotoxicity(annexiia,point5.4)notgenotoxic-'", "j.efsa.2008.139r.pdf": "pointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu43of78appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandextensivelyabsorbed.approximately29-58%excretedinurinewithin24hours(64-78%biliaryexcretionwithin48hourswithsignificantre-absorptionandexcretioninurine).distributionwidespread(highestlevelsinratliverandkidneys).potentialforaccumulationlowbasedonresiduelevelsinrattissuesat7days.rateandextentofexcretionrapidlyeliminatedinexcreta.approximately56-80%ofradioactivitywith24hoursofdosing.metabolisminanimalsthemainpathwayistheoxidationofoneofthemethylgroupsonthephenylringtoformtralkoxydimalcoholwhichisfurtheroxidisedviaanintermediaryaldehydemetabolitetoformtralkoxydimacid.toxicologicallyrelevantcompounds(animalsandplants)parentandtralkoxydimacidtoxicologicallyrelevantcompounds(environment)parent,tralkoxydimacidandmetaboliter173642acutetoxicity(annexiia,point5.2)ratld50oral934mg/kgbwforfemalesr22ratld50dermal>2000mg/kgbwratlc50inhalation>3.5mg/l(noseonly,4hrs);thehighestdosetested.skinirritationmildirritant(classificationnotwarranted)eyeirritationmildirritant(classificationnotwarranted)skinsensitisationnegative(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdogs::liver:increasedweightandenzymeactivities,fattychange,vacuolationandproliferationofser.adrenals:increasedweightandvacuolationofthecortex.testiculareffectsathigherdoselevels.rats:reducedbwgain,clinicalchemistry,reducedkidneyweight,increasedliverweight.relevantoralnoael0.5mg/kgbw/day(90dand1y-dogstudies).20.5mg/kgbw/day(90d-rat)'", "j.efsa.2008.140r.pdf": "ointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu48of74appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%basedonurinary(15%)andbiliary(78%)excretionwithin24h.highestbloodconcentrationafter6hours.distributionuniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(approx.90%)within72h.majorityexcretedwithin24hoursmainlyviaurine(42-52%)and23-34%viafaeces,78%ofdoseviabilewithin24hindicatingextensiveenterohepaticcirculation.metabolisminanimalsextensivelymetabolised(>99%);15metabolitesinurineandfaeces;metabolicpathway:dealkylation,hydroxylation,hydrolysisfollowedbyconjugation.toxicologicallyrelevantcompounds(animalsandplants)parentcompound1-naphtol,o-phthalicacid,1,4-naphtoxyquinone22toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.8mg/lair/4h(nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(modifiedbuehlertests)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver;rat,dog(increasedweight,hepatotoxicity)bodyweightchange;rat,dogrelevantoralnoael1-year,dog:50mg/kgbw/day90-day,rat:50mg/kgbw/dayrelevantdermalnoael30-day,rabbit:>1000mg/kgbw/day22nonpeerreviewedinformationfromtheapplicantafterprapermeetingshowsnogenotoxicityorclassificationastoxicorverytoxicofanyofthe3impurities.rmsconsidersthe3metabolitesnottoxicologicallyrelevant.'", "j.efsa.2008.144r.pdf": "intidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu49of89appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandcompleteabsorption(basedonurinaryandassumedbiliaryexcretion,afterlowdoseapplication)distributionhighestresiduesinliverandfatpotentialforaccumulationnoaccumulatingpotentialrateandextentofexcretionfastandnearlycompleteexcretionwithin96h(30%-52%inurine,40%-55%infaeces,inbilecannulatedanimalsupto80%inbile)metabolisminanimalscompletelymetabolised,oxydationofsidechainandmethylgroups,ringopening,breakdownofmorpholinemoiety,conjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundmetabolitebf421-1toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral1670mg/kgbwr22ratld50dermal>4000mg/kgbwratlc50inhalation2.9<lc50<9.1mg/l(4h,noseonly,aerosol)skinirritationirritantr38eyeirritationnonirritantskinsensitisationnotaskinsensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweightgain,liverweightrelevantoralnoaelrat,90-day:0.7mg/kgbw/drelevantdermalnoaelrat,28-day:2mg/kgbw/d(highestdosegroup)relevantinhalationnoaelrat,28-day:0.01mg/lgenotoxicity(annexiia,point5.4)unlikelytobegenotoxic'", "j.efsa.2008.145r.pdf": "pointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu61of125appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidabsorption(tmax4-8hours);extensivelyabsorbed(85-95%basedonurinaryandbiliaryexcretion.distributionrapidlyandextensivelydistributed;highestlevelsassociatedwithredbloodcellsduetobinding.potentialforaccumulationlimitedevidence(bloodcells)rateandextentofexcretionrapidlyexcreted(~80%within24hours),inurine(~30-40%)andbile(~50-60%).metabolisminanimalsextensivemetabolismbyanumberofroutes;theinitialstepinthemajorrouteisformationofglutathioneconjugation.noevidenceofcleavage.toxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)metazachlormetabolitesm4,m8,m9,m11,m12**basedontheproposedclassificationofmetazachlorasr40,tobediscussedattheechaacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>34.5mg/l(noseonly/4h)-skinirritationsomeevidenceofirritation(basf)non-irritant(fsg).-eyeirritationminimaltoslightirritation.-skinsensitisationstrongsensitiser(m&k;basf)noevidenceofsensitisation(oet/buehler;fsg)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(adaptivechangesatlowdoselevels);redbloodcell(mildanaemia)intherat.increasedliverandkidneyweightsinthemouse.liverandkidney(increasedweights)andredbloodcellinthedog.relevantoralnoael90-dayrat:110mg/kgbw/d(basf)90-dayrat:21mg/kgbw/d(fgs)90-daydog(gav):90mg/kgbw/d(basf)90-daydog:48mg/kgbw/d(fgs)1-ydog:29mg/kgbw/d(basf)relevantdermalnoael1000mg/kgbw/d(28-dayrat);basfrelevantinhalationnoaelnotrequired'", "j.efsa.2008.146r.pdf": "ointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu39of73appendix1.3impactonhumanandanimalhealthallvaluesinthissectionarereportedasmepiquatchlorideandmaybeexpressedasmepiquationbymultiplyingbyafactorof0.77absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed.bioavailabilityafteranoraldoseof12mg/kgbwwasapproximately85%distributionextensivelydistributedintoorgansandtissues.peaklevelsinbloodwithin40minutesafteranoraldosepotentialforaccumulationlow.rateandextentofexcretionrapidlyeliminatedmostlyinurine,approximately70%waseliminatedwithin12hafteranoraldose.excretioninbothfaecesandurineamountedto80-90%oftheadministereddoseafteronedayandwasmostly>90%after2days.metabolisminanimalsnoevidenceofmetabolismwasobservedinrats.however,afterarelativelylargedose,conjugatesof4-hydroxymepiquatchloridewereobservedinliverandmilkoflactatinggoats.toxicologicallyrelevantcompounds(animalsandplants)parentmepiquatchloridetoxicologicallyrelevantcompounds(environment)parentmepiquatchlorideacutetoxicity(annexiia,point5.2)ratld50oral464mg/kgbw(270mgai/kgbw)formalesand200464mg/kgbwinfemales).combined:464mg/kgbw(270mgai/kgbw).noclearsexdifferences.classifiedwithr22harmfulifswallowed.r22ratld50dermal>2,000mg/kgbw(testsubstance)=>1,160mga.s./kgbwratlc50inhalation>4.89mg/l(testsubstance)>2.84mga.s./latmaximumattainableconcentration.mortalities(2/5inmalesand1/4infemales)suggeststhatatlimitdoseforclassificationof5mg/lmortalityof>50%couldbeexpectedformales,henceproposaltoclassifywithr20harmfulbyinhalation.r20skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitisingtoskin(landsteiner-draizemethod;includesanon-adjuvantintradermalinductionexposure)'", "j.efsa.2008.147r.pdf": "ointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu52of106appendix1.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionmaximumbloodconcentrationwithin4-8h.approximately86%oforaldoseisabsorbed(basedonurinaryexcretionafteroralorintravenousadministration).distributiondistributedthroughoutallmajororgansandtissuespotentialforaccumulationnopotentialforaccumulationuponrepeatedoraladministrationrateandextentofexcretionrapidlyeliminated,almostexclusivelyvianon-biliaryexcretionbackintotheintestineandeliminatedwiththefaeces.metabolisminanimalsmajorpathwaysincludedemethylation,hydroxylation,cleavageoftheoleandrosylringandoxidationreactions.toxicologicallyrelevantcompounds(animalsandplants)parentand8,9-zisomerofavermectinb1a(photodegradationproduct)toxicologicallyrelevantcompounds(environment)parentand8,9-zisomerofavermectinb1a(photodegradationproduct)acutetoxicity(annexiia,point5.2)ratld50oral8.7mg/kgbw(oilvehicle)r28ratld50dermal>330mg/kgbw(highestdosetested);>2000mg/kgbw(rabbit)ratlc50inhalation0.034mg/l<lc50<0.051mg/l(4h;noseonly)r26skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnon-sensitizing(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffecttremors,ataxiaandmydriasis,liver,absentordecreasedpupilreflexrelevantoralnoael0.25mg/kgbw/day(18-wand53-w,dog)r48/25relevantdermalnoaelnodatanotrequiredrelevantinhalationnoael0.577g/l(30-d,rat)'", "j.efsa.2008.148r.pdf": "intidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu66of120appendix1.3.impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive(>92%),basedonurinaryandbiliaryexcretionandtissueresidues.distributionwidelydistributed,highestresiduesafter48hrfoundinliver,kidney,lungandskinpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandvirtuallycomplete(7375%inurinewithin48hr,20-25%infaeces,);biliaryexcretionofupto36%suggestingsignificantenterohepaticcirculationmetabolisminanimalsextensivewithatleast16metabolitesoccurring;mainpathways:oxidativecleavagewithsubsequentconjugationandhydroxylationoftheimidazolidineringtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandimidaclopridnitrosimine(m07)toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral~500mg/kgbwmouseld50oral131mg/kgbwt;r25ratld50dermal>5000mg/kgbwratlc50inhalation>0.069mg/l(aerosol)>5.33mg/l(dust)(4-hnose-onlyexposure,maximumtechnicallyattainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgaininrodentsanddogs;liver(clinicalchemistryandhistopathologicalfindings)inrats;cns(tremblingandtremors)indogsrelevantoralnoael9.3mg/kgbw/day(90-d,ratneurotoxicitystudy)8mg/kgbw/day(28dayand90-day,dog)'", "j.efsa.2008.149r.pdf": "/www.efsa.europa.eu41of80chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(approx.80%within24h,basedonurinaryandbiliaryexcretion;lowerabsorptionathighdoselevel)distributionwidelydistributed.afterrepeatedoraldosing(14d)mainlyfoundinliver,kidney,lung,thyroidandskin/furpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionnearlycomplete(within48h);39-65%infemales38-50%inmalesviaurine,mostoftheremainingmaterialviafaecesmetabolisminanimalsextensive,mainpathways:hydroxylationofthephenylring,cleavageoftheetherbond,reductionofthenitrogroupandsubsequentacetylation,methylation,andphaseiitypeconjugationtoxicologicallyrelevantcompounds(animalsandplants)aclonifentoxicologicallyrelevantcompounds(environment)aclonifenacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.06mg/l/4h,nose-onlyskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneyandliver:organweight,clinicalchemistrychanges,macroscopicalandhistologicalfindingsindicativeofkidneydamage(rat:,nephrosis,nephritis,necrosis);bwrelevantoralnoael3.6mg/kgbw/day,(90-d,rat)15mg/kgbw/day(26-week,dog)relevantdermalnoael500mg/kgbw/day(28-d,rat,5daysapplicationperweek)relevantinhalationnoaelnodataavailable,notrequired'", "j.efsa.2008.150r.pdf": "/www.efsa.europa.eu41of86impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandcomplete(8292%within24hours,basedonurinaryexcretionandintravenous/oralcomparison)distributionpoorpenetrationintotissues,higherconcentrationsonlyinliverandkidneypotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionnearlycompleteafter96hours,mainlyintheurine(>90%)metabolisminanimalsgenerallylimited(<10%ofdose)withtheexceptionofmoreextensive(>30%)metabolisminrateyes;mainpathways:hydroxylation,hydrolysistoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandcmba(aplantandsoilmetaboliteoccurringinthewholeratorganismonlyintracesof<1%buttoaratherlargeamountintheeyes)toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwrabbitld50dermal>4000mg/kgbwratlc50inhalation>1.63mg/l(highesttechnicallyavailableconcentration,4-hour,nose-onlyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffecteyedamage(cornealopacity,keratitis),liverandkidneyeffectsrelevantoralnoael90-day,rat:3.3mg/kgbw/day90-day/1-year,dog(overallnoael):50mg/kgbw/dayrelevantdermalnoael28-day,rat:1000mg/kgbw/dayrelevantinhalationnoaelnodata,notrequired'", "j.efsa.2008.151r.pdf": "//www.efsa.europa.eu36of62chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>60%basedonurinaryexcretionwithin72hoursand>25%basedonbiliaryexcretionwithin24hours,inseparatestudiesdistributionuniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionurinaryandfaecalexcretionaccountedfor95.5-99.8%ofadministereddosewithin7days;61.6-74.7%appearedinurine.metabolisminanimalsextensivelymetabolized.lessthan2.5%ofradioactivityappearedintheurineandfaecesasunchangedparent.twelveprimarymetaboliteswereidentified,themostabundantaccountingfor10-20%ofadministereddoseandappearingprimarilyasaurinarymetabolite.othermetabolitesindividuallyaccountedforlessthan6%oftheradioactivity.oxidationanddehydrationreactions.toxicologicallyrelevantcompounds(animalsandplants)flurprimidolandmetabolitestoxicologicallyrelevantcompounds(environment)flurprimidolandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral709mg/kgbwr22rabbitld50dermal>5000mg/kgbwratlc50inhalation>5.231mg/lair/4h(nose-only,air-milledsample)skinirritationslightlyirritatingeyeirritationslightlyirritatingskinsensitisationnon-sensitiser(m&k)'", "j.efsa.2008.152r.pdf": "/www.efsa.europa.eu52of86chapter2.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionmorethan80ofabsorptionintheratwithin16-18hoursbasedonurinaryexcretion(repeateddose).distributionhighestconcentrationingastrointestinaltract,liver,muscleandfat(16-18h)potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionapprox.95%within24hmainlyviaurine(72.9%).morethan99%within72hmainlyviaurine(75.8%)metabolisminanimalsextensivelymetabolised(approx84%),byoxidation/hydrolysis,cleavageoftriazole-phenylringbridge,glutationeconjugation.mainmetabolites:m14360-acid;m14360-alcohol;1,2,4-triazole;p1andp4,fluorine.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral1031mg/kgbwr22ratld50dermal>2000mg/kgratld50inhalation>3.66mg/l(maximumattainableconcentration,4hrswholebody)skinirritationnonirritant(rabbit)eyeirritationnonirritant(rabbit)skinsensitisation(testmethodusedandresults)nonsensitising(guineapig-buehlertest)nonsensitising(guineapig-maximisationtest)short-termtoxicity(annexiia,point5.3)target/criticaleffectliver/adaptivemodificationssecondarytocytochromep450dependentenzymaticactivitiesinductionlowestrelevantoralnoael4.10mg/kgbw/d(13wkrat)2.95mg/kgbw/d(1-yeardog)lowestrelevantdermalnoael240mg/kgbw/d(21-daydermalrabbit)performedwiththeformulationandcorrectedforcontentofa.s..lowestrelevantinhalationnoaelnotdata,notrequired.'", "j.efsa.2008.153r.pdf": "pointsidentifiedbyeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu66of130appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandalmostcomplete,basedonurineandbileexcretion(>80%)inratat10mg/kgbw/day,repeateddose.distributionwidelydistributed.potentialforaccumulationnoevidencerateandextentofexcretionrelativelyrapid(48h:85.85-86.47%inmale-females).inurine,61.75-71.05%andinfaeces,24.-15.42%inmale-femaleratsat10mg/kgbw/day,repeateddose.metabolisminanimalsacetochlorundergoesconjugationandmixedfunctionoxygenation.themainmetaboliteidentifiedinratandmonkeywasthetert-mercatpturicacidwith25-27%oftheradioactivityexcretedinmonkeyurinetoxicologicallyrelevantcompounds(animalsandplants)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oral1929mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation3.99mg/l/4hexposurenose-only.testmaterial:aerosolr20skinirritationirritantr38eyeirritationnon-irritantskinsensitisationsensitising;modifiedbuehlertestandgpmtofmagnussonandkligmanr43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneyandtestes,histopathologicalalterations(dog)relevantoralnoael2mg/kgbw/day(1-yeardog)r48/22?relevantdermalnoael400mg/kgbw/d(21-dayrabbit)'", "j.efsa.2008.167r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(tmax0.53hinplasma)butincomplete75%within48h(basedonurinaryandbiliaryexcretion+carcass)aftersinglelowdoseinratsdistributionwidelydistributed;highestresiduesinliverandkidneyspotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(>80%)within48h,mainlyviaurine(6070%)metabolisminanimalsextensivelymetabolised(>95%);allmetabolitesidentifiedareintermediatesleadingtotheformationofglycineusedforincorporationandconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundandin-kq960(identifiedbyefsa)acutetoxicity(annexiia,point5.2)ratld50oral960mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation>5.6mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationslightlyirritating(noclassificationrequired)skinsensitisationsensitsing(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffecttestes(organweight,macroscopicandmicroscopicchanges),epididymides(macroscopicandmicroscopicchanges),liver(organweight,histology),kidney(organweight)andthymus(histology)r48/22relevantoralnoael1-yeardog:1.3mg/kgbw/day90-dayrat:6.5mg/kgbw/day90-daymouse:84.4mg/kgbw/day'", "j.efsa.2008.168r.pdf": "ssionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu49of94impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionquantitativelyadsorbed(greaterthan97%ofthedosewithin72hours)andrapid(94-97%ofthetotalurinaryexcretedradioactivitywithin24hours)forthesinglelowdoselevel.distributionwidelyanduniformlydistributed.potentialforaccumulationnopotential.rateandextentofexcretiontheexcretionwasrapidprimarilyviaurine(94-97%ofthedose)within24hours.noradioactivitywasdetectedintheexpiredair.totalradioactivityrecoverieswere>97%oftheadministereddose.metabolisminanimalsthemajorpartoftheexcretedradioactivitywasattributedtotheparentcompound(greaterthan80%oftheradioactivityexcreted).metabolites,methyl-cyromazine,hydroxy-cyromazineandmelaminewerealsopresent,eachrepresentinglessthan5%ofthedose.toxicologicallyrelevantcompounds(animalsandplants)parentcompound.toxicologicallyrelevantcompounds(environment)parentcompound.acutetoxicity(annexiia,point5.2)ratld50oral3387mg/kgbwrabbitld50dermal>3100mg/kgbwratlc50inhalation>3.6mg/lair/4h.noseonly,maximumattainableconcentrationskinirritationslightlyirritanteyeirritationnon-irritantskinsensitisationnon-sensitizer(m&ktest)'", "j.efsa.2008.169r.pdf": "sionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu49of111impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption>94%(basedonurinaryandbiliaryexcretionandtissueresidueswithin168h)distributioninitiallywidelydistributed;highestresiduesinhighlyperfusedorgans(lungs,heart,kidneys,liver,spleen)potentialforaccumulationaccumulationduetothebindingofdimethachlortotherathaemoglobinmolecule(ratspecific)rateandextentofexcretion>91%within168h,mainlyviaurine(44.14%male;59.79%female)andviafaeces(47.07%male,30.95%female)metabolisminanimalsalmostcompletelymetabolized;majormetabolicreactionsweretheo-dealkylationleadingtoo-desmethylderivatives,thesubstitutionofthechlorineglutathione,andtheoxidationofthemethyl-phenylgroupresultinginhydroxy-methylderivatives,conjugationwithglucuronicacidorglutathionefollowedbydegradation,neitherfreeanilinederivativesnorsulfateesterofthep-hydroxylatedanilineweredetectabletoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundpotentialgroundwatermetabolitescga50266,cga354742,cga373464,cga369873,cga373464,syn528702,syn530561andcga102935acutetoxicity(annexiia,point5.2)ratld50oral1600mg/kgbw(xn-r22)ratld50dermal>2000mg/kgbwratlc50inhalation>4.45mg/l(nose-only,4h,aerosol)skinirritationnonirritatingeyeirritationnonirritatingskinsensitisation(testmethodusedandresult)sensitising(maximisationtest)r43'", "j.efsa.2008.170r.pdf": "issionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu33of60chapter2.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextentofabsorption:ca40%basedonurine(ca25%),exhaledair(ca10%)andbody(ca4%)within24hat10mg/kgbw.plasmapeakconcentrationafter6-8hat10mg/kgbwdistributionuniformlydistributed,slightlyincreasedlevelsintheliverpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(>90%within24h,atlowdose(10mg/kgbw).slowerathighdose(1000mg/kgbw).excretioninurine(40%)andinfeces(60%,possiblypartlyviabile).metabolisminanimalsextensivelymetabolised.nododemorphacetateisexcretedinurine,lowpercentageofdodemorphacetateexcretedinfeces.metabolitesareverypolar.nometaboliteshavebeenidentified.toxicologicallyrelevantcompounds(animalsandplants)dodemorphtoxicologicallyrelevantcompounds(environment)dodemorphacutetoxicity(annexiia,point5.2)ratld50oral>4100mg/kgbw(dodemorphacetate>4920mg/kgbw)ratld50dermal>1640mg/kgbw(dodemorphacetate>2000mg/kgbw)ratlc50inhalationnodata,notnecessary.corrosivecompoundr37skinirritationcorrosivec,r34eyeirritationcorrosivec,r34skinsensitisationsensitizing(gpmt)r43'", "j.efsa.2008.176r.pdf": "endpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu53of109impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>98%(basedonurinary(7.4%)andbiliary(90.9%)excretionwithin48hours)distributionwidelydistributed,highestconcentrationsinkidneyandliverpotentialforaccumulationnopotentialrateandextentofexcretionrapidandextensively.65-80%viafaecesand16-35%viaurinemetabolisminanimalsextensivelymetabolisedbyphase-1oxidationandphase-2conjugationtoxicologicallyrelevantcompounds(animalsandplants)parentandtriazolemetabolitestoxicologicallyrelevantcompounds(environment)parentandtriazolemetabolitesacutetoxicity(annexiia,point5.2)ratld50oral1700mg/kgbw(f)r22ratld50dermal>2000mg/kgbwratlc50inhalation>5.093mg/l(noseonly,4h)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectadrenals/hypertrophyofzonafasciculatecells(dogs)liverbloodsystemandadrenals(rats)relevantoralnoael3mg/kgbw/day(1yeardog)9mg/kgbw/day(90dayrat)relevantdermalnoael1000mg/kgbw/day(3we", "j.efsa.2008.177r.pdf": "//www.efsa.europa.eu61of134impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%(basedonurinaryandbiliaryexcretionwithin24hours).maximalconcentrationinplasmaat1hourafteradministration.distributionwidelydistributed.highestpeakconcentrationsinfat,urinarybladderandliver(rapideliminationfromallorgansandtissues).potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensive(>95%)within24hours,mainlyviabile(>90%)inmales.urineisasignificantrouteofexcretioninfemales(50%);nobiledataforfemales.metabolisminanimalsextensivelymetabolised(>85%)bystepwiseoxidations;mainmetabolitestriadimenol-carboxy(60%)andtriadimenol-hydroxy(20%).toxicologicallyrelevantcompounds(animalsandplants)parentcompound1,2,4-triazole,triazoleaceticacid,triazolealanine36toxicologicallyrelevantcompounds(environment)parentcompound1,2,4-triazole,triazoleaceticacid,triazolealanine37acutetoxicity(annexiia,point5.2)ratld50oral689-752mg/kgbwr22ratld50dermal>5000mg/kgbwratlc50inhalation>0.954mg/l/4h(noseonly;aerosol;max.attainableconcentration)skinirritationnon-irritanteyeirritationslightlyirritating(noclassificationproposed)skinsensitisationnon-sensitiser(magnusson&kligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(liverweight,enzymeinduction,clinicalchemistryeffects)relevantoralnoael90dayrat:8-9mg/kgbw/day)90day&2yeardog:15mg/kgbw/day)relevantdermalnoael21dayrabbit:250mg/kgbw/day(15exposures)36notreportedbecausenoradiolabeldataforthetriazolering37notreportedbecausenoradiolabeldataforthetriazolering'", "j.efsa.2008.180r.pdf": "ointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu30of50impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive>90%(basedon24hourrenalexcretionfollowingoralandintravenousadministrationof10mgdcbme/kgbw)distributioninitiallywidelydistributed;highestresiduesinhighlyperfusedorganspotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandcomplete(>99%renallywithin7dayspost-doseforsinglelowdose)metabolisminanimalscompletelymetabolised;majormetabolite(60-80%)2,5-dichloro-benzoicacid(m11.7);conjugationproducts:2,5-dichlorobenzoylglycine(m7.2)andthreeacylglucuronides(m5.8,m5.0,m6.5)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundand2,5-dichloro-benzoicacid(m11.7)toxicologicallyrelevantcompounds(environment)noexposureacutetoxicity(annexiia,point5.2)ratld50oral1030mg/kgbwxnr22ratld50dermal10000mg/kgbwratlc50inhalationnodata,reportedtobenottechnicallyachievableskinirritationnotirritatingeyeirritationtransientlyirritatingat10%dilutionxir36skinsensitisationnotsensitising(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffecteffectsinneurologicalscreeningfromday1onwards,slightanaemia,increasedliverandkidneyweight,fattyinfiltrationintheheart,oligospermiarelevantoralnoael28-dayrat:100mg/kgbw/day'", "j.efsa.2008.183r.pdf": "/www.efsa.europa.eu31of59impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionreadyabsorptionofphosphinethroughthelungsandafteroralexposuretozincphosphidedistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionexcretionwithurineashypophosphiteandphosphiteandvialungsasphosphinemetabolisminanimalshydrolysistophosphine,oxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)phosphinetoxicologicallyrelevantcompounds(environment)phosphineacutetoxicity(annexiia,point5.2)ratld50oral8.7mg/kgbw(aluminiumphosphide)t+;r28ratld50dermalca.460-900mg/kgbw(aluminiumphosphide)xn;r21ratlc50inhalation>11ppm(>0.015mgph3/lairor>2.8mg/kgbw)51ppm(0.072mgph3/lair)(4hexposure,wholebody)(phosphine)t+;r26skinirritationnoinformation,basedoncalciumhydroxidethereisskinirritationpotentialxi;r38eyeirritationnoinformation,basedoncalciumhydroxidethereiseyeirritationpotentialxi;r41skinsensitisationnoindicationofskinsensitisation(buehler-test,3inductionsusingaproductcontaining56%w/waluminiumphosphideandm&k-testusingzincphosphide)shorttermtoxicity(annexiia,point5.3)target/criticaleffectmortalityrelevantoralnoaelnoreliabledata,nostudyrequired'", "j.efsa.2008.185r.pdf": "/www.efsa.europa.eu42of95impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidly(peakplasmalevelsareattained20-40minutesafteralowdoseandslightlyhigher1-8hafterahighdose.)andalmostcompletelyabsorbed(91-105%inbilecannulationstudies)34-56%inurineand55-65%inbiledistributionrapidlydistributedevenlybetweenbloodandvariousorgans,withthehighestconcentrationsinliverandkidneyspotentialforaccumulationnoevidenceofanytissueaccumulationrateandextentofexcretionrapid>90%over48hoursmetabolisminanimalsmetamitronisextensivelyandrapidlymetabolisedwithafastinitialdesamination,followedbyseveralhydroxylation,conjugationandoxidationreactions;onlysmallamountsofmetamitron(<4.3%)isrecoveredinexcreta.majormetabolitesinurineandfaecesweremetamitron-triazinium-acetic-acid,metamitron-4-hydroxy-desamino,metamitron-3-hydroxy-desaminoandmetamitron-desamino;toxicologicallyrelevantcompounds(animalsandplants)metamitrontoxicologicallyrelevantcompounds(environment)metamitronacutetoxicity(annexiia,point5.2)ratld50oral1183mg/kgbwr22ratld50dermal>5000mg/kgbwratlc50inhalation3.17mg/l(4hours,noseonly)r20skinirritationnotirritatingtoskineyeirritationnotirritatingtoeyesskinsensitisationnotsensitisingtoskin(m&k)'", "j.efsa.2008.187r.pdf": "/www.efsa.europa.eu59of101impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorption36%inhumanonacopperadequatediet56%(lowcopperdiet)12%(highcopperdiet)similarabsorptioninrats:50%distributionwidelydistributed,theliverbeingtheregulationorgan;copperisboundtoceruloplasminpotentialforaccumulationnopotentialforaccumulation,exceptincasesofgeneticdiseaseorchronicadministrationofhighdose(60mg/person/day),wherecopperaccumulatesintheliverrateandextentofexcretionrapidlyexcreted(>90%)within48hours.terminalhalf/lifeinratof10.1hours.excretionviathebile.noentero-hepaticcirculationoccurs.excretionmainlyboundtometallothioneinsoftheintestinalbrushborderandlostinfaeces.minoramountsinurineandfromskinandhair.metabolisminanimalsdoesnotoccur;copperisamonoatomicionandcannotbemetabolizedtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)copperhydroxide:4891280mg/kgbwr22copperoxychloride:rat:9501862mg/kgbwmouse:299mg/kgbwr22bordeauxmixture:>2000mg/kgbwtribasiccoppersulphate:300500mg/kgbwr22ratld50oralcopper(i)oxide:300500mg/kgbwr22'/www.efsa.europa.eu60of101ratld50dermalcopperhydroxide,copperoxychloride,bordeauxmixture,tribasiccoppersulphate,copper(i)oxide:>2000mg/kgbwcopperhydroxide:0.50mg/lair/4h(wholebody)r23copperoxychloride:2.83mg/lair/4h(noseonly)r20bordeauxmixture:1.97mg/lair/4h(wholebody)r20tribasiccoppersulphate:technicallynotfeasibleratlc50inhalationcopper(i)oxide:2.92mg/lair/4h(noseonly)r20skinirritationslightlyirritantcopperhydroxide:severelyirritantr41copperoxychloride:slightlyirritantbordeauxmixture:severelyirritantr41tribasiccoppersulphate:notirritanteyeirritationcopper(i)oxide:slightlyirritantskinsensitisationcopperhydroxide,copperoxychloride,bordeauxmixture,tribasiccoppersulphate,copper(i)oxide:notsensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney:proteinsdropletsinepithelialcellsoftheproximalconvolutedtubulesinrats.stomach:hyperplasiaandhyperkeratosisofthesquamousmucosaofthelimitingridgeseparatingforestomachandglandularstomachinratsandmice.liver:inflammationinratsblood:haematologicalchanges(increaseinhct,hgb,plateletscountandrbc)inrats.relevantoralnoael90-dayrat:16mgcu/kgbw/day90-daymouse:97mgcu/kgbw/day1-yeardog:15mgcu/kgbw/day(testsubstance:coppergluconate)'", "j.efsa.2008.197r.pdf": "nasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu52of104appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionapproximately60%,basedonexcretionviabile(47-55%)andurine(5-10%)within48hoursdistributionwidelydistributed,thehighestamountsofradioactivitywerefoundinthegastrointestinaltract,liver,fatandkidney;168hafteradministrationtissueresiduesbelowlimitofdetectionpotentialforaccumulationnonerateandextentofexcretion168hafteradministrationof2mg/kgbwtheextentofexcretionamountedto70-85%viafaecesand12-18%viaurine,eliminationhalflive6.1-8.9h,delayedeliminationofhighdose(400mg/kgbw),alowdosewasexcretedmorerapidlyinmales,ahighdosemorerapidlyinfemales.metabolisminanimalsintensivelymetabolised:cleavageofthebenzylmoietyfromthepyrazoleringwithfurtheroxidation,oximehydrolysis,esterhydrolysis,otherpathwaysofmetabolismwere4-hydroxylationofthe5-phenoxyringandoxidationofthet-butylmoietytoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitem1toxicologicallyrelevantcompounds(environment)parentcompoundandmetabolitem1acutetoxicity(annexiia,point5.2)ratld50oral245mg/kgbw(f),480mg/kgbw(m)r22ratld50dermal>2000mg/kgbwratlc50inhalation0.21mg/lair(m),0.33mg/lair(f)(noseonly,4h)t+,r26skinirritationnotirritatingeyeirritationirritating(basedonhumanexperience)r36skinsensitisationsensitising(m&-ktest)r43shorttermtoxicity(annexiia,point5.3)'", "j.efsa.2009.1326.pdf": null, "j.efsa.2009.1341.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandcomplete,basedonurinary,faecalandco2excretioninratandmouse,accounting>90%doseafter48hofsingleoraladministrationof1and50mg/kgand1and100mg/kg,respectively.inhalationroute:rat:>73-79%human:cis-isomer:72-80%andtransisomer:77-82%within15minaftercessationofexposure(basedonexpiredairconcentrations)distributionat48hourspost-dosing,practicallyeliminated.about6%ofthedoseremainedintissuesandcarcassofrat,inwhichhighestvalueswerefoundinnon-glandularstomach,glandularstomach,bladder,liverandkidneys.potentialforaccumulationnoevidenceofaccumulationinratsorhumansrateandextentofexcretionoraladministrationinrat(50mg/kg):93.5%eliminatedwithin48h,mainlyviaurine(61.3%),faeces(17.1%)andco2(15.1%).inhalationrouteinhuman:89-99%within24h.mainlyviaurine(cisisomer-75%,trans-isomer-25%)biphasicexcretion.half-lives:cis-isomer:phase1-4.2h;phase2-12.3h;trans-isomer:phase1-3.2h;phase2-17.1hmetabolisminanimalsextensivelymetabolised.themajorroutewasglutathione-conjugation.thehydrolysiswasasecondrouteaffordingdimercapturateandco2andtheminorroutewastheepoxidationofdcpordcp-glutathione.threemainmetabolites:dimercapturate,c-3-chloroallylalcoholandc-3-chloroacrylicacid.basedonindirectevidenceofmutagenesisstudy,epoxidescouldbeformed.toxicologicallyrelevantcompounds(animalsandplants)1,3-dichloropropene.themetabolitesc-3-chloroallylalcoholandc-3-chloroacrylicacid.toxicologicallyrelevantcompounds(environment)1,3-dichloropropene.themetabolitesc-3-chloroallylalcoholandc-3-chloroacrylicacid.acutetoxicity(annexiia,point5.2)ratld50oral110mg/kgbwr25ratld50dermal1200mg/kgbw333mg/kgbw(rabbit)r24ratlc50inhalation2.70mg/lair/4h(wholebody,vapourexposure)r20skinirritationirritantr38'eyeirritationirritantr36skinsensitisationsensitising(buehlertest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectstomach(rat,hyperkeratosisandbasalcellshyperplasia),liver(miceandrat,hepatotoxicity),decreasedbodyweight(dog,mouse)nasalcavity(ratandmice,inhalationexposure,hyperplasiaofrespiratoryepithelium)andurinarybladder(mice,females).hypochromicandmicrocyticanaemiaindogs.relevantoralnoael5mg/kgbw/day(90-dayrat)150mg/kgbw/day(mouse)2.5mg/kgbw/day(1-yeardog)relevantdermalnoaelnodata-notrequiredrelevantinhalationnoael0.046mg/l(10ppm)i.e.9.72mg/kg/day(rat,13-week)genotoxicity(annexiia,point5.4)somestudiesshowclearindicationsfordnafragmentationinvivo;negativeresultsaredemonstratedinmicronucleus,udsanddominantlethaltests.notclassifiedbythetechnicalcommitteeforclassificationandlabelling(31statp)longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectdepressionofinlifebodyweights(ratsandmice)basalcellhyperplasiaofthenon-glandularmucosaofstomach,fociofalteredcellsintheliver(rats).hyperplasiaoftheurinarybladder,hyperplasticchangesoftherespiratoryepithelium(mice).relevantnoael2.5mg/kgbw/day(2-yeardietary,rat)7.69mg/kgbw/day(2-yearinhalationstudy,mouse)carcinogenicitybenignlungtumoursat60ppmandsubmucosalmesenchymaltumoursintheurinarybladderat25mg/kgbw/day(inmice).hepatocellularadenomainliver(inrats)at25mg/kgbw/day.notclassifiedbythetechnicalcommitteefor'", "j.efsa.2009.1348.pdf": "ionasrelevantformemberstateswhenapplyingtheuniformprinciples58efsajournal2009;7(10):13481.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensiveinallspeciestested,includinghumans(>80%).distributionprimarilybloodandliverpotentialforaccumulationnonerateandextentofexcretionspeciesandsexdependent.inrats,excretionwasmainlyviaurineinfemalesandfaecesinmalesandfasterinfemalesthanmales.indogsexcretionwasmainlyviafaecescomparedwithurineformonkeysandhumans.metabolisminanimalslimitedtoesterhydrolysis/acidconjugation.toxicologicallysignificantcompounds(animals,plantsandenvironment)haloxyfop-pacutetoxicity(annexiia,point5.2)ratld50oral300mg/kgbwxn;r22ratld50dermal>2000mg/kgbwratlc50inhalationnodatanotrequiredskinirritationnonirritanteyeirritationirritatingtoeyes(haloxyfop-p)nonirritant(haloxyfop-rmethylester)xi;r41skinsensitization(testmethodusedandresult)non-sensitiser(buehlerandm&ktests)shorttermtoxicity(annexiia,point5.3)target/criticaleffectratandmice:liverandkidney,andrbc.dogandmonkey:liver,thyroid,kidney,serumcholesterol.lowestrelevantoralnoael/noel0.2mg/kgbw/day16-daystudyinrat0.2mg/kgbw/day,90-daystudiesindogandmonkeyeffectsat2mg/kgbw/day0.5mg/kgbw/day,oneyeardogstudylowestrelevantdermalnoael/noelnodata'", "j.efsa.2009.1350.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption83-84%within24h(c.60%inbile,c.20%inurine)inbiliarycannulationexperimentdistributionwidelydistributed.atplasmatmax(ieat5-7h)afterasingleoraldoseof1mg/kgbw,highestlevelsinliver,kidneys,adrenalandfat.similarfindings4-6hafterthelastof7dailydosesof1mg/kgbwpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensiveat1and20mg/kgbw(85-88%ofdosewithin48h;43-56%ofdoseinurineand31-43%doseinfaeceswithin48h).biliaryexcretionwasextensive.metabolisminanimalsextensivelymetabolised(>98%);themajormetabolicreactionswerephenylringhydroxylationandhydroxylationatthepropylandpropoxysidechains,aswellassomehydrolysisofsidechainstoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)nometabolitesarepredictedtooccuringroundwaterat>0.1g/lnoimpuritiesappeartobeofcleartoxicologicalconcern.acutetoxicity(annexiia,point5.2)ratld50oral4846mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.2mg/lair/4h(noseonlyexposuretoproquinazidasairbornedust)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(magnussonandkligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectthyroid(hypertrophyandhormonechanges):ratincreasedliverweightandoculardischarge:dogrelevantoralnoael90drat:30ppm(2mg/kgbw/d)1ydog:<15mg/kgbw/d'", "j.efsa.2009.1354.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionhighbioavailability(>70%)within24hdistributionlarge,highestlevelinexcretoryorgansandcarcasspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandextensive(app.90%)within24hmainlyviaurine(63-78%)metabolisminanimalsextensivemetabolism(>80%):hydrolysisatc-7toformcarbofuran-7-phenolandatn-stoformcarbofurananddibutylamine.carbofuran-7-phenolandcarbofuranareoxidizedatc-3generating3-oh-metabolites.dibutylamineisoxidizedtoco2andvolatiles.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolites(carbofuranandcarbamatemetabolitesofcarbofuran)toxicologicallyrelevantcompounds(environment)parentcompound(carbosulfan),carbofuran,3-oh-carbofuran,3-keto-carbofuranacutetoxicity(annexiia,point5.2)ratld50oralrat:101mg/kgbw();180mg/kgbw()rabbit:42.7mg/kgbwt,r25ratld50dermal3700mg/kgbwratlc50inhalation0.61mg/lair/1h(wholebody,aerosolexposure=164mg/kgbw)t,r23skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(guineapigpatchtest)r43'", "j.efsa.2009.1390.pdf": "impactonhumanandanimalhealthalldoselevelslistedbelowrefertopicloram(becausesomestudieshavebeenconductedwithsaltsofpicloram)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandextensivelyabsorbed;cmaxattainedwithin5minutes.oralabsorption>80%(basedonurinaryexcretionandbiliarycontribution).distributionrapidandextensivedistribution;tissuelevelslowduetotherapidurinaryexcretionofpicloram.potentialforaccumulationnopotentialforaccumulation.rateandextentofexcretionrapidlyexcreted;largelyintheurine(77.584.7%).findingsindicateactivesecretionbythekidney.limitedbiliaryexcretion(5.5%).metabolisminanimalsnoevidenceformetabolismintherat.toxicologicallyrelevantcompounds(animalsandplants)picloramtoxicologicallyrelevantcompounds(environment)picloramacutetoxicity(annexiia,point5.2)ratld50oral4012mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>0.0351mg/l(themaximumattainableconcentration);wholebody4h-skinirritationnon-irritant-eyeirritationmildirritant-skinsensitisationnoevidencewithpicloram(buehlerstudy;limitedvalidity)positiveresultsreportedforsaltsandesterofpicloram.r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat,dog,mouse:liver(increasedweightand'", "j.efsa.2009.1415.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionatleast72%,basedonradiolabelrecoveredfromurine,tissuesandcarcass48haftersingleandrepeatedadministration(10mg/kgbw).takingalsothesimilarpatternofmetabolitesinurineandfeacesintoaccountitisassumedthatoralabsorptionis>80%.inthefirst24hatleast66%distributionhighestconcentrationinliver,well-perfusedorganshigherconcentrationsthanotherorgans,brainamongtop-3highestconcentrationspotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionca.95%within48h,mainlyviaurine(ca.75%)ca.90%withinthefirst24hmetabolisminanimalsextensivelymetabolised:<2%parentcompoundinurineandfaeces16metabolitesidentifiedinurineandfaeces(60-75%ofradiolabel)majormetabolitesinurine:sulphateconjugatesofn-(4-chloro-2-trifluoro-methylphenyl)-2-hydroxy-acetamidineand2-amino-5-chloro-3-trifluoromethylphenol(eachca.20%ofurinaryradiolabel)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitescontainingthe4-chloro-2-(trifluoromethyl)phenylgrouptoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral1057mg/kgbwr22ratld50dermal>5000mg/kgbwratlc50inhalation>3.6mg/l(4h,noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitizer(maximisationtest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectincreasedliverweight,liverhistopathologyrelevantoralnoael13-w,neurotoxicitystudyrat:70ppm(4.1'", "j.efsa.2009.179r.pdf": "ide)appendix1listofendpointshttp://www.efsa.europa.eu48of77impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(cmax2hours)andalmostcomplete(>80%within48hbasedonurinaryexcretion)distributionwidelydistributed.highestamountsintheexcretoryorgans(gastro-intestinaltract,liverandkidneys).potentialforaccumulationnoevidenceforaccumulationinanycompartment.rateandextentofexcretionexcretionrapidand>90%viaurine.eliminationinfaecesandbile<5%.metabolisminanimalsbarelymetabolised,excretedessentiallyunchanged(>90%asparent,upto3%ascholinechloride).toxicologicallyrelevantcompounds(animalsandplants)parentcompound.toxicologicallyrelevantcompounds(environment)parentcompound.acutetoxicity(annexiia,point5.2)rabbitld50oral115mg/kgbwratld50oral520mg/kgbwr22mouseld50oral544mg/kgbwrabbitld50dermal964mg/kgbwr21ratld50dermal>4000mg/kgbwratlc50inhalation>5.2mg/l(4h,aerosol,head/noseexposure)skinirritationnotirritanteyeirritationnotirritantskinsensitisationnotsensitising(m&k,buehler)shorttermtoxicity(annexiia,point5.3)target/criticaleffectneurologicaleffects(salivationanddiarrhoea)indogs.reducedbwinmiceandrats.'", "j.efsa.2009.181r.pdf": "ww.efsa.europa.eu55of100impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbedafteranoraldose.urinaryradiolabelmostlyeliminatedwithin6hafteralowdose.evidenceforcompleteabsorptionconsideredtobeinconclusiveandhenceestimateof50%basedonratdata.distributionrapidlyandwidelydistributedintoorgansandtissues.highestconcentrationsinbloodcellsfollowedbyspleen.potentialforaccumulationlimitedpotential.verylowretention,however,evidenceofcovalentbindingtobloodcellsconsideredresponsibleforprolongedbetaphaseofelimination.rateandextentofexcretionrapidlyandalmostcompletelyeliminatedexceptforbloodcells(2%ofapplieddoseafter10days)intherat,upto80%ofthemajormetabolitewereeliminatedinfaecesorurinewithin6hafteroraldoseof5mg/kgbw.metabolisminanimalsextensivelymetabolised.noparentfoundinurineand<10%infaecesafteralowdoseinrats.toxicologicallyrelevantcompounds(animalsandplants)parentandtcpsatoxicologicallyrelevantcompounds(environment)parent(tcpsaisnotrelevantingroundwater)acutetoxicity(annexiia,point5.2)ratld50oral1100mg/kgbwr22ratld50dermal>5000mg/kgbwratlc50inhalation>5.3mg/lair(4hours,wholebody,asaerosolatmosphere)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationsensitisinginmagnusson&kligmanstudy,butnotsensitisingin9-inductionbuehlermethodstudyr43'", "j.efsa.2009.182r.pdf": "/www.efsa.europa.eu48of78impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionreadyabsorptionofphosphinethroughthelungsandafteroralexposuretozincphosphidedistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidexcretionwithurineashypophosphiteandphosphiteandvialungsasphosphinemetabolisminanimalshydrolysistophosphine,oxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)phosphinetoxicologicallyrelevantcompounds(environment)phosphineacutetoxicity(annexiia,point5.2)ratld50oral8.7mg/kgbw(aluminiumphosphide)t+;r28ratld50dermalapprox.460-900mg/kgbw(aluminiumphosphide)xn;r21ratlc50inhalation11ppm(>0.016mgph3/lairor>2.8mg/kgbw)51ppm(0.072mgph3/lair)(4hexposure,wholebody)lc50=0.048mg/l(phosphinelevelsfromaluminiumphosphidedust)skinirritationnotirritant(aluminiumphosphide)eyeirritationnotirritant(aluminiumphosphide)skinsensitisationnoindicationofskinsensitisation(buehler-test,3inductionsusingaproductcontaining56%w/waluminiumphosphideandm&k-testusingzincphosphide)shorttermtoxicity(annexiia,point5.3)target/criticaleffectmortalityrelevantoralnoaelnoreliabledata,nostudyrequiredrelevantdermalnoaelnodata,nostudyrequired'", "j.efsa.2009.184r.pdf": "/www.efsa.europa.eu56of106impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioninrats,teflubenzuronwasabsorbedonlypartially(approx.20%with16%inbile+4%inurineandcarcasswithin48hoursat25mg/kgbw)fromthegastrointestinaltract,absorptionbeingdose-dependentandsaturable.absorptionwasrelativelyrapidwithpeakplasmalevelsseenatca18hoursdistributionlowlevels(<1%inliver,muscleandfatat6hours)potentialforaccumulationtherewasnoevidenceofbioaccumulationinorgansortissues,plasmalevelsincreasedwiththelevelofdosingintherat2-yearstudyrateandextentofexcretionmostoftheradiolabel(91-95%ofthetotaldose)wasexcretedinthefaeces,predominantlywithin24h,andonlysmallquantities(<1%)werefoundinurineduringeightdaysaftertreatment.absorbedteflubenzuronwasexcretedmainlyviathebile(ca15%),urinaryexcretionrepresentingonlyaminorroute(<5%).metabolisminanimalsteflubenzuronwaseliminatedlargelyunchangedinfaeces,althoughanumberofunidentifiedminormetabolites(each<1%)werefound.toxicologicallyrelevantcompounds(animalsandplants)teflubenzuron,3,5-dichloro-2,4-difluorophenylureatoxicologicallyrelevantcompounds(environment)teflubenzuron,3,5-dichloro-2,4-difluoroanilineacutetoxicity(annexiia,point5.2)ratld50oral>5,000mg/kgratld50dermal>2,000mg/kgratlc50inhalation>5.038mg/l(4-hour,nose-onlyexposuretodustaerosol)skinirritationnotirritanteyeirritationnotirritantskinsensitisationnegativeinaninadequatestudyr43'", "j.efsa.2009.186r.pdf": "ntidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu62of109impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption50%absorptionviaoralrouteinratein4-6hoursdistributionfateandskinmainly(3%ofthedoseremainsintissues)potentialforaccumulationno,t=51days(fat),50days(skin),19days(liver),28days(kidney),40days(ovariesandsciaticnerve)rateandextentofexcretioneliminationcompletewithin48hoursurine(13-25%)andfaeces(63-88%),3%remainedintissuesandorgansmetabolisminanimalsviahydrolysis,oxidationandconjugationtoxicologicallyrelevantcompounds(animalsandplants)nomainmetabolites,alllessthan10%toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oralld50:54.5mg/kg(dilutedincornoil)186.1mg/kg(undiluted)r25ratld50dermal>2000mg/kg-ratlc50inhalation1.01mg/l/4h(ci:066-1.1)r23skinirritationnonirritant-eyeirritationnonirritant-skinsensitisationsensitiser(m&k)notsensitising(buehler)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectneurotoxiceffect:tremors;reductionintaillatency;staggeredgaitandexaggeratedhindlimbflexionrelevantoralnoaelnoael:2.5mg/kg/day(90daydog)'", "j.efsa.2009.188r.pdf": "/www.efsa.europa.eu36of60classificationandproposedlabellingwithregardtophysicalandchemicaldata(annexiia,point10)rms/peerreviewproposalactivesubstancedoesnotclassifyfromaphysical/chemicalpointofview.impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed,>79%within48hours(basedonexcretionviaurineandtissuecontent)distributionnarrowdistribution,highestresiduesassociatedwiththeliver,bloodandresidualcarcasspotentialforaccumulationunlikelyrateandextentofexcretionatalldosagelevelsthemajorrouteofeliminationinratsisviatheurineforbothsexes(7289%),inaddition,femalestendtoexcreteahigheramountinfaecesthanmalesforthelowdosegroupswhilethereverseistrueforhighdoseadministrationofdpametabolisminanimalsextensivelymetabolised,>84%(13metabolitesincludingparentidentified);4-oh-dpawasthemajorfreemetabolitedetectedinbothurineandfaecesandparentisfoundinsmallamountsinfaecestoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>15000mg/kgbwrabbitld50dermal>7500mg/kgbwratlc50inhalationnodata,studyrequiredskinirritationnotirritanteyeirritationsevereirritantr41skinsensitisationnon-sensitiser(magnusson&kligman)'", "j.efsa.2009.189r.pdf": "/www.efsa.europa.eu52of130impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionsystemicbioavailabilityofca70%.distributioninitiallywidelydistributed;highestresiduesinfatat168hours.potentialforaccumulationpotentialforaccumulationinfat,terminalhalflifeofupto37days.rateandextentofexcretionslow:33%within24h,stillmeasurableafter21daysmainlyinfaecesbyanonbiliaryprocessmetabolisminanimalsmetabolismisminimal(app.1%)bydeacylationfollowedbycleavageoftheureidogroup.toxicologicallyrelevantcompounds(animalsandplants)lufenuron.toxicologicallyrelevantcompounds(environment)lufenuron.acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.35mg/l4h,noseonly,aerosol(maximumachievableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(magnusson&kligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffecttonic-clonicconvulsions(rats,mice,dogs)liverchanges(rats,dogs),thyroidchanges(dogs)mortalityathigherdoses(loael30mg/kgbw/dindogs)relevantoralnoael1.5mg/kgbw/d(1-yr,dog)10mg/kgbw/d(90-d,rat)xn;r48/22'", "j.efsa.2009.190r.pdf": "/www.efsa.europa.eu42of73impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorptionreadyabsorptionofphosphinethroughthelungsandafteroralexposuretozincphosphidedistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionexcretionwithurineashypophosphiteandphosphiteandvialungsasphosphinemetabolisminanimalshydrolysistophosphine,oxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)phosphinetoxicologicallyrelevantcompounds(environment)phosphineacutetoxicity(annexiia,point5.2)ratld50oral10.4mg/kgbw(magnesiumphosphide)t+,r28ratld50dermalca.460-900mg/kgbw(aluminiumphosphide)xn,r21ratlc50inhalation>11ppm(>0.015mgph3/lairor>2.8mg/kgbw)51ppm(0.072mgph3/lair)(4hexposure,wholebody)(phosphine)t+;r26skinirritationnotirritant(aluminiumphosphide)eyeirritationnotirritant(aluminiumphosphide)skinsensitisationnoindicationofskinsensitisation(buehler-test,3inductionsusingaproductcontaining66%w/wmagnesiumphosphideand56%w/waluminiumphosphide;m&k-testusingzincphosphide)shorttermtoxicity(annexiia,point5.3)target/criticaleffectmortalityrelevantoralnoaelnoreliabledata,nostudyrequiredrelevantdermalnoaelnodata,nostudyrequired'", "j.efsa.2009.191r.pdf": "//www.efsa.europa.eu50of130impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionrapidandextensive(>80%basedonurinaryexcretion)distributionwidelydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionmainlyexcretedviaurine(upto95%within96hours)metabolisminanimalsextensivelymetabolized.mainmetabolitesinurine:glucuroandsulfoconjugatestoxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)impurities:phenol,2,4-dinitrophenol,2,6-dinitrophenolacutetoxicity(annexiia,point5.2)ratld50oralna5-ng:716.0mg/kgbwnao-np:960.1mg/kgbwnap-np:345.5mg/kgbwr22rabbit,ratld50dermalna5-ng:>2000mg/kgbwnao-np:>2000mg/kgbwnap-np:>2000mg/kgbwratlc50inhalationna5-ng:>2.38mg/lair(mac)nao-np:>1.24mg/lair(mac)nap-np:>1.20mg/lair(mac)skinirritationna5-ng:nonskinirritantnao-np:nonskinirritantnap-np:nonskinirritantna5-ng:severeeyeirritantr41nao-np:eyeirritantr36eyeirritationnap-np:eyeirritantr36skinsensitisationna5-ng:nonskinsensitizer(buehlertest)nao-np:nonskinsensitizer(buehlertest)nap-np:nonskinsensitizer(buehlertest)-'", "j.efsa.2009.192r.pdf": "/www.efsa.europa.eu41of100chapter3(impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextensive(80%basedon16-30%urinaryandbiliary48-74%excretionandtissueresiduesinbilecannulatedrats),butrelativelyslow(cmaxreachedafter8h)afterapplicationofthelowdoseof10mg/kgbwtoratsdistributioninitiallywidelydistributed,after168hhighestresiduesinmesentericlymphnodesand(at50mg/kgbwonly)inbonepotentialforaccumulationnopotentialofaccumulationinanyorganinspiteofdelayedeliminationrateandextentofexcretionrelativelyslowbutvirtuallycompleteafter168hourspostdosing,mainlyviafaeces(48-74%)withurinaryelimination(24-44%)lessimportant;significantbiliaryexcretion(about60%in24hr)andenterohepaticcirculationmetabolisminanimalsextensivewithatleast22identifiedmetabolites;mainpathwayshydroxylation,oxidation,sulfateconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral202-320mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation2.7mg/lair(4-hrnose-onlyexposure)r20skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(m&k)r43'", "j.efsa.2009.193r.pdf": "//www.efsa.europa.eu53of104impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidwithmorethan80%ofthedoseabsorbedwithin24hours(maxplasmaconcentrationsat20-90minutes)basedonurineandbile.only50%consideredavailabletothetargettissues.distributionwidespreadwiththehighestlevelsinliver,kidney,brownandperi-renalfat,adrenalandthyroidglandsandnasalmucosa.potentialforaccumulationnoevidenceofaccumulationat72hours;someevidencethatthedeclineinradioactivitywasslowerfrombloodcomparedtoothertissues.rateandextentofexcretionrapidwithatleast87%ofthedoseeliminatedwithin24hours.metabolisminanimalsmainlybydechlorination,hydroxylation,de-oxidation,removaloftheimidazoleringandconjugation;minimalcleavageofthebenzotriazineringstructure.toxicologicallyrelevantcompounds(animalsandplants)triazoxideandmetabolitestoxicologicallyrelevantcompounds(environment)triazoxideandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral98mg/kgbwr25ratld50dermal>5000mg/kgbwratlc50inhalation0.7mg/l(4hourexposure,primarilynose).r23skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnegative(m&ktest)'", "j.efsa.2009.194r.pdf": "//www.efsa.europa.eu51of92chapter3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:80%within72h(basedonurine,bileandcarcass)distribution:preferablydistributedinfattytissues,alsofoundinblood,liver,kidney,lungandspleen.potentialforaccumulation:nopotentialforaccumulation.rateandextentofexcretion:almostcompletelyexcretedviaurineandfaeceswithin48h(with~40to50%bybiliaryexcretion).metabolisminanimalsinrats,metaboliteswereformedthroughhydrolysisfollowedbysubsequentconjugation,orbyhydroxylationoftheparentcompoundfollowedbyhydrolysisand/orconjugation.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolites(4-trifluoromethoxyaniline,4-trifluoromethoxyphenylurea,2-chlorobenzamide,2-chlorobenzoicacid)toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5mg/lair/4h(aerosol,nose-only)skinirritationnotirritanteyeirritationnotirritantskinsensitisation(testmethodusedandresult)notsensitiser(magnusson&kligmantest)shorttermtoxicity(annexiia,point5.3)target/criticaleffecthaematopoieticsystem(haemolyticanaemia)relevantoralnoael3.6mg/kgbw/d(rat,90-daystudy)1.42mg/kgbw/d(dog,12-monthstudy)relevantdermalnoael100mg/kgbw/d(rabbit,3-weekstudy)relevantinhalationnoaec0.0045mga.s./l(rat,3-weekstudy)genotoxicity(annexiia,point5.4)nogenotoxicproperties'", "j.efsa.2009.195r.pdf": "www.efsa.europa.eu51of115impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:rapid,65%inratsatlowdose,basedonurineandcarcassdistribution:welldistributedpotentialforaccumulation:nopotentialforaccumulationinorgansrateandextentofexcretion:almostcompletein72hoursviatheurineandfaecesmetabolisminanimalsextensivelymetabolisedbyhydroxylation/demethylationonthetriazineringandcleavageofthesulphonylureabridgetoxicologicallysignificantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallysignificantcompounds(environment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgb.w.ratld50dermal>2000mg/kgb.w.ratlc50inhalation>5.1mg/l(4hours,noseonly)skinirritationnonirritanteyeirritationnonirritantskinsensitization(testmethodusedandresult)nonsensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweight,foodintake/decrease;liver:increasedweight/elevatedbloodenzymes/;hypertrophy;erythrocytes:regenerativeanaemialowestrelevantoralnoael/noel6.6mg/kgbw(90daysrat)lowestrelevantdermalnoael/noel1000mg/kgbw(21daysinrabbit)lowestrelevantinhalationnoael/noelnodatanotrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2009.196r.pdf": "//www.efsa.europa.eu60of119impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)(cypermethrin)rateandextentofabsorption50%basedonurinaryexcretionwithin24hlowerabsorptionathighdoselevelsdistributioninitiallywidelydistributed;highestresiduesinfatandskinat8dayspotentialforaccumulationfat(t1/2>24h)rateandextentofexcretionrapidandextensive(>95%)within1-3days,mainlyviaurine(53-74%)andfeces(19-35.5%)metabolisminanimalsextensivelymetabolized(>95%)byestercleavageto2,2-dimethyl-3-(2,2-dichlorovinyl)cyclopropanecarboxylicacidand3-phenoxybenzoylmoiety;furtherconjugationandoxidation.mostfaecalradioactivitywasunchangedparentcompoundtoxicologicallyrelevantcompounds(animalsandplantsandenvironment)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral(zeta-cypermethrin)ld50male=134mg/kgbwld50female=86mg/kgbwt,r25ratld50dermal(zeta-cypermethrin)ld50>2000mg/kgbwratlc50inhalation(cypermethrin)lc50=1.26mg/lxn,r20skinirritation(zeta-cypermethrin)notirritatingeyeirritation(zeta-cypermethrin)notirritatingskinsensitization(testmethodusedandresult)(zeta-cypermethrin)sensitiser(buehlertest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectnervoussystem(blockclosinggatesodiumchannels),mortalityandsevereclinicalsignsathighdoselevelslowestrelevantoralnoael(cypermethrin)2yeardogstudy:7.5mg/kgbw/dxn,r48/22lowestrelevantdermalnoael(zeta-cypermethrin)<100mg/kgbw/dforlocaleffects,>1000mg/kgbw/dforsystemiceffects'", "j.efsa.2009.201r.pdf": "www.efsa.europa.eu59of107impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionrapidlyabsorbed(>80%oftotalurinaryexcretedradioactivitywithin24hrs).oralabsorptionupto71%within72h(basedonurine,cagerinse,totaltissues/organsorcarcassinfemales).distributionwidelyanduniformlydistributed.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretionrapid,primarilyviaurine(52-95%)andsecondarilyviafaeces(4-27%),upto97%within72hrs.metabolisminanimalshydrolyticcleavageofthesulfonylureabridgeoftheparentcompound.twominormetabolitesidentified(upto3%inurine,upto8.5%infaeces):2-chlorobenzenesulfonamide(in-a4097)and2-amino-4-methoxy-6-methyl-1,3,5-triazine(in-a4098).toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolites.toxicologicallyrelevantcompounds(environment)parentcompoundandmetabolites.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwrabbitld50dermal>3400mg/kgbwratlc50inhalation>5.5mg/lair(4h,noseorheadonly,aerosol)skinirritationnon-irritanteyeirritationslightlyirritant(noclassificationproposed)skinsensitisationnon-sensitiser(m&ktest)'", "j.efsa.2009.203r.pdf": "intidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu61of97impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)metamandmitcrateandextentoforalabsorption85%(basedonurinary(50%)andexpiredair(35%)excretionwithin48h)distributionuniformlydistributedpotentialforaccumulationslightpotentialforaccumulationinthyroidrateandextentofexcretionrapidandextensive(app.85%)within48h,mainlyviaurine(50%)within24h,4%viafaeces,35%viaexpiredairmetabolisminanimalsextensivedegradationofmetamintomitcwhichisfurtherconjugatedwithgshordecomposesintomic,cosandco2.anotherimportantmetabolicpathwayisformationofcs2whichisrelatedtoacidicconditionsofstomachtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolites:methylisothiocyanate(mitc),methylisocyanate(mic),cos,cs2toxicologicallyrelevantcompounds(environment)methylisothiocyanate(mitc),methylisocyanate(mic),cos,cs2acutetoxicity(annexiia,point5.2)metamsodiumratld50oral896mg/kgbwr22ratld50dermal>2000mg/kgbw-ratlc50inhalation2.54mg/lair/4h(wholebody)r20skinirritationcorrosiver34eyeirritationnon-irritant-skinsensitisationsensitising(m&k)r43acutetoxicity(annexiia,point5.2)mitcratld50oral147mg/kgbwr25ratld50dermal1290mg/kgbwr21ratlc50inhalation0.54mg/lair/4h(wholebody)r23r37skinirritationcorrosiver34eyeirritationnostudyrequired-skinsensitisationsensitising(m&k)r43shorttermtoxicity(annexiia,point5.3)metamsodiumtarget/criticaleffectnasalcavity(rat),urinarybladder(mice),liver(dog)relevantoralnoael1-year,dog0.1mg/kgbw/day90-dayrat:0.5mg/kgbw/day90-daymice:0.8mg/kgbw/dayr48/22relevantdermalnoael21-day,rabbit:31.2mg/kgbw/dayrelevantinhalationnoael90-dayrat:6.5mg/m3correspondingto'", "j.efsa.2009.204r.pdf": "tsfortheactivesubstanceandtherepresentativeformulationendpointidentifiedbytheeu-commissionasrelevantformemberstateswhenapplyingtheuniformprincipleshttp://www.efsa.europa.eu56of171impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionpropaquizafopwasabsorbedoveralongperiod(cmax8-12h),withanoralabsorptionvalueof65%.distributiongenerallydistributedwithhighestlevelsinblood,liverandkidneypotentialforaccumulationnonerateandextentofexcretionrapidlyexcretedinfaecesandurinemetabolisminanimalsextensivelymetabolised.majormetabolitesarethefreeacidoftheparentcompoundandfurtheroxidationproductstoxicologicallyrelevantcompounds(animalsandplants)propaquizafoptoxicologicallyrelevantcompounds(environment)propaquizafopacutetoxicity(annexiia,point5.2)ratld50oral5000mg/kgbwratld50dermal2000mg/kgbwratlc50inhalation>2500mg/m3skinirritationnon-irritatingeyeirritationnon-irritatingskinsensitisationsensitizer(magnusson&kligman)r43;xnshorttermtoxicity(annexiia,point5.3)target/criticaleffecthepatotoxicityrelevantoralnoael6.25mg/kgbw/day(rat)10mg/kgbw/day(mouse)20mg/kgbw/day(dog)relevantdermalnoael250mg/kgbw/day(rat)'", "j.efsa.2009.205r.pdf": "sfortheactivesubstanceandtherepresentativeformulationshttp://www.efsa.europa.eu110of216impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionquizalofop-p-ethyl:racemate:male:67%;female:89%.basedonurinary(6,14%)andbiliary(52,49%)excretionwithin48handresiduesinliver(2,4%)andcarcass(8,23%)at48h.quizalofop-p-tefuryl:males:58%;females:61%.basedonurinary(12,36%)excretionwithin168handfaecalelimination(43,36%)after24handtotaltissueresidues(3,1%)at168h.distributionquizalofop-p-ethyl:uniformlydistributedquizalofop-p-tefuryl:widelydistributed;highestresiduesinfat,ovary,wholeblood,carcass,kidneyandliverat168h.potentialforaccumulationquizalofop-p-ethyl:noevidenceforaccumulation,althoughtheeliminationfromthefatveryseemtobeslow.quizalofop-p-tefuryl:noevidenceforaccumulation,althoughtotaleliminationhalf-lifewasslightlylongerthan24hoursinmales.rateandextentofexcretionquizalofop-p-ethyl:elimination:56-70%within48h.urinaryexcretionwas43-54%infemalesand26-28%inmaleswithin7daysandeliminationviafaeces44-57%infemalesand64-69%inmalesafteralowdose.quizalofop-p-tefuryl:elimination:68%inmalesand82%infemaleswithin48h.urinaryexcretionwas35-48%infemalesand12-41%inmaleswithin7daysafteraloworhighdoseadministrationandeliminationviafaeceswas38-59%infemalesand38-80%inmales.metabolisminanimalsquizalofop-p-ethyl:extensivelymetabolised(>90%ofradioactivityinplasmawasassociatedwithquizalofopacid);de-ethylation,hydroxylation,bridgecleavage.quizalofop-r-tefuryl:extensivelymetabolised(lessthan15%ofadministereddoseinexcretawasparentcompound).rapidlyhydrolysedtoitsacidforminthestomachorgastrointestinaltract(38-58%ofdoseinexcretawasacidform).furthermetabolism:hydroxylation,hydrolysis,conjugation.'sfortheactivesubstanceandtherepresentativeformulationshttp://www.efsa.europa.eu111of216toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oralquizalofop-p-ethyl:1182mg/kgbw(females)quizalofop-p-tefuryl:1012mg/kgbw(combinedforbothsexes)r22r22ratld50dermalquizalofop-p-ethyl:racemate:>5000mg/kgbwquizalofop-p-tefuryl:>2000mg/kgbwratlc50inhalationquizalofop-p-ethyl:racemate:5.8mg/lair/4h(nose-only)quizalofop-p-tefuryl:>3.9mg/lair/4h(nose-only)skinirritationquizalofop-p-ethyl:racemate:non-irritantquizalofop-p-tefuryl:non-irritanteyeirritationquizalofop-p-ethyl:racemate:slightlyirritatingtransiently(noclassificationproposed)quizalofop-p-tefuryl:slightlyirritating(noclassificationproposed)skinsensitisationquizalofop-p-ethyl:notsensitising(m&k,racemate:buehler)quizalofop-p-tefuryl:sensitiser(sensitisinginm&k,non-sensitisinginbuehler)r43'", "j.efsa.2009.213r.pdf": "chapter2.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorption:rapidbutlimitedabsorption:30%averagebothsexesbasedonurineandbileexcretion.distribution:uniformlydistributedwithhighestconcentrationfoundinfat,adrenals,liver,ovary,thyroidandgitract.transferredviaplacentatothefoetusbutplacentalandfoetalconcentrationsarelowrelativetomaternalplasmaconcentrationandfoetaleliminationisrapid.activelysecretedintomaternalmilk,buttransferdecreasesmarkedlyoncessationofdosing.potentialforaccumulation:nopotentialforaccumulationrateandextentofexcretion:rapidandextensiveexcretion,predominantlyinthefaeces(86.490.4%oftheadministereddose).urinaryexcretion6.310.7%,biliaryexcretion15.229.6%within48hours.metabolisminanimals63%metabolized,basedonurinaryandfaecalmetabolites.twomajormetabolites(de,19.525.1%and4-oh,7.213.8%)formedbyo-deethylationofethoxyphenylmoietyandringhydroxylationofphenoxybenzylmoiety,subsequentlyeliminatedinbileandurineasglucuronideorsulphateconjugates.toxicologicallyrelevantcompounds(animalsandplants)etofenproxand-co(toxicityof-cosimilartoparentstoxicity)toxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.88mg/lair/4hbywholebodyexposuretoaliquidaerosol.skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(maximisationtest)'", "j.efsa.2009.214r.pdf": "pactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionlowabsorption(1.2-2.5%basedonradiolabelrecoveredfromurine,tissuesandresidualcarcasswithin168h)distributionwidelydistributed,highestresiduesinpancreasandadrenalsat168h.potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionextensivewithin168h:mainlyviafaeces(89-99%),1.2-2.3%viaurinemetabolisminanimalspartlymetabolised,parentand4oxidationproducts(tentativelyidentifiedinfaeces)toxicologicallyrelevantcompounds(animalsandplants)ddactoxicologicallyrelevantcompounds(environment)ddacacutetoxicity(annexiia,point5.2)ratld50oral256mgddac/kgbwr22ratld50dermal>4000and<6400mgddac/kgbwratlc50inhalationnodataavailablenotrequiredskinirritationcorrosiver34eyeirritationnodataavailablenotrequiredskinsensitisationnodataavailablenotrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgain,clinicalsigns(oral)localepidermitis(dermal)relevantoralnoael13-week,rat:60.7mgddac/kgbw/day1-year,dog:10mgddac/kgbw/dayrelevantdermalnoael13-week,rat:<2mgddac/kgbw/dayrelevantinhalationnoaelnodataavailablenotrequired'", "j.efsa.2009.215r.pdf": "relevantformemberstateswhenapplyingtheuniformprinciplesefsascientificreport(2008)215,26-48impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextensiveandrapidabsorptionfromthegitract(basedongeneralscientificandmedicalliterature).distributionrapidandwidespreadthroughoutthebody(basedongeneralscientificandmedicalliterature).potentialforaccumulationnopotentialforaccumulation(basedongeneralscientificandmedicalliterature).rateandextentofexcretionrapidlyandextensivelyeliminated(basedongeneralscientificandmedicalliterature).metabolisminanimalsethanolisoxidisedtoacetaldehydewhichisconvertedtoacetatewhichismetabolisedtoco2,h20andfattyacidsviathekrebscycle(basedongeneralscientificandmedicalliterature).toxicologicallyrelevantcompounds(animalsandplants)parent.toxicologicallyrelevantcompounds(environment)parent.acutetoxicity(annexiia,point5.2)ratld50oral>6g/kgbwratld50dermal>20g/kgmouselc50inhalation39mg/lair(4-hourexposure)skinirritationnon-irritanteyeirritationlimiteddataindicatingirritation*8skinsensitisationnegative(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,kidneysandcnsrelevantoralnoaelinsufficientdatanotrequiredrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnovaliddatanotrequired8*:insufficientdatatoconclude,echatoconsiderclassification'", "j.efsa.2009.216r.pdf": "impactonhumanandanimalhealththedataincludedbelowwerebasedontheassumptionthatnotoxicologicalconcernwasraisedovertheimpurityprofileoftheactivesubstance,whilethishasnotbeendemonstrated,theyarenotapplicableabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionpoorabsorptionafteringestion;mostofitbythesmallintestine(approx.2%)distributionitmaybedepositedinbodyfat(ingestionorinhalation),inkidneys,liver,brainandblood(inhalation)orinstratumcorneum(skin)potentialforaccumulationnotexpectedtoaccumulaterateandextentofexcretionitisexcretedviafaecesalmostunchanged(paraffinoilsarecommonlyusedaslaxativesduetotheirphysicalproperties)metabolisminanimalsaverysmallfractionmayundergofurtherbiochemicaltransformation(hydroxylationviacytochromep450monooxygenasetotherespectivealcohol;itmaythenbefurtheroxidizedtocarboxylicacids,andfurthertoco2orbesolubilisedbybuildingaglucuronide.)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50orallowacuteoraltoxicityratld50dermallowdermaltoxicityratlc50inhalationlowinhalationtoxicityskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotaskinsensitisershorttermtoxicity(annexiia,point5.3)target/criticaleffectlimitedanimaldataindicatinglowsubchronictoxicityafteroral,dermalandinhalativerouterelevantoralnoaelinsufficientdatanotrequiredrelevantdermalnoaelinsufficientdatanotrequiredrelevantinhalationnoaelinsufficientdatanotrequired'", "j.efsa.2009.217r.pdf": "mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrelativelyrapidandalmostcomplete,about90%,basedonurinary(87.8%)fecal(2.9%)excretionwithin24h.aftersingleoraldoseof160mg/kgtomalerats.distributionwidelydistributedinrats.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandcompleteafterasingledoseof500mg/kg.mainlyviaurine(95.6%),faeces(6.%)at96hours.bileandco2notestimated.rapidandcompleteafterrepeateddoseof500mg/kg.mainlyviaurine(88.1%),faeces(3.3.%)at96hoursmetabolisminanimalsinrodentssulphationof2-phenylphenolwasthepredominantmetabolicpathwayatthelowdoselevels,whileglucuronidationgainedsignificancehighdoselevels.phenylhydroquinoneformationincreasingindose-dependentmodeandrespectivephenylhydroquinoneconjugatesappearsinurine.catsanddogs:excretethemajorityof2-phenylphenolastheunmetabolisedparedcompound.humansvolunteers(2-phenylphenoldermallyapplied):inurinesulphateconjugatedof2-phenylphenolisthemajormetabolite,lowlevelsofglucuronideconjugatedof2-phenylphenolandglucuronideconjugatedofphenylhydroquinonewerealsopresent.toxicologicallyrelevantcompounds(animalsandplants)2-phenylphenol;phqnodataavailabletoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oralld50:2733mg/kgbwratld50dermalld50>2000mg/kgbwratlc50inhalationlc50rat>0.036mg/l(maximumattainableconcentrationnose-only.testmaterial:aerosol'skinirritationirritatingtoskinr38eyeirritationirritatingtoeyesr41skinsensitizationnosensitizing(buehlertest)respiratorysystemirritationirritatingtorespiratorysystemr37shorttermtoxicity(annexiia,point5.3)target/criticaleffecturinarybladderandkidneyinmalerats,rat:abnormalgrowthintheinthebladderurotheliumandkidneydamageinmales.relevantoralnoael391mg/kgbw/day(13-weeksrat).relevantdermalnoael100mg/kgbw/day(21daysrat).relevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)genotoxicinvitroatcytotoxicdoses.overall,nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffecturinarybladder(rats),kidney(ratsandmice)andliver(mice)relevantnoael39mg/kgb.w/day(2-yearrats)<250mg/kgbw/day(2-year-mice)carcinogenicityrats:papillomasandtransitionalcellcarcinomasinurinarybladderofmale(at200mg/kgb.w/day)mice:hepatictumors(adenoma,carcinomasandhepatoblastomas)inmalesat500mg/kgb.w./day.cat3r40reproductivetoxicity(annexiia,point5.6)multigenerationstudyreproductiontarget/criticaleffectparental:bw/bwgaindepression(8-10%).kidney,urinarybladder(hyperplasiaofthetransitionalepitheliumcells,chronicinflammation).reproductive:noeffectsoffspring:bwdepression(11%)'", "j.efsa.2009.218r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(peaklevelinbloodat4h)andextensive:82%basedonliverandothertissues,carcass,urine,co2,andthemetabolizedportioninfaeces(168hafterdosing)distributionwidelydistributed:liver>pancreas>gastrointestinaltract>kidneypotentialforaccumulationyes:3.34%oflabelpersistedintheliver182daysafterdosingrateandextentofexcretionbiphasic;half-livesof3and118days.withinsevendays37to55%eliminatedinfaecesand2%inurinemetabolisminanimals24to36%oftheadministereddoseisasmetabolitesinfaeces.2to5unidentifiedmetabolitesfoundinliver.metabolismisassumedtodrasticallyreducetheanticoagulantpotentialtoxicologicallyrelevantcompounds(animalsandplants)difenacoumtoxicologicallyrelevantcompounds(environment)difenacoumacutetoxicity(annexiia,point5.2)ratld50oral1.8mg/kgbwt+r28ratld50dermal63mg/kgbw(95%confidencelimits34-85)t+r27ratlc50inhalation3.646to5.848g/l/4h,head-onlyt+r26skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectbloodcoagulation/haemorrhagerelevantoralnoael0.03mg/kgbw/day(90-day,rat)t;r48/25'", "j.efsa.2009.219r.pdf": "impactonhumanandanimalhealththedataincludedbelowwerebasedontheassumptionthatnotoxicologicalconcernwasraisedovertheimpurityprofileoftheactivesubstance,whilethishasnotbeendemonstrated,theyarenotapplicableabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionpoorabsorptionafteringestion;mostofitbythesmallintestine(approx.2%)distributionitmaybedepositedinbodyfat(ingestionorinhalation),inkidneys,liver,brainandblood(inhalation)orinstratumcorneum(skin)potentialforaccumulationnotexpectedtoaccumulaterateandextentofexcretionitisexcretedviafaecesalmostunchanged(paraffinoilsarecommonlyusedaslaxativesduetotheirphysicalproperties)metabolisminanimalsaverysmallfractionmayundergofurtherbiochemicaltransformation:hydroxylationviacytochromep450monooxygenasetotherespectivealcohol;itmaythenbefurtheroxidizedtocarboxylicacids,andfurthertoco2orbesolubilisedbybuildingaglucuronide.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50orallowacuteoraltoxicityratld50dermallowdermaltoxicityratlc50inhalationlowinhalationtoxicityskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotaskinsensitisershorttermtoxicity(annexiia,point5.3)target/criticaleffectlimitedanimaldataindicatinglowsubchronictoxicityafteroral,dermalandinhalationrouterelevantoralnoaelinsufficientdatanotrequiredrelevantdermalnoaelinsufficientdatanotrequired'", "j.efsa.2009.220r.pdf": "impactonhumanandanimalhealththedataincludedbelowwerebasedontheassumptionthatnotoxicologicalconcernwasraisedovertheimpurityprofileoftheactivesubstance,whilethishasnotbeendemonstrated,theyarenotapplicableabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionpoorabsorptionafteringestion;mostofitbythesmallintestine(approx.2%)distributionitmaybedepositedinbodyfat(ingestionorinhalation),inkidneys,liver,brainandblood(inhalation)orinstratumcorneum(skin)potentialforaccumulationnotexpectedtoaccumulaterateandextentofexcretionitisexcretedviafaecesalmostunchanged(paraffinoilsarecommonlyusedaslaxativesduetotheirphysicalproperties)metabolisminanimalsaverysmallfractionmayundergofurtherbiochemicaltransformation:hydroxylationviacytochromep450monooxygenasetotherespectivealcohol;itmaythenbefurtheroxidizedtocarboxylicacids,andfurthertoco2orbesolubilisedbybuildingaglucuronide.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50orallowacuteoraltoxicityratld50dermallowdermaltoxicityratlc50inhalationlowinhalationtoxicityskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotaskinsensitisershorttermtoxicity(annexiia,point5.3)target/criticaleffectlimitedanimaldataindicatinglowsubchronictoxicityafteroral,dermalandinhalationrouterelevantoralnoaelinsufficientdatanotrequiredrelevantdermalnoaelinsufficientdatanotrequiredrelevantinhalationnoaelinsufficientdatanotrequired'", "j.efsa.2009.221r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionwellabsorbedatlowdoselevelsbasedonhumanstudiesdistributionuniformlydistributed.potentialforaccumulationnopotentialforaccumulation.rateandextentofexcretionnodata.notrequired.homeostasismaintained.metabolisminanimalsextensivelymetabolisedtosulphatesandsulphides.toxicologicallyrelevantcompounds(animalsandplants)sulfurtoxicologicallyrelevantcompounds(environment)sulfuracutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.43mg/l(4h/noseonly)skinirritationirritatingxir38eyeirritationnotirritatingskinsensitisationnonsensitising[mandktest]shorttermtoxicity(annexiia,point5.3)target/criticaleffectnoeffectsrelevantoralnoaelnoael>1000mg/kgbw/d(28-drat)noael>1000mg/kgbw/d(90-drat)relevantdermalnoael28-drats:noael400mg/kgbw/dlocalreversibledermalhyperkeratosisat1000mg/kgbw/dayrelevantinhalationnoaelnodata.notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2009.222r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidaftergavageadministrationwithpeakeffectsseen0.5to3hourspostdosing.absorption>90%intheratandapproximately75%inthemonkey(urineandexpiredair,5mg/kgbw).distributionrat:widespread(highestlevelsinthegastro-intestinaltract,liver,blood,andskin).monkey:widespread(highestlevelsinfatandmuscle).potentialforaccumulationalthoughtheradioactivetissuesresiduesappeartobehighat168hours,(8-9%intherat&approximately5%inthemonkey),methomylisbrokendownintosmallcarboncompoundswhichjointhepoolofnaturallyoccurringcarboncompoundsandareincorporatedintothetissues.rateandextentofexcretionradiolabelwasrapidlyexcretedinexpiredairandurine(within24hoursofdosing(80%intheratand63%inthemonkey)andextensiveeliminationintheratat168hourspostdosing(approximately91%).inthemonkey,approximately75%eliminatedat168hourspostdosing.metabolisminanimalsthreemajorpathwayswereproposed:displacementofs-methylfromsyn-methomylbyglutathionefollowedbytransformationtothemercapturicacidderivative(18%ofthedose);conversionofmethomyltomethomyloxime(mhtaorin-x1177)andco2release;andisomerisationofsyn-methomyltoanti-methomyl(in-b1884),followedbyabeckmannrearrangementandformationofacetonitrile.toxicologicallyrelevantcompounds(animalsandplants)methomyl,inhuz57,(ing6520)toxicologicallyrelevantcompounds(environment)methomyl,inhuz57,(ing6520)'acutetoxicity(annexiia,point5.2)ratld50oral30mg/kgbwt,r25ratld50dermal>2000mg/kgbwratlc50inhalation0.215mg/linmale&femalest+,r26skinirritationnon-irritant(notclassified)eyeirritationslight-irritant(notclassified)skinsensitisationnegativeinabuehler(notclassified).shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasesinbodyweightandchangesinthehaematologicalparameters.relevantoralnoaeloverallnoaelofapproximately10mg/kgbw/dayfromdietarystudiesinrats,dogsandmice.reliabledataoneffectsoncheactivitynotalwaysdetermined.relevantdermalnoael90mg/kgbw/day(rabbit,21days).relevantinhalationnoaelnodatasubmitted.genotoxicity(annexiia,point5.4)invitro:negative.invivo:negative.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffecthistopathologyinkidneyandspleen.relevantnoael3mg/kgbw/day(2yeardogstudy)carcinogenicitynoevidenceofcarcinogenicactivityinratsormice.reproductivetoxicity(annexiia,point5.6)reproductiontoxicityreproductiontarget/criticaleffectparental:reducedbodyweightandfoodconsumptionreproductive:noeffectsoffspring:reducedpupweight'", "j.efsa.2009.269r.pdf": "53-113impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioncomparativei.vandoralstudiessuggest50%conservativeestimateforenteralabsorptiondistributionwelldistributedwithhighestconcentrationinliverpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion80-90%in48hoursalmostcompleteby96hoursmetabolisminanimalssimilarinallspeciesrat,mouse,rabbit,anddog,baboon,apparentlymostextensiveintheratmainpathway:methylthiolationandthanhydroxylationtoxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)-acutetoxicity(annexiia,point5.2)ratld50oralrat/mouse>5200mg/kgbwratld50dermalrat>2100mg/kgbwratlc50inhalationlc50>1.51mga.i/litre(4h,noseonly)skinirritationveryslight(noclassificationneeded)eyeirritationmild(noclassificationneeded)skinsensitisationnegativeinmagnusson&kligmanassay.shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverandblood(reducedhaemoglobinlevels)'", "j.efsa.2009.296r.pdf": "onandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionabsorbedrapidlyinratsfollowingoraladministration(81%).highdoselevels(500mg/kgbw)incompletelyabsorbed.distributionwidelydistributedfollowinginitialabsorption,buttissueresiduesnegligiblebecauseofrapidexcretion.potentialforaccumulationverylow.rateandextentofexcretionrapidexcretionviaurineandfaeces.metabolisminanimalsmetaboliccleavageofthenitrogen-sulphurbond.toxicologicallysignificantcompounds(animals,plantsandenvironment)captanacutetoxicity(annexiia,point5.2)ratld50oral>2,000mg/kgbw(rat,mouse)ratld50dermal>2,000mg/kgbw(rat,rabbit)ratlc50inhalation0.67mg/lt;r23skinirritationnotirritating.eyeirritationseverelyirritatingr41skinsensitization(testmethodusedandresult)sensiter(magnussonandkligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectminoreffects(emesis)indogfollowingoraladministration,responsestotasteandphysicalnatureoftestsubstanceratherthantoxicologicaleffects.treatment-relatedeffectsinrabbitfollowingdermalexposureweredecreasedbodyweight,bodyweightgainandfoodconsumption.treatment-relatedeffectsinratfollowinginhalationexposurewereconfinedtotherespiratorytractandconsistentwithexposuretoanirritantparticulate.lowestrelevantoralnoael/noel60mg/kgbw/day(90day,dog)lowestrelevantdermalnoael/noel110mg/kgbw/day(21-dayrabbit)lowestrelevantinhalationnoael/noel0.60g/l(90-dayrat)'", "j.efsa.2009.297r.pdf": "retionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionabsorbedrapidlyinratsfollowingoraladministration(>80%).distributionwidelydistributedfollowinginitialabsorption,buttissueresiduesnegligiblebecauseofrapidexcretion.potentialforaccumulationverylow.rateandextentofexcretionrapidexcretionviaurineandfaeces.metabolisminanimalsmetaboliccleavageofthenitrogen-sulphurbond.toxicologicallysignificantcompounds(animals,plantsandenvironment)folpetacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation1.89mg/lr20skinirritationnotirritating.eyeirritationseverelyirritating.r41skinsensitization(testmethodusedandresult)sensitising(magnussonandkligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectminoreffectsinrat-reducedbodyweightandbodyweightgain.higherdosesassociatedwithreversiblehyperkeratosisofthenon-glandularstomach.skinirritationindermalstudy.decreasesinbodyweightandfoodconsumptionindogspluspoorgeneralcondition,vomiting,diarrhoea,salivation,reductionintesticularweightassociatedwithmicroscopictesticulardegenerationathighdoses.lowestrelevantoralnoael/noel10mg/kgbw/day(1-yeardog)lowestrelevantdermalnoael/noel1mg/kgbw/day(28-daymalerat);>30mg/kgbw/day(28-dayfemalerat).lowestrelevantinhalationnoael/noel-'", "j.efsa.2009.298r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rapidandextensive(100%within96h)afterlowdoseapplicationwidelydistributed;highestlevelsinliver,kidneys,intestineandadrenalsnoevidenceofaccumulation>80%within96hevenlydividedbetweenurine(35-48%)andfaeces(31-44%)extensivemetabolisminrats(lowlevelofparentcompoundinurineandfaeces)byoxidationofthebutylsidechain;nocleavageofthemolecule.toxicologicallysignificantcompoundsmyclobutanilandmetabolites(rh-9089,rh-9090)toxicologicallysignificantcompoundsmyclobutanilacutetoxicity(annexiia,point5.2)ratld50male=1600mg/kgbwxn,r22female=2290mg/kgbwratld50>2000mg/kgbwratlc50>5.1mg/l4h,noseonly,highestobtainableconcentrationnon-irritantnotirritating(accordingtoavailableinformation),butalreadyclassifiedatecbr36skinsensitization(testmethodusedandnon-sensitizer(maximisationtest)shorttermtoxicity(annexiia,point5.3)liver3.09mg/kgbw/day.(90dand1ydog)100mg/kgbw/d(4wkrat)nodata-notrequiredgenotoxicitynogenotoxicpotential'", "j.efsa.2009.299r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)moderatelyrapidabsorption.cmaxinbloodat68h.approximately62%forthepyridylradiolabelwelldistributedintoorgansandtissues.highestconcentrationsinliver,kidneys,spleenandbloodnoevidenceofaccumulationrapidandextensive(approximately95%)within48hmainlyviafaeces.biliaryfractionwasapproximately52%forthepyridylradiolabelextensivelymetabolised.biotransformationsobservedincludedaromaticringhydroxylation,hydrolysis,dealkylation,acetylation,oxidativen-dealkylationandconjugationwithglucuronicacid,sulphateandglutathione.furthermetabolismofglutathioneconjugatestocysteineconjugates.toxicologicallyrelev(animalsandplants)parentcompoundandm01(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>5000mg/kgbwratlc50inhal>5.16mg/l(themeanachievedconcentration,4hnoseonly)non-irritantnon-irritantnotsensitising(buehlerandmagnussonandkligmanmethods)shorttermtoxicity(annexiia,point5.3)liver,kidney,spleenandredbloodcellparameters17.7mg/kgbw/day;28-daydietarystudyinrats7.4mg/kgbw/day;90-daydietarystudyinrats70mg/kgbw/day;90-daydog300mg/kgbw/day;1-yeardog'", "j.efsa.2009.310r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsor83-92%(urineandair)within32hour(0.4mg/kgbw,rat)large,highestresidueinlivernoevidenceofaccumulation92%ofphenylpartwithin48hmainlyviaurine(89%)andfaeces(2.5%);carbamatemoietyexcretedwithin32hinairasco2oxidationatc-3,generating3-oh-metabolites,furtheroxidation(3-ketocarbofuran)and/orexcretionasconjugateshydrolysisofcarbamatebondintoco2t(animalsandplants)carbofuranandmetaboliteswiththecarbamatemoiety(environment)carbofuranandmetaboliteswiththecarbamatemoietyacutetoxicity(annexiia,point5.2)ratld507mg/kgbwt+,r28ratld501000<ld50<2000mg/kgbwxn,r21ratlc500.05mg/l(13mg/kgbw)t+r26non-irritantnon-irritant,butmortalityreported(rabbits)t;r39/41skinnon-sensitiser(bhlerandm&k)shorttermtoxicity(annexiia,point5.3)testiculardegeneration,clinicalsignsofneurotoxicityrelatedtoacheinhibition(ratsanddogs)0.1mg/kgbw/day,1-yeardogand60day,rat(publishedstudy)25mg/kgbw/day(21day,rabbit)nodata-notrequired'", "j.efsa.2009.327r.pdf": "appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandnearlycomplete(82%at48hrsaftersingleoraladministration),plasmacmaxat0.75-4hrsafterbothsinglelowandhighoraldoseadministrationdistributionwidelydistributed;highestconcentrationinadrenals,fat,kidneys,liver,skinandbloodpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandhigherthan90%at168hrs,mainlyviabile,otherwiseviafaeces,regardlessofdoselevelmetabolisminanimalsextensivelymetabolized,mainlythroughconjugation(75%oftheurineresidue),reductionofnitro-groups,n-dealkylation,hydroxylationandcyclizationreactions.numerousminorurinarymetabolites(<5%oftheurineresidueor<2%oftheinitialdose);fourfaecalidentifiedmetabolites(1-9%ofthedose).nospeciesdifferencetoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.252mg/l/4-hour,headonlyexposureskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweightgain,increasedalpha-1globulinandalbuminconcentrations(rat),anaemia'", "j.efsa.2009.332r.pdf": "impactonhumanandanimalhealthefsanoteafterthewrittenprocedure:thermsinformedefsathatunderthebiocideapplication10,diflubenzuronwasdiscussedatthebiocidetechnicalmeetingheldinarona,march200911accordingtotherms,thedatabaseavailablewasdifferentfromtheonediscussedinthepraper64.basedonthatdataset,themetabolismandthereferencevaluesfordiflubenzuronmightbedifferent.theissuehasbeenhighlightedtothecommissionforconsideration.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionoralabsorptionapprox.33%,basedonurinaryexcretiondistributionuniformlydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionexcretionalmostcompletein24hoursmetabolisminanimalsextensivelymetabolised(approx.40%bydechlorination,glucuronidation,sulphationandhydrolysis).toxicologicallyrelevantcompounds(animalsandplants)parentcompound,pcaandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>4640mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.5mg/l,4h(nose-only,dust)skinirritationnon-irritant10evaluatedunderdirective98/8/ecoftheeuropeanparliamentandofthecouncilof16february1998concerningtheplacingofbiocidalproductsonthemarket11biocidestechnicalmeeting(tmi09).arona,italy,16-20march2009'eyeirritationnon-irritantskinsensitisationnon-sensitizer(magnusson&kligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffecthaemolyticanaemiarelevantoralnoaelrat(90-day):11mg/kgbw/dmouse(90-day):9.7mg/kgbw/ddog(1-year):10mg/kgbw/drelevantdermalnoaelrat(21-day):1000mg/kgbw/d(highestdoseleveltested).rabbit(3-weeks):322mg/kgbw/d(highestdoseleveltested).relevantinhalationnoaelrat(4-weeks):0.1mg/l(highestdoseleveltested).rabbit(3-weeks):1.9mg/l(highestdoseleveltested).genotoxicity(annexiia,point5.4)..nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffecthaemolyticanaemiarelevantnoaelrat(2-years):31mg/kgbw/dmouse(91-weeks):6.4mg/kgbw/dcarcinogenicitynocarcinogenicpotential'", "j.efsa.2009.333r.pdf": "appendix1.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionuptoabout90%absorbedwithin72h,basedonurinaryexcretiondata.distributionlessthan1.5%ofadministereddosedetectedintissuesandcarcassat72hafterdosing,mainlyinliverfollowedbyskin,fat,boneandgitract.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion>90%oftotaldoseexcretedwithin72h.76-88%oftotaldoseexcretedinurineand6-14%oftotaldoseexcretedinfeces.metabolisminanimalsmalathionismainlymetabolisedthroughhydrolysis.majormetabolitesaremalathiondicarboxylicacidandmalathionmonocarboxylicacid.toxicologicallysignificantcompounds(animals,plantsandenvironment)malathionandmalaoxonimpurities(isomalathionsignificantlyincreasesthetoxicityofmalathion).desmethylmalathion,malathionmono-anddicarboxylicacidswhichareallcholinesteraseinhibitors.acutetoxicity(annexiia,point5.2)ratld50oral1778mg/kgbw(0.44%isomalathion)r22ratld50dermal>2000mg/kgbw(0.43%isomalathion)ratlc50inhalation>5mg/lair/4h(0.43%isomalathion)skinirritationnon-irritant(0.43%isomalathion)eyeirritationnon-irritant(0.43%isomalathion)skinsensitization(testmethodusedandresult)sensitising(magnussonandkligmantest)(0.43%isomalathion)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectacetylcholinesteraseinhibition(enzymeactivityinbrain)lowestrelevantoralnoael/noel34.4mg/kgbw/d,90drat(0.03%isomalathion),lowestrelevantdermalnoael/noel300mg/kgbw/d,21drabbit(0.2%isomalathion),lowestrelevantinhalationnoael/noel90drat:0.45mg/l(0.03%isomalathion)'", "j.efsa.2009.334r.pdf": "mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodata,notrequired.potentialforacc(animalsandplants)(environment)acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbw(f)ratld50>2000mg/kgbw(m/f)ratlc50nodata,notrequirednonirritantnonirritantnonsensitiser(llna)shorttermtoxicity(annexiia,point5.3)tarrat28-doralstudy:nocriticaleffectnoael:1000mg/kgbw/d(highestdoseleveltested)nodata,notrequirednodata,notrequired(annexiia,point5.4)amestest:negativemutationassayatthetklocusinmouselymphomacells:negativenogenotoxicpotential.longtermtoxicityandcarcinogenicity(annexiia,point5.5)nodata,notrequiredreleva'", "j.efsa.2009.336r.pdf": "hapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption40%basedonradiolabelrecoveredinurine,cagewashandbilewithin48h.distributionlimited(0.1-0.3%intissues);highestresiduesinfatandliver.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapid:mainlyfaecal(46-74%in24h)andurinary(3-9%in24h)metabolisminanimalsextensivelymetabolisedtoxicologicallyrelevantcompounds(animalsandplants)pyriproxyfentoxicologicallyrelevantcompounds(environment)pyriproxyfenacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.3mg/l(max.attainableconc.)(4h;wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,redbloodcellsrelevantoralnoael10mg/kgbw/d(1-yr,dog)24mg/kgbw/d(13-wkand6-mo,rat)relevantdermalnoael1000mg/kgbw/d(21-d,6h/d,rat)relevantinhalationnoael482mg/m3(4-wk,rat,4h/day,wholebody)genotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2009.343r.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive(>80%,basedonurinaryandbiliaryexcretion,tissues,carcassandcagewashwithin24h)atlowdoses(singleandrepeated).saturationathighdosage.distributionprimarilyblood,liverandkidneyspotentialforaccumulationnonerateandextentofexcretionrapidandextensive.sexanddosedependent.atlowdoses,excretioninmalesisprimarilyinfaeces(56%),whileinfemalesprimarilyinurine(69%).athighdoses,faecalexcretionpredominantinbothsexes,verylikelyduetounabsorbedmaterial.metabolisminanimals36metabolitesidentified,duetohydroxylation,demethylation,minorsulphonamidebridgecleavage,andconjugationreactions.however,mostoftheexcretedradioactivity(>55%)wasassociatedwiththeparentcompound.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitebstcatoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>3.5mg/lair/4hhighestattainableairconcentration,zerodeathsin10animalstested(nose-only)skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitizer(maximizationtest)'", "j.efsa.2010.1389.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretion,andmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption80-85%oralabsorptioninratsforfemalesandmalesrespectively(basedonurinary+cagewash,biliaryandtissues-excludinggicontent)within48hdistribution168hpostdosing,tissueradioactivitylevelwasbetween0.15%-0.84%;highestmeantissueresidueswerefoundinliver,fatandgitpotentialforaccumulationnopotentialforaccumulationinrepeatedoralcomparedtosingleoraldoseadministrationrateandextentofexcretionrapidlyexcreted(about80%)inratswithin48hours;themajorrouteisfaecesformales(67%)whileinfemaleseliminationismorebalancedbetweenurineandfaeces(42%urine,46%faeces)metabolisminanimalsbyhydroxylation,oxydationando-decarboxylation,andconjugationtosulphateand/orglucuronideconjugatestoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.77mg/l/4h,wholebodyexposureskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotaskinsensitizer(buehlerandm&mtests)short-termtoxicity(annexiia,point5.3)target/criticaleffectrat:liver(increaseliverweight,hepatocyticvacuolation,increaseserumast,protoporphyrinixaccumulation),anaemiarelevantoralnoaelrat90-day:18mg/kgbw/daydog90-day:25mg/kgbw/daydog1-year:20mg/kgbw/dayrelevantdermalnoael<250mg/kgbw/day(28-dayrat)1000mg/kgbw/day(21-dayrabbit)'", "j.efsa.2010.1441.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidlyabsorbedviainhalationexposure(noseonly),achievingmaximumconcentrationsof35s-sulfurylfluoride-derivedradioactivityinbothplasmaandredbloodcellsneartheendofthe4-hrexposureperiod.theabsorbeddosewasestimatedtobe14%at30ppmand11%at300ppmdistributionsevendayspost-exposure,the35swasnotlocalisedtoanyspecifictargetornon-targettissue.potentialforaccumulationincreasedintakeoffluoridemayleadtofluorosis(i.e.accumulationoffluorideinbonesandteeth)rateandextentofexcretionrapidlyexcreted,primarilyviatheurine.alargeportionoftheabsorbed35swasexcretedintheurineevenduringthe4-hourexposureperiod.metabolisminanimalssulfurylfluorideisfirsthydrolysedtofluorosulfate,withreleaseoffluoride,followedbyfurtherhydrolysistosulfateandreleaseoftheremainingfluoride.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentandfluorideion.acutetoxicity(annexiia,point5.2)ratld50oralca.100mg/kgt,r25ratld50dermalnoadverseeffectsfrom40.3mg/litre(4hourexposure)ratlc50inhalation4.1-4.7mg/litre(4hourexposure)mouselc50inhalation1.668-2.802mg/litre(4hourexposure):toxic;r23toxicbyinhalationskinirritationnodata(notrequired)eyeirritationnodata(notrequired)skinsensitization(testmethodusedandresult)nodatasubmitted,butuseexperiencehasshownoadverseeffectswithrespecttothisendpoint.shorttermtoxicity(annexiia,point5.3)target/criticaleffectlocaleffectonrespiratorytractinallspecies(brainvacuolationincerebrum(rat/dog/mouse)kidney-mildhyperplasia(rat)brainminimalvacuolation&gliosis(dog)r48/20harmful:dangerofseriousdamagetohealthbyprolongedexposurethrough'", "j.efsa.2010.1445.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive>80%within24htmax=0.4hatlowdose(2mg/kg)distributionextensivewithpeaktissueconcentrationspeakbloodconcentrationsexceptinliver,kidney,adrenals,thyroidandgitract.potentialforaccumulationnonerateandextentofexcretionrapidmostlyviaurine7080%within24h;lowbiliaryexcretion(~5%ad).metabolisminanimalsproceedsintheratbynitrile&amidehydrolysis,n-oxidation,hydroxylationofpyridineringmaincomponentinurine,faecesandbile:iki-220(upto70%ad);mainmetaboliteinurineandbile:tfna-am(upto27%ad);minormetabolites:tfnaandconjugates,tfng-am,tfna-amnoxideconjugate,oh-tfna-am,tfngtoxicologicallyrelevantcompounds(animalsandplants)parentsubstancetoxicologicallyrelevantcompounds(environment)parentsubstance,impuritytolueneacutetoxicity(annexiia,point5.2)ratld50oral8841768mg/kgbw(mf)r22ratld50dermal>5000mg/kgbw-ratlc50inhalation>4.9mg/l(4h,nose-onlyaerosol)(mmad4.8m)-skinirritationnonirritant-eyeirritationnonirritant-skinsensitisationnotsensitising(m&ktest)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney(rat,dog),liver(mouse,rat),haematopoieticsystem(mouse,dog)relevantoralnoael8mg/kgbw/d(dog90-dand52w)60mg/kgbw/d(rat,90-d)15.3mg/kgbw/d(mouse,90-d)-relevantdermalnoael1000mg/kgbw/d(rat,28-daystudy)-relevantinhalationnoaelnostudynotrequired-'", "j.efsa.2010.1448.pdf": "commissionasrelevantformemberstateswhenapplyingtheuniformprinciples29efsajournal2010;8(1):1448water(analyticaltechniqueandloq)nodatasubmitted.notrequiredair(analyticaltechniqueandloq)nodatasubmitted.notrequiredbodyfluidsandtissues(analyticaltechniqueandloq)nodatasubmitted.notrequiredclassificationandproposedlabellingwithregardtophysicalandchemicaldata(annexiia,point10)rapporteurmemberstate/peerreviewproposalactivesubstancenoneimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:nodatanotrequireddistribution:nodatanotrequiredpotentialforaccumulation:nodatanotrequiredrateandextentofexcretion:nodatanotrequiredmetabolisminanimalsnodatanotrequiredtoxicologicallysignificantcompoundsfenugreekseedpowderacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kg(defattedfenugreekseedpowder)ratld50dermalnodatanotrequiredratlc50inhalationnodatanotrequiredskinirritationnonirritant'commissionasrelevantformemberstateswhenapplyingtheuniformprinciples30efsajournal2010;8(1):1448eyeirritationnonirritantskinsensitization(testmethodusedandresult)nonsensitiser(llna).short-termtoxicity(annexiia,point5.3)target/criticaleffectnonerelevantoralnoael2500mg/kg(90-dayoralrat)studyofpoorqualityrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)negative(amestest)long-termtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodatarelevantnoaelnodatacarcinogenicitynodatanotrequiredreproductivetoxicity(annexiia,point5.6)reproductiontarget/criticaleffectinsufficientdata.potentialforreproductivetoxicityinhumanscannotbefullyexcludedbasedontheavailabledataandindicationsfromthetherapeuticuseoffenugreek.relevantreproductivenoaelsnotderivablefromtheavailableinformation.'", "j.efsa.2010.1523.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,60%in0-8hurine;tmax0.5hat15mg/kgbwextensive,80-90%(basedonurinaryexcretionwithin48hofsingleorrepeatdoseof15mg/kgbw).lowerabsorptionathigherdoselevel(600mg/kgbw/d).distributionat4hpostdose,highestsystemicconcentrationsinblood,plasmaandkidneyspotentialforaccumulationevidencesuggestsnosignificantpotentialforbioaccumulationatlowdoselevelsrateandextentofexcretion>85%ofacutedoseexcretedwithin24h,mainlyviaurine(>75%ofdose)metabolisminanimalslimitedmetabolism(80-90%oflowdoseexcretedunchanged),involvingoxidationandglucuronidation.2unconjugatedmetabolites:bh518-2andbh518-4.toxicologicallyrelevantcompounds(animalsandplants)parentand/ormetabolitesaccountfortoxicitytorats.noplantmetabolitesofparticulartoxicologicalconcernforhumanhealthhavebeenidentified.toxicologicallyrelevantcompounds(environment)quinmeracacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.4mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationslightlyirritating(noclassificationproposed)skinsensitisationnon-sensitiser(magnusson&kligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectredbloodcells(dog)relevantoralnoael1-yeardog:7.9mg/kgbw/day'", "j.efsa.2010.1526.pdf": "rateandextentofabsorptionoral,24hours,ratslowdose(1.25mg/kgbw):71(m)117(f)%ratshighdose(20mg/kgbw):63(m)117(f)%(basedonurinaryexcretion(96hours)afteroralorintravenousadministration).distributionwidelydistributed,highestconcentrationinliverandkidney.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidlyexcreted(ca50%urineand40%faecesafter24hours).metabolisminanimalsmajorpathwaysincludeepoxidation,epoxidehydratation,alcoholoxidation,oxidative0-dealkylation.toxicologicallysignificantcompounds(animalsandplants)imazaliltoxicologicallyrelevantcompounds(environment)imazalilratld50oral227(f)371(m)mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation1.84mg/lairskinirritationnonirritanteyeirritationsevereeyeirritantsensitizationnon-sensitizing(m&k)target/criticaleffectliverandkidney(increasedweight)relevantoralnoael2.5mg/kgbw/day(1-yrdog)5mg/kgbw/day(90-dand6-morat)relevantdermalnoael>160mg/kgbw/day(28-drabbit)relevantinhalationnoaelnodata,notrequirednogenotoxicpotentialtarget/criticaleffectliver(weight,pathology)relevantnoael3.5mg/kgbw/day(24-morat)8.1mg/kgbw/day(24-momouse)carcinogenicityliverandthyroidtumoursathighdoses(60mg/kgbw/d),thyroidtumoursnotrelevantforhumanbasedon'", "j.efsa.2010.1554.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandextensivelyabsorbedafteroraladministration(>90%within48h)distributionhighestlevelsinliver,plasmaandkidney.lessthan0.2%oftheradioactivedosewasretainedinerythrocyte(m-label).potentialforaccumulationnopotentialforaccumulationrateandextentofexcretion74-81%waseliminatedintotheurineand16-25%tofaeces.11%(females)and17%(males)weredetectedinbileexcretain48hours.metabolisminanimalsapproximately60-73%ofthedosewaseliminatedunchangedintotheurineandfaeces.testsubstancewasmetabolisedbythefollowingroutes:o-demethylationtoin-jj999,mainmetaboliteaccountingforca.40-50%ofthetotalmetabolitesinexcreta;pyrimidineringhydroxylationandcleavage;hydrolysisofthesulfonylureabridge;n-demethylationofthemethylpyrazoleormethyltetrazole.13metaboliteswereidentifiedinurine,faeces,bileandtissues.toxicologicallyrelevantcompounds(animalsandplants)azimsulfurontoxicologicallyrelevantcompounds(environment)azimsulfuronacutetoxicity(annexiia,point5.2)ratld50oral>5,000mg/kgbwmouseld50oral7,161mg/kgbwratld50dermal>2,000mg/kgbwratlc50inhalation>5.94mg/l(4h,whole-bodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotaskinsenzitizer(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectpancreas,liverandbodyweight(rat,mouse,dog),redandwhitebloodcellsandassociatedorgans(rat,dog)relevantoralnoael17.9mg/kgbw/d(1-yrdog)75.3mg/kgbw/d(90-drat)131.7mg/kgbw/d(90-dmouse)relevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2010.1555.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabout80%basedonurinaryexcretiondistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidlyexcreted;about80%viaurineand20%viafaecesin24hoursmetabolisminanimalshydrolysis,excretedessentiallyasfreeacidandglucuronideconjugatestoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.21mg/lskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneyandhaematotoxicityathighdoselevelsrelevantoralnoael90-drat:73mg/kgbw/d90-dmice:384mg/kgbw/d1-year,dog:20mg/kgbw/drelevantdermalnoael28-drat:1000mg/kgbw/drelevantinhalationnoaelnodata,notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectkidneyatveryhighdoselevels'", "j.efsa.2010.1558.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabsorptionwasrapidandalmostcomplete(>88%).distributionwidelydistributed.highestlevelsinliver,kidneysandadrenals.potentialforaccumulationnoevidenceforbioaccumulation.rateandextentofexcretionrapidlyexcreted(>75%in24hours,urineandmetabolisminanimalsextensivelymetabolised,mainlybyoxidation,hydrolysisandconjugation(3-7%ofunchangedparentinfaeces).ca2.5%ofthedosewascleaved.toxicologicallyrelevantcompounds(animalsandplants)parentandtriazolederivativemetabolites(tdms).toxicologicallyrelevantcompounds(environment)parentand1,2,4-triazoleacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation>2.10mg/l(4h,noseonly,maximumtechnicallyachievable)-skinirritationnotirritant-eyeirritationnotirritant-skinsensitisationnon-sensitising(buehlertestandm&ktest)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgain,livereffects(clinicalchemistry,increasedliverweight,hepatocellularhypertrophy).relevantoralnoael5.7mg/kgbw/d(3-morat)3.3mg/kgbw/d(3-modog)0.62mg/kgbw/d(12-modog)relevantdermalnoael1000mg/kgbw/day(topdosetested).relevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)noevidenceofgenotoxicityintheavailablestudies.-'", "j.efsa.2010.1565.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorption>90%basedonurinary(15%)andbiliary(78%)excretionwithin24h.highestbloodconcentrationafter6hours.distributionuniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(approx.90%)within72h.majorityexcretedwithin24hoursmainlyviaurine(42-52%)and23-34%viafaeces,78%ofdoseviabilewithin24hindicatingextensiveenterohepaticcirculation.metabolisminanimalsextensivelymetabolised(>99%);15metabolitesinurineandfaeces;metabolicpathway:dealkylation,hydroxylation,hydrolysisfollowedbyconjugationtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.8mg/l/4h(nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)non-sensitiser(modifiedbuehlertests)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver;rat,dog(increasedweight,hepatotoxicity)bodyweightchange;dogrelevantoralnoael1-year,dog:50mg/kgbw/day90-day,rat:50mg/kgbw/dayrelevantdermalnoael30-day,rat:>1000mg/kgbw/dayrelevantinhalationnoaelnodataavailable-notrequiredgenotoxicity(annexiia,point5.4)overallnegativeininvitrotests,butpositiveresponseinin-vitro(mammaliancellgenemutationtest).noevidenceforgenotoxicityin-vivo.'", "j.efsa.2010.1592.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrats(bothsexes):tmax=4h,theoralabsorptionbeingat5mg/kgbw:68.4-76.2%inmales83.4-89.7%infemalesenhancedbyrepeateddosingat100mg/kgbw:59.1%inmales70.6%infemalesmice(males):tmax=6h,20.6%oralabsorption(at100mg/kgbw)dogs(males):tmax=4h,19.2%oralabsorption(at100mg/kgbw)distributionwidelydistributedthroughoutthebody(rats,dogs),maximalresidueconcentrationintheplasma.potentialforaccumulationratiosoftissue/plasmalevelslowerthan1,suggestingnopotentialstorageofresiduesintissues.rateandextentofexcretionrats:biphasiceliminationinitialandterminaldepurationhalf-lives:9hand60heliminationviaurine(21%inmales,65%infemales)andfaeces(28%inmales,14%infemales);quickerinfemales(ca.80%within48hours)thaninmales(ca.50%within48hours)dogs(males):monophasicelimination(half-life:73h)4.2%eliminatedinurineand73%viafaeceswithin24hoursmice(males):monophasicelimination(half-life:54h)11%eliminatedinurineand80%viafaeceswithin24hoursgoats:verylowexcretioninmilk(0.05%)metabolisminanimalsrats:mainurinarycomponentisunchangedmetosulam.aliphaticoxidationtoform3-ohmetosulam,o-demethylationtoform5-ohmetosulamandanilinephenyloxidationtoform4-ohmetosulam,whichissecondarilyconjugatedwithglucoseorsulfate.mice(males):extensivelymetabolized(4%ofurineradioactivityasunchangedmetosulam)dogs(males):'minimalmetabolismindogs(75-88%ofurineradio-activityasunchangedmetosulam)toxicologicallyrelevantcompounds(animalsandplants)metosulamtoxicologicallyrelevantcompounds(environment)metosulamacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.9mg/lair(4h/noseonly,twicegroundparticlesaerosol);maximalattainableconcentrationskinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitizing(m&kandbuehlermethods)shorttermtoxicity(annexiia,point5.3)target/criticaleffectretina(detachmentanddegenerationindogs)<50mg/kgbwkidneys(tubularepitheliumdegenerationinflammationinrats,dogsandrabbits)<50mg/kgbwindogsgallbladder(mucinaccumulationindogs,degenerationinflammationinrabbits)liver(inflammationnecrosisinmiceanddogs)relevantoralnoael10mg/kgbw/day(1-year,dog)9.4mg/kgbw/day(90-day,rats)250mg/kgbw/day(90-day,mice)<300mg/kgbw/day(14-day,rabbit)xnr48/22relevantdermalnoaelsystemicnoael:1000mg/kgbw/day(21-day,rabbits)localnoael:<100mg/kgbw/day(epidermichyperplasiaatthetestsite)relevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential(invitroandinvivo)'", "j.efsa.2010.1598.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,about80-85%,basedonoralandivstudiesdistributionwide,highestresiduesinliverandkidneypotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionabout85%completewithin72h(urine:~60%,faeces:~25%),morethan45%within6hmetabolisminanimalsextensivelymetabolised(oxidation,sulphateandglucuronideconjugates)toxicologicallyrelevantcompounds(animalsandplants)carbendazimandmetabolitestoxicologicallyrelevantcompounds(environment)carbendazimandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>10000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.8mg/lair(4-hexposure,head/nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(buehler)sensitiser(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(wt,clinicalchemistry,histologicalfindings),testes(wt,azoospermiaathighdoses),bwgainandfeedintakerelevantoralnoael90-d,rat:163mg/kgbw/d90-d,dog:2.7mg/kgbw/drelevantdermalnoael10-d(7d/wk)&21-d(5d/wk),rabbit(overall):localeffects:10mg/kgbw/dsystemiceffects:2000mg/kgbw/drelevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)numericalchromosomeaberrationsbothinvitroandinvivoasaresultoftheinterferencewithmitoticspindleproteins.thresholdconcentrationforaneugenicactivityinvitrobetween0.2-0.6g/ml;noelforaneuploidyinductioninvivo:50mg/kgbw.r46(muta.cat.2)'", "j.efsa.2010.1631.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabout45%,basedonurinaryexcretionwithin24h.maximumconcentrationinplasmawithin4hafteradministration.distributioninitiallywidelydistributed;highestresiduesinfat(mainly),ovaries,thyroidandskinat96h.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion>90%after48h(at40mg/kgbw)orafter120h(at400mg/kgbw);about45%viaurineand45%viafaeces.metabolisminanimalsextensivemetabolismofdoseexcretedinurine:beta-oxidationpathwaytohydroxydodecylguanidine(m2,11-23%majormetaboliteinurine)andmixtureofacidicproductsofbeta-oxidation(m4,8-13%inurine);othermetabolitesinurine:m3(7-11%,unidentified)andm5(urea,3-5%).upto55%ofdoseexcretedasparentinfaeces(m1).toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral851mg/kgbwxn,r22ratld50dermal>5000mg/kgbwratlc50inhalation>0.45mg/l4h,noseonly,particulateaerosolt;r23skinirritationirritantxi;r38eyeirritationriskofseriousdamagetoeyesxi;r41skinsensitisationnon-sensitiser(magnusson&kligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweightgainandfoodintakerelevantoralnoael10mg/kgbw/day(90daysand1yrdog)relevantdermalnoael50mg/kgbw/day(28-drat,systemiceffects)<50mg/kgbw/day(28-drat,localeffects)relevantinhalationnoaelnodataavailablenotrequired.'", "j.efsa.2010.1632.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption50%(basedonbiliaryandurinaryexcretionwithin48h)distributionhighestresiduesinliver,kidneys,uterus,ovaryandlymphnodesat2h.potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionextensivewithin72h:mainlyviafaeces(67-84%),4-24%viaurine,<0.07%viaexpiredair(168h)metabolisminanimalsmetabolised;manymetaboliteswereidentified,buttheidentificationofonlyafewwasconfirmed.toxicologicallyrelevantcompounds(animalsandplants)pyridabentoxicologicallyrelevantcompounds(environment)pyridabenacutetoxicity(annexiia,point5.2)ratld50oral161mg/kgbwtr25ratld50dermal>2000mg/kgbwratlc50inhalation0.62mg/lair/4h(wholebody)tr23skinirritationnon-irritanteyeirritationnon-irritantskinsensitisation(m&k)non-sensitisingshorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgainor/andbodyweightrelevantoralnoael2.7mg/kgbw/day(13-wkrat)4.1mg/kgbw/day(13-wkmouse)1.0mg/kgbw/day(3-moand1-yrdog)relevantdermalnoael100mg/kgbw/day(4-wkrat)relevantinhalationnoael3.0mg/m3(0.84mg/kgbw/day)(4-wkrat)genotoxicity(annexiia,point5.4)nogenotoxicpotential.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectreducedbodyweightgainor/andbodyweight'", "j.efsa.2010.1653.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive(>95%within24h)basedonexcretioninurine.maximumbloodconcentrationreachedat0.5hafterlowdoseadministration.distributionsmallamountfoundincarcass(0.3%)andinallothertissuescombined(lessthan0.01%)168hafteradministration.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion>95%excretedinurineand1%infaeceswithin24h.slightlylowerexcretionrateathighdoselevelandinfemales.metabolisminanimalsextensivelymetabolised,mainlybyconjugationwithsulphuricacidandglucuronicacidtoformhymexazol-o-sulfate(tos,about50%atthelowdoselevel)andhymexazol-o-glucuronide(togl,about40%atthelowdoselevel).anotherminorpathwayinvolvesenzymaticreductiontoform3-hydroxybutamideand3-hydroxybutyricacid.toxicologicallyrelevantcompounds(animalsandplants)hymexazoltoxicologicallyrelevantcompounds(environment)hymexazolacutetoxicity(annexiia,point5.2)ratld50oral1600mg/kgbwr22mouseld50oral1700mg/kgbwrabbitld50dermal>2000mg/kgbwratlc50inhalation>0.65mg/l/4h(highestattainableconcentration,aerosol,wholebody)skinirritationnon-irritanteyeirritationseverecornealopacitywithhyperaemicbloodvessels.r41skinsensitisationsensitising(magnusson-kligmanmaximisationtest)r43'", "j.efsa.2010.1669.pdf": "6.6.impactonhumanandanimalhealth6.6.1.1.absorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive(>95%),basedonurinaryandbilaryexcretionwithin48hdistributionwidelydistributed;highestlevelsfoundinliver,kidneys,thyroidglandandbloodcellspotentialforaccumulationnopotentialforaccumulationrateandextentofexcretion95%excretedwithin120h,mainlyviaurine(72-86%),14-26%viafaecesmetabolisminanimalsextensivelymetabolized:mainmetabolitestso(oxidationofsulphur);andt1so(oxidationofsulphurandn-de-ethoxylation)toxicologicallyrelevantcompounds(animalsandplants)cycloxydimtoxicologicallyrelevantcompounds(environment)cycloxydim6.6.1.2.acutetoxicity(annexiia,point5.2)ratld50oral3940mg/kgbwmouseld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.28mg/lair;4h,head/nose-exposureskinirritationslightlyirritantnoclassificationrequiredeyeirritationslightlyirritantnoclassificationrequiredskinsensitizationnotsensitizing(m&k-test)6.6.1.3.shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(increasedorganweight,clinicalchemistrychanges)(rat,dog);anaemia(dog)relevantoralnoael3-modog:10mg/kgbw/d3-morat:22mg/kgbw/drelevantdermalnoael4-wkrat:300mg/kgbw/drelevantinhalationnoaelnodata-notrequired6.6.1.4.genotoxicity(annexiia,point5.4)weaklygenotoxicinvitroatcytotoxicconcentrations.nogenotoxicpotentialinvivo.6.6.1.5.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectbodyweightreduction,decreaseintriglycerides(females)relevantnoael24and18-morat:7mg/kgbw/d24-momouse:32mg/kgbw/dcarcinogenicitynoevidenceofacarcinogenicpotential'", "j.efsa.2010.1671.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorptionfollowingoraladministration,rapidabsorptionoftheevolvingphosphinedistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidexcretionwithurineashypophosphiteandphosphiteandvialungsasphosphinemetabolisminanimalshydrolysistophosphine,oxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)phosphinetoxicologicallyrelevantcompounds(environment)zincphosphideandphosphineacutetoxicity(annexiia,point5.2)ratld50oral12mg/kgbw(zincphosphide)r28ratld50dermalapprox.1000mg/kgbw(zincphosphide)r21ratlc50inhalation>11ppm(>0.016mgph3/lairor>2.8mg/kgbw)(4hexposure,wholebody)(phosphine)skinirritationnotirritant(zincphosphide)eyeirritationnotirritant(zincphosphide)skinsensitisationnoindicationofskinsensitisation,m&k-testusingzincphosphideshorttermtoxicity(annexiia,point5.3)target/criticaleffectmortalityrelevantoralnoaelnoreliabledata,nostudyrequiredrelevantdermalnoaelnodata,nostudyrequiredrelevantinhalationnoaelnoael3ppmphosphine(equivalentto1.1mg/kgbw/d),rat90-d,thehighestdosetestedgenotoxicity(annexiia,point5.4)noevidenceofagenotoxicpotentialatrealisticexposurelevels'", "j.efsa.2010.1682.pdf": "revisedinfebruary2010impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionrapidandextensive(100%within96h)afterlowdoseapplicationdistributionwidelydistributed;highestlevelsinliver,kidneys,intestineandadrenalspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion>80%within96hevenlydividedbetweenurine(35-48%)andfaeces(31-44%)metabolisminanimalsextensivemetabolisminrats(lowlevelofparentcompoundinurineandfaeces)byoxidationofthebutylsidechain;nocleavageofthemolecule.toxicologicallysignificantcompounds(animals,plants)myclobutanilandmetabolites(rh-9089,rh-9090)toxicologicallysignificantcompounds(environment)myclobutanilacutetoxicity(annexiia,point5.2)ratld50oralmale=1600mg/kgbwxn,r22female=2290mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.1mg/l4h,noseonly,highestobtainableconcentrationskinirritationnon-irritanteyeirritationnonirritating(accordingtoavailableinformation),butalreadyclassifiedatecbxi,r36skinsensitization(testmethodusedandresult)non-sensitiser(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverlowestrelevantoralnoael/noel3.09mg/kgbw/day.(90dand1ydog)lowestrelevantdermalnoael/noel100mg/kgbw/d(4wkrat)lowestrelevantinhalationnoael/noelnodata-notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffecttestes(atrophy,oligospermatogenesis)(rats);liver(mice)'", "j.efsa.2010.1692.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionabsorptioncompleteandrapid(peakplasmalevelswithin15minto1hafterdosing),somesaturationofabsorptiveprocessesevident(30mg/kgbw)distributionprimarilytoliver,lung(andplasma);considerableradioactivityingitatsacrificepotentialforaccumulationnonerateandextentofexcretionrapid,extensive(>90%);primaryroute:faecal,mainlybybiliaryexcretion(~80%inmalesand50%infemales)secondaryroute:urinary(10%inmales,30%infemales)metabolisminanimalslimitedmetabolism:bispyribac-sodiumisthemajorcomponentinallmediaexceptmalemiceurine.sixmetabolitesformed,noneofthemmajor.demethylationistheprimarymetabolicpathway,leadingtotheprimarymetabolitedesme-2023/desme-5750(m06/m01);m06wastheprimarycomponentinmalemouseurinetoxicologicallyrelevantcompounds(animalsandplants)bispyribac(andbispyribac-sodium)toxicologicallyrelevantcompounds(environment)bispyribacanditssalt,expressedasbispyribac-sodiumacutetoxicity(annexiia,point5.2)ratld50oral2635mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.48mg/l/4h(wholebody,dustexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitization(testmethodusedandresult)sensitiser(magnusson&kligmantest);r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver/bileductproliferation(rat,mouseanddog)redbloodcells(rat)relevantoralnoael7.2mg/kgbw/d(90-drat)10mg/kgbw/d(52-wkdog)6.8mg/kgbw/d(90-dmouse)relevantdermalnoael1000mg/kgbw/d(21-drat,highestdosetested)relevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectliver,redbloodcells(ratsandmice)relevantnoael1.1mg/kgbw/d(2-yrrat)14.1mg/kgbw/d(104-wkmouse)carcinogenicitynocarcinogenicpotentialreproductivetoxicity(annexiia,point5.6)reproductiontoxicityreproductiontarget/criticaleffectnoreproductivetoxicity.liverandbileductsin'", "j.efsa.2010.1698.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption:rapidandalmostcomplete(>93.4%),basedonurinaryandfaecalexcretion.majorradioactivityrecoveredwithin24-48h.distribution:highestlevelsinliver,carcass,kidneyandblood.potentialforaccumulation:noevidencerateandextentofexcretion:mainlyviaurine.at5mg/kg(repeated):urine:86.3%,faeces:9%(168h).at5mg(single):urine:76.6%,faeces:13.6%(96h).at500mg/kg(single):urine67.9%;faeces:21.9%.metabolisminanimalsrats:extensivelymetabolised.metabolitesinurine61.1-84.2%oftheurinaryradioactivity.threemainmetabolicpathways:1)reduction,deaminationandhydroxylationofthenitrogroup(mainpathway).2)dechlorinationandhydroxylation.3)glutationepathway.majorurinemetabolites:dcha,dcha-sulfate,dcha-glucuronide,dcapanddcnap.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompound.acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationduetotechnicalrestrictions,testnotpossibleatconcentrationsconcentrations<0.6mg/lisnotjustified.skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising.gpmtofmagnussonandkligmanrespiratorysystemirritationnon-irritantshorttermtoxicity(annexiia,point5.3)target/criticaleffectliverpolycythemia,hypercholesterolemiaandsplenichaematopoiesisandhemosiderosis/increaseinliverweights,apandcholesterollevels,hepatocytehypertrophyandhaemolyticanaemia.relevantoralnoael2.5mg/kgbw/day(52-weeksindog)relevantdermalnoael120mg/kgbw/day(21daysrabbit)relevantinhalationnoaelnodata-notrequired'", "j.efsa.2010.1705.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandalmostcompletelyabsorbedafteraloworaldoseof5-6mg/kgbw.bilecannulatedratsshoweliminationof80%ofa5mg/kgbwdosewithin24h.atleast60%(basedonurinaryexcretion(ca.58%)andcagewash(ca.2%)within24h.athigherdosestheabsorptionwithin24hwasca.10-15%lower.afterrepeatedlowdose,theamountabsorbedfromthegutintotheliverismorethan80%.distributionrapidandwelldistributedintoorgansandtissues.highestamountsofradiolabelwerefromliver,kidney,kidneyfatandbrownfatwithconcentrationpeakbetween1and3hours.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapid,afterrepeateddosing,approximately80%or65%ofthelastadministereddoseisexcretedwithin24hafterrespectivelylowandhighdoses.metabolisminanimalsextensive,10metabolitesinurineandnoparentcompoundtoxicologicallyrelevantcompounds(animalsandplants)dichlobenil(parentcompound)andrelevantplantmetabolite:2,6-dichlorobenzamide(bam)toxicologicallyrelevantcompounds(environment)dichlobenilacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationnoacceptabledata-nostudyrequiredskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitizer(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(rat,mouse,hamster,dog)kidney(hamster,mouse)malereproductiveorgans(hamsters)relevantoralnoael52-weekdog:1mg/kgbw/day2-yeardog:1.3mg/kgbw/dayrelevantdermalnoael21-daymouse:>1000mg/kgbw/dayrelevantinhalationnoael28-dayrat:>12mg/m3'", "j.efsa.2010.1707.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorption:83%inbile-cannulatedratswithin24h(basedonurine+bile+tissuesandcarcass)maxbloodconcentrationby0.5to1hpost-dosing.a10-foldincreaseindoseonlyyieldsa3-foldincreaseinwholebloodauc.distribution:widelydistributedthroughoutthebody,highestresiduesafter7daysincarcass,blood,skinandliver.potentialforaccumulation:noevidenceofaccumulationrateandextentofexcretion:rapidandextensive:viaurine(44%ofthedosewithin24h),viafaeces(5%),viabile(26%).metabolisminanimalsextensivelymetabolised,verylargevarietyofmetabolites:upto31detectedinliver,19infecesand24inurine.metabolicreactionsincludeoxidation,de-alkylation,hydroxylation,cyclisation,nitro-reductionandacetylation.toxicologicallyrelevantcompounds(animalsandplants)oryzalintoxicologicallyrelevantcompounds(environment)oryzalin,or20,or13andor15acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(rat,mouse)rabbitld50dermal>2000mg/kgbwratlc50inhalation>4.79mg/lair(nominal)equivalentto>1mgrespirableparticles/lair(4h,aerosol,noseonly,maximumtechnicallyachievable)skinirritationnonirritanteyeirritationnonirritantskinsensitizationsensitiser(magnusson&kligman)r43'", "j.efsa.2010.1708.pdf": null, "j.efsa.2010.1709.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorptionoralabsorptionof~30%(within96h),basedonurinaryexcretionindogstakingintoaccountsomebiliaryexcretion(5-16%)observedinratsdistributionwidelydistributed,highestresiduesinliver,kidneyandfat(rat,dog)potentialforaccumulationnopotentialforaccumulationrateandextentofexcretion~90%within48hinrats,viafaeces(45-64%)andurine(25-39%);>90%within4dindogs,viafaeces(66-70%)andurine(25-27%)metabolisminanimalsextensivelymetabolised,oxidationofaliphaticgroupsintheacidandalcoholmoieties,estercleavagetoxicologicallyrelevantcompounds(animalsandplants)tefluthrintoxicologicallyrelevantcompounds(environment)tefluthrinacutetoxicity(annexiia,point5.2)ratld50oral21.8mg/kgbwt+,r28mouseld50oral45.6mg/kgbw-ratld50dermal177mg/kgbwt,r24ratlc50inhalation0.037mg/l(4h,noseonly,aerosol)t+,r26skinirritationslightlyirritating,noclassification-eyeirritationslightlyirritating,noclassification-skinsensitisation(testmethodusedandresult)notsensitising(m&ktest)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectbwgaindecreasedinratsanddogs,nervoussystem(tremor,ataxia)andthyroid(increasedweight)indogsrelevantoralnoaeldog:0.5mg/kgbw/d(13-and52-wk)rat:13.6mg/kgbw/d(13-wk)relevantdermalnoaelrat,21day:50mg/kgbw/d(systemiceffects);<0.11.0mg/kgbw/day(localeffectsincludingparesthesia)relevantinhalationnoaelnodatagenotoxicity(annexiia,point5.4)noevidenceofgenotoxicity'", "j.efsa.2010.1710.pdf": null, "j.efsa.2010.1711.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption4%:urinary(0.64%)andbiliaryexcretion(2.6%)andcarcassretaineddose(0.5%)within48hdistributionliver,kidney,heart(higherthanlimitofdetection)potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionfaeces(96%within48h)metabolisminanimalslimitedmetabolism.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandimpuritysd31723toxicologicallyrelevantcompounds(environment)parentcompoundandimpuritysd31723acutetoxicity(annexiia,point5.2)ratld50oral>3000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation0.046mg/l(wholebody,4hours)acuteinhalationnoaec:0.0285mg/l(nose-only,4hours)(=5.13mg/kgbw/d)t+;r26xi;r37skinirritationirritantr38eyeirritationirritantr36skinsensitisationmaximisationtest:notsensitiserllnawithformulation:sensitiserxi,r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectirritationonthesiteofcontactrelevantoralnoael90-dayrat:13.5mg/kgbw/d2yeardog:15mg/kgbw/drelevantdermalnoael15-dayrabbit:150mg/kgbw/d(loael)relevantinhalationnoaelnodataavailablegenotoxicity(annexiia,point5.4)fenbutatinoxideisunlikelytobegenotoxiclongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectirritationonthesiteofcontactrelevantnoael2-yearrat:5mg/kgbw/d18-monthmice:46mg/kgbw/dcarcinogenicityfenbutatinoxideisunlikelytoposeacarcinogenicrisktohumans'", "j.efsa.2010.1716.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption~80%(basedurine+bile+residualcarcass)distributionratshighestconcentrationwasfoundinstomachwall.greaterlevelsthanthatassociatedwithwholebloodwereintestinewall,liverkidneys,lungsandovaries.potentialforaccumulationnopotentialforaccumulationrateandextentofexcretion80-95%within24hmainlyviaurine(60%)metabolisminanimalsthemajorcomponentfoundinurinewashippuricacid;themonohydroxylatedmetaboliteof6bawasalsopresentasamajorcomponentinurine.otherminorcomponentsidentifiedinurinewerethehydratedadductofmonohydroxylated6ba,dihydroxylated6ba,andtheglucuronideconjugatesofboththemonoanddihydroxylated6ba.parent6bawasalsodetectedinurine,butwasveryclosetothelimitofquantification.themajoridentifiedcomponentsinthefaecalextractswerehippuricacidandisomersofbothmonoanddihydroxylated6ba.themajoridentifiedcomponentinbilewastheglutathioneconjugateofmonohydroxylated6ba.toxicologicallyrelevantcompounds(animalsandplants)6-benzyladeninetoxicologicallyrelevantcompounds(environment)6-benzyladenineacutetoxicity(annexiia,point5.2)ratld50oral2094and814mg/kgbwinmalesandfemalesrespectivelyand1584mg/kgbw(combined)r22ratld50dermal>2000mg/kgbwinbothsexesratlc50inhalation>5.0mg/linbothsexesskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitizingshorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:lowerbodyweight,lowerbloodglucoselevel,kidneychanges:dilatedrenalpelvises,mineralisedsemifluidmaterialwithinthepelvisesandsecondaryinflammation.limitedinformationonotherspecies(miceanddogs)'", "j.efsa.2010.1718.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%,basedonbile,urine,blood,carcassandskinrecoveries48hafteradministrationdistributionwidelydistributedwithlowlevelsintotheorgansandtissues(ratbileexcretionstudy).thehighestresiduesarefoundinfatpotentialforaccumulationnonerateandextentofexcretionrapidandcomplete(97%in4days)eliminatedmainlyviafaeces(77%)andurine(16%)until96h;73%excretedviabileafter48hmetabolisminanimals2mainmetabolites(cleavageoftheestermoietyandhydroxylationofdichlorophenylring)toxicologicallyrelevantcompounds(animalsandplants)diclofop-methyltoxicologicallyrelevantcompounds(environment)diclofop-methylacutetoxicity(annexiia,point5.2)ratld50oral>512mg/kgbwr22ratld50dermal>2000mg/kgbw(rat)~200mg/kgbw(rabbit)-t,r24*ratlc50inhalation>1.36mg/lair/4h,nose-onlyexposure-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationsensitising(m&k)r43*noclassificationbythedermalroutehasbeenagreedbyecha(seeclassificationandproposedlabellingwithregardtotoxicologicaldata)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver:liverenzymeactivities,livermorphologicalchanges,peroxisomeproliferation(rat,mice)liverenzymeactivities,increasedweightliver,steatosis(dog)relevantoralnoael90-dayrat:1.6mg/kgbw/day90-daymice:0.3mg/kgbw/day90-daydog:4.3mg/kgbw/day15-monthdog:0.44mg/kgbw/day'", "j.efsa.2010.1719.pdf": "appendixiii.3:chapter3(impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,about60%within48h,basedonurinaryexcretiondistributionwide,highestresiduesinliver,thymus,adrenals(highdose:fat)potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion>80%within48h(urine:>60%,faeces:>20%)metabolisminanimalsextensivelymetabolised(oxidation,sulphateconjugation,dealkylation)toxicologicallyrelevantcompounds(animalsandplants)spiroxaminetoxicologicallyrelevantcompounds(environment)spiroxamineandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral~500mg/kgbwr22ratld50dermal1068mg/kgbwr21ratlc50inhalation2mg/lair;slightpulmonaryirritation(4-hexposure,nose-only)r20skinirritationsevereirritantr38eyeirritationnon-irritantskinsensitisationsensitiser(m&k;buehler)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectoral:liver(histologicalfindings,wt,clinicalchemistry),clinicalsigns,effectsonmucosalepitheliumofoesophagusandfore-stomach;additionallyindogs:eye(cataracts)dermal:skinirritationbyinhalation:irritationoftherespiratorytractrelevantoralnoael28-day,rat:3.4mg/kgbw/day90-day,rat:1.9mg/kgbw/day90-day,dog:15.1mg/kgbw/day1-year,dog:2.5mg/kgbw/day90-day,mouse:25mg/kgbw/dayrelevantdermalnoael21-day,rabbit:localeffects:0.2mg/kgbw/daysystemiceffects:5mg/kgbw/dayhighestdosetested)relevantinhalationnoael28-day,rat:14.3mg/mair(6-hexposure,noseonly,3.9mg/kgbw/day)'", "j.efsa.2010.1721.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiontmax<1hourdistributionmainlydistributedinkidney,liver,adrenal,bloodandskinpotentialforaccumulationnopotentialforbioaccumulationbasedonquicklydecreasingfat/bloodratioandlowtissueresiduelevels(<0.2%)after7days.rateandextentofexcretionrapidandextensiveviaurine(~80%withphenyllabel,61%withisopropyllabel),expiredair(21%withisopropyllabelonly)andfeces(~20%withphenyllabel,13%withisopropyllabel).nodataonenterohepaticrecirculation.metabolisminanimalsextensivelyandrapidlymetabolized,mainlybydeethylation,cleavageofthecarbamatelinkage,acetylation,conjugationwithsulphuricand/orglucuronicacid.mainurinarymetabolites:4-oh-dfcsulfateandglucuronide,3-oet-4-oh-aasulfateandglucuronide,sulfateand/orglucuronideof3-oet-4-oaca-aa;mainfecalmetabolite:4-oh-dfctoxicologicallyrelevantcompounds(animalsandplants)diethofencarbtoxicologicallyrelevantcompounds(environment)diethofencarbacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(rat,mouse)ratld50dermal>5000mg/kgbw(rat,mouse)ratlc50inhalation>1.05mg/lair(4-hourwholebody,maximumattainableconcentration)skinirritationnon-irritanteyeirritationslightlyirritant(noclassificationrequired)skinsensitisationnotsensitizing(m&k,maximisationtest)'", "j.efsa.2010.1722.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabout30%absorbedwithin72h,basedonurinaryexcretiondataandtheamountrecoveredintissuesandcarcass.absorptionwaslower(11%within96h)atahighdoselevel.distribution1-10%oftheadministereddosedetectedintissuesandcarcassat72or96hafterdosing.highestlevelswereobservedinfatfollowedbyadrenalsandliver.residuelevelsinfatweregenerallytwo-foldhigherinfemalesthaninmales.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretion>90%excretedwithin72h.about30%excretedinurineand>60%infaeces.metabolisminanimalsalmost20%ofadministereddosewasexcretedasparentinfaeces;about0.5%wasexcretedinurine.hexythiazoxwasmainlyoxidisedinthecyclohexaneringtoformpt-1-8(cis)(about8%oftheadministereddoseinfaeces,0.5%inurine)andpt-1-8(trans)(1%oftheadministereddoseinfaeces,0.4%inurine).60%oftheradioactivityinurineandfaeceswasnotidentifiedasmetabolites.toxicologicallyrelevantcompounds(animalsandplants)hexythiazox;metabolitept-1-3(toxicologicaldatainsufficient)inprocessedcommoditiestoxicologicallyrelevantcompounds(environment)hexythiazoxacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.0mg/l/4h(wholebodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(magnusson-kligmanmaximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectlivertoxicityandreducedbodyweightgain,mousechangesinclinicalchemistry,increasedliverweights,fattydegenerationofadrenalcortex,and'", "j.efsa.2010.1769.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionslow,maximalbloodconcentrationsat8.09.2hourspostdosing.>90%absorbedbasedoncomparisonofexcretionpatternafteroralandivadministrations.distributionpreferentialbindingtobloodcells;highlevelsinhighlyperfusedorgans(liver,kidneys,spleen,lungs,heart,bonemarrow)potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionslowbutextensive,97%within7days,mainlyviaurine(54.668.3%),23.543.3%viafaeces.metabolisminanimalsextensivelymetabolised.nounchangedparentcompoundidentifiedinurineorfaeces.thefirststepsofthebiotransformationofpropisochlorwereproposedtobethesidechaincleavageattheaminogroupandtheconjugationwithglutathion.thephaseiimetabolitesproducedfromtheglutathionconjugatewereformedbythedegradationofglutathion.thephaseimetabolitesweretheproductsofhydroxylationandoxidationtocarboxylicacidderivatives.toxicologicallyrelevantcompounds(animalsandplants)propisochlortoxicologicallyrelevantcompounds(environment)propisochloracutetoxicity(annexiia,point5.2)ratld50oral3765mg/kgbw(males)2290mg/kgbw(female)rabbitld50dermal>2000mg/kgbwratlc50inhalation5.0mg/lair/4h(headonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(buehlertest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectdogclinicaleffectsingastro-intestinaltract(vomitinganddiarrhoea)reductioninbodyweight;subacutefocalinflammation(atthelowestdoselevel)andfocalcholestasisinliverratreducedbodyweight'", "j.efsa.2010.1779.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionbasedonthecomparisonbetweenoralandivadministration:complete,basedonurinary(14-23%),faeces(assumedbiliary)(73-81%)excretionwithin168hdistributionhighestresiduesinfat,liverandkidneysat168h(<0.01%ar).potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidandextensivewithin72h:mainlyviafaeces(73-81%),alsoviaurine(16-22%).metabolisminanimalsextensivelymetabolised,mainlybyconjugationtoxicologicallyrelevantcompounds(animalsandplants)fenoxycarbtoxicologicallyrelevantcompounds(environment)fenoxycarbacutetoxicity(annexiia,point5.2)ratld50oral>10000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.4mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(weightandhypertrophy)inrats,dogs,micethyroid(weightandhypertrophy)andkidneys(weight)inratsrelevantoralnoael9.7mg/kgbw/d(13-wkrat)loael25mg/kgbw/d(1-yrdog)loael100mg/kgbw/d(13-wkmouse)relevantdermalnoael200mg/kgbw/d(4-wkrat)relevantinhalationnoael99mg/m3(4-wkrat)genotoxicity(annexiia,point5.4)fenoxycarbhasnogenotoxicpotential'", "j.efsa.2010.1783.pdf": "missionasrelevantformemberstateswhenapplyingtheuniformprinciples22efsajournal2010;8(10):1783impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionoralabsorption70%(basedoncarcass,urinaryandbiliaryexcretiondistributionnorelevantdatapotentialforaccumulationaccumulatesintheliver(50-200dayt=318days(initial28dayt=17days))rateandextentofexcretioneliminatedprimarilyviafaecesafterbiliaryexcretion.within48hours,53.3%oftheradioactivedoseisexcretedviafaecesand0.86%viaurinethecorrespondingvaluesinbile-ductcannulatedratsare18.9%and19.4%respectivelyand46.5%inbile.tissue/carcassresiduesnotanalysed.plasmat=25.7hand57.5hafteradministrationof0.8and3mg/kgrespectively.metabolisminanimalsextensivelymetabolisedtoasinglemetabolite(15and4%oftheradioactivityinfaecesandgitractrespectively)and10minorcomponents.metabolitetentativelyidentifiedasabenzyliccarbonhydroxylatedanalogueofbromadiolonewhichisconjugatedwithglucuronicacidpriortoexcretioninbileandthenhydrolysedinthegitract.toxicologicallyrelevantcompounds(animalsandplants)bromadiolonetoxicologicallyrelevantcompounds(environment)bromadioloneacutetoxicity(annexiia,point5.2)ratld50oral0.56-0.84mg/kgbwt+,r28ratld50dermal1.30mg/kgbw(males),2.38mg/kgbw(females)t+,r27ratlc50inhalation0.43g/lair/4hundilutedfinepowder,wholebody(1highdosegroup)/noseonlyexposure(allothergroups)t+,r26skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(modified9inductions-buehlertest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectincreasedprothrombintime(rat,dog,pig,ferret,rabbit);'", "j.efsa.2010.1786.pdf": "6chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorption:oralabsorptionisrapidandassumedtobe100%distribution:limitedinformationavailable;distributestoliverandkidney,buthardlytofat;noinformationonotherorgansavailable.potentialforaccumulation:bupirimateoritsmetabolitesdonotseemtoaccumulateinfatuponrepeatedoraladministration,butinkidneyandliver,noplateauhadyetbeenreachedafter21daysofdosing.rateandextentofexcretion:rapidelimination(75%in24h),mainlyviaurine(65%in24h)metabolisminanimalsextensivelymetabolised,noparentdetectedinexcreta.majorpathwaysforbiotransformationinclude:lossofdimethylsulphamategroup,hydroxylationandde-ethylation.toxicologicallysignificantcompounds(animalsandplants)bupirimate,ethirimol,de-ethylatedethirimolandhydroxy-de-ethylatedethirimoltoxicologicallyrelevantcompounds(environment)bupirimate,ethirimol,de-ethylatedbupirimateandanunidentifiedcompounda.toxicityofde-ethylatedbupirimateandtheunidentifiedcompoundaisnotknown.acutetoxicity(annexiia,point5.2)ratld50oralapprox.4000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.34(highestattainable)skinirritationnotirritatingeyeirritationslightlyirritating(noclassificationproposed)skinsensitisation(testmethodusedandresult)sensitiser(magnusson&kligman)r43short-termtoxicity(annexiia,point5.3)target/criticaleffectthymus(dog),bodyweight,liverandthyroidweight(rat)lowestrelevantoralnoael/noel90-day,dog:15mg/kgbw/day90-day,rat:50mg/kgbw/daylowestrelevantdermalnoael/noelnodataavailablenotrequired'", "j.efsa.2010.1822.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandextensivelyabsorbed;tmax~30minutes.oralabsorption80%basedonurinaryexcretionwithin24h.distributionrapidlyandwidelydistributed;higherlevelsinskin/fur,kidneysandgastro-intestinaltract.someevidenceofbindingtobloodcells.potentialforaccumulationnoevidenceforaccumulationinthebody.rateandextentofexcretionrapidexcretion,predominantly(80%)intheurine.limitedbiliaryexcretion.metabolisminanimalslimitedmetabolism:excretedlargelyunchanged.majormetabolite:acetyl-asulam(upto15%inurine,upto22%infaeces)minormetabolites:sulphanilamide(upto1%inurine)andacetyl-sulphanilamide(upto2.8%inurine).toxicologicallyrelevantcompounds(animalsandplants)asulamandsulphanilamide(includingacetyl-sulphanilamide)toxicologicallyrelevantcompounds(environment)asulamandsulphanilamide(includingacetyl-sulphanilamide)acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(asulamsodium)-ratld50dermal>2000mg/kgbw(asulamsodium)-rabbitld50dermal>4000mg/kgbw(asulamsodium)-ratlc50inhalation>5.46mg/l(asulamsodium)(4hour,wholebody,aerosol)-skinirritationslightirritant(asulamsodium)-eyeirritationmoderateirritant(asulamsodium)-skinsensitisationsensitiser(m&k)(asulamsodium)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:blood,kidney,thyroidmouse:decreasedbodyweightdog:thyroid(hypertrophy),clinicalsigns(e.g.'", "j.efsa.2010.1823.pdf": ".3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionca.100%(basedonurinary(58-73%),faeces(assumedbiliary,basedonexcretionpatterncomparisonafterivandoraladministrations,14-16%),tissues(excludingresidualcarcass,2.4-3.9%)andexpiredair(4.2-7.4%),excretionwithin168h)distributionhighestresiduesinliver,kidney,lung,bloodcellsandboneat168hpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensivewithin72h:mainlyviaurine(55-67%),13-16%viafaeces,4.2-7.4%viaexpiredair(168h)metabolisminanimalsextensivelymetabolised;mainmetaboliteetridiazolecarboxylicacidtoxicologicallyrelevantcompounds(animalsandplants)etridiazoletoxicologicallyrelevantcompounds(environment)etridiazole,dichloro-etridiazoleandetridiazoleacidacutetoxicity(annexiia,point5.2)ratld50oral>945mg/kgbwr22rabbitld50dermal>5000mg/kgbwratlc50inhalation>5.7mg/lair/4h(nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(m&k)r43short-termtoxicity(annexiia,point5.3)target/criticaleffectliver:increasedweight(rat&dog)andhypertrophy(rat)relevantoralnoael13-week,rat:2.7mg/kgbw/day1-year,dog:3.1mg/kgbw/dayrelevantdermalnoael4-week,rat:20mg/kgbw/dayrelevantinhalationnoael4-week,rat:noael(systemic)15mg/m3(correspondingto4mg/kgbw/day)loael(local)15mg/m3basedonlocalsquamous/squamoidmetaplasiainthelarynxmucosar37'", "j.efsa.2010.1856.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandessentiallycomplete(>95%)basedonexcretionviaair(80%within48h)andurine(2-5%within7days).distributionwidelydistributed;mostofradioactivityfoundincarcassandnotinspecificorgans.8-10%stillpresentinthebodyafter7days.potentialforaccumulationnoevidenceofaccumulationafterrepeatedadministration.rateandextentofexcretionafter7days:expiredair(85%);urine(2-5%);faeces(2-3%)metabolisminanimals85%metabolisedtoacetaldehydeandexpiredasco2;2-5%metabolisedandexcretedviapolardegradatesintheurine(noparentcompoundinurine);2-3%infaecesnotidentified.toxicologicallyrelevantcompounds(animalsandplants)metaldehydetoxicologicallyrelevantcompounds(environment)metaldehydeacutetoxicity(annexiia,point5.2)ratld50oral283mg/kgbwr22ratld50dermal>5000mg/kgbw-ratlc50inhalationnovaliddataavailablebutnofurtherdatanecessaryduetothephysico-chemicalproperties.skinirritationnon-irritating-eyeirritationslightlyirritating-skinsensitisationnotsensitizingtotheskin(llna)-'", "j.efsa.2010.1868.pdf": "1impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensiveabsorption:>90%basedonurinaryandbiliaryexcretion.distributionwidelydistributed;highestlevelsinredbloodcellsduetoextensivebinding.potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidlyexcretedwithapproximatelyequalproportionspresentintheurineandfaeces.extensivebiliaryexcretion(~80%)withevidenceforenterohepaticcirculation.metabolisminanimalsextensivemetabolism;onlytraceamountofunchangedparentdetected.limitedcleavageofthemolecule.toxicologicallyrelevantcompounds(animalsandplants)flutriafoltoxicologicallyrelevantcompounds(environment)flutriafolacutetoxicity(annexiia,point5.2)ratld50oral1140-1480mg/kgbwr22mouseld50oral179365mg/kgbwrabbitld50oral300400mg/kgbw(female)guineapigld50oral300400mg/kgbw(male)ratld50dermal>1000mg/kgbwratlc50inhalation>5.2mg/lair/4h(nose-only,solidparticulateaerosols)skinirritationnon-irritanteyeirritationmild-irritantskinsensitisationnoevidenceofskinsensitisation(m&k,llna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectratanddog:decreasedbodyweightgain;redbloodcell(anaemia)andliver(lipidmetabolism)mouse:lipidaccumulationintheliverrelevantoralnoael90-day&1-yeardog:5mg/kgbw/day90-dayrat:13.3mg/kgbw/day90-daymouse:loael:7.5mg/kgbw/dayrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2010.1869.pdf": "23impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%ofapplieddosewithin42-90hafteradministrationbasedonthecomparisonoftheexcretionpatternsafteroralandipadministrations(rat)distributionlowtissueresiduesat72-90hafteradministration;highestresiduesfoundinliver,kidney,epididymis(males)andbloodpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretioninrats,>97%ofapplieddosewithin72hafteradministration,3847%inurineand4958%infaecesinrabbits,8791%applieddosewithin96h,6267%inurineand2224%infaecesmetabolisminanimalsextensivemetabolisminratsandrabbitsinvivo(excretionofunchangedflc1.5%ofapplieddose).largenumberofnodiscerniblefractions(inurine,faecesandplasma),3metabolitesinratsand4metabolitesinrabbitsidentifiedinurinewereacetylcysteineconjugates.threeoxidativemetabolitesidentifiedinvitrotoxicologicallyrelevantcompounds(animalsandplants)flctoxicologicallyrelevantcompounds(environment)flcacutetoxicity(annexiia,point5.2)ratld50oralrat:3650mg/kgbwmice:5000mg/kgbwratld50dermalrabbit:>5000mg/kgbwratlc50inhalation>4.82mg/lair/4h,nose-onlyexposureskinirritationnon-irritanteyeirritationnon-irritantskinsensitizationsensitising(m&ktest)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverandtestes(highdoserat)decreaseinbodyweightandbodyweightgain(rat&dog)haematologicaleffects(dog)relevantoralnoael90-dayrat:5.4mg/kgbw/day6-monthdog:7.1mg/kgbw/dayrelevantdermalnoaelnodata-notrequired'", "j.efsa.2010.1871.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid;approximately40%(basedonpercentofdoserecoveredinbile,urineandcarcassover72hours)distributionminimaldistribution;highestresiduesfoundinliver,kidneyandfat.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapid,80%viafaeceswithin24hoursor>80%viafaecesand<1%to8%viaurinewithin168hours,upto34%viabilemainly(23%)within6hrs.metabolisminanimalsextensivefortheabsorbedportion,primarilybysequentialoxidationofethylandmethylgroupsofthemoleculeatthebenzylicpositions.toxicologicallyrelevantcompounds(animalsandplants)tebufenozidetoxicologicallyrelevantcompounds(environment)tebufenozideacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwmouseld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.3mg/l(4-hr)(wholebody)skinirritationnoirritationeyeirritationnoirritationskinsensitisationnotsensitising(buehlertestandm&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectslightreductioninerythrocytevalues,low-gradehaemolyticprocess,methaemoglobinformationinrats,miceanddogsrelevantoralnoael2mg/kgbw/d(90-ddog,52-wkdog)13mg/kgbw/d(90-drat)3.4mg/kgbw/d(90-dmouse)relevantdermalnoael1000mg/kgbw/d(28-drat)relevantinhalationnoaelnodata-notrequired'", "j.efsa.2010.1872.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionoralabsorptionofacrinathrinisrapid(tmaxof4-12h)andextensive(71%within48h)distributionwidelydistributed:higheraffinityforthyroidandkidneys(earlyafterdosingonly)andadrenals,fat,ovaries,pancreasandliver(stillafter7days).potentialforaccumulationlongerpersistenceoftheradioactivecompoundinfattissues,butnosignificantbioaccumulationpotentialasterminalresiduesarelow.rateandextentofexcretionrapidexcretionofmetabolitesinurineandbile(respectivetotalexcreteddoseover48h:39%inintactrats,50%inbileduct-cannulatedrats).urinaryexcretionlowerincannulatedrats(20%ofthedoseover48h),suggestingthatbilemayplayaroleinabsorption,and/orenterohepaticrecirculation.metabolisminanimalsrapidlyandcompletelymetabolised.significantfirstpasseffectintheliver.biotransformationincludeshydrolysis,hydroxylation,carboxylation,oxidationandfinalconjugationofsomecompounds(glycine-orsulpho-conjugation).toxicologicallyrelevantcompounds(animalsandplants)acrinathrintoxicologicallyrelevantcompounds(environment)acrinathrinacutetoxicity(annexiia,point5.2)ratld50oralcd/sdrats:>5000mg/kgbwhanwistarrats:>2000mg/kgbw-ratld50dermalcd/sdrats:>2000mg/kgbwhanwistarrats:>2000mg/kgbw-ratlc50inhalation1.21mg/l(wholebody,4hexposure,aerosol)xnr20skinirritationnonirritant-eyeirritationveryslightlyirritant-skinsensitisationnotasensitizer(magnusson&kligman)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectneurovegetativesystem:diarrhoea,vomiting,salivation(dog);dyspnoea,loweractivity,salivation(rats,mice).skin:scabs,sores,alopecia,hyperkeratosis,ulcerativecellulitis,epidermalnecrosis,acanthosis(rat,mouse);(triggeringhumanekillingforsomeanimals;xnr48/22)kidney:acutetubularnecrosis,papillarynecrosis,corticaltubulardegeneration(malerats);blood:leukocyte,lymphocyteandneutrophilcounts'", "j.efsa.2010.1873.pdf": "11):1873impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%(basedonurine,expiredco2excretionover7d)distributionwidelydistributed,highestresiduesinliverandkidneypotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid(>67%first24hourspost-dose);79%viaurine,4.2%viafaeces,10%viaco2over7dforsinglelowdosemetabolisminanimalsintensivelymetabolised;majormetaboliteinurineandfaeces:n-toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral142223mg/kgbwr25ratld50dermal848mg/kgbwr21ratlc50inhalation>1mg/l(4hr,wholebody;highestattainableconcentration,mist)skinirritationirritantr38eyeirritationirritantr36skinsensitisationsensitising(magnusson&kligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectthyroirelevantoralnoael90-dayrat:1.5mg/kgbw/day(30ppm)90-daydog:0.6mg/kgbw/day(til,1986:noael;til1982:loael)1-yeardog:1mg/kgbw/dayrelevantdermalnoaeldermal:12.5mg/kgbw/day(21-day)systemic:noacceptabledatarelevantinhalationnoael<0.15mg/l(14d,6-hourexposure,headonly,5day/week)(about40mg/kgbw/day)genotoxicity(annexiia,point5.4)clastogenicpotentialinvitro,negativeinvivo;unlikelytobegenotoxicinvivo'", "j.efsa.2010.1876.pdf": "impactonhumanandanimalhealthrateandextentoforalabsorptionrapidand>80%,basedonurineandbileexcretionwholebloodtmax:2hdistributionwidelydistributed,asmallproportionofradioactivityequilibratedintothetissuesandwassubsequentlyeliminated.highestconcentrationintheliver.potentialforaccumulationnoneidentifiedrateandextentofexcretionmorethan70%excretedwithin48hours.significantentero-hepaticrecirculationathighdose.biliaryexcretionatlowdoserepresented>50%ofadministereddose.metabolisminanimals2-stageoxidationprocessprobablymediatedviathehepaticmixedfunctionoxidasesystem.lessthan10majormetabolitesproduced.toxicologicallyrelevantcompounds(animalsandplants)paclobutrazol,1,2,4-triazole,1,2,4-triazoleaceticacid,1,2,4-triazolelacticacid.toxicologicallyrelevantcompounds(environment)paclobutrazol,1,2,4-triazole,1,2,4-triazoleaceticacid,1,2,4-triazolelacticacid.acutetoxicity(annexiia,point5.2)ratld50oral1336mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation3.13mg/l(noseonly,4hours)r20skinirritationmildlyirritating(nottriggeringc&l)eyeirritationmildlyirritating(nottriggeringc&l)skinsensitisationnonsensitizing(maximizationtestofm&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdog:liver(increasedactivityofhepaticenzymes,increasedweight,balloonedhepatocytes)rat:liver(increasedcholesterol,alt;increasedweight;marginalincreasesinhydropicandfattychanges)relevantoralnoaeldog:15mg/kgbw/d(13-weekand1-year)rat:20mg/kgbw/d(13-week)relevantdermalnoaelrabbit:1000mg/kgbw/d(topdosetested,6h/d,5d/wk,3weeks)forsystemictoxicity.'", "j.efsa.2010.1889.pdf": "mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)(1)rateandextentoforalabsorptionlessthan1%(foraluminium)withdifferentaluminiumchemicalspecies.fortheriskassessmentavalueof1%wasused.distributioninblood,aluminiumispresentinplasmaboundtotransferrin(89%ofaluminiuminplasma).potentialforaccumulationaluminiumshowsslightpotentialforaccumulationinthebrain,bone,muscleandkidney(orallyexposedanimals).rateandextentofexcretionmostofaluminiumingestedisunabsorbedandexcretedinthefaeces(7698%oforaldose).absorbedaluminiumiseliminatedviatheurine.metabolisminanimalsnometabolismoccurtoxicologicallyrelevantcompounds(animalsandplants)aluminiumsulfatetoxicologicallyrelevantcompounds(environment)aluminiumsulfate(1)datafromdifferentaluminiumchemicalspecies(notaluminiumsulfate)acutetoxicity(annexiia,point5.2)(2)ratld50oralld50>5000mg/kgbwratld50dermalbasedonthedatafromtherepresentativeformulation(chrysalrvb),anld50>2000mg/kgbwcanbeassumed.ratlc50inhalationnoclassification,basedonweightofevidence(nostudyprovided)skinirritationnotirritatingeyeirritationseverelyirritatingr41skinsensitizationnonsensitiser(llna)respiratorysystemirritationirritatingtorespiratorysystemr37(2)thestudieshavebeenperformedwithalum17(whichisal2(so4)314h2ooralternativelyas17%al2o3.whichisthenotifiedactivesubstanceshorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,kidneyandbraininrats.multifocaldegenerationoftheliver,swellinganddegenerationofcorticalanddistalrenaltubules,degenerationofnervecells(3)relevantoralnoael21-day,rat:loael:212mgal2(so4)3/kgbw/day.(3)relevantdermalnoaelnodata,notrequired'", "j.efsa.2010.1890.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodataavailable,notneededdistributionnodataavailable,notneededpotentialforaccumulationnodataavailable,notneededrateandextentofexcretionnodataavailable,notneededmetabolisminanimalsnodataavailable,notneededtoxicologicallyrelevantcompounds(animalsandplants)hydrogensulfidetoxicologicallyrelevantcompounds(environment)hydrogensulfideacutetoxicity(annexiia,point5.2)ratld50oral1343mg/kgbw(rat)r22ratld50dermal>2000mg/kgbwratlc50inhalationnotrequiredskinirritationaccordingtoannexiofeudirective67/548/eecr38eyeirritationaccordingtoannexiofeudirective67/548/eecr36skinsensitizationpolisolfurodicalcioinducesdelayedcontacthypersensitivityinguineapigswithan80%reactionobservedatchallenge.r43respiratorysystemirritationaccordingtoannexiofeudirective67/548/eecr37shorttermtoxicity(annexiia,point5.3)target/criticaleffectlocal:severeburnsofgastro-intestinalmucosasystemic:metabolicacidosisrelevantoralnoael150mg/kgbw/day(rat)relevantdermalnoaelnodata,notneededrelevantinhalationnoaelnodata,notneededgenotoxicity(annexiia,point5.4)genotoxicinvitro.noclastogenicpotentialinvivo.nofurtherdatainvivoneededconsideringthenegligibleexposuretolimesulfurofoperators'", "j.efsa.2010.1891.pdf": "mmaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionapprox.63%within48hours(basedonrecoveryinurineandbile,lowdose,rat)distributionwidelydistributed.potentialforaccumulationnegligiblerateandextentofexcretionrapidexcretion(ca.90%within48hours)metabolisminanimalssaturationathighdoses(esterolyticdetoxification)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundandbf-490-1(acidofkresoxim-methyl)acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.6mg/lskinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnon-sensitiser(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasedbodyweight;increasedliverweight;increasedggtrelevantoralnoael146mg/kgbw/day(90drat)relevantdermalnoaelnotapplicablerelevantinhalationnoaelnotapplicablegenotoxicity(annexiia,point5.4)nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectdecreasedbodyweight;increasedliverweightrelevantnoael36mg/kgbw/day(2-yroral,rat)carcinogenicityratlivertumoursatthemtd(8000ppm),consideredtoariseviaanon-genotoxicthresholdmechanism.notoncogenicinmice.r40'", "j.efsa.2010.1892.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)20%(basedonradioactivitydetectedinurine,organ/tissuesandcarcass168hourspost-dosing;singleorallowdoseratstudy).nobiliarydatawereavailable.widelydistributed:highestconcentrationinfat,bone,andthefemalegenitalorgans(singleloworhighdoselevelandrepeatedlowdosinggroups),lungs(repeatedlowdosegroup)andliverandspleen(singleoralhighdosegroup).noevidenceforaccumulation.rapidandextensive(>75%within48hours),mainlyviafeces(72-89%)andminorinurine(16-21%).extensivelymetabolised,involvedoxidationandhydrolysisreactions.majoridentifiedmetabolitesweretheurinaryan-1(4.2-5.8%ofthedose)andthefecalf-2(11.9-19.9%ofthedose),f-3(4.7-10.5%ofthedose),andf-1(3.5-8.4%ofthedose).theparentcompoundwasdetectedmostlyinfeces(1.0-15.0%oftheadministereddose)andatminoramountsinurine(<0.5%ofthedose).toxicologicallyrelevan(animalsandplants)fenazaquinandtbpe(environment)fenazaquinacutetoxicity(annexiia,point5.2)ratld50134mg/kgbwt;r25rabbitld50>5000mg/kgbwratlc50>1.9mg/lairxn;r20non-irritantnon-irritantnonsensitizer(m&k)'", "j.efsa.2010.1897.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed,>85%within144hours,basedonurinaryandbiliaryexcretionandcarcassresiduesdistributionwidelydistributed,highestresiduesassociatedwiththeorgansofelimination(kidney,liver,pancreas)potentialforaccumulationnoevidenceofbioaccumulationrateandextentofexcretionmajorrouteisbiliaryexcretionformales(75%)andfemales(59%),followedbywithrenal(26.7%and9.5%respectively);<5%faecalexcretionmetabolisminanimalsextensivelymetabolised(35metabolitesidentified)toxicologicallyrelevantcompounds(animalsandplants)cyproconazoletoxicologicallyrelevantcompounds(environment)cyproconazoleacutetoxicity(annexiia,point5.2)ratld50oralrat:350mg/kgbwmouse:200&218mg/kgbw,males&femalesrespectively;270mg/kgbw(males)rabbit:460mg/kgbw(females)r22ratld50dermalrat:>2000mg/kgbwrabbit:>2000mg/kgbwratlc50inhalation>5.465mg/l,4hours,nose-onlyexposureskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectlivertoxicityandreducedweightgaininrats,miceanddogs.relevantoralnoael90-day,rat:6.4mg/kgbw/day90-daymouse:2.2mg/kgbw/day,loael43.8mg/kgbw/day1-yeardog:3.2mg/kgbw/dayrelevantdermalnoael28-day,rat:10mg/kgbw/day,basedonchangesinclinicalchemistry.relevantinhalationnoaelnodata,notrequired'", "j.efsa.2010.1904.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionincomplete(averaged45%ofthedosewithin48hoursforthesinglelowdosedbile-cannulatedrats)andrapid(theplasmacmaxachievedwithin6hrsaftersingleorallowdoseadministration)distributionwidelydistributed;highestconcentrationinthyroid,kidneys,gi-tract,whole-blood,lungsandheartpotentialforaccumulationnopotentialforbodyaccumulationrateandextentofexcretionrapidandextensive(>90%oftheurinaryradioactivitywasexcretedwithin24hrs)firstlyviafeces(43.46-72.15%ofthedose),secondlyviaurine(23.54-31.43%ofthedose)andlastlyviabile(7.21-11.59%ofthedose)at168hrsmetabolisminanimalsextensivemetabolismleadingtotheformationofmostlypolarproducts.themetabolicreactionsincludedoxidationofthesulphuratoms,cleavageofthedithiinering,reductionofthe1,4-naphthoquinonemoiety,glucuronidationaswellassubstitutionofthecarbonitrilemoietiesbyaminoandcarboxygroups.theonlypredominantmetaboliteinquantitativetermswasm216f020,detectedmainlyinurine(upto10%)andsecondlyinkidneyandplasma.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral300mg/kgb.w.(females)r22ratld50dermal>2000mg/kgb.w.(males&females)ratlc50inhalation0.31mg/lair(males)0.58mg/lair(females)r23skinirritationnon-irritanteyeirritationsevereeyeirritantr41skinsensitisationskinsensitizer(gpmt)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver&kidneys(rat,dog,mouse)relevantoralnoael1.6mg/kgb.w./day(40ppm),52-week,dog'", "j.efsa.2010.1905.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionhigherthan80%basedonradiolabelrecoveredfromurine,bile,cagewash,faecesandtissues.distributionfat,kidneysandliver.enterohepaticrecirculationinmalerats.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionca90%infemaleratsviaurinewitht1/2=2.5hca90%inmaleratsviaurineandbilewitht1/2=33-38hmetabolisminanimalsextensivelymetabolisedtothecarboxylicacidmetabolitefluazifopacid,furtherconjugatedwithtaurine.toxicologicallyrelevantcompounds(animals,plantsandenvironment)fluazifop-p-butyl,fluazifopacidandcompoundxacutetoxicity(annexiia,point5.2)ratld50oral2451mg/kgbw(rat)>2000mg/kgbw(mouse)ratld50dermal>2110mg/kgbwratlc50inhalation>5.2mg/l/4h(noseonly)skinirritationnon-irritatingeyeirritationnon-irritatingskinsensitisationsensitizing(llna)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney,spleenandliver.cataract,decreasedplasmacholesterollevelsr48/22relevantoralnoael90drat:0.9mg/kgbw/d90-dand1-yeardog:25mg/kgbw/d(fluazifop-butyl)90-dhamster:78mg/kgbw/drelevantdermalnoael21-drabbit:100mg/kgbw/d(fluazifop-butyl)relevantinhalationnoaelnodatanotrequired'", "j.efsa.2010.1906.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption:60%basedonurinaryandbiliaryexcretionwithin24hdistribution:highestconcentrationsinfat,adrenals,liver,thyroid,ovariesandbonemarrowpotentialforaccumulation:noevidenceofaccumulationrateandextentofexcretion:rapidandextensive(82-95%)within48h,mainlyviabile35.83%,faeces39.16%andurine4.66%.metabolisminanimalssignificantmetabolictransformation.faeces:parentcompound,rh-45469,thehydro-oxyfluorfen(rh-34670),andaminometabolites.urine:rh-34800,rh-45298-c.noparentcompound.toxicologicallysignificantcompounds(animals,plantsandenvironment)oxyfluorfenacutetoxicity(annexiia,point5.2)ratld50oralld50>5000mg/kgbwratld50dermalld50>5000mg/kgbwratlc50inhalationlc50rat>3.71mg/lexposurenose-only.testmaterial:aerosolskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitisingrespiratorysystemirritationnon-irritantshorttermtoxicity(annexiia,point5.3)target/criticaleffectliver,spleen,andhaematopoieticsystem/decreasesinbodyweightgains,increasesinabsoluteandrelativeliverandspleenweights,anaemiaandalterationsinclinicalchemistryparametersrelevantoralnoael2.17mg/kg/bw/day(90-daydietarystudyinfemaledog,supportedbythe2-yrstudyindog)relevantdermalnoael100mg/kg/bw/day(rat)relevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)nogenotoxicpotential.'", "j.efsa.2010.1913.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrat:rapidandextensive(>80%)within24h.dog:tmax0.5-4hoursdistributionrat:poorlydistributed.organwithhigheramount:liver(at96hand21days)potentialforaccumulationrat:nonerateandextentofexcretionrat:rapideliminationviaurine(81%),faeces(12%)within24hoursafterdosing.metabolisminanimalsrat:degradationofthecarbamatemoietyandpara-hydroxylationtoxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentcarbetamide-coohacutetoxicity(annexiia,point5.2)ld50oralrat:ld50>2000mg/kg(combinedsexes)mice:ld50=1,718mg/kgbw(combinedsexes)r22ratld50dermal>2,000mg/kgbw-ratlc50inhalationnostudyrequired(vapourpressureofcarbetamideat20cis3.10-7pa)-skinirritationnonirritant-eyeirritationnonirritant-skinsensitisationnonsensitizer(m&k)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectrats:slighthematotoxicity(anemia),liver(centrolobularhypertrophy).dogs:slightneurologictoxicity,slighthematotoxicity(anemia),liver(increasedweight),thyroids(follicularepitheliumhypertrophy).inhibitionofach-e.lowestrelevantoralnoael/noel12.5mg/kg/day;13weekrat30mg/kgbw/day;90dayand1yearlowestrelevantdermalnoael/noelnostudylowestrelevantinhalationnoael/noelnostudy'", "j.efsa.2010.1931.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>80%(basedonthecomparisonoftheexcretionpatternsafteroralandivadministrations).sintofenisrapidlyandextensivelyabsorbedfromgit.distributionallindividualtissuesshowed<0.05%administereddoseretainedat168hours,exceptskinthatcontained0.1-0.4%potentialforaccumulationnopotentialforaccumulationrateandextentofexcretionmostoftheadministereddosewaseliminatedinurine(64%,males;74.4%,females)andfaeces(20.9%,males;10.9%,females)over24hours.at72h:urine:66%,males;76.6%,females;faeces30.4%males;18.8%femalesmetabolisminanimalstestsubstancewasmetabolisedtoamoderateextent.unmetabolisedtestsubstanceinurineandfaecesaccountedfor64.4-92.4%inurineand24.3-59.8%ofthedoseinfaeces.onemajormetabolitewasidentifiedinurineandfaecesasdesmethylsintofen(sc3095)toxicologicallyrelevantcompounds(animalsandplants)sintofentoxicologicallyrelevantcompounds(environment)sintofenacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(diisopropanolaminesaltandacid)ratld50dermal>2000mg/kgbw(diisopropanolaminesalt)equivalentto>1466mg/kgbwsintofenacidratlc50inhalation>7.34mg/lair/4h(nose-onlyasliquidaerosol,diisopropanolaminesalt)equivalentto>5.27mg/lair/4hsintofenacidskinirritationnonirritant-diisopropanolaminesalteyeirritationslightirritant-diisopropanolaminesaltskinsensitisationnonsensitising-diisopropanolaminesalt(maximisationtestm&k)'", "j.efsa.2011.1858.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionazadirachtintechnicalisamixtureofseveraldifferentlimonoidsandothercompoundsextractedfromtheseedkernelsoftheneemtree.itisthereforenotfeasibletoperformadmestudieswithazadirachtintechnical.itisfurthermorealsonotpossibletoperformsuchastudyforitsseveralcomponents(azadirachtinaandothers)duetotheunavailabilityofchemicallysynthesisedandradioactivelylabelledcomponents,sinceitcanbeobtainedbyextractionandcleanupoftheseedkernelsoftheneemtreeonly.thereforeitisnotpossibletoobtainradioactivelabelledmaterial.distributionpotentialforaccumulationrateandextentofexcretionmetabolisminanimalstoxicologicallyrelevantcompounds(animalsandplants)azadirachtinextract(aswholeextract)toxicologicallyrelevantcompounds(environment)azadirachtinextract(aswholeextract)acutetoxicity(annexiia,point5.2)ratld50oral>5000mgtrifolioextract/kgbw>5000mgsipcamextract/kgbw>5000mgmitsuiextract/kgbwratld50dermal>2000mgtrifolioextract/kgbw>2000mgsipcamextract/kgbw>2000mgmitsuiextract/kgbwratlc50inhalationallstudies:highestattainableconcentration>0.72mgtrifolioextract/lair(4h,wholebody)>2.45mgsipcamextract/lair(4h,wholebody)skinirritationnotirritating(trifolio,sipcam,mitsuiextracts)eyeirritationnotirritating(trifolio,sipcam,mitsuiextracts)skinsensitisationsensitising(m&k,trifolio,sipcamextracts)sensitising(buehler,mitsuiextract)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:liver,thyroid(organweight,clinicalchemistry)nostudyindogsubmitted,notrequiredrelevantoralnoaelrat,90-day:32mgtrifolioextract/kgbw/dayrat,90-day:33mgsipcamextract/kgbw/dayrat,90-day:35mgmitsuiextract/kgbw/dayrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequired'", "j.efsa.2011.1893.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)14conly;nodataonthebromideionrateandextentofabsorptionorally:relativelyrapidandextensive(>80%),basedonurine(40%),exhaledair(32%)andcarcass(14%);ratsdosedat~25mg/kgbw.inhalation:veryrapid(tissuelevelswithin3minutes)andcomplete(>90%inurineandexhaledco2)distributionextensive,highestlevelsinliverandspleenpotentialforaccumulationlow.14cincorporatedintoonecarbonmetabolismrateandextentofexcretionrapidandextensive,byexhalation,urineandbilemetabolisminanimalsnodata;predictedtohydrolysetobromideionandmethanoltoxicologicallyrelevantcompounds(animalsandplants)methylbromidetoxicologicallyrelevantcompounds(environment)methylbromideacutetoxicity(annexiia,point5.2)ratld50oral104mg/kgbw(t;r25)ratld50dermalnodataratlc50inhalation1.2mg/l(wholebody,8h),3mg/l(wholebody4hour)(t,r23)skinirritationnodata-irritatingtoskin(humanreports)(r38)eyeirritationnodata-irritatingtoeyes(humanreports)(r36)skinsensitizationnospecificdatanoindicationsfromrepeatedexposures.shorttermtoxicity(annexiia,point5.3)shorttermtoxicity(annexiia,point5.3)target/criticaleffectclinicalchemistryandhaematology,parathyroidandthymuspathology(dog).brainlesionsfollowinginhalation(rats)relevantoralnoael1yeardog0.13mg/kgbw/dayrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoael6weekdog20ppm(0.08mg/l)'", "j.efsa.2011.1941.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption80%within72h(basedonurine,bileandcarcass)distributionpreferablydistributedinfattytissues,alsofoundinblood,liver,kidney,lungandspleen.potentialforaccumulationnopotentialforaccumulation.rateandextentofexcretionalmostcompletelyexcretedviaurineandfaeceswithin48h(with~40to50%bybiliaryexcretion).metabolisminanimalsinrats,metaboliteswereformedthroughhydrolysisfollowedbysubsequentconjugation,orbyhydroxylationoftheparentcompoundfollowedbyhydrolysisand/orconjugation.toxicologicallyrelevantcompounds(animalsandplants)triflumuronandmetabolites(4-trifluoro-methoxyaniline,1-[4-(trifluoromethoxy)phenyl]urea,2-chlorobenzamide,2-chlorobenzoicacid)toxicologicallyrelevantcompounds(environment)triflumuronacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation>5mg/lair4h(aerosol,nose-only)-skinirritationnotirritant-eyeirritationnotirritant-skinsensitisationnonsensitiser(magnusson&kligmantest)-short-termtoxicity(annexiia,point5.3)target/criticaleffecthematopoieticsystem(haemolyticanaemia)relevantoralnoael3.6mg/kgbw/d(rat,90-daystudy)1.42mg/kgbw/d(dog,12-monthstudy)-relevantdermalnoael100mg/kgbw/d(rabbit,3-weekstudy)-relevantinhalationnoaec0.0045mga.s./l(rat,3-weekstudy)-genotoxicity(annexiia,point5.4)nogenotoxicproperties-'", "j.efsa.2011.1958.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionabout80%ofthedosewithin168hoursbasedonradioactivityinurine,cagerinseandtotaltissues/organsorcarcassdistributionwidelydistributedpotentialforaccumulationnopotentialrateandextentofexcretiontheexcretionwasrapid(>66%ofthedosewasexcretedinurinewithin24hrs)primarilyviaurine(70.89-83.56%ofthedose)andsecondaryinfaeces(5.68-14.22%ofthedose)within168hrs.metabolisminanimalsfluometuronismetabolisedinratsthroughhydroxylationofthephenylring,demethylationofoneorbothmethylgroupsoftheanilinesidechainandsubsequentringhydroxylation.glucuronidationandsulphateconjugationoftheformedcompoundswasobserved.themajormetabolitewasdi-desmethylfluometuron(12.8%).theparentcompoundwasfoundonlyinfaeces(2.4%)toxicologicallyrelevantcompounds(animalsandplants)parentcompounddesmethylfluometuron(cga41686)andcga72903.tfaa(notoxicologicaldataavailable)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwrabbitld50dermal>2000mg/kgbwratlc50inhalation>4.62mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitizer(buehlertestwitha.s.,m&ktestwitha50%formulation)shorttermtoxicity(annexiia,point5.3)target/criticaleffecthaemolyticanaemia(rats,mice,dogs)relevantoralnoael13-weekrat:5.9mg/kgb.w./day,28-daymice:200mg/kgbw/day1-yeardog:13mg/kgbw/dayrelevantdermalnoael1000mg/kgbw/day,21-day,rabbitrelevantinhalationnoaelnodata-notrequired'", "j.efsa.2011.1962.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>60%basedonurinaryexcretionwithin72hoursand>25%basedonbiliaryexcretionwithin24hours,inseparatestudiesdistributionuniformlydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionurinaryandfaecalexcretionaccountedfor95.5-99.8%ofadministereddosewithin7days;61.6-74.7%appearedinurine.metabolisminanimalsextensivelymetabolized.lessthan2.5%ofradioactivityappearedintheurine,bileandfaecesasunchangedparent.twelveprimarymetaboliteswereidentified,themostabundantaccountingfor10-20%ofadministereddoseandappearingprimarilyasaurinarymetabolite.othermetabolitesindividuallyaccountedforlessthan6%oftheradioactivity.oxidationanddehydrationreactions.toxicologicallyrelevantcompounds(animalsandplants)flurprimidoltoxicologicallyrelevantcompounds(environment)flurprimidolacutetoxicity(annexiia,point5.2)ratld50oral709mg/kgbw(rat)602mg/kgbw(mouse)r22rabbitld50dermal>5000mg/kgbwratlc50inhalation>5.231mg/lair/4h(nose-only,air-milledsample)skinirritationslightlyirritatingeyeirritationslightlyirritatingskinsensitisationnon-sensitiser(m&kandmodifiedbuehlertests)'", "j.efsa.2011.1964.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextensiveandrapid(80%basedonurinaryexcretionwithin8hours).distributionwidelydistributed;mainlyinspleen,kidneyandliverpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapid,mainlyviaurine(80%within8h)metabolisminanimalsextensivelymetabolisedintosulfateandglucuronideconjugatestoxicologicallyrelevantcompounds(animalsandplants)8-hydroxyquinolinetoxicologicallyrelevantcompounds(environment)8-hydroxyquinolineacutetoxicity(annexiia,point5.2)ratld50oral790mg/kgbwr22mouseld50oral177mg/kgbwratld50dermal>10000mg/kgbwratlc50inhalationnodata-notrequiredskinirritationnotirritatingeyeirritationcornealopacitynotreversibler41skinsensitizationsensitising;medicaldatar43short-termtoxicity(annexiia,point5.3)target/criticaleffectrat:haematologicalalterations,increasedkidneyandspleenrelativeweightdog:notreatment-relatedeffectsrelevantoralnoaelrat:97.7mg/kgbw/d(90-d)dog:100mg/kgbw/d(90-d,highestdoseleveltested)relevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)genotoxicinvitro.nogenotoxicinvivo.nogenotoxicpotentialrelevantforhumans.'", "j.efsa.2011.1965.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption93-100%(basedonurinary(>86%)andfaecal(<2%)excretionaswellastoxicokineticmeasurementswithin48h)distributionwidelydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive,mainlyviaurine(87-99%).viaurine>86%within24h,<2%viafaeces.metabolisminanimalsverylimitedmetabolism.unchangedexcretionof86-98%ofapplieddose;mainmetabolitedcsa(0.6-0.8%);demethylationofthemethylethertotherespectivealcohol.toxicologicallyrelevantcompounds(animalsandplants)dicambaand5-oh-dicambatoxicologicallyrelevantcompounds(environment)dicambaacutetoxicity(annexiia,point5.2)ratld50oral1581mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation4.46mg/lair/4h(noseonly)r20skinirritationslightlyirritatingeyeirritationirritantr41skinsensitisationnon-sensitizershorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(hepatotoxicity)(rat),haematology(rat,dog)decreasedfoodintakeandbodyweightgain(rat,dog)relevantoralnoael90-daydog:50mg/kgbw/day90-dayrat:479mg/kgbw/dayrelevantdermalnoael28-dayrat:>1000mg/kgbw/dayrelevantinhalationnoaelnodataavailablenotrequiredgenotoxdicambaisunlikelytobegenotoxic.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectdecreasedbodyweightgainrelevantnoael2-year,rat:107mg/kgbw/day104-week,mouse:121mg/kgbw/day'", "j.efsa.2011.1967.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)about80-90%basedonthebiliary(73-76%)andurinary(14-9%)excretionwithin48hours.initiallyhighestresiduesinfat,liver,brownfat,harderiangland,adrenalglandandstomach.at168hours,residuesabovetheplasmaconcentrationonlydetectedinfat.noevidenceforaccumulationrapidandextensivewithin48hoursmainlyviafaeces(>77%)andinurine(>12%).enterohepaticrecirculationdemonstrated.extensivelymetabolised,mainlybyhydrolysisoftheketalandhydroxylation;alsobycleavageofthetriazole(1,2,4-triazoledeterminedtorepresent<10%inmalerats).(animalsandplants)triazolederivativemetabolites(1,2,4-triazole,triazoleaceticacid,triazolealanine,triazolelacticacid).(environment)difenoconazoleacutetoxicity(annexiia,point5.2)ratld501453mg/kgbwr22mouseld50oral>2000mg/kgbwrabbitld50>2010mg/kgbwratlc50inhala>3.3mg/l(4hexposure,nose-only,highesttechnicallyachievableconcentration)non-irritantnon-irritantnon-sensitiser(modifiedbuehlertest)shorttermtoxicity(annexiia,point5.3)rat:reducedbodyweight,heartandcarcassweight,reducedfoodandwaterconsumption;liver(athighdosesafteroralexposure);liverandthyroid(follicularhypertrophy)afterdermalexposuremouse:reducedbodyweightgain,reducedovaryweight,liver(increasedweightwithenlargement,vacuolizationandcoagulativenecrosis)dog:decreasedbodyweightgain,liver(increasedweightandchangesinclinicalchemistry),cataractformation(athighdoses)relevantoralrat:20mg/kgbw/d(90-day)mouse:34mg/kgbw/d(90-day)dog:31mg/kgbw/d(28-week)rat:100mg/kgbw/d(28-day)nodatanotrequired.equivocalincreasesinchromosomalaberrationsinchocellsinvitro.difenoconazoleisunlikelytobegenotoxicinvivo.longtermtoxicityandcarcinogenicity(annexiia,point5.5)rat:reducedbodyweightgain;liver(increasedrelativeweight,hepatocytehypertrophy)mouse:reducedbodyweight(gain);liver(increasedweight,histopathologicalchangesincludingnecrosis,hypertrophy,fattychangeandbilestasis.'", "j.efsa.2011.1968.pdf": null, "j.efsa.2011.1969.pdf": "9impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption79%followinglowdoseadministrationinfemalesbasedonurinaryandbiliaryexcretion,cagewashandcarcassresidues48hafteradministration.distributionwidelydistributed;initialdistributionintofat.significantandpersistentbindingtobloodcells.potentialforaccumulationnoevidenceforbioaccumulation.rateandextentofexcretionrapidexcretion:60-65%inurineand30-40%infaeceswithin96h(mostofitduringthefirst48h).biliaryexcretionwithin48h:40-64%(infemalesandmalesrespectively).metabolisminanimalsextensivemetabolismintherat;onlytracelevelofunchangedterbuthylazinedetected.toxicologicallyrelevantcompounds(animalsandplants)terbuthylazinetoxicologicallyrelevantcompounds(environment)terbuthylazineandmetabolites(mt1,mt13,mt14,lm1,lm2,lm3,lm4,lm5,lm6)acutetoxicity(annexiia,point5.2)ratld50oral1000-1590mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation>5.3mg/lair/4h(dustaerosol,nose-onlyexposure)skinirritationminimalirritanteyeirritationslightirritantskinsensitisationweaksensitiser(m&ktest),noclassificationrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectbodyweightandfoodconsumptioneffectsinrats,micedogsandrabbitsrelevantoralnoael1-year,dog:0.4mg/kgbw/day90-day,rat:2.1mg/kgbw/day28-day,mouse:loael43.2mg/kgbw/day28-day,rabbit:loael5mg/kgbw/dayrelevantdermalnoael28-day,rabbit:0.5mg/kgbw/day28-day,rat:10mg/kgbw/dayrelevantinhalationnoaelnodata-notrequired'", "j.efsa.2011.2018.pdf": "impactonhumanandanimalhealth:absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidwithmorethan80%ofthedoseexcretedwithin24hours(maxplasmaconcentrationsat20-90minutes)viaurineandbile.only50%consideredavailabletothetargettissues,byexcludingbileexcretion(~43%)duringthefirst4hours(firstpassmetabolism).widespreadwiththehighestlevelsinliverandkidney.noevidenceofaccumulationat72hours;someevidencethatthedeclineinradioactivitywasslowerfrombloodcomparedtoothertissues.rapid,withmorethan80%ofthedoseeliminatedwithin24hoursviabile(64-75%),urine(26-30%)andfaces(<10%)mainlybydeoxygenation,cleavages(mainlyoftheimidazolering,minimalcleavageofthebenzotriazineringstructure)andconjugations.(animalsandplants)triazoxideandmetabolites(environment)triazoxideandmetabolitesacutetoxicity(annexiia,point5.2)ratld5098mg/kgbwr25ratld50>5000mg/kgbwratlc500.7mg/l(4hourexposure,primarilynose).r23non-irritantnon-irritantnegative(m&ktest)'", "j.efsa.2011.2019.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)1-naa1-nadrateandextentoforalabsorptionoralabsorption:70%ratsat1mg/kg:>80%basedonurinaryexcretion(24h)at100mg/kg:74%basedonurinaryexcretion(24h)at250mg/kg:77%basedonurinaryexcretion(24h)manat5mg/man:90%basedonurinaryexcretion(48h).oralabsorption:70%ratsat1mg/kg:70%basedonurinaryexcretion(24h)at100mg/kg:65%basedonurinaryexcretion(24h)tmax=1hour,auc350g/ml/h(males)and305g/ml/h(females)distributionratshighestresidueslevelsfoundinliverandkidney(followingoraltreatmentwith1-naa-ethylester)ratshighestresidueslevelsfoundinliver,kidney,renalfatandcarcassbutremainedlowpotentialforaccumulationrats:nobioaccumulationpotentialrats:nobioaccumulationpotentialrateandextentofexcretionrats:at100mg/kg:90%at48hmainlyviaurine(70%)rats:at100mg/kg:90%at48hmainlyviaurine(70%)at500mg/kgbw/day:3to14%oftheparentcompoundfoundinfaecesmetabolisminanimalsrats:conjugationwithglycineafteralowdoseadministrationandtoglucuronicacidathighdose(1-naa).estercleavagefollowedbyglycineandglucuronideconjugationatthelowandrepeateddosesandglucuronideconjugationatthehighdose(1-naa-et).formationofhydroxy-naaisomers(1-naaand1-naa-et)rats:amidecleavagefollowedmainlybyglycineconjugationatlowdoseandglucuronideconjugationathighdose.hydroxylationofthenaphthaleneringisanadditionalrouteofmetabolismandseveralhydroxy-naaisomersanddihydrodiolmetabolitewereformed.toxicologicallyrelevantcompounds(animalsandplants)parentparenttoxicologicallyrelevantcompounds(environment)parentparent'acutetoxicity(annexiia,point5.2)1-naa1-nadratld50oral1750mg/kgbw(1-naa),933mg/kgbw/day(1-naa-na)1655mg/kgbw(males)ratld50dermal>2000mg/kgbw/day(1-naaand1-naa-na)>2000mg/kgbw/dayratlc50inhalation>0.45mg/l(1-naa,wholebody),>5.0mg/l(1-naa-na,nose-only)>2.17mg/l(wholebody)skinirritationnotirritant(1-naaand1-naa-na)notirritanteyeirritationirritant(1-naaand1-naa-na)irritantskinsensitisation1-naa:notsensitizer(llna)1-naa-na:notsensitizer(m&k)notsensitizer(m&k)shorttermtoxicity(annexiia,point5.3)1-naa1-nadtarget/criticaleffectrats:-rbccounts,haemoglobulinandhematocrit,alaninoaminotransferaseandalkalinephosphatase;liverandkidneyorganweights,hepatocellularhypertrophy(1-naa)-erythrocytescounts,hematocrit,hemoglobin,andplateletcounts,liverandkidneyorgansweights,hepatocellularhypertrophyandvacuolationofperiportalhepatocytes(1-naa-na)dog:-congestivepericholangitis,toxicdegenerationofhepatocytes,centrilobularnecrosis,periportalfibrosis,hepatocellularhypertrophyanddevelopmentofahyperplasticnoduleinonedog(1-naa)-transaminases,liverweights,lesionsinthegastrointestinaltract(ulcerativeduodenitisanderosivegastritis),hypocellularityofthebonemarrow,sinusoidalhistiocytosisintheliver(1-naa-na).mice:plateletscounts;liverandkidneyorgansweightswithouthistopathologyinjuries(1-naa-na)rats:liverandkidneyweight,centrilobularhepatocellularhypertrophy,fociofmineralizationofpeyerspatchesand/ormucosaofthesmallandlargeintestineandlargeintestinedilatationdog:erythrocytes,haemoglobinandhaematocrit;haemolysis;haematopoiesis;liverweight(f);pigmentaccumulationinliverandspleenrelevantoralnoael90-day,rat:10mg/kgbw/day(1-naa)90-day,rat:5mg/kgbw/dayrelevantdermalnoael21-day,rat:1000mg/kgbw/day21-day,rat:300mg/kgbw/dayrelevantinhalationnoaelnodata.notrequired.nodata.notrequired.'", "j.efsa.2011.2020.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)1-naa1-nadrateandextentoforalabsorptionoralabsorption:70%ratsat1mg/kg:>80%basedonurinaryexcretion(24h)at100mg/kg:74%basedonurinaryexcretion(24h)at250mg/kg:77%basedonurinaryexcretion(24h)manat5mg/man:90%basedonurinaryexcretion(48h).oralabsorption:70%ratsat1mg/kg:70%basedonurinaryexcretion(24h)at100mg/kg:65%basedonurinaryexcretion(24h)tmax=1hour,auc350g/ml/h(males)and305g/ml/h(females)distributionratshighestresidueslevelsfoundinliverandkidney(followingoraltreatmentwith1-naa-ethylester)ratshighestresidueslevelsfoundinliver,kidney,renalfatandcarcassbutremainedlowpotentialforaccumulationrats:nobioaccumulationpotentialrats:nobioaccumulationpotentialrateandextentofexcretionrats:at100mg/kg:90%at48hmainlyviaurine(70%)rats:at100mg/kg:90%at48hmainlyviaurine(70%)at500mg/kgbw/day:3to14%oftheparentcompoundfoundinfaecesmetabolisminanimalsrats:conjugationwithglycineafteralowdoseadministrationandtoglucuronicacidathighdose(1-naa).estercleavagefollowedbyglycineandglucuronideconjugationatthelowandrepeateddosesandglucuronideconjugationatthehighdose(1-naa-et).formationofhydroxy-naaisomers(1-naaand1-naa-et)rats:amidecleavagefollowedmainlybyglycineconjugationatlowdoseandglucuronideconjugationathighdose.hydroxylationofthenaphthaleneringisanadditionalrouteofmetabolismandseveralhydroxy-naaisomersanddihydrodiolmetabolitewereformed.toxicologicallyrelevantcompounds(animalsandplants)parentparenttoxicologicallyrelevantcompounds(environment)parentparent'acutetoxicity(annexiia,point5.2)1-naa1-nadratld50oral1750mg/kgbw/day(1-naa),933mg/kgbw/day(1-naa-na)1655mg/kgbw/day(males)ratld50dermal>2000mg/kgbw/day(1-naaand1-naa-na)>2000mg/kgbw/dayratlc50inhalation>0.45mg/l(1-naa,wholebody),>5.0mg/l(1-naa-na,nose-only)>2.17mg/l(wholebody)skinirritationnotirritant(1-naaand1-naa-na)notirritanteyeirritationirritant(1-naaand1-naa-na)irritantskinsensitisation1-naa:notsensitizer(llna)1-naa-na:notsensitizer(m&k)notsensitizer(m&k)shorttermtoxicity(annexiia,point5.3)1-naa1-nadtarget/criticaleffectrats:-rbccounts,haemoglobulinandhematocrit),alaninoaminotransferaseandalkalinephosphatase;liverandkidneyorganweights,hepatocellularhypertrophy;(1-naa)-erythrocytescounts,hematocrit,hemoglobin,andplateletcounts,liverandkidneyorgansweights,hepatocellularhypertrophyandvacuolationofperiportalhepatocytes(1-naa-na)dog:-congestivepericholangitis,toxicdegenerationofhepatocytes,centrilobularnecrosis,periportalfibrosis,hepatocellularhypertrophyanddevelopmentofahyperplasticnoduleinonedog(1-naa)-transaminases,liverweights,lesionsinthegastrointestinaltract(ulcerativeduodenitisanderosivegastritis),hypocellularityofthebonemarrow,sinusoidalhistiocytosisintheliver(1-naa-na).rats:liverandkidneyweight,centrilobularhepatocellularhypertrophy,fociofmineralizationofpeyerspatchesand/ormucosaofthesmallandlargeintestineandlargeintestinedilatationdog:erythrocytes,haemoglobinandhaematocrit;haemolysis;haematopoiesis;liverweight(f);pigmentaccumulationinliverandspleen.'", "j.efsa.2011.2084.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabove80%(basedonexcretioninexpiredair,urineandcarcasswithin168h)maxbloodconcentrationbetween6and24hafterdosingdistributionsmallamountsoftotalradioactivitywerefoundintissues,mainlyinthestomachandliver.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandextensive:mainlyviaexpiredair(60%);urine(20%)andfaeces(15%)metabolisminanimalsextensivelymetabolized.mainpathway:dechlorinationtochcl2no2withconversionofgshtogssg,andconversiontoraphanusamicacidviathiophosgene.minorpathway:adductformationwiththiolproteins(hb-adduct)toxicologicallyrelevantcompounds(animalsandplants)chloropicrintoxicologicallyrelevantcompounds(environment)chloropicrinacutetoxicity(annexiia,point5.2)ratld50oral250mg/kgbwr22ratld50dermalnovaliddatanotrequiredratlc50inhalation0.044mg/l(4h;noseonly)r26skinirritationirritantr38eyeirritationirritantr36inhalationirritantirritantr37skinsensitisationnodatanotrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectrat(90-doral):mortality,decreasedbodyweightandfoodconsumption,lesionsofnonglandularstomachrat/mouse(90-dinhalation):decreasedfoodconsumption(mice);increasedlungweightwithinflammatorylesions(rats,mice);gobletcellhyperplasiainthenasalcavities(localeffect,rats),hyalineinclusionsinthenasalepithelium(localeffect,mice)dog:increasedincidenceandseverityofemesisr48/22relevantoralnoaelrat:10mg/kgbw/d(90-d)dog:0.1mg/kgbw/d(1-yr)'", "j.efsa.2011.2085.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorption:readilyabsorbed(~80%),basedonurinaryexcretionwithin24h.distribution:widelydistributed,highestlevelinliverpotentialforaccumulation:nopotentialforaccumulation.verylowlevelsoftissueresiduesafteroneweek.rateandextentofexcretion:extensiveandrapid(90%within168h,mainlyduringthefirst24h);mostlyviaurine(78-87%)andfaeces(10%)metabolisminanimalsextensivelymetabolised(90%).intheproposedmetabolicpathway,theprimarymetabolitesare3,4-dichloroaniline(3,4-dca)andn-hydroxy-3,4-dichloroaniline.themajorityofmetabolitesareeliminatedinurineaspolarconjugates.toxicologicallyrelevantcompounds(animals,plants)propanil;3,4-dichloroaniline(3,4-dca)andn-hydroxy-3,4-dichloroanilinetoxicologicallyrelevantcompounds(environment)propanilacutetoxicity(annexiia,point5.2)ratld50oral960mg/kgbwr22rabbitld50dermal>2000mg/kgbwratlc50inhalationnodata-notrequiredskinirritationnonirritanteyeirritationirritantr36skinsensitisationnonsensitising(m&ktestandmodifiedbuehlertest,9inductions)shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat,dog,mouse:haematologicalchanges(includingincreasedmethgb);andhistopathologicalchangesinliver,kidneyandspleen(a.o.ironpigment)rabbit:haematologicalchangesrelevantoralnoaelrat:23mg/kgbw/d(90-d)dog,30-day:7mg/kgbw/ddog,1-yr::loael5mg/kgbw/dmouse:loael71mg/kgbw/d(13-wk)relevantdermalnoaelrabbit:250mg/kgbw/d(21-d,importantdeviations)relevantinhalationnoaelnodata-notrequired'", "j.efsa.2011.2087.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrats:75%basedonurinaryexcretion+fixationintissues+biliaryexcretionevaluatedasfaecalmetabolitesat25mg/kgbw;samepercentageexpectedatlowerconcentrations;noinfluenceofapre-treatment;maximalconcentrationinbloodat6hrs.lowerabsorptionathighdose-levels.distributionrats:highestresiduelevelsinkidneys(1-3mg/kg),followedbyfattissue,heartandliver,at96to168h.potentialforaccumulationrats:nobioaccumulationpotential.rateandextentofexcretionrats:at25mg/kgbw:95%at48h,mainlyviaurineinmales(58%at48h),similarurinaryandfaecalexcretioninfemales.metabolisminanimalsrats:hydrolysisofthepropynylsulfiteside-chain,subsequentoxidationandconjugationoftheter-butylmoiety,andhydroxylationofthecyclohexylmoiety.anadditionalpathwayismetabolismoftheside-chainbyglutathioneconjugation.toxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50oral2639mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation0.89mg/lair/4h(aerosol,noseonly)r23skinirritationirritantr38eyeirritationirritantr41skinsensitisationsensitising(modifiedbuehlermethod&modifiedmagnusson&kligmanmethod)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectsignificantgrowthimpairmentorweightlossatleastpartiallyduetolowerfoodintake(ratsanddogs)dogs(oral):hematopoieticsystem'", "j.efsa.2011.2088.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionrats:rapid>80%inbothsexesaftersingledosingat3.5mg/kg>3%inmalesand12%infemalesaftersingledosingat350mg/kg;2timeshigheraucthanatlow-doselevel.dogs:rapid>30%inbothsexesaftersingledosingat3.5mg/kg.distributionrats&dogs:widespreaddistribution,highestconcentrationfoundinfatandtoalesserextentbonemarrow.presenceinmilkinlactatingrats.potentialforaccumulationfat/bloodresidueconcentrationratioswere53(rat)and19(dogs)7dayspostdosing.within28dailyrepeateddosesat3.5mg/kg,bloodandtissueresiduesrisecontinuously.rateandextentofexcretionslowmainlyviafaeces(biliaryexcretion)andurinerats:depurationt1/2ofvariousorgansafterrepeatedadministrationtoratsareintherangeof20to48days,33%oftheasingledoseof3.5mg/kgwithin7daysdogs:depurationt1/2inbloodis33days.metabolisminanimalslimitedmetabolism;majormetabolitewas2,6-difluorobenzoicacidaccountingfor10-12%oftheadministereddosein0-48hurinetoxicologicallyrelevantcompounds(animals,plants)parent,metabolitereg.no.102719toxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50oral>3000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>3.3mgrespirableparticles/lairskinirritationnon-irritant(rabbit)eyeirritationnon-irritant(rabbit)skinsensitization(testmethodandresult)notsensitising'", "j.efsa.2011.2091.pdf": "1impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%;peakplasmaconcentration:30-40min.afteroraladministration[acid,mhe]distributionhighestresidues:gastro-intestinal-tractandkidneys[acid,mhe]potentialforaccumulationnoindicationofaccumulationafterrepeatedadministration[mhe]rateandextentofexcretionefficientlyeliminatedwithin2days:urine(91-94%);faeces(4-6%)[acid,mhe]metabolisminanimalsmhe;rapidlyandcompletelyhydrolysedtofluroxypyr,sodiumsalt;unchangedexcretedtoxicologicallyrelevantcompounds(animalsandplants)fluroxypyrtoxicologicallyrelevantcompounds(environment)fluroxypyracutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw[mhe]ratld50dermal>2000mg/kgbw[mhe]ratlc50inhalation>1.0mg/lair/4hours(whole-bodyexposure,highestattainableconcentration)[mhe]skinirritationnon-irritant[mhe]eyeirritationnon-irritant[mhe]skinsensitisationnon-sensitising(m&kandbuehlertests)[mhe]shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney[acid,mhe]relevantoralnoael90-day,rat&mouse:80mg/kgbw/day[acid]1-year,dog:150mg/kgbw/day[acid]relevantdermalnoael21-day,rabbit:300mg/kgbw/day[mhe]relevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)noevidenceofgenotoxicity[acid]isattributedtotheactivesubstanceinstudieswherenoinformationisavailableonthepurityandimpurityprofileofthebatchestested.avalid'", "j.efsa.2011.2096.pdf": "olemammaliantoxicology31efsajournal2011;9(5):2096impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyadsorbed,57-68%basedonurineandbiliaryexcretion,cagewashandcarcassresidues48hafteradministration.distributionwidelydistributed,highestresiduesinthesexglands(preputial/clitoris),fattytissues,liverandblood.potentialforaccumulationindicationofbioaccumulationuponrepeatedadministration(bloodandfat).rateandextentofexcretionslowlyexcreted(t65h),>90%after7days;majorrouteisfaecalexcretion(~80%after168h)formalesandfemales,withrenal(59%after168h)andbiliary(921%after48h)comprisinglesserroutes(dichlorophenylradiolabelledfluquinconazole).higherrenalexcretionwasobservedwhenfluquinconazolewasradiolabelledonthetriazolegroup.metabolisminanimalsmajorityofadsorbeddoseismetabolisedto1,2,4triazoleandthedionepluspolarconjugates(upto10minormetabolites).infaeces,mainradioactivityrepresentedunchangedfluquinconazoleandupto14minormetabolites.toxicologicallyrelevantcompounds(animalsandplants)fluquinconazoletoxicologicallyrelevantcompounds(environment)fluquinconazoleacutetoxicity(annexiia,point5.2)ratld50oral112mg/kgbw(rat)180mg/kgbw(mouse)t,r25ratld50dermal2679mg/kgbwinmales625mg/kgbwinfemalesxn,r21ratlc50inhalation0.514mg/lair/4h(headonly)t,r23skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&k)'", "j.efsa.2011.2143.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption:rapidandalmostcomplete,basedonurineandbileexcretion(>80%)inratat10mg/kgbw/day,repeateddose.distribution:widelydistributed.potentialforaccumulation:low:someaccumulationinnasalturbinatesinratsbutnotinmice.rateandextentofexcretion:relativelyrapid(~86%within48h).mainlyinurine(66-72%)andinfaeces(12-21%,fromwhich80-85%viabile)metabolisminanimalsacetochlorundergoesconjugationandmixedfunctionoxygenation.themainmetaboliteidentifiedinratandmonkeywasthetert-mercatpturicacidwith25-27%oftheradioactivityexcretedinmonkeyurinetoxicologicallysignificantcompounds(animalsandplants)acetochlortoxicologicallyrelevantcompounds(environment)acetochlor,t-oxanilicacid,t-sulfinylaceticacid,t-norchloroacetochlor,t-sulfonicacid,s-sulfonicacidacutetoxicity(annexiia,point5.2)ratld50oral1929mg/kgbwr22ratld50dermal>2000mg/kgbwratlc50inhalation3.99mg/l/4hexposurenose-only.testmaterial:aerosolr20skinirritationirritantr38eyeirritationnon-irritantskinsensitisationsensitising;modifiedbuehlertestandgpmtofmagnussonandkligmanr43respiratorysystemirritationirritantr37shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneyandtestes(histopathologicalalterations)(dog)liverandkidney(rat)relevantoralnoael2mg/kgbw/d(1-yrdog)16mg/kgbw/d(13-wkrat)r48/22relevantdermalnoael400mg/kgbw/d(21-drabbit,localnoael)relevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)positiveinvitro,invivoudspositiveattoxicdoselevels,negativeinmicronucleusanddominantlethalstudies.nogenotoxicpotentialrelevanttohumans.longtermtoxicityandcarcinogenicity(annexiia,point5.5)'", "j.efsa.2011.2152.pdf": "2impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)approx.80%basedonurinaryexcretion,residuesincarcassandcagewash.rapidlyabsorbed(tmax=30min2h)widelydistributednopotentialforaccumulationrapidlyexcretedmostlywithin48h(males)andwithin72h(females),mainlyviaurine(7580%within168h)hydroxilationandglucosilation.theparentisthemaincompoundinurine.(animalsandplants)2-naphthyloxyaceticacid(environment)2-naphthyloxyaceticacidacutetoxicity(annexiia,point5.2)ratld501417mg/kgbw(rat)1557mg/kgbw(mice)r22h302ratld502000mg/kgbwratlc504.87mg/lair(4h,noseonly)nonirritantsevereirritantr41h318skinsensitisationsensitising(m&k)r43h317shorttermtoxicity(annexiia,point5.3)rat:kidney(increasedweight,tubulardilationinpresenceofeosinophilicmaterial,increasedcreatininelevel)liver(increasedweight,hepatocytecentrolobularhypertrophyandincreasedalpandsgpt)nodatainnon-rodentspecies.90-dayrat:10mg/kgbw/daynodata-notrequirednodata-notrequirednexiia,point5.4)2-naphthyloxyaceticacidisunlikelytobe'", "j.efsa.2011.2159.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption50%absorptionviaoralrouteinratin4-6hoursdistributionfatandskinmainly(3%ofthedoseremainsintissues)potentialforaccumulationpotentialforaccumulationinfat,terminalhalf-lifeofupto51days.rateandextentofexcretioneliminationcompletewithin48hoursurine(13-25%)andfaeces(63-88%),3%remainedintissuesandorgansmetabolisminanimalsviahydrolysis,oxidationandconjugation.nopreferentialenantiomericabsorption,biotransformationoreliminationofbifenthrins-andr-enantiomerstoxicologicallyrelevantcompounds(animalsandplants)nomainmetabolites,alllessthan10%bifenthrintoxicologicallyrelevantcompounds(environment)bifenthrinacutetoxicity(annexiia,point5.2)ratld50oralld50:54.5mg/kg(dilutedincornoil)186.1mg/kg(undiluted)r25ratld50dermal>2000mg/kg-ratlc50inhalation1.01mg/l/4h(ci:066-1.1)r23skinirritationnonirritant-eyeirritationnonirritant-skinsensitisationsensitiser(m&k)notsensitising(buehler)r43short-termtoxicity(annexiia,point5.3)target/criticaleffectneurotoxiceffect:tremors;reductionintaillatency;staggeredgaitandexaggeratedhindlimbflexionrelevantoralnoaelnoael:2.5mg/kg/day(90-daydog)noael:1.5mg/kg/day(1-yeardog)relevantdermalnoaelnoael:50mg/kg/day(rat)noael:100mg/kg/day(rabbits)relevantinhalationnoael-genotoxicity(annexiia,point5.4)negative'", "j.efsa.2011.2162.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionrapidandalmostcomplete(84%within24h).tmax:0.5hr.distributionwidelydistributed.highestlevelsinwholeblood.potentialforaccumulationnoevidenceofaccumulation.rateandextentofexcretionmainlyviaurine(70-80%at24h)butalsoviafaeces(5-10%at24h).biliaryexcretionnotmeasured.metabolisminanimalsinvolvedthiophosphorylhydrolysis,s-methylation,oxidationofthesulfurtothesulfoxideandtothesulfone(u6),hydrolysisofthephthalimideringtotherespectivephthalimideacid.toxicologicallysignificantcompounds(animals,plantsandenvironment)phosmetandphosmet-oxonacutetoxicity(annexiia,point5.2)ratld50oral113mg/kgbwt;r25ratld50dermal>1000mg/kgbwrabbitld50dermal>5000mg/kgbwratlc50inhalationlc50>0.152mg/lskinirritationnon-irritanteyeirritationmoderateirritantskinsensitization(testmethodusedandresult)non-sensitising(modifiedbuehlertest,10-induction)shorttermtoxicity(annexiia,point5.3)target/criticaleffectplasma,rbcandbrainacetylcholinesteraselowestrelevantoralnoael/noeloverallnoael:2mg/kgbw/day(90dayrat,28-daymouseanddog)lowestrelevantdermalnoael/noel22.5mg/kgbw/day(rat21-days,brainche)lowestrelevantinhalationnoael/noelnodata.notrequiredgenotoxicity(annexiia,point5.4).....................................................................positive.negative.weightofevidenceindicatesnosignificantgenotoxic'", "j.efsa.2011.2285.pdf": "85impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiondataavailableoflimitedvalidity.nofurtherdatarequired.distributiondataavailableoflimitedvalidity.nofurtherdatarequired.potentialforaccumulationdataavailableoflimitedvalidity.nofurtherdatarequired.rateandextentofexcretiondataavailableoflimitedvalidity.nofurtherdatarequired.metabolisminanimalsdataavailableoflimitedvalidity.nofurtherdatarequired.toxicologicallyrelevantcompounds(animalsandplants)dataavailableoflimitedvalidity.nofurtherdatarequired.toxicologicallyrelevantcompounds(environment)dataavailableoflimitedvalidity.nofurtherdatarequired.acutetoxicity(annexiia,point5.2)ratld50oraldataavailableoflimitedvalidity.nofurtherdatarequired.ratld50dermaldataavailableoflimitedvalidity.nofurtherdatarequired.ratlc50inhalationdataavailableoflimitedvalidity.nofurtherdatarequired.skinirritationdataavailableoflimitedvalidity.nofurtherdatarequiredeyeirritationdataavailableoflimitedvalidity.nofurtherdatarequired.skinsensitisationdataavailableoflimitedvalidity.nofurtherdatarequired.shorttermtoxicity(annexiia,point5.3)target/criticaleffectdataavailableoflimitedvalidity.nofurtherdatarequired.relevantoralnoaelrelevantdermalnoaelrelevantinhalationnoael'", "j.efsa.2011.2298.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodataavailable,notneeded.distributionnodataavailable,notneeded.potentialforaccumulationnodataavailable,notneeded.rateandextentofexcretionnodataavailable,notneeded.metabolisminanimalsnodataavailable,notneeded.toxicologicallyrelevantcompounds(animalsandplants)nodataavailable,notneeded.toxicologicallyrelevantcompounds(environment)nodataavailable,notneeded.acutetoxicity(annexiia,point5.2)ratld50oraldataavailableoflimitedvalidity,nofurtherdataneeded.ratld50dermaldataavailableoflimitedvalidity,nofurtherdataneeded.ratlc50inhalationdataavailableoflimitedvalidity,nofurtherdataneeded.skinirritationdataavailableoflimitedvalidity,nofurtherdataneeded.eyeirritationdataavailableoflimitedvalidity,nofurtherdataneeded.skinsensitisationdataavailableoflimitedvalidity,nofurtherdataneeded.shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataavailable,notneeded.relevantoralnoaelnodataavailable,notneeded.relevantdermalnoaelnodataavailable,notneeded.relevantinhalationnoaelnodataavailable,notneeded.nodataavailable,notneeded.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailable,notneeded.relevantnoaelnodataavailable,notneeded.carcinogenicitynodataavailable,notneeded.'", "j.efsa.2011.2299.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)dataavailableoflimitedvalidity,nofurtherdataneeded.nodataavailable,notneeded.potentialnodataavailable,notneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.toxicologicallyrelevantcom(animalsandplants)nodataavailable,notneeded.(environment)nodataavailable,notneeded.acutetoxicity(annexiia,point5.2)ratld50dataavailableoflimitedvalidity,nofurtherdataneeded.-ratld50nodataavailable,notneeded.-ratlc50dataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.nodataavailable,notneeded.-shorttermtoxicity(annexiia,point5.3)nodataavailable,notneeded.nodataavailable,notneeded.-nodataavailable,notneeded.-nodataavailable,notneeded.-nodataavailable,notneeded.-longtermtoxicityandcarcinogenicity(annexiia,point5.5)nodataavailable,notneeded.nodataavailable,notneeded.nodataavailable,notneeded.-'", "j.efsa.2011.2300.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabdataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.rateandextentdataavailableoflimitedvalidity,nofurtherdataneeded.dataavailableoflimitedvalidity,nofurtherdataneeded.(animalsandplants)dataavailableoflimitedvalidity,nofurtherdataneeded.(environment)-acutetoxicity(annexiia,point5.2)ratld50dataavailableoflimitedvalidity,nofurtherdataneeded.-rabbitld50dataavailableoflimitedvalidity,nofurtherdataneeded.-ratlc50dataavailableoflimitedvalidity,nofurtherdataneeded.-dataavailableoflimitedvalidity,nofurtherdataneeded.-dataavailableoflimitedvalidity,nofurtherdataneeded.-dataavailableoflimitedvalidity,nofurtherdataneeded.-shorttermtoxicity(annexiia,point5.3)dataavailableoflimitedvalidity,nofurtherdataneeded.relevantor-'", "j.efsa.2011.2323.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:rapidlyabsorbed,>70%within48hours.distribution:widelydistributed,highestresiduesassociatedwiththeorgansofelimination(kidneyandliver).potentialforaccumulation:noevidenceforbioaccumulation.rateandextentofexcretion:inmaleratsthemainrouteofexcretionisviatheurinewithlevelsrangingfrom45%to72%(lowsingledose-highmultipledose).infemalesthemainrouteofeliminationvariesdependingonexposuretype.singledosesareprimarilyexcretedviathefaeces,however,therouteofexcretioncanvaryaccordingtodoselevelinmulti-dosestudies.highmulti-dosesfavourexcretionviatheurine.metabolisminanimalsextensivelymetabolisedwithaninitialcleavageoftheimidazolefollowedbyhydroxylationofthephenylringand/orsidechainhydrolysis.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundacutetoxicity(annexiia,point5.2)prochlorazprochloraz-copperratld50oral1,023mg/kgbwxn:r22>2000mg/kgbwratld50dermal2,100mg/kgbw>5000mg/kgbwratlc50inhalation>2.16mg/l(wholebody,4h)nodata.skinirritationnotirritantnotirritanteyeirritationnotirritantnotirritantskinsensitisation(testmethodusedandresult)non-sensitising(m&k)non-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdogs,mice,rats:liversize/weightdogs:prostateweightlowestrelevantoralnoaeldogs:2.5mg/kgbw/daymice:6mg/kgbw/day(males)rats:6mg/kgbw/daylowestrelevantdermalnoael1000mg/kgbw/day(21dayratstudy)basedonintracytoplasmicinclusionsoftherenalcorticalepithelium(males)lowestrelevantinhalationnoael/noelnotrelevantgenotoxicity(annexiia,point5.4)prochloraznogenotoxicpotentialprochloraz-copperamestest:negative'", "j.efsa.2011.2334.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)metamandmitc85%(basedonurinary(50%)andexpiredair(35%)excretionwithin48h)uniformlydistributedslightpotentialforaccumulationinthyroidrapidandextensive(app.85%)within48h,mainlyviaurine(50%)within24h,4%viafaeces,35%viaexpiredairextensivedegradationofmetamintomitcwhichisfurtherconjugatedwithgshordecomposesintomic,cosandco2.anotherimportantmetabolicpathwayisformationofcs2whichisrelatedtoacidicconditionsofstomach(animalsandplants)parentcompoundandmetabolites:methylisothiocyanate(mitc),methylisocyanate(mic),cos,cs2(environment)methylisothiocyanate(mitc),methylisocyanate(mic),cos,cs2acutetoxicity(annexiia,point5.2)metam-sodiumratld50896mg/kgbwr22ratld50>2000mg/kgbw-ratlc502.54mg/lair/4h(wholebody)r20skinircorrosiver34non-irritant-sensitising(m&k)r43acutetoxicity(annexiia,point5.2)mitcratld50147mg/kgbwr25ratld501290mg/kgbwr21ratlc500.54mg/lair/4h(wholebody)r23r37corrosiver34nostudyrequired-sensitising(m&k)r43shorttermtoxicity(annexiia,point5.3)metam-sodiumnasalcavity(rat),urinarybladder(mice),liver(dog)1-year,dog0.1mg/kgbw/day90-dayrat:0.5mg/kgbw/day90-daymice:0.8mg/kgbw/dayr48/2221-day,rabbit:31.2mg/kgbw/day90-dayrat:6.5mg/m3correspondingto1.75mg/kgbw/dshorttermtoxicity(annexiia,point5.3)mitcnasalcavity(rat),liver(dog)90-day,dog0.4mg/kgbw/daynodata-notrequiredreleva28-dayrat:5mg/m3(1.35mg/kgbw/d)metamandmitcareunlikelytobegenotoxic'", "j.efsa.2011.2417.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point6.1)rateandextentofabsorption:88-95%basedonurine,tissues,expiredco2,cagewash,andresidualcarcasswithin168h.distribution:widely(0.2-0.7%intissues);highestresiduesinadrenals,liverandkidneys.potentialforaccumulation:noevidenceofaccumulationrateandextentofexcretion:urinary:80-86%in24h;faecal8.5-14%in24hmetabolisminanimalsextensivelymetabolised,>99%byoxidationtoclethodimsulfoxide.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point6.2)ratld50oral1133mga.s./kgbwr22ratld50dermal>4167mga.s./kgbwratlc50inhalation>3.25mga.s./lair/4h(wholebody)(maximalattainableconcentration)skinirritationirritating,r38eyeirritationnon-irritantskinsensitization(testmethodusedandresult)sensitizer,r43(m&ktest)shorttermtoxicity(annexiia,point6.3)target/criticaleffectliver,redbloodcells(rat,mouse,dog)relevantoralnoael21mga.s./kgbw/d(90-dand1-yrdog)25mga.s./kgbw/d(90-drat)74mga.s./kgbw/d(4-wk,range-finding,mouse)relevantdermalnoael83mga.s./kgbw/d(4-wkrat)relevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point6.4)unlikelytobegenotoxic.longtermtoxicityandcarcinogenicity(annexiia,point6.5)target/criticaleffectdecreasedbodyweight(rat)liver:increasedweightandassociatedhistopathologicalfindings(rat,mouse)lungs:increasedincidenceofalveolarmacrophages(mouse).lowestrelevantnoael/noel16mga.s./kgbw/d(2-yrrat)24mga.s./kgbw/d(18-monthmouse)carcinogenicitynocarcinogenicpotential.'", "j.efsa.2011.2419.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioncalciumcarbide:nodataavailable,notneededcalciumphosphide:readyabsorptionofphosphinethroughthelungsandafteroralexposuretozincphosphidedistributioncalciumcarbide:nodataavailable,notneededcalciumphosphide:widelydistributedpotentialforaccumulationcalciumcarbide:nodataavailable,notneededcalciumphosphide:nopotentialforaccumulationrateandextentofexcretioncalciumcarbide:nodataavailable,notneededcalciumphosphide:excretionwithurineashypophosphiteandphosphiteandvialungsasphosphinemetabolisminanimalscalciumcarbide:nodataavailable,notneededcalciumphosphide:hydrolysistophosphine,oxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)calciumcarbide:calciumcarbidecalciumphosphide:phosphinetoxicologicallyrelevantcompounds(environment)calciumcarbide:calciumcarbidecalciumphosphide:phosphineacutetoxicity(annexiia,point5.2)ratld50oralcalciumcarbide:nodataavailable,notneeded:basedonthemeasuredphof12.48ofa1%solutionindeionisedwaterofcalciumcarbide,noexperimentwasundertakenforhumanereasonsonliveanimals.calciumphosphide:8.7mg/kgbw(basedonaluminiumphosphide)t+;r28ratld50dermalcalciumcarbide:nodataavailable,notneeded:basedonthemeasuredphof12.48ofa1%solutionindeionisedwaterofcalciumcarbide,noexperimentwasundertakenforhumanereasonsonliveanimals.calciumphosphide:460-900mg/kgbw(aluminiumphosphide)xn;r21ratlc50inhalationcalciumcarbide:nodataavailable,notneeded:becausecalciumcarbideisagranule47mm,theparticlesizeindust<50missmallerthan10%w/w.humandatasupportclassificationwithr37.calciumphosphide:>11ppm(>0.015mgph3/lairor>2.8mg/kgbw)51ppm(0.072mgph3/lair)(4hexposure,wholebody)(phosphine)t+;r26xi;r37'skinirritationcalciumcarbide:nodataavailable,notneeded:basedonthemeasuredphof12.48ofa1%solutionindeionisedwaterofcalciumcarbide,noexperimentwasundertakenforhumanereasonsonliveanimals.c;r35eyeirritationcalciumcarbide:nodataavailable,notneeded:basedonthemeasuredphof12.48ofa1%solutionindeionisedwaterofcalciumcarbide,noexperimentwasundertakenforhumanereasonsonliveanimals.[xi;r41]skinsensitisationcalciumcarbide:nodataavailable,notneeded:basedonthemeasuredphof12.48ofa1%solutionindeionisedwaterofcalciumcarbide,noexperimentwasundertakenforhumanereasonsonliveanimals.non-sensitiseraccordingtoliteraturedataoncomponents.shorttermtoxicity(annexiia,point5.3)target/criticaleffectcalciumcarbide:nodataavailable,notneeded:doesnotenterthehumanfoodchain.calciumphosphide:mortalityrelevantoralnoaelcalciumcarbide:nodataavailable,notneeded.calciumphosphide:nodataavailable,notneededrelevantdermalnoaelcalciumcarbide:nodataavailable,notneededcalciumphosphide:nodataavailable,notneededrelevantinhalationnoaelcalciumcarbide:nodataavailable,notneededcalciumphosphide:3ppmphosphine(equivalentto1.1mg/kgbw/d),rat90-d,thehighestdosetestedgenotoxicity(annexiia,point5.4)calciumcarbide:nodataavailable,notneeded:calciumcarbidedoesnotenterthehumanfoodchain.calciumphosphide:nogenotoxicpotentialrelevantathumanexposurelevels'", "j.efsa.2011.2543.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionnodataavailable(1)distributionnodataavailable(1)potentialforaccumulationnodataavailable(1)rateandextentofexcretionnodataavailable(1)metabolisminanimalsnodataavailable(1)toxicologicallyrelevantcompounds(animalsandplants)nodataavailable(1)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50orallimitedinformationavailable(1)rabbitld50dermalnodataavailable(1)ratlc50inhalationnodataavailable;(1)skinirritationnodataavailable(1)eyeirritationnodataavailable(1)skinsensitisationnodataavailable.oneofthecomponentsoftalloilcrude(i.erosin)isaskinsensitizer.shorttermtoxicity(annexiia,point5.3)target/criticaleffectlimitedinformationavailable(1)relevantoralnoaelrelevantdermalnoaelnodataavailable(1)relevantinhalationnoaelnodata-available(1)genotoxicity(annexiia,point5.4)limitedinformationavailable(1)longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailable(1)relevantnoaelnodataavailable(1)carcinogenicitynodataavailable(1)'", "j.efsa.2011.2544.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionnodataavailable(1)distributionnodataavailable;(1)potentialforaccumulationnodataavailable(1)rateandextentofexcretionnodataavailable(1)metabolisminanimalsnodataavailable;(1)toxicologicallyrelevantcompounds(animalsandplants)nodataavailable(1)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50orallimitedinformationavailable(1)rabbitld50dermalnodataavailable(1)ratlc50inhalationnodataavailable;(1)skinirritationnodataavailable(1)eyeirritationnodataavailable(1)skinsensitisationnodataavailable(1).oneofthecomponentsoftalloilpitch(i.erosin)isaskinsensitizer.shorttermtoxicity(annexiia,point5.3)target/criticaleffectlimitedinformationavailable(1)relevantoralnoaelrelevantdermalnoaelnodataavailable(1)relevantinhalationnoaelnodata-available(1)genotoxicity(annexiia,point5.4)limitedinformationavailable(1)longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailable(1)relevantnoaelnodataavailable(1)carcinogenicitynodataavailable(1)'", "j.efsa.2012.2483.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodatadistributionnodatapotentialforaccumulationnodatarateandextentofexcretionnodatametabolisminanimalsnodatatoxicologicallyrelevantcompounds(animalsandplants)-toxicologicallyrelevantcompounds(environment)-acutetoxicity(annexiia,point5.2)ratld50oralm:841mg/kgbw;f:648mg/kgbwxn,r22ratld50dermal>2000mg/kgbw-ratlc50inhalationm&f:0.20mg/lt+,r26skinirritationnoirritation-eyeirritationseverelyirritantxi,r41skinsensitisationnosensitizing-shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodatarelevantoralnoaelnodatarelevantdermalnoaelnodatarelevantinhalationnoaelnodatagenotoxicity(annexiia,point5.4)apparentlynotgenotoxic;(puritynotstatedinthestudies)'", "j.efsa.2012.2486.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidlyabsorbed,>79%within48hours(basedonexcretionviaurineandtissuecontent)narrowdistribution,highestresiduesassociatedwiththeliver,bloodandresidualcarcassunlikelyatalldosagelevelsthemajorrouteofeliminationinratsisviatheurineforbothsexes(7289%),inaddition,femalestendtoexcreteahigheramountinfaecesthanmalesforthelowdosegroupswhilethereverseistrueforhighdoseadministrationofdpaextensivelymetabolised,>84%(13metabolitesincludingparentidentified);4-oh-dpawasthemajorfreemetabolitedetectedinbothurineandfaecesandparentisfoundinsmallamountsinfaecestoxicologicallyrelevantcompoun(animalsandplants)diphenylamine(environment)diphenylamineacutetoxicity(annexiia,point5.2)>15000mg/kgbw>7500mg/kgbwnodata,studywasnottechnicallyfeasibletoperformnotirritantsevereirritantr41non-sensitiser(magnusson&kligman)short-termtoxicity(annexiia,point5.3)rbc;spleniccongestionandhaemosiderosis;extramedullaryhaematopoiesis;clinicalchemistry(dog,ratsandmice)1-yeardog+90-daydog:10mg/kgbw/day90-dayrat:9.6mg/kgbw/day90-daymouse:1.7mg/kgbw/day(withaloaelof94mg/kgbw/day)21-dayrabbit:100mg/kgbw/daynodata-notrequired'", "j.efsa.2012.2491.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioninsufficientdataavailablenotrequired1%foraluminium(efsa,2010)distributioninsufficientdataavailablenotrequiredpotentialforaccumulationinsufficientdataavailablenotrequired.rateandextentofexcretioninsufficientdataavailablenotrequiredmetabolisminanimalsnodataavailablenotrequiredtoxicologicallyrelevantcompounds(animalsandplants)aluminiumtoxicologicallyrelevantcompounds(environment)aluminiumacutetoxicity(annexiia,point5.2)ratld50oral(curbpowder,88.8%a.s)>2000mg/kgbwratld50dermal(curbpowder,88.8%a.s)>2000mg/kgbwratlc50inhalationnodataavailablenotrequiredskinirritation(curbpowder,88.8%a.s)nonirritanteyeirritation(curbpowder,88.8%a.s)nonirritantskinsensitisationnodataavailablenotrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectinsufficientdataavailablenotrequiredrelevantoralnoaelinsufficientdataavailablenotrequiredrelevantdermalnoaelnodataavailablenotrequiredrelevantinhalationnoaelnodataavailablenotrequiredgenotoxicity(annexiia,point5.4)negativeintwoamestestlongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectinsufficientdataavailablenotrequiredrelevantnoaelinsufficientdataavailablenotrequiredcarcinogenicityinsufficientdataavailablenotrequired'", "j.efsa.2012.2492.pdf": "impactonhumanandanimalhealthsea-algaeextractsareallaqueousextracts(cellcontents)ofoneormoreofthespeciesascophyllumnodosum,laminariadigitataandmacrocystisintegrifoliaoftheordersfucalesandlaminarialesoftheclassphaeophyceae(brownseaweeds).thesespecieshaveanon-toxicmodeofactionandarenon-toxicbythemselves;theyareusedasanimaland/orhumanfeedorherbalremediesandthereforethereisnoadditionalrisktoconsumersfromanyresiduesthatmaypossiblyoccurasaresultoftheuseasaplantprotectionproduct.itisconcluded,therefore,thattoxicologicaldatarequirementsdonotneedtobefulfilled.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodata-notrequireddistributionnodata-notrequiredpotentialforaccumulationnodata-notrequiredrateandextentofexcretionnodata-notrequiredmetabolisminanimalsnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)nodata-notrequiredtoxicologicallyrelevantcompounds(environment)nodata-notrequiredacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationnodata-notrequiredskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodata-notrequiredrelevantoralnoaelnodata-notrequiredrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)nodata-notrequired'", "j.efsa.2012.2493.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiondataavailableoflimitedvalidity.nofurtherdataneeded.distributiondataavailableoflimitedvalidity.nofurtherdataneeded.potentialforaccumulationdataavailableoflimitedvalidity.nofurtherdataneeded.rateandextentofexcretiondataavailableoflimitedvalidity.nofurtherdataneeded.metabolisminanimalsdataavailableoflimitedvalidity.nofurtherdataneeded.toxicologicallyrelevantcompounds(animalsandplants)-toxicologicallyrelevantcompounds(environment)-acutetoxicity(annexiia,point5.2)ratld50oraldataavailableoflimitedvalidity.nofurtherdataneeded.ratld50dermaldataavailableoflimitedvalidity.nofurtherdataneeded.ratlc50inhalationdataavailableoflimitedvalidity.nofurtherdataneeded.skinirritationdataavailableoflimitedvalidity.nofurtherdataneeded.eyeirritationdataavailableoflimitedvalidity.nofurtherdataneeded.skinsensitisationdataavailableoflimitedvalidity.nofurtherdataneeded.shorttermtoxicity(annexiia,point5.3)target/criticaleffectdataavailableoflimitedvalidity.nofurtherdataneeded.relevantoralnoael-relevantdermalnoael-'", "j.efsa.2012.2495.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentofabsorption:kineticparametersinhumananddatafromotherketonesinratssuggestthatabsorptionofketonesisimportantandrapid(peakbloodlevelwithin1-2hafterdosing)distribution:nospecificdataformethylnonylketone;datawithotherketonesshowadistributionreachingliverandlungpotentialforaccumulation:nodataprovidedrateandextentofexcretion:nospecificdataformethylnonylketone;datawithotherketonesshowurinaryandbiliaryexcretionasglucuronicacid;exhalationplaysalsoaroleforexcretionofunchangedcompoundmetabolisminanimalsgeneralinfoforaliphaticlinearketones:efficientmetabolicdetoxificationviareductiontothecorrespondingsecondaryalcoholwhichisfurtherglucuronoconjugated.omega-oxidationisimportantathighconcentrations.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationnodata,possibledatagapbasedontheoutcomeofvapourpressurestudy(datagapinphys-chem)skinirritationirritatingxi,r38eyeirritationnotirritatingskinsensitization(testmethodusedandresult)notsensitiser(m&ktestnotsensitiser)shorttermtoxicity(annexiia,point5.3)target/criticaleffectgeneraldeteriorationinhealth(reducedgripstrength,increaseinserumpandca,increasedliverweightandkidneyeffectsat1000mg/kgbw/day)lowestrelevantoralnoael/noel50mg/kgbw/day;90dayratstudylowestrelevantdermalnoael/noelnodata,notnecessarygenotoxicity(annexiia,point5.4)nogenotoxicpotential'", "j.efsa.2012.2496.pdf": "2impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextensive(>80%),almosttotallymetabolisedafteradministrationofsingleorallowandhighdosedistributionevenlydistributed,highestamountinliverandkidneypotentialforaccumulationnopotentialforaccumulationrateandextentofexcretion>80%viaurineinmalesandfemalesmetabolisminanimalsextensivelymetabolized;mainmetabolitesinurineandfeces:s-2188-dc,mppz,mppzsulphate,s-2188-ch2oh-dctoxicologicallyrelevantcompounds(animalsandplants)fenpyrazaminetoxicologicallyrelevantcompounds(environment)fenpyrazamineacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.84mg/l(maximumattainableconcentration),4hours,noseonlyskinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(increasedorganweight,hepatocellularhypertrophy)(rat,dogandmouse)andthyroid(follicularcellhypertrophy)(rat)relevantoralnoael90daysrat:64mg/kgbw/d90daysand1yeardog:25mg/kgbw/d90daysmouse:28mg/kgbw/drelevantdermalnoael28daysrat:300mg/kgbw/drelevantinhalationnoaelnodata-notrequired'", "j.efsa.2012.2498.pdf": null, "j.efsa.2012.2502.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)40%infemalesand18%inmales(basedonurinaryexcretionwithin48h).widelydistributed.noevidenceofaccumulation.rapidandextensive(app.98%)within48h;mainlyviaurine,faecesandbile.metahydroxylationandglucuronideconjugationofparentcompoundsandhydroxyls.(animalsandplants)parentcompound(gibberellinsga4/ga7)(environment)parentcompound(gibberellinsga4/ga7)acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>2000mg/kgbwratlc50>2.98mg/lair/4h(noseonly)non-irritantmoderateirritantnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)liver(hepatocelularvacuolationinrats;increasedweightindogs)kidney(tubule-interstitialnephritisandnephronlossinratsandincreasedweightindogs).reducedfoodconsumptionandbodyweightgain(ratsanddogs).90-daydog650mg/kgbw/day90-dayrat:500mg/kgbw/daynodatanotrequiredrelevantinhalationnoaenodata-notrequiredgenotoxicitygibberellinsga4/ga7areunlikelytobegenotoxiclongtermtoxicityandcarcinogenicity(annexiia,point5.5)limiteddataavailable;nofurtherdataneeded.--'", "j.efsa.2012.2503.pdf": "0impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiondataavailableoflimitedvalidity.nofurtherdataneeded.distribution-potentialforaccumulation-rateandextentofexcretion-metabolisminanimalsdataavailableoflimitedvalidity.nofurtherdataneeded.toxicologicallyrelevantcompounds(animalsandplants)-toxicologicallyrelevantcompounds(environment)-acutetoxicity(annexiia,point5.2)ratld50oraldataavailableoflimitedvalidity.nofurtherdataneeded.ratld50dermalnodata.nofurtherdataneeded.ratlc50inhalationdataavailableoflimitedvalidity.nofurtherdataneeded.skinirritationdataavailableoflimitedvalidity.nofurtherdataneeded.eyeirritationdataavailableoflimitedvalidity.nofurtherdataneeded.skinsensitisationnodata.nofurtherdataneeded.shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodata.nofurtherdataneededrelevantoralnoael-relevantdermalnoael-relevantinhalationnoael-genotoxicity(annexiia,point5.4)dataavailableoflimitedvalidity.nofurtherdataneeded.'", "j.efsa.2012.2504.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption68%basedontheradioactivityrecoveredfromurine(29%),bile(37%),tissuesandresidualcarcass(2.4%),within48hours.distributionwidelydistributed.thehighestconcentrationswerefoundintheliver,followedbykidney.potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionthemajorityoftheradioactivity(>90%)wasexcretedintheurineandfecesby72hr.urine:5867%,feces:2533%oftheadministereddose.metabolisminanimalsextensivelymetabolisedbymolecularcleavage,hydrolysisandconjugation.toxicologicallyrelevantcompounds(animalsandplants)cyflumetofentoxicologicallyrelevantcompounds(environment)cyflumetofenandb-3acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.65mg/lair/4h(noseonly;maximumattainableconcentration)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(m&k)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat&mouse:vacuolationandhypertrophyofadrenalcorticalcells.dog:vacuolationanddegenerationadrenalcortex.relevantoralnoael90-dayrat:16.5mg/kgbw/day90-daymouse:117mg/kgbw/day1-yeardog:loael30mg/kgbw/dayrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2012.2505.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataavailable,notneedednodataavailable,notneededpotentialfonodataavailable,notneededdataavailableoflimitedvalidity,nofurtherdataneededammoniumions,afterintestinalabsorption,aretransformedintoureaintheliverandexcretedinurine(animalsandplants)ammoniumacetate(environment)ammoniumacetateacutetoxicity(annexiia,point5.2)ratld50nodataavailable,notneededratld50nodataavailable,notneededratlc50nodataavailable,notneededdataavailableoflimitedvalidity,nofurtherdataneedednodataavailable,notneededshorttermtoxicity(annexiia,point5.3)notidentifiedbasedontheavailabledatadataavailableoflimitedvalidity,nofurtherdataneedednodataavailable,notneededrelevantinodataavailable,notneedednodataavailable,notneededlongtermtoxicityandcarcinogenicity(annexiia,point5.5)nodataavailable,notneededrelevantnoaenodataavailable,notneedednodataavailable,notneeded'", "j.efsa.2012.2506.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioncloveoil:nodataavailableeugenol:rapid(>70%excretedwithin3h);extensive(>90%inurinewithin24h)humans2mg/kgbwdistributionnodataavailablepotentialforaccumulationcloveoil:nodataavailableeugenol:minimalrateandextentofexcretioncloveoil:nodataavailableeugenol:extensiveandrapid(>90%inurinein24hours)metabolisminanimalscloveoil:nodataavailableeugenol:conjugationandhydroxylationtoxicologicallyrelevantcompounds(animalsandplants)eugenolinsufficientdataavailablefortheothercomponentsofcloveoiltoxicologicallyrelevantcompounds(environment)eugenolinsufficientdataavailablefortheothercomponentsofcloveoilacutetoxicity(annexiia,point5.2)ratld50oralcloveoil:nodataavailableeugenol:1930mg/kgbwr22dogld50oraleugenol:<2000mg/kgbwratld50dermalnodataavailableratlc50inhalationnodataavailableeugenol:datagapskinirritationcloveoil:nodataavailableeugenol:irritatingr38eyeirritationcloveoil:nodataavailableeugenol:irritating(nodata,basedonskinirritation)r36skinsensitisationcloveoil:nodataavailableeugenol:sensitising(maximisationtestwithguineapigs,locallymphnodeassaywithmice,humanreports)r43shorttermtoxicity(annexiia,point5.3)'", "j.efsa.2012.2507.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodataavailable.nofurtherdatarequired.distributionnodataavailable.nofurtherdatarequired.potentialforaccumulationnodataavailable.nofurtherdatarequired.rateandextentofexcretionnodataavailable.nofurtherdatarequired.metabolisminanimalsnodataavailable.nofurtherdatarequired.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>4.94mg/lair/4h(noseonly)-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationnonsensitising(m&k)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidneyandliver(increasedrelativeweight);rats.limiteddataindogs.nofurtherdatarequired.relevantoralnoael90-dayrat:680mg/kgbw/day-relevantdermalnoaelnotrequired-relevantinhalationnoaelnotrequired-genotoxicity(annexiia,point5.4)gibberellicacidisunlikelytobegenotoxic.-longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectlimiteddataavailable.nofurtherdatarequired.relevantnoaelcarcinogenicityreproductivetoxicity(annexiia,point5.6)reproductiontoxicityreproductiontarget/criticaleffectnodataavailable.nofurtherdatarequired.-relevantparentalnoael-relevantreproductivenoael-relevantoffspringnoael-developmentaltoxicitydevelopmentaltarget/criticaleffectnoeffectseeninthehighestdose(ratsandrabbits)-relevantmaternalnoael1000mg/kgbw/day(ratsandrabbits)-relevantdevelopmentalnoael1000mg/kgbw/day(ratsandrabbits)-neurotoxicity(annexiia,point5.7)acuteneurotoxicitynodataavailable.nofurtherdatarequired.-'", "j.efsa.2012.2508.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateannooraldataavailable.basedoninhalationdataoflimitedvalidity,distributioniswidespreadthroughoutthebody.basedoninhalationdataoflimitedvalidity,ethyleneexposureresultsintheformationofadductswithdnaandprotein.dataavailableoflimitedvalidity.basedoninhalationdataoflimitedvalidity,ethyleneisoxidisedtoethyleneoxideinexperimentalanimalsandhumans.(animalsandplants)ethyleneandethyleneoxide(environment)ethyleneandethyleneoxide.acutetoxicity(annexiia,point5.2)ratld50nodataavailableratld50nodataavailableratlc50dataavailableoflimitedvaliditydataavailableoflimitedvaliditydataavailableoflimitedvaliditydataavailableoflimitedvalidityshorttermtoxicity(annexiia,point5.3)basedoninhalationdataoflimitedvalidity,asphyxia,haematologicalchanges,somepoorlyreportedlivereffects(includingincreasedweight)andeffectsonthenervoussystem.nodataavailablenodataavailablenodataavailabledataavailableoflimitedvalidity'", "j.efsa.2012.2516.pdf": "impactonhumanandanimalhealththetoxicologicaldatabasewasconsideredoflimitedvalidityabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataavailable,notneededwidelydistributed,highestlevelsfoundinmuscle,liverandkidney(i.p.applicationinrats,oraladministrationinchicks)noevidenceforbioaccumulationnodataavailable,notneededintracellularputrescinelevelsaretightlyregulatedbydenovosynthesis,interconversion,terminaldegradationandtransport(animalsandplants)parentcompoundtoxicologically(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50463mg/kgbw(females)r22ratld501576mg/kgbw(males)r21ratlc50nodataavailable,notneedednotifierproposedr20r20corrosiver34severedamagetoeyes(r41isoverruledbyr34)-nodataavailable,notneededshorttermtoxicity(annexiia,point5.3)foodconsumption(males);bodyweight,alatandrelativebrainweight(females)5weeks,rat:180mg/kgbw/dnodataavailablenotneedednodataavailable-notneeded'", "j.efsa.2012.2517.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionoralabsorptionconsiderednegligiblebasedonitsphysico-chemicalproperties.distribution-potentialforaccumulation-rateandextentofexcretion-metabolisminanimals-toxicologicallyrelevantcompounds(animalsandplants)aluminiumsilicate.toxicologicallyrelevantcompounds(environment)aluminiumsilicateacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation>2.18mg/l/4h-skinirritationnon-irritant-eyeirritationslightlyirritant-skinsensitisationnotsensitizing.-shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataavailablenotrequiredrelevantoralnoaelnodataavailablenotrequired-relevantdermalnoaelnodataavailablenotrequired-relevantinhalationnoaelnodataavailablenotrequired-genotoxicity(annexiia,point5.4)nodataavailablenotrequired-longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailablenotrequiredrelevantnoaelnodataavailablenotrequiredcarcinogenicitynodataavailablenotrequired-reproductivetoxicity(annexiia,point5.6)reproductiontoxicityreproductiontarget/criticaleffectdataavailableoflimitedvalidity-nofurtherdataneeded.-relevantparentalnoaelnodataavailable-relevantreproductivenoaelnodataavailable-'", "j.efsa.2012.2518.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodataavailableforcitronellaoildistributionnodataavailableforcitronellaoilpotentialforaccumulationnodataavailableforcitronellaoilrateandextentofexcretionnodataavailableforcitronellaoilmetabolisminanimalsnodataavailableforcitronellaoiltoxicologicallyrelevantcompounds(animalsandplants)-toxicologicallyrelevantcompounds(environment)-methyleugenolandmethylisoeugenolacutetoxicity(annexiia,point5.2)ratld50oralinsufficientdataavailable-ratld50dermalinsufficientdataavailable-ratlc50inhalationinsufficientdataavailable-skinirritationinsufficientdataavailable-eyeirritationinsufficientdataavailable-skinsensitisationinsufficientdataavailableevidenceofskinsensitisationinhumans(seemedicaldata)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataareavailableforcitronellaoilrelevantoralnoaelnodataavailableforcitronellaoil-relevantdermalnoaelnodataavailableforcitronellaoil-relevantinhalationnoaelnodataavailableforcitronellaoil-genotoxicity(annexiia,point5.4)insufficientdataavailable-'", "j.efsa.2012.2519.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataavailable;notneedednodataavailable;notneedednodataavailable;notneededrateandextentofexcrenodataavailable;notneedednodataavailable;notneeded(animalsandplants)nodataavailable;notneeded(environment)nodataavailable;notneededacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbw(female)ratld50>2000mg/kgbwnodataavailable;notneedednonirritantslightirritant(norequiredclassification)nonsensitisershorttermtoxicity(annexiia,point5.3)nodataavailable;notneedednodataavailable;notneededrelevantdermalnoaelnodataavailable;notneedednodataavailable;notneededfatdistillationresiduesdoesnotproducegenemutationsinbacterialcellsinvitro(ames).longtermtoxicityandcarcinogenicity(annexiia,point5.5)nodataavailable;notneedednodataavailable;notneedednodataavailable;notneededreproductivetoxicity(annexiia,point5.6)reproductiontoxicitynodataavailable;notneedednodataavailable;notneedednodataavailable;notneedednodataavailable;notneeded'", "j.efsa.2012.2520.pdf": "ethodsofanalysisanalyticalmethodsfortheactivesubstance(annexiia,point4.1)technicalas(principleofmethod)note:asthegarlicextractisavegetableextractactivesubstancewasnotreallyidentified.sulfide,diallyldisulfide,diallyltrisulfane,diallyltetrasulfanewereusedasmarkers.ananalyticalmethodusinghplcwithuvdetection(240nm)wasdevelopedtoquantifythesemarkers.impuritiesintechnicalas(principleofmethod)nomethoddevelopedasnoimpuritiesidentifiedplantprotectionproduct(principleofmethod)nomethoddeveloped.theplantprotectionproductecoguardliquidisquitesimilartotheactivesubstance.openforvalidationofthemethodforecoguardgranulesanalyticalmethodsforresidues(annexiia,point4.2)food/feedofplantorigin(principleofmethodandloqformethodsformonitoringpurposes)notapplicablefood/feedofanimalorigin(principleofmethodandloqformethodsformonitoringpurposes)notapplicablesoil(principleofmethodandloq)notapplicablewater(principleofmethodandloq)notapplicableair(principleofmethodandloq)notapplicablebodyfluidsandtissues(principleofmethodandloq)notapplicableimpactonhumanandanimalhealthasgarlicextractisoffoodgradequality,alltoxicologicaldatarequirementsarewaived.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodata-notrequireddistributionnodata-notrequiredpotentialforaccumulationnodata-notrequiredrateandextentofexcretionnodata-notrequiredmetabolisminanimalsnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)garlicextract'oxicologicallyrelevantcompounds(environment)garlicextractacutetoxicity(annexiia,point5.2)ratld50oralnodata-notrequiredratld50dermalnodata-notrequiredratlc50inhalationnodata-notrequiredskinirritationnotirritanteyeirritationnotirritantskinsensitisationskinsensitizer(basedonhumancasesreports)shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodata-notrequiredrelevantoralnoaelnodata-notrequiredrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(annexiia,point5.4)nodatanotrequiredlongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodata-notrequiredrelevantnoaelnodata-notrequiredcarcinogenicitynodata-notrequiredreproductivetoxicity(annexiia,point5.6)reproductiontoxicityreproductiontarget/criticaleffectnodata-notrequiredrelevantparentalnoaelnodata-notrequiredrelevantreproductivenoaelnodata-notrequiredrelevantoffspringnoaelnodata-notrequired'", "j.efsa.2012.2521.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed(10%upto60%incaseofirondeficiency)within2to6hours.distributionhumandata:uniformlydistributedviablood.greatestconcentrationsinliver,bonemarrow,andspleen.potentialforaccumulationhumandata:excessiveironisstoredinliver,endocrineorgans(pancreas)andspleen.rateandextentofexcretionhumandata:0.01to0.02%oftheabsorbedironareexcreteddaily.metabolisminanimalsfe2+andfe3+canbeconvertedintoeachother.mostironisboundtoproteinssuchashaemoglobin,myoglobin,ferritin,andhaemosiderin.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundanddissociatedforms:fe(ii)andfe(iii)toxicologicallyrelevantcompounds(environment)parentcompoundanddissociatedforms:fe(ii)andfe(iii)acutetoxicity(annexiia,point5.2)ratld50oral11851750mg/kgbwfeso4(r22)harmfulifswallowedratld50dermalnodatawereavailable.fromthemolecularstructure(inorganicsalt),itissuggestedthatitisunlikelythatsignificantamountsofferroussulfate(fe(ii)so4)canberesorbedthroughintactskin.ratlc50inhalationnodatanotnecessary.theactivesubstanceisneitherappliedasadustwithaparticlesizeoflessthan50mnorasanaerosol.furthermore,thevapourpressureoftheinorganicsaltisnegligibleatambienttemperature.therefore,notoxicologicallyrelevantexposureoccurs.skinirritationirritant.classifiedwithr38(humandataprecautionary,basedonphysicalproperties,onlyoneoldreferencewithothercitationsinliteratureasmoderateirritantwithoutfurtherevidenceeyeirritationirritant(r36)(humandataprecautionary,basedonphysicalproperties,onlyoneoldreference)'", "j.efsa.2012.2522.pdf": "7impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionatleast68%ofadministereddoseabsorbedwithin72hbasedonurine(11.5%)andbile(51%)excretion,cagewashandcarcassresidues.distributionwidespreaddistribution,withhighestconcentrationsingastrointestinaltract,liver,adrenalsandadiposetissuesatearlysamplingtimes.potentialforaccumulationlowrateandextentofexcretionrapid,excretionalmostcomplete2-3daysafterdosing.85-91%excretedviafaeces(51-55%viabile)and3.4-9.3%viaurineby7days.metabolisminanimalsextensive.majormetabolitesformedbyhydroxylationatthebiphenylring,n-demethylationatthepyrazolering,lossofafluorineatomatthebiphenylring,andconjugationwithglucuronicacidorwithglutathionederivatives.traceamountsofproductsfromcleavagebetweenthepyrazoleandanilinerings.toxicologicallyrelevantcompounds(animalsandplants)fluxapyroxad(bas700f)toxicologicallyrelevantcompounds(environment)fluxapyroxad(bas700f)acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.31mg/lair(4h,noseonly,todust)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitising(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:liver(increasedweight,hepatocellularcentrilobularhypertrophy,enzymeinduction),thyroid(follicularcellhypertrophy/hyperplasia,thyroidhormonechanges),blood(acceleratedclotting),increasedcalcium,globulinandcholesterollevelsmouse:clinicalchemistrychanges(decreasedtriglyceride,cholesterol)dog:clinicalchemistrychangesinspleen(ironstainingofconnectivetissue)andliver(ironstainingofhepatocytes,fibrosis)'", "j.efsa.2012.2523.pdf": "impactonhumanandanimalhealth(1)limitedinformationornodataareavailable.ageneraldatagaphasbeenestablishedinthesectiononmammaliantoxicologytoprovidestudiesonthetoxicologicalprofileofurea.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rate/extentofabsorptionnodataavailable(1)distributionnodataavailable(1)potentialforaccumulationnodataavailable(1)rateandextentofexcretionnodataavailable(1)metabolisminanimalsnodataavailable(1)toxicologicallyrelevantcompounds(animalsandplants)nodataavailable(1)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oralnodataavailable14300mg/kgb.w./day(males)rabbitld50dermalnodataavailable,notneededratlc50inhalationnodataavailable,notneededskinirritationnodataavailablelimitedindicationofirritancyslightirritanteyeirritationnodataavailablelimitedindicationofirritancyslightirritantskinsensitisationnodataavailable.notskinsensitisershorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataavailable(1)relevantoralnoaelnodataavailable(1)relevantdermalnoaelnodataavailable(1)relevantinhalationnoaelnodataavailable(1)genotoxicity(annexiia,point5.4)nodataavailable(1)longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailable(1)'", "j.efsa.2012.2524.pdf": "1chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed,approximately100%distributionwidespreadpotentialforaccumulationnotrelevantrateandextentofexcretionnotrelevantmetabolisminanimalsnormalhomeostasismaintainedthroughwellknownmechanismstoxicologicallyrelevantcompounds(animalsandplants)k+iontoxicologicallyrelevantcompounds(environment)-acutetoxicity(annexiia,point5.2)ratld50oralfemales:2064mg/kgbw/dayratld50dermal>2000mg/kgbwratlc50inhalation>4.88mg/l(wholebody,41/2hours)skinirritationnon-irritanteyeirritationmoderate,reversibleskinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectalteredurinaryph/hypertrophyofadrenalzonaglomerulosa/increasedpotassiumexretion.urinarybladderhyperplasia(rats)lowestrelevantoralnoael/noel4-and13-weekratloael:2%lowestrelevantdermalnoael/noelnodata-notrequiredlowestrelevantinhalationnoael/noelnodata-notrequiredgenotoxicity(annexiia,point5.4)genotoxicitydataavailableoflimitedvalidity.nofurtherdatarequired.longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectgrowthretardation,serumpotassiumin,urinarypotassium,urinaryphandvolume,hypertrophyofadrenalzonaglomerulosa;lowestrelevantnoael/noelneoplasiaat4%ofdietandpre-neoplasticalterationsat2%.carcinogenicityhyperplasia,papillomaandcarcinomaofurinarybladderinratsthroughwell-recognisedmechanism,notconsideredrelevanttohumans'", "j.efsa.2012.2525.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptiondataoflimitedvalidity.nofurtherdataneeded.distributiondataoflimitedvalidity.nofurtherdataneeded.potentialforaccumulationnodataavailable;notneeded.rateandextentofexcretionnodataavailable;notneeded.metabolisminanimalsdataoflimitedvalidity.nofurtherdataneeded.toxicologicallyrelevantcompounds(animalsandplants)nodataavailable;notneeded.toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oraldataoflimitedvalidity.nofurtherdataneeded.rabbitld50dermalratlc50inhalationskinirritationeyeirritationskinsensitisationshorttermtoxicity(annexiia,point5.3)target/criticaleffectdataoflimitedvalidity.nofurtherdataneeded.relevantoralnoaelrelevantdermalnoaelrelevantinhalationnoaelgenotoxicity(annexiia,point5.4)dataoflimitedvalidity.nofurtherdataneeded.'", "j.efsa.2012.2540.pdf": "chapter2analyticalmethodsanalyticalmethodsforthemicro-organism(annexiim4.2,4.3;iiim5.4)manufacturedmicro-organism(principleofmethod):openimpuritiesandcontaminatingmicro-organismsinmanufacturedmaterial(principleofmethod):openmicrobialplantprotectionproduct(principleofmethod):openanalyticalmethodsforresidues(viableandnon-viable)(annexiim4.5)oftheactivemicro-organism(principleofmethod):openofrelevantmetabolites(principleofmethod):openchapter3impactonhumanandanimalhealth(annexiim5;iiim7)chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:onlyinafewcasesbthasbeenisolatedfromhumanbacterialinfection.onecaseofcornealulcerafteraccidentalsplashingofaworkerwithbtkproduct.noevidenceofadversehealtheffectamongmanufacturingplantpersonnelexposedtostrainabts-351.nogastro-intestinalsymptomscorrelatedwiththepresenceofbtinthefaeceswereobservedingreenhouseworkerssprayingbtkabts-351.nomajoreffectswereobservedinpopulationsexposedtoaerialsprayingofbtk(upperairwaysandgastrointestinalsymptoms)butnoclearrelationshipcouldbeestablishedwithbtk.sensitisation(experienceinhumansandstudyresults;typeofstudy):positiveresultsinadermalsensitizationstudy(magnussonkligmanmethod)oflimitedrelevanceformicrobials.consideringthatallmicrobialsshouldberegardedaspotentialsensitizers,theagreedwarningphraseismicro-organismsmayhavethepotentialtoprovokesensitisingreactions.potentialriskofskinsensitizationandinductionofigeandiggantibodiesinpersonsexposedtob.thuringiensiskurstaki.'", "j.efsa.2012.2542.pdf": "3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnovaliddata-becauseofitslipophilicnature,teatreeoilisassumedtobereadilyabsorbedbydermalandbyoralroutes.distributionnovaliddatapotentialforaccumulationnovaliddatarateandextentofexcretionnovaliddatametabolisminanimalsnovaliddatatoxicologicallyrelevantcompounds(animalsandplants)teatreeoiltoxicologicallyrelevantcompounds(environment)teatreeoilacutetoxicity(annexiia,point5.2)ratld50oral1682-1721mg/kgbwxnr22ratld50dermal>2,000mg/kgbw(rabbits)ratlc50inhalationnodataskinirritationirritantxir38eyeirritationirritantxir41skinsensitisationnotsensitising(magnusson&kligman)sensitisingtohumanskin(basedonclinicalcasesandpoisoningincidents)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodatarelevantoralnoaelnodatarelevantdermalnoaelnodatarelevantinhalationnoaelnodatagenotoxicity(annexiia,point5.4)notmutagenicinvitro(amestest)andinvivo(micronucleusassay);investigationoninvitromammaliancellgenemutationrequired'", "j.efsa.2012.2545.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionnodataavailable.*distributionpotentialforaccumulationrateandextentofexcretionmetabolisminanimalstoxicologicallyrelevantcompounds(animalsandplants)toxicologicallyrelevantcompounds(environment)acutetoxicity(annexiia,point5.2)ratld50oraldataavailableoflimitedvalidity.*rabbitld50dermaldataavailableoflimitedvalidity.*ratlc50inhalationdataavailableoflimitedvalidity.*skinirritationdataavailableoflimitedvalidity.*eyeirritationdataavailableoflimitedvalidity*.skinsensitisationdataavailableoflimitedvalidity*.shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataavailable*.relevantoralnoaelrelevantdermalnoaelrelevantinhalationnoaelgenotoxicity(annexiia,point5.4)nodataavailable*.'", "j.efsa.2012.2546.pdf": "impactonhumanandanimalhealthfishoildoesnothaveatoxicmodeofactionanddoesnotpresentatoxicologicalconcernbyitself.itisusedasafeedstuffobtainedfromfreshfishby-productsnotsuitableforhumanconsumption;basedonitsnature,thewaiverfortoxicologicalstudieswasdeemedacceptable.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionnodata-notrequireddistributionnodata-notrequiredpotentialforaccumulationnodata-notrequiredrateandextentofexcretionnodata-notrequiredmetabolisminanimalsnodata-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)nodata-notrequiredtoxicologicallyrelevantcompounds(environment)nodata-notrequiredacutetoxicity(annexiia,point5.2)ratld50oralnodata-notrequiredrabbitld50dermalnodata-notrequiredratlc50inhalationnodata-notrequiredskinirritationnodata-notrequiredeyeirritationnodata-notrequiredskinsensitisationnodata-notrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectnodata-notrequiredrelevantoralnoaelnodata-notrequiredrelevantdermalnoaelnodata-notrequiredrelevantinhalationnoaelnodata-notrequired'", "j.efsa.2012.2595.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidabsorptionthroughthelungsdistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionexcretionwithurineashypophosphiteandphosphiteandvialungsasphosphanemetabolisminanimalsoxidationtohypophosphiteandphosphitetoxicologicallyrelevantcompounds(animalsandplants)phosphanetoxicologicallyrelevantcompounds(environment)phosphaneacutetoxicity(annexiia,point5.2)ratld50oralnodata,nostudyrequiredratld50dermalnodata,nostudyrequiredratlc50inhalation>11ppm(>0.016mgph3/lairor>2.8mg/kgbw,6hexposurewholebody)-51ppm(0.072mgph3/lair)(4hexposure,wholebody)t+,r26skinirritationcorrosiver34eyeirritationcorrosiver34skinsensitisationnoindicationofskinsensitisation(m&k-testusingzincphosphide)shorttermtoxicity(annexiia,point5.3)target/criticaleffectmortalityrelevantoralnoaelnodata,nostudyrequiredrelevantdermalnoaelnodata,nostudyrequiredrelevantinhalationnoael3ppm(equivalentto1.1mg/kgbw/d),rat90-d,thehighestdosetestedgenotoxicity(annexiia,point5.4)nogenotoxicpotentialatrealisticexposurelevelslongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnonerelevantnoael3ppmequivalentto1.1mg/kgbw/d(rat2-yrinhalation)carcinogenicitynotcarcinogenicintheratdataonmicenotrequired'", "j.efsa.2012.2600.pdf": "8impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption64%consideringtheliverasthetargetorgan,basedonthesumofradioactivityinurine,bileandresidualcarcasswithin48h.distributionwidespread,highestlevelsinliver,kidneysandadrenalspotentialforaccumulationlowrateandextentofexcretionfairlyrapidandextensive(>90%within48h)aftersingleexposure(bloodeliminationhalf-life4-7.5h),butslowerafterrepeatedadministration(bloodeliminationhalf-life251h).mainlyviafaeces(48-58%inbile,26-36%infaecesand15-16%inurineby48hourspost-dosing).metabolisminanimalshydroxylationinthebicyclo-isopropylregion,followedbyfurtheroxidationtoformthecarboxylicacidand/ortogiverisetomultiplehydroxylmoietieswithsubsequentformationofglucuronicacidorsulphateconjugates.thisoxidativepathwayalsooccursfollowingn-demethylationofisopyrazamgivingrisetoacorrespondingsetofoxidativen-desmethylmetabolitesandtheirconjugates.toxicologicallyrelevantcompounds(animalsandplants)isopyrazamtoxicologicallyrelevantcompounds(environment)isopyrazam,metabolitescscd465008,cscd459488andcscd459489arerelevantaccordingtotheguidancedocumentontheassessmentofthegroundwatermetabolites(europeancommission,2003)acutetoxicity(annexiia,point5.2)ratld50oralpuresyn-isomers>2000mg/kgbwpureanti-isomers310mg/kgbwsyn-:anti-isomers93:7%>2000mg/kgbwsyn-:anti-isomers70:30%2000mg/kgbwsyn-:anti-isomers50:50%310mg/kgbwxn;r22ratld50dermalsyn-:anti-isomers93:7%>5000mg/kgbwratlc50inhalationsyn-:anti-isomers93:7%>5.28mg/lair/4h(nose-only)skinirritationnon-irritanteyeirritationnon-irritant'", "j.efsa.2012.2654.pdf": "9impactonhumanandanimalhealthmedicaldata,surveillanceandobservations:noevidenceofanyhealtheffectsincludingallergicreactionsinmanufacturingpersonneloroperatorsdirectlyexposedtoadoxophyesoranagvorotherbaculoviruses.noadversereactionsinhumanvolunteerstudieswithheliothiszeanpv,orinhumanpopulationsthatwereexposedtonaturallyoccurringbaculoviruses.sensitisation:noevidenceinhumans.noexperimentaldataforadoxophyesoranagvoritsformulationavailable,butcontradictoryresultsinsensitisationtestswithformulationscontainingcydiapomonellagv.consideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseismicroorganismsmayhavethepotentialtoprovokesensitisingreactionstoxicityafteracuteoralexposure:rat,autographacalifornicanpv:ld50>5x109polyhedrainclusionbodies(pib)/kgbwafteracuteinhalationexposure:guineapig,cydiapomonellagv:nodeathsuponexposureto2x1013granula/lairfor15min.afteracuteintraperitonealexposure:mouse,cydiapomonellagv,intraperitoneal:ld50>1011granula/animal.infectivitybaculoviruseshavebeenfoundonlyinarthropodsandhavenotbeendemonstratedtoinfectvertebrates.fewindicationsoftransientseroconversionindifferentspeciesincludingmanbutnoevidenceofvirusreplication.afteracuteoralexposure:notinvestigatedintheavailablestudiesnotrequiredafteracuteinhalationexposure:notinvestigatedintheavailablestudiesnotrequiredafteracuteintraperitonealexposure:notinvestigatedintheavailablestudiesnotrequiredpathogenicityafteracuteoralexposure:autographacalifornicanpv:noevidenceofadverseeffectsafteracuteinhalationexposure:cydiapomonellagv:nodeathsandnoclinicalsignsorothereffectsafteracuteintraperitonealexposure:cydiapomonellagv:nodeathsandnoclinicalsignsorothereffects'", "j.efsa.2012.2655.pdf": "25impactonhumanandanimalhealthmedicaldata,surveillanceandobservationsnoevidenceofanyhealtheffectsincludingallergicreactionsinmanufacturingpersonneloroperatorsdirectlyexposedtocpgvorotherbaculoviruses.noadversereactionsinhumanvolunteerstudieswithheliothiszeanpv.nohealthdeteriorationinhumanpopulationsthatwereexposedtonaturallyoccurringbaculoviruses.sensitisation:methodandfollowinginhalationchallenge)consideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseismicroorganismsmayhavethepotentialtoprovokesensitisingreactionstoxicityafteracuteoralexposure:rat:ld50>1.015x108granulaofcpgv/animal50>5x1010granulaofcpgv/kgbwafteracuteinhalationexposure:50>2x1013granulaofcpgv/lair(4-hrnose-onlyexposure)afterintraperitonealexposure:rat:ld50>1.015x107granulaofcpgv/animalinfectivityafteracuteoralexposure:notinvestigatedintheavailablestudiesnotrequiredafteracuteinhalationexposure:notinvestigatedintheavailablestudiesnotrequiredafterintraperitonealexposure:notinvestigatedintheavailablestudiesnotrequiredpathogenicityafteracuteoralexposure:cpgv:nodeathsandnoclinicalsignsorothereffectschanges,nomortalityafteracuteinhalationexposure:nodeathsandnoclinicalsignsorothereffectsafterintraperitonealexposure:nodeathsandnoclinicalsignsorothereffectsgenotoxicity:noinvitrodataforcpgv,negativeresultsforotherbaculoviruses.invivostudiesinsomaticcells:negativeresults(noincreasedsceorchromosomalaberrationsinhamstersorguineapigs,followingsingleandrepeatedadministrationofcpgv).'", "j.efsa.2012.2666.pdf": "impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:nostrainspecificdata.somet.viridestrainshavebeenidentifiedininfectionsofimmunocompromisedhumans.itcannotbeexcludedthatthecurrentt.asperellumstraint34couldbeinvolvedinclinicalcases.however,inmostofthecases,therouteofexposureisnotrelevantfortheuseoftrichodermaasplantprotectionproduct.noadverseeffectsreportedinmonitoringofproductionplantworkers.sensitisation(experienceinhumansandstudyresults;typeofstudy):consideringthatallmicrobialsshouldberegardedaspotentialsensitizers,theagreedthepotentialpositiveresultwithformulatedproductinamaximisationassayinguineapigs.noreactionsinmanufacturingplantpersonnel.toxicityafteracuteoralexposure:rat:ld50>1x108cfu/animalrat:ld50>1x109cfu/kgbwafteracuteinhalationexposure:somedeathsat1x107cfu/rat(intratracheal)deathsarelikelytobeduetohighvolumeandrouteofadministration.ratlc50.>3.65x106cfu/animal(noseonly)afteracuteintraperitoneal/subcutaneousexposure:deathsseenintwostudieswith7x107-108/rat.nodeathsinsubsequentstudieswith1.4x107-4.9x107/ratdeathsarelikelytobeduetohighvolumesandrouteofadministration.infectivityafteracuteoralexposure:notinfectiverapidlyclearedafteracuteinhalationexposure:notinfectiverapidlyclearedafteracuteintraperitoneal/subcutaneousexposure:notinfectiverapidlyclearedpathogenicityafteracuteoralexposure:red/pinkdiscolourationofpancreas/adrenalat1x108cfu/ratbutnotreplicatedinasecondoraltoxicitystudyat1x109cfu/kg'", "j.efsa.2012.2706.pdf": null, "j.efsa.2012.2754.pdf": "chapter3:impactonhumanandanimalhealthmedicaldata:(includingsurveillanceonmanufacturingplantpersonnel)zymvdoesnotinfectorganismsthatbelongtotheanimalkingdom.accordingtoliteraturesearchesandmedicalsurveillanceofemployeesthatwereexposedtothevirus,noadverseeffectswereobserved.sensitisation:nodatasubmitted.therearenoreportsofsensitisationinworkers,researchersorfarmstaffexposedtostrainsofzymv.consideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseistoxicityafteracuteoralexposure:nodatasubmittednotrequired.afteracuteinhalationexposure:nodatasubmittednotrequired.afterintraperitoneal/subcutaneousexposure:nodatasubmittednotrequired.afterintramuscularexposure:noadverseeffectswereobservedinrabbitsexposedweeklytozymv-wk(upto7injectionsintotal)fortheproductionofantiserum.infectivityafteracuteoralexposure:nodatasubmittednotrequired.zymv,beingaplantvirus,doesnotinfectorganismsthatbelongtotheanimalkingdom.afteracuteinhalationexposure:nodatasubmittednotrequired.zymv,beingaplantvirus,doesnotinfectorganismsthatbelongtotheanimalkingdom.afterintraperitoneal/subcutaneousexposure:nodatasubmittednotrequired.zymv,beingaplantvirus,doesnotinfectorganismsthatbelongtotheanimalkingdom.pathogenicityafteracuteoralexposure:nodatasubmittednotrequired.afteracuteinhalationexposure:nodatasubmittednotrequired.afterintraperitoneal/subcutaneousexposure:nodatasubmittednotrequired.genotoxicity:nodatasubmittednotrequired.zymvdoesnotinfectorganismsthatbelongtotheanimalkingdom.cellculturestudy:zymvdoesnotinfectorganismsthatbelongtotheanimalkingdom.accordingtoliteraturesearchesandmedicalsurveillanceofemployeesthatwereexposedtothevirus,noadverseeffectswereobserved.short-termtoxicityandpathogenicity:zymvdoesnotinfectorganismsthatbelongtotheanimalkingdom.accordingtoliteraturesearchesandmedicalsurveillanceofemployeesthatwereexposedtothevirus,noadverseeffectswereobserved.'", "j.efsa.2012.2796.pdf": "impactonhumanandanimalhealth(1)limitedinformationornodataareavailable.ageneraldatagaphasbeenestablishedinthesectiononmammaliantoxicologytoprovidestudiesonthetoxicologicalprofileofsodiumhypochlorite.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodataavailable(1)distributionnodataavailable(1)potentialforaccumulationnodataavailable(1)rateandextentofexcretionnodataavailable(1)metabolisminanimalsnodataavailable(1)toxicologicallyrelevantcompounds(animalsandplants)sodiumhypochloritetoxicologicallyrelevantcompounds(environment)sodiumhypochloriteacutetoxicity(annexiia,point5.2)ratld50oralnodataavailable(1)ratld50dermalnodataavailable(1)ratlc50inhalationnodataavailable(1)skinirritationr34h314eyeirritationnaclosolutionr34h314skinsensitisationnotsensitising(guineapigsensitisationstudiesandhumandata)(indicativedata)shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataavailable(1)relevantoralnoaelnodataavailable(1)relevantdermalnoaelnodataavailable(1)relevantinhalationnoaelnodataavailable(1)genotoxicity(annexiia,point5.4)nodataavailable(1)longtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataavailable(1)relevantnoaelnodataavailable(1)carcinogenicitynodataavailable(1)reproductivetoxicity(annexiia,point5.6)'", "j.efsa.2012.2797.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentofabsorptionnodataavailablenodataavailablenodataavailablenodataavailablenodataavailable(animalsandplants)nodataavailable(environment)nodataavailableacutetoxicity(annexiia,point5.2)ratld50nodataavailablerabbitld50nodataavailableratlc50nodataavailablenodataavailablenodataavailablenodataavailableshorttermtoxicity(annexiia,point5.3)targetorgans:lungseffects:inflammatoryresponsesandemphysema,especiallyinratsandmonkeys.nodataavailablenodataavailablenodataavailablegenotoxicity(annexiia,point5.4)nodataavailablelongtermtoxicityandcarcinogenicity(annexiia,point5.5)nodataavailablenodataavailableinadequateevidenceofcarcinogenicity(iarcreport,1997)'", "j.efsa.2012.2823.pdf": "1impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption87-89%basedonurineandbileexcretion,carcassandcagewashresidueswithin48htmaxvalue1-1.5hdistributionwidelydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidexcretionmainlyviafaecesurinary(11.8-17.2%within72h)faeces(72-83%within72h)bile(78-81%in48hours)t:22-24hmetabolisminanimalsextensivemetabolisminrat:demethylation,hydroxylation,oxidationandsubsequentconjugation.toxicologicallyrelevantcompounds(animalsandplants)sedaxanetoxicologicallyrelevantcompounds(environment)sedaxaneacutetoxicity(annexiia,point5.2)ratld50oralbetween2000-5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.25mg/lair(4h,nose-only)skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitizer(llna)short-termtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightandbodyweightgain(allspecies)rats:liver(increasedweight),reducedforegripstrengh(females)mice:testisandliver(increaseadjustedweight)dogs:clinicalbiochemistryparameters,liver(increasedweight)relevantoralnoael90-dayrat:28mg/kgbwperday90-day&1-yeardog:50mg/kgbwperday90-daymice:567mg/kgbwperday'", "j.efsa.2012.2860.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(tmax90-100%)distributionwidespread,withthehighestconcentrationsbeingpresentintheliver,erythrocytes,kidneyandadrenalsofbothsexesandthebrownfatoffemales.potentialforaccumulationlowrateandextentofexcretionrapidandextensive,withexcretionbeingalmostcompleteafter2-3daysmetabolisminanimalsextensive.mainlytopyrozoleringdemethylatedproductsorbyhydroxylationtotrihydroxyanddihydroxycompounds.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgratld50dermal>2000mg/kgratlc50inhalation>2.02mg/l(4h,noseonly,todust)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitising(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectprincipaltargetsaretheliver(diffusecentrilobularhepatocellularhypertrophyandincreasedorganweight)andthyroid(diffusefollicularcellhypertrophy,sometimesaccompaniedbyfocal/multifocalcolloid)relevantoralnoael7.7mg/kgbwperday(1yearstudyindogs)relevantdermalnoael300mg/kgbwperday(28daystudyinrats)relevantinhalationnoaeltestnotconducted'", "j.efsa.2012.2864.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:noevidenceofanyhealtheffectsincludingallergicreactionsinmanufacturingpersonneloroperatorsdirectlyexposedtosplinpvorotherbaculoviruses.noadversereactionsinhumanvolunteerstudieswithheliothiszeanpv.nohealthdeteriorationinhumanpopulationsthatwereexposedtonaturallyoccurringbaculoviruses.sensitisation(experienceinhumansandstudyresults;typeofstudy):noevidenceinhumans.skinsensitisationtestinguineapigswithsplinpvnegative(landsteinermethod)norespiratorysensitisationtestwithsplinpvconsideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseismicroorganismsmayhavethepotentialtoprovokesensitisingreactionstoxicityafteracuteoralexposure:availabledatawithdifferentbaculovirusesconfirmthatbaculovirusesdonotinfectvertebratesandcanbeconsiderednonpathogenicandnontoxic.noael,rat:5x109pib/kgbwnpv1.8x1011pib/kgbw,orgyiapseudotsugatanpv2x1013pib/kgbw,lymantriadisparnpv3x109pib/kgbw,spodopteralituranpvnoael,mouse:3x109polyhedraperanimal,mamestrabrassicaenpv5x1011granules/kgbw,cydiapomonellagvnoael,rhesusmonkeys:6x108pib/kgbw,heliothiszeanpvafteracuteinhalationexposure:noael,guineapigs:2x1013granula/l,cydiapomonellagv2x1012granula/l,cydiapomonellagv1x1010pib/l,mamestrabrassicaenpvnoael,rats:3.6x1010pib/kgbw,orgyiapseudotsugatanpvnoael,rhesusmonkeys:>1.2x108pib/mgvirussuspension,heliothiszeanpvsprayedtotheopenmouthandinstilledineachnostril'", "j.efsa.2012.2865.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:noevidenceofanyhealtheffectsincludingallergicreactionsinmanufacturingpersonneloroperatorsdirectlyexposedtohearnpvorotherbaculoviruses.noadversereactionsinhumanvolunteerstudieswithheliothiszeanpv.nohealthdeteriorationinhumanpopulationsthatwereexposedtonaturallyoccurringbaculoviruses.sensitisation(experienceinhumansandstudyresults;typeofstudy):noevidenceinhumans.nosensitisationtestwithhearnpv.consideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseismicroorganismsmayhavethepotentialtoprovokesensitisingreactionstoxicityafteracuteoralexposure:noael,rat:5x109pib/kgbw,autographacalifornicanpv>1.8x1011pib/kgbw;orgyiapseudotsugatanpv2x1013pib/kgbw;lymantriadisparnpv3x109pib/kgbw;spodopteralituranpvnoael,mouse:3x109polyhedraperanimal;mamestrabrassicaenpv5x1011granules/kgbw;cydiapomonellagvnoael,rhesusmonkeys:6x108pib/kgbw;heliothiszeanpvalsooraladministrationofmamestrabrassicanpvtoguineapigs,andpierisrapaegvtopigs,cows,lambs,chickens,rabbitsandmicedidnotcauseanyadverseeffect.afteracuteinhalationexposure:noael,guineapigs:2x1013granula/l,cydiapomonellagv2x1012granula/l,cydiapomonellagv1x10103pib/l,mamestrabrassicaenpvnoael,rats:3.6x1010pib/kgbw;orgyiapseudotsugatanpvnoael,rhesusmonkeys:1.2x108pib/mgvirussuspension,heliothiszeanpvsprayedtotheopenmouthandinstilledineach'", "j.efsa.2012.2868.pdf": null, "j.efsa.2012.2869.pdf": "chapter2analyticalmethodsanalyticalmethodsforthemicro-organism(annexiim4.2,4.3;iiim5.4)manufacturedmicro-organism(principleofmethod):directcountinhaemocytometerofnumberofspores;microscopicobservationofgerminatedandun-germinatedspores;biologmicroplateassayandpcranalysisarerecommendedforstrainidentification.impuritiesandcontaminatingmicro-organismsinmanufacturedmaterial(principleofmethod):microbiologicalmethodusingspecificmediaandmethodtoidentifyproductionofsecondarymetabolitesmicrobialplantprotectionproduct(principleofmethod):microbiologicalmethod:directcountinhaemocytometerofnumberofspores;microscopicobservationofgerminatedandun-germinatedspores;standardspreadplatecountusingpdamedium.analyticalmethodsforresidues(viableandnon-viable)(annexiim4.5)oftheactivemicro-organism(principleofmethod):notrelevantofrelevantmetabolites(principleofmethod):thestraindoesnotproducemetabolitesofspecialconcernknowninspeciesofthegenuspaecilomyceschapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:noadversehealtheffectsobservedamongpersonnelinvolvedinlaboratoryinvestigationssensitisation:consideringthatallmicrobialsshouldberegardedaspotentialsensitisers,theagreedwarningphraseismicroorganismsmayhavethepotentialtoprovokesensitisingreactionsacutetoxicity/infectivity/pathogenicityafteroralexposure:noadverseeffectsobservedafterinhalationexposure:noadverseeffectsobservedafterintraperitonealexposure:noadverseeffectsobservedgenotoxicity:notgenotoxicinvitrocellculturestudy:cytotoxicityandantiproliferativeactivityweretestedtowardshumanlymphoblastslikecellsbutresultsareinconclusive.'", "j.efsa.2012.2870.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateoralabsorptionapprox.33%,basedonurinaryexcretionuniformlydistributednoevidenceofaccumulationexcretionalmostcompletein24hoursextensivelymetabolised(approx.40%bydechlorination,glucuronidation,sulphationandhydrolysis).(animalsandplants)parentcompound,pcaandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50>4640mg/kgbwratld50>2000mg/kgbwratlc50>2.5mg/l,4h(nose-only,dust)non-irritantnon-irritantnon-sensitizer(magnusson&kligman)shorttermtoxicity(annexiia,point5.3)haemolyticanaemiarat(90-day):11mg/kgbwperdaymouse(90-day):9.7mg/kgbwperdaydog(1-year):10mg/kgbwperdayrat(21-day):1000mg/kgbwperday(highestdoseleveltested).rabbit(3-weeks):322mg/kgbwperday(highestdoseleveltested).rat(4-weeks):0.1mg/l(highestdoseleveltested).rabbit(3-weeks):1.9mg/l(highestdoseleveltested).nogenotoxicpotentiallong-termtoxicityandcarcinogenicity(annexiia,point5.5)haemolyticanaemiarrat(2-years):31mg/kgbw/dmouse(91-weeks):6.4mg/kgbw/dnocarcinogenicpotential'", "j.efsa.2012.2879.pdf": "appendixa.3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorptionrapid,butincompletetotalrateofabsorptionamountedtoatleast48%distributionwidelypotentialforaccumulationnegligiblerateandextentofexcretionrapid,onlynegligibleradioactivitywasfoundinthetissuesandorgans72hoursaftertheadministrationmetabolisminanimalscompletetoxicologicallyrelevantcompounds(animalsandplants)spiromesifentoxicologicallyrelevantcompounds(environment)spiromesifenacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.87mg/l(highestachievableconcentration)skinirritationnoneeyeirritationnoneskinsensitization(testmethodusedandresult)positiveinamagnusson&kligmanassayr43shorttermtoxicity(annexiia,point5.3)target/criticaleffectadrenalsandmetabolicdisturbance(reducedcholesterol)relevantoralnoael3mg/kgbwperday(mouse)relevantdermalnoael1000mg/kgbwperday(rat,notmostsensitivespecies)relevantinhalationnoael5.0mgspiromesifen/m3perdayforfourweeks(rat)genotoxicity(annexiia,point5.4)..negativeinvitro(amestest,amammaliancellgenemutationassaywithv79cells,andacytogenetictestinv79cells)andinvivo(mousebonemarrowmicronucleustest)'", "j.efsa.2012.2914.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid(>70%excretedwithin3h)andextensive(>90%inurinewithin24h)humans,2mg/kgbwdistributionnodataavailablepotentialforaccumulationaccumulationisunlikelybasedonrapidandextensiveexcretionrateandextentofexcretionrapidandextensive(>90%inurinewithin24hours)metabolisminanimalsglucuronideandsulphateconjugatesarethemajorpathways.metabolismtopolarmetabolitesalsooccurs.toxicologicallyrelevantcompounds(animalsandplants)eugenol,methyleugenoltoxicologicallyrelevantcompounds(environment)eugenol,methyleugenolacutetoxicity(annexiia,point5.2)ratld50oral1930mg/kgbw(rat)mg/kgbw(dog)r22ratld50dermalnodataavailablenotrequiredratlc50inhalation>2.58mg/lskinirritationirritantr38eyeirritationnodataavailable,consideredeyeirritantbasedonskinirritationpotentialr36skinsensitisationsensitising(maximisationtestwithguineapigs,locallymphnodeassaywithmice,humanreports)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgains(rat)relevantoralnoaelrat:600mg/kgbwperday(13-wk)dog:100mg/kgbwperday(highestdosetested,10administrations)mouse:900mg/kgbwperday(13-wk)relevantdermalnoaelnodataavailablerelevantinhalationnoaelnodataavailable'", "j.efsa.2012.2915.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)likelytobeextensivelyandrapidlyabsorbedbasedoninformationfromstructurally-relatedchemicalslikelytoberapidlyandextensivelydistributedbasedoninformationfromstructurally-relatedchemicalsdatafromstructurally-relatedchemicalsindicatethataccumulationisunlikelyrapidexcretionviaurineisanticipatedbasedoninformationfromstructurally-relatedchemicals.excretionofgeraniolmetabolitesinurinehasbeenconfirmed.successiveoxidativereactionsatthesidechainstoproducepolaracidicmetaboliteshavebeendemonstrated(animalsandplants)geraniol(environment)geraniolacutetoxicity(annexiia,point5.2)ratld50>4000mg/kgbw-ratld50nodataavailable*-ratlc50nodata*irritantr38eyeirritancyassumedr36inconsistentresultsinanimaltests,reportsofskinsensitisationinhumansr43'", "j.efsa.2012.2916.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)likelytobeextensivelyandrapidlyabsorbedbasedoninformationfromstructurally-relatedchemicalslikelytoberapidlyandextensivelydistributedbasedoninformationfromstructurally-relatedchemicalsaccumulationisunlikelybasedonrapidandextensiveexcretionmoderatelyrapidexcretionviaurine(atleast50%within24hours)basedonlimitedstudieswiththymolandinformationfromstructurally-relatedchemicals.predominantlyconjugationwithglucuronicacidorsulfate;hydroxylationandotheroxidativereactionsoccurtoalesserextent.(animalsandplants)thymol(environment)thymolacutetoxicity(annexiia,point5.2)ratld50980mg/kgbw(rat)1050-1200mg/kgbw(mouse)880mg/kgbw(guineapig)r22ratld50basedonpublishedinformationintherabbitandotherquotedvaluesintheliterature,ld50likelytobe>2000mg/kgbwratlc50nodataprovided;notrequiredbasedonthefactthatthymolisusedinhumanandveterinarymedicineviatheinhalationrouteuptothelimitdosefortesting.corrosiver34extremelyirritantr41inconsistentresultsinanimaltests,reportsofskinsensitisationinhumansr43'", "j.efsa.2012.2917.pdf": "6impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidandextensiveabsorption(approximately85%)widespreadwiththehighestresiduelevelsintheliverandkidneys.noevidenceofbioaccumulationineithersex.rapideliminationpredominantlyinbilewithminoramountsinurine.themajorreactionsinvolveddemethylationofthepyrazoleringtoformm21,hydroxylationoftheparentandthem21metaboliteandconjugationwithglucuronicacidorglutathione.aminormetabolicreactionwasthecleavageoftheamidebridgeofbixafen.t(animalsandplants)bixafen,m21(environment)bixafenacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>2000mg/kgbwratlc50>5.383mg/l(4h,nose-onlyexposure)non-irritantnon-irritantnotaskinsensitiserinamodifiedllnainmice'", "j.efsa.2012.2921.pdf": "7chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionapproximately20%athighdose(500mg/kgbw)and40%atlowdose(50mg/kgbw),basedonexcretionviabile,urine,cagewash,andcarcass/tissueresiduesdistributionwidelydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionmainlyviafaeces(73-100%over72h),with3-10%viabileand6-8%viaurine(highdose)metabolisminanimalsterminaloxidationofoctylsidechain,subsequentdegradationofthecarboxylicsidechainandconjugationwithtaurineandglucuronicacid.severalmetaboliteswithm650f06beingmostabundantone.toxicologicallyrelevantcompounds(animalsandplants)ametoctradin(bas650f)toxicologicallyrelevantcompounds(environment)ametoctradin(bas650f)acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.5mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(gpmtandllna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectnoadverseeffectsrelevantoralnoael90-day,rat:1083.2mg/kgbwperday(thehighestdosetested)90-day,mouse:1119mg/kgbwperday(the'", "j.efsa.2012.2935.pdf": "6impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)70%absorbed(ratstudy,3mg/kgbw),basedonexcretionviaurineandbileuniformlydistributed;highestlevelsfoundinliverandkidneynoevidenceforbioaccumulationrapid,mainlyviafaeces(7080%within48hours)metabolisminanimalslossofoneorbothpropargylgroups,followedbyglucuronidationando-demethylation(animalsandplants)mandipropamid(environment)mandipropamidacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>5050mg/kgbwratlc50>5.19mg/lair/4h;noseonly-exposurenotirritantnotirritantnotasensitiser(lln)shorttermtoxicity(annexiia,point5.3)bodyweight,haematologicalandclinicalchemicalfindings,liverweight41mg/kgbwperday(90-dayrat)25mg/kgbwperday(90-daydog)5mg/kgbwperday(52-weekdog)1000mg/kgbwperday(28dayrat)nodata,notrequirednogenotoxicpotential'", "j.efsa.2012.2944.pdf": null, "j.efsa.2012.2945.pdf": "0impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionhigherthan80%basedonradiolabelrecoveredfromurine,bile,cagewash,faecesandtissues.distributionfat,kidneysandliver.enterohepaticrecirculationinmalerats.potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionca90%infemaleratsviaurinewitht1/2=2.5hca90%inmaleratsviaurineandbilewitht1/2=33-38hmetabolisminanimalsextensivelymetabolisedtothecarboxylicacidmetabolitefluazifopacid,furtherconjugatedwithtaurine.toxicologicallyrelevantcompounds(animals,plantsandenvironment)fluazifop-p-butylandfluazifopacid.acutetoxicity(annexiia,point5.2)ratld50oral2451mg/kgbw(rat)>2000mg/kgbw(mouse)ratld50dermal>2110mg/kgbwratlc50inhalation>5.2mg/l/4h(noseonly)skinirritationnon-irritatingeyeirritationnon-irritatingskinsensitisationsensitizing(llna)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney,spleenandliver.cataract,decreasedplasmacholesterollevelsr48/22relevantoralnoael90drat:0.9mg/kgbwperday90-dand1-yeardog:25mg/kgbwperday(fluazifop-butyl)90-dhamster:78mg/kgbwperdayrelevantdermalnoael21-drabbit:100mg/kgbwperday(fluazifop-butyl)relevantinhalationnoaelnodatanotrequired'", "j.efsa.2012.2954.pdf": null, "j.efsa.2012.2955.pdf": "0chapter2.3impactonhumanandanimalhealth9absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionapproximately55%(basedoncomparisonaucvaluesfollowingoralandi.vdosing)distributionmainlyinglandulartissue,spleen,lungs,gi-tract,kidneyandliverpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionmainlyviafaeces(>90%over168h),withlessthan3%viabileand0.1-0.3%viaurinemetabolisminanimalsonemetabolitecharacterized(ab1a,byn-demethylationofemamectin)toxicologicallyrelevantcompounds(animalsandplants)emamectinandmetaboliteab1atoxicologicallyrelevantcompounds(environment)emamectinacutetoxicity(annexiia,point5.2)ratld50oral208between73and92mg/kgbwbetween83and105mg/kgbw(expressedasemamectinbenzoate)r25ratld50dermalbetween439and877mg/kgbwr21ratlc50inhalation0.582mg/lair/4h(noseonly)r23skinirritationnon-irritanteyeirritationirritantr41skinsensitisationnotsensitising(gpmtandllna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectclinical(tremors)andhistopathological(neuronaldegenerationinbrainandspinalcord)evidenceofneurotoxicityrelevantoralnoael14-wkand52-wk,dog:0.25mg/kgbwperday13-wk,rat:0.5mg/kgbwperdayr48/25relevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)emamectinhasnogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)9allthevaluesareexpressedasemamectinfreebaseunlessstateddifferently.'", "j.efsa.2012.2963.pdf": null, "j.efsa.2012.2987.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidlyabsorbed(highestconcentrationsat0.5hourpost-dosing)andhighbioavailability(>80%ofdose,basedonurinaryandbiliaryexcretionandresiduesinthecarcass).noevidenceforabsorptionsaturation.widelydistributedtodifferentorgansverylowpotentialforaccumulation(<1%ofresidues168hoursafterdosing,independentlyontreatmentregimen)rapidandextensive(>70%within12hoursinurineandwithin48hoursinfaeces).between79-102%excretedwithin7days.urinaryexcretion:33-55%ofthedose;faecalexcretion:35-55%ofthedosewithin7days.biliaryexcretion:29-40%within48hextensivelymetabolised:noparentcompounddetectedinurineandlowamount(0.6-1%)infaeces.majorpathways:demethylationandhydroxylationofpyrimidinemoietywithaminorpathway(<3%)ofcleavagebetweenpyrimidineandpyrazolemoieties.majormetabolites:demethylhalosulfuron-methyl(urine:13-35%;faeces:7-8%)and5-hydroxydemethylhalosulfuron-methyl(urine:9-14%;faeces:15-25%)(animalsandplants)halosulfuron-methyl(environment)halosulfuron-methylacutetoxicity(annexiia,point5.2)ratld50oralrat:7758mg/kgbwmouse:9295mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>6.0mg/lair/4h(wholebody)non-irritantnon-irritantnon-sensitiser(magnussonandkligmantest)shorttermtoxicity(annexiia,point5.3)reducedbodyweightgain,livereffectsandhaematologicalchanges(dogandrat)increasedhaemosiderinpigmentationintherenaltubularepithelium(rat)'", "j.efsa.2013.2922.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammalsrateandextentofabsorption:thiocyanateisrapidlyandalmostcompletelyabsorbeddistribution:widely,extracellularpotentialforaccumulation:noevidenceofaccumulationrateandextentofexcretion:excretionprimarilyviaurine,smallamountsinexpiredairandfaeces.thiocyanateissecretedbymammaryandsalivaryglandsandgastricmucosa.ittherehasafunctionaluseasasubstrateforperoxidaseinmilk,salivaandgastricjuice.eliminationhalflife:3days.metabolisminanimalssmallamountsofabsorbedscnareexcretedintheexpiredairasco2orhcnoraretakenupintheone-carbonpoolviaformicacid;cyanideisanintermediateproduct.thiocyanatecanalsobeformedinthebodybytranssulfurizationfromcyanidetoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandcyanideacutetoxicityratld50oral854mg/kgbw;r22ratld50dermal>2000mg/kgbwratlc50inhalationstudynotavailableskinirritationstudynotacceptableeyeirritationstudynotacceptableskinsensitisationstudynotacceptableshort-termtoxicitytarget/criticaleffectthyroidfunctionisreportedtobethemostsensitivetarget.however,noaelisbasedonnon-specificchangesinparametersinhaematologyandclinicalchemistry;noparametersforthyroidfunctionwereexaminedrelevantoralnoael26mgkscn/kgbwperday(rat)(limitedvalidity)relevantdermalnoaelnodata,notrequired'", "j.efsa.2013.2923.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammalsrateandextentofabsorption:inadults,approximately100%oforaldoseisabsorbed.ininfantsapproximately30-70%ofanoraldoseisabsorbed.distribution:thehumanbodycontainsapproximately10-15mgofiodine,ofwhichapproximately90%isinthethyroidglandfortheproductionofthyroidhormones,whichareexportedtothebloodandothertissues.thetissuedistributionofiodideandorganiciodineisverydifferent.iodineuptakeintothethyroidglandishighlysensitivetotheiodineintake.potentialforaccumulation:accumulationinthethyroidglandfortheproductionofthyroidhormones,whichareexcretedtothebloodandothertissues.rateandextentofexcretion:absorbediodineisexcretedprimarilyintheurine(>97%)andfaeces(1-2%),butalsoinbreastmilk,exhaledair,sweatandtearsmetabolisminanimalsiodideisincorporatedinthyroidhormones.toxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompound;norelevantmetabolitesacutetoxicityratld50oral1862mg/kgbw(mouse);between200and500mg/kgbwinexperimentalanimalsreportedbythejecfa;r22ratld50dermal>2000mg/kgbwratlc50inhalationnodataavailableskinirritationnotirritatingeyeirritationnodataavailableskinsensitisation(testmethodusedandresult)nodataavailableshort-termtoxicitytarget/criticaleffectthyroidrelevantoralnoael<6mg/kgbwperday(rat)relevantdermalnoaelnodata'", "j.efsa.2013.3007.pdf": "0impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataprovided.nodataprovided.nodataprovided.nodataprovided.maltodextrinisrapidlybrokendowntoglucosefollowingingestion.(animalsandplants)none(environment)noneacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbwratld50>2000mg/kgbwratlc50>5.16mg/litrenotirritatingnodataprovided.mightbeanirritantasadustcloud.nodataprovided.containsalpha-amylase.mayproduceanallergicreaction.shorttermtoxicity(annexiia,point5.3)nodataprovided.notnecessary.nodataprovided.notnecessary.nodataprovided.notnecessary.nodataprovided.notnecessary.nodataprovided.notnecessary.'", "j.efsa.2013.3023.pdf": "impactonhumanandanimalhealth1theassessmentofthedifferentgroupsoffattyacidshadbeenbasedontheassumptionthattheyareoffoodgradequalityandthereforeexposuretofattyacidsfromtheuseasplantprotectionproductswouldbeconsideredoflowtoxicologicalconcernandnoreferencevalueswouldbeneeded.however,becauseofdatagapsidentifiedintheidentitysectionthisassumptioncannotbeconfirmedandthereforetheriskassessmenttooperator,workerandbystandercannotbeconcluded.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidlyabsorbed,variabledependingmainlyonchainlength(from60to91%)completelydistributed,noresiduesoftoxicologicalconcern.essentialcomponentsineverycell.adiposetissueservesasastoragedepot.eliminationcanapproach100%whenfattyacidsaremetabolisedcompletelyforenergyproduction,givingrisetoh2oandco2.nometaboliteswhencompletelyoxidisedbythemitochondria.fattyacidscanbeshuntedintodifferentmetabolicpathwaysdependingontheenergystatusofthecell.canbeusedtoformessentialstructuralandregulatorycomponents.(animalsandplants)none.(environment)none.acutetoxicity(annexiia,point5.2)ratld50ld50>2,000mg/kgbw(c9:0)ld50>2,000mg/kgbw(fattyacidmethylesterproduct)ld50>5,000mg/kgbw(fattyacidalkalisaltsproduct)ratld50ld50>2,000mg/kgbw(c9:0)ld50>2,000mg/kgbw(fattyacidmethylesterproduct)ld50>5,000mg/kgbw(fattyacidalkalisaltsproduct)ratlc50lc50>1.82mg/l(k+fattyacidsproduct;4h,noseonly)lc50>1.66mg/l(c9:0product;4h,noseonly)9freefattyacids:corrosive2.chainlength>c9:irritating3.methylesters:nonirritating.c;r34xi;r37/381.freefattyacidsandsalts:irritatingxi;r36'", "j.efsa.2013.3024.pdf": null, "j.efsa.2013.3031.pdf": "chapter3:impactonhumanandanimalhealthmedicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(oecddatapointiim5.1,5.2)noadverseeffectsinemployeeswhohadbeeninoccupationalcontactwithstrainatccreported.forbeauveriabassianaingeneral,fewcasesoflocal(eye)andsystemicinfectionswerereportedwiththelatteroccurringonlyinimmunocompromisedorseverelyillpatients.evidenceofallergenicitybyrespiratoryorskincontact.sensitisation:(oecddatapointiim5.3.1&iiim7.1.6)microorganismsmayhavethepotentialtoprovokesensitisingreactionsforbeauveriabassianaingeneral,thereisevidenceofallergenicitybyinhalationinlaboratoryanimalsandhumansandindicationsofallergicskinreactionsinhumans.theavailablesupplementarym&ktestwithstrainatccinguineapigs,althoughnegative,wasnotsufficienttocontravenethesefindings.acuteoralinfectivity,toxicityandpathogenicity(oecddatapointiim5.3.2&iiim7.1.1)rat:ld50>1.9x108cfu/animal;noevidenceoftoxicity,pathogenicity,orinfectivity.sporesstilldetectableinfaecesatendofstudyonday14.acuteintratracheal/inhalationtoxicity,pathogenicityandinfectivity:(oecddatapointiim5.3.3&iiim7.1.3)rat:ld50>2.5x109cfu/animal;initialbwdecrease,localreversiblesignsoflunginflammation.noevidenceofpathogenicityorinfectivity.clearanceinlungtissuecompletedbyday15post-dosing.acuteintravenous/intraperitonealtoxicity,pathogenicityandinfectivity:(oecddatapointiim5.3.4&iiim7.1.2)rat:ld50>2.0x107cfu;noevidenceoftoxicity(nasalsecretiononday1),pathogenicityorinfectivity.clearanceinbloodcompletedbyday2post-dosing.genotoxicity:(oecddatapointiim5.3.5)negativeintheamestestcellculturestudy:(oecddatapointiim5.3.6)nodatanotrequired.informationonshort-termtoxicityandpathogenicity:(oecddatapointiim5.3.7)nodatanotrequired.dermaltoxicity:(oecddatapointiiim7.1.2)rabbit:ld50>1x1010cfu/animal;nosystemiceffects,slightlyirritatingtotheskin(noclassificationneeded).specific-toxicity,pathogenicityandinfectivity:(oecddatapointiim5.5)rabbit:ld50>1x1010cfu/animal;nosystemiceffects,slightlyirritatingtotheskin(noclassificationneeded).certainpotentialofthemicroorganism(strainnotspecified)todamagethecorneaconfirmedinrabbits.long-terminhalativeexposuretob.bassiana(strainnotspecified)causedallergiclungreactionsinratsandmice.datagapforspecificrepeateddosetoxicitygenotoxicityinvivostudiesingermcells:(oecddatapointiim5.5.3)nodatanotrequired.'", "j.efsa.2013.3032.pdf": "chapter3:impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)rateandextentofabsorption:(a/b)55%absorbedbygastrointestinaltract(basedonurineexcretionwithin72handtissuecontent)distribution:(a/b)highlydistributed.tissueswithmorethandoubledconcentrationsofradioactivitycomparedtowholebloodweretheliver,ovaries,carcassandfatpotentialforaccumulation:(a/b)noindicationofbioaccumulationafterrepeatedadministration.rateandextentofexcretion:(a/b)half-life5-6h,excretionalmostcompletewithin72h.mainlyexcretedinfaecesformales(upto71%versus52%forfemales),butexcretedinequalamountsinurineforfemales(49-57%versus32-47%formales).metabolisminanimals(a/b)metabolicpathwayincludehydrolysisandoxidationprocesses.majormetaboliteinurine:chrysanthemumdicarboxylicacid(21-23%)majormetaboliteinfaeces:metabolitee(19-25%)toxicologicallyrelevantcompounds(animalsandplants)(a/b)pyrethrinstoxicologicallyrelevantcompounds(environment)(a/b)pyrethrinsacutetoxicityratld50oral(a)(a/b)700mg/kgbw(females)1030mg/kgbw(females)r22h302rabbitld50dermal(a/b)>2000g/kgbwratlc50inhalation(a/b)3.4mg/lr20h332skinirritation(a/b)non-irritatingeyeirritation(a/b)non-irritatingskinsensitisation(testmethodusedandresult)(a/b)notsensitisinginamodifiedbuehlerassayshorttermtoxicitytarget/criticaleffect(a/b)liver:increasedweight(mouse,rat,dog),microscopicchanges(mouse).haematologyand/orclinicalchemistrychanges(rat,dog).afterinhalation(rat):squamourmetaplasiainthelarynx(localeffect),anaemia(systemiceffect).relevantoralnoael(a)(a/b)(a/b)mouse:160mg/kgbwperday(13-week)rat:57mg/kgbwperday(13-week)dog:14mg/kgbwperday(1-year)relevantdermalnoael(a/b)rabbit:1000mg/kgbwperday(21-day)'", "j.efsa.2013.3033.pdf": null, "j.efsa.2013.3034.pdf": "hapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:noliteraturereportsoranyotherreportsofadverseeffectsduetopythiumoligandrum.sensitisation(experienceinhumansandstudyresults;typeofstudy):nodataavailable.consideringthatallmicrobialsshouldberegardedaspotentialsensitizers,theagreedwarningphrasemicroorganismsmayhavethepotentialtotoxicityafteracuteoralexposure:ratld50>5000mg/kgbw,correspondingto3.13.8x106oospores/animal.mouseld50>5000mg/kgbw,correspondingto5.66x105oospores/animalnoadverseeffectobserved.afteracuteinhalationexposure:ratlc50>5mg/lcorrespondingto11.5x104oospores/l(intranasaladministration)focalemphysema(2females)andbloodaspiration(1male)inlungsrelatedtoterminalsacrifice.afteracuteintraperitoneal/subcutaneousexposure:ratld50>3.6x104oospores/animal.noadverseeffectobserved.afteracutesubcutaneousexposure:rabbitld50>1x105oospores/animal.afteracutedermalexposure:ratld50>5000mg/kgbw,correspondingto1x107oospores/kgbw.noadverseeffectobserved.infectivityafteracuteoralexposure:clearancenotinvestigated.afteracuteinhalationexposure:clearancenotinvestigated.afteracuteintraperitoneal/subcutaneousexposure:clearancenotinvestigated.afteracutedermalexposure:clearancenotinvestigated.pathogenicityafteracuteoralexposure:noindicationofpathogenicitybasedonlimiteddataavailable.afteracuteinhalationexposure:noindicationofpathogenicitybasedonlimiteddataavailable.afteracuteintraperitoneal/subcutaneousexposure:noindicationofpathogenicitybasedonlimiteddataavailable.afteracutedermalexposure:noindicationofpathogenicitybasedonlimiteddataavailable.genotoxicity:nodataprovided.datamayberequiredpendingontheidentification/quantificationoftoxins/secondary'", "j.efsa.2013.3035.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:trichodermapolysporumimi206039hasbeenusedasaplantprotectionproductinseveralcountriesforupto30yearswithoutanyreportsofadverseeffects.theuseofbiosafetylevels(bsls)hasbeenproposedasameanstoclassifymicroorganismsaccordingtotheirpathogenicpotential.trichodermalongi-brachiatum,trichodermapseudokoningiiandtrichodermaviridewereproposedtobeclassifiedasbsl1trichodermapolysporumimi206039hasbeenshownnottogrowathumanbodytemperature,thuspreventingdeepinfectionsinmammals,eveninimmunocompromisedpersons.availableliteraturedataalsosuggestsaverylowrisktohumansandmammals,sincetherearenoknownhumanoranimalpathogensbelongingtothetrichodermagenusotherthanoccasionalincidentsinimmunocompromisedpersonsrecordedforsomespecies.sensitisation(experienceinhumansandstudyresults;typeofstudy):negativeinanindicativemagnusson&kligmanmaximisationtest;negativeinanindicativetestforanaphylacticreaction;negativeinanindicativetestforantibodiesagainsttrichodermainanexposedperson.mayhavethepotentialtoprovokesensitizingtoxicityafteracuteoralexposure:ld50>2g/kgbw;accordingtonotifiercorrespondingto4.8x109spores/kgbwconductedwithanunidentifiedextractoftrichodermaviride.afteracuteinhalationexposure:nodataavailableafteracuteintraperitoneal/subcutaneousexposure:nodataavailableinfectivityafteracuteoralexposure:nodataavailableafteracuteinhalationexposure:nodataavailableafteracuteintraperitoneal/subcutaneousexposure:nodataavailablepathogenicity'", "j.efsa.2013.3036.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:nostrainspecificdata.singlecasesoffatalinfectionsinimmuno-compronisedpatientshavebeenreportedfort.harzianum(formeridentificationoft.asperellumicc012),butthespeciesidentityoftheisolateswasquestioned(mightberestrictedtotrichodermalongibrachiatum).theuseoftrichodermaharzianumingreenhouseshasbeenrelatedtocough,difficultyofbreathing,itchinginthenose,andmoreunspecificannoyance.sensitisation(experienceinhumansandstudyresults;typeofstudy):nocasesonhypersensitivityhavebeenreportedinassociationwithtrichodermaharzianumduringproductionorapplication.nostudyhasbeenperformed.consideringthatallmicrobialsshouldberegardedaspotentialsensitizers,theagreedwarningphraseis:microorganismsmayhavethepotentialtoprovokesensitizingreactionstoxicityafteracuteoralexposure:icc012:ratld50>2000mg/kgbw,correspondingto>8.6x109cfu/kgbwafteracuteinhalationexposure(intratracheal):icc012:ratld50>2000mg/kgbw,correspondingto>1.1x107cfu/animalafteracuteintraperitonealexposure:icc012:ratld50>1x108cfu/animal.infectivityafteracuteoralexposure:nodatanotrequiredafteracuteinhalationexposure:icc012:incompleteclearanceofthelungsafter21days(2of6animals),butcleardecreaseinthenumberofcfuintissues.afteracuteintraperitoneal/subcutaneousexposure:nodatanotrequiredpathogenicityafteracuteoralexposure:icc012:noindicationofpathogenicitybasedonthedataavailable.afteracuteinhalationexposure:icc012:noindicationofpathogenicitybasedonthedataavailableafteracuteintraperitonealexposure:icc012:noindicationofpathogenicitybasedonthedataavailablegenotoxicity:nodata.datamayberequiredpendingontheidentification/quantificationoftoxins/secondary'", "j.efsa.2013.3052.pdf": "23impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,morethan93%within48h,basedonurinary(7.3%)andbiliary(78.5%)excretionandamountincarcass(7.6%)experimentwith[phenyl-ul-14c]-labelledcompoundandevenhigherwith[pyridyl-2,6-14c]-labelledcompound;remarkableenterohepaticcirculationwasobsevedinthenon-cannulationtrialsdistributionwide,highestresiduesinliver,kidneys,andtoalesserextent,inerythrocytes,adrenals,thyroidandovariesafter168haccountingfor2-6%oftheadministereddoseintotal;plasmacmax:~1.5-2.2g/g(tmax:11-15hpostapplication),auc:107-148g/gxh;meanresidencetime52-84hpotentialforaccumulationlowevidenceforaccumulation(logpo/w=3.3and6%res.after168h,butresultsofrepeateddosestudydonotshowaccumulation)rateandextentofexcretionnearlycompletewithin168h(urine:35-45%/45-60%(m/f);faeces:47-64%/39-53%withmostpartexcretedwithin72hmetabolisminanimalsextensivelymetabolised(hydroxylation,oxidationandmolecularcleavageyieldingthebenzamidefollowedbyconjugationwithglutathione,glucuronicacidorsulphate);largenumberofmetabolitesthatmaybeallocatedtodifferentgroupsandoccurmostlyinlowamountsonly,mostabundantmetabolites:fluopyrambenzamide,fluopyrampyridylaceticacid,7-oh-phenolfluopyram,7-or8-ohfluopyramandfluopyramethyldiolglucuronideaccountingeachfor6-28%oftheadministereddosetoxicologicallyrelevantcompounds(animalsandplants)fluopyramandmetabolitestoxicologicallyrelevantcompounds(environment)--acutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.11mg/lair(4-hexposure,noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(llna)'", "j.efsa.2013.3053.pdf": null, "j.efsa.2013.3054.pdf": null, "j.efsa.2013.3055.pdf": "chapter2analyticalmethodsanalyticalmethodsforthemicro-organism(annexiim4.2,4.3;iiim5.4)manufacturedmicro-organism(principleofmethod):openimpuritiesandcontaminatingmicro-organismsinmanufacturedmaterial(principleofmethod):openmicrobialplantprotectionproduct(principleofmethod):openanalyticalmethodsforresidues(viableandnon-viable)(annexiim4.5)oftheactivemicro-organism(principleofmethod):notrequiredofrelevantmetabolites(principleofmethod):open.chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:singlecasesoffatalinfectionsinimmuno-compromisedpatientshavebeenreportedfort.harzianum,butthespeciesidentityoftheisolatesmightbequestioned.pathogenicstrainsarenowbelievedtoberestrictedtothesectionlongibrachiatum.theuseoftrichodermaingreenhouseshasbeenrelatedtocough,difficultyofbreathing,itchinginthenose,andmoreunspecificannoyance.sensitisation(experienceinhumansandstudyresults;typeofstudy):nocasesonhypersensitivityhavebeenreportedinassociationwithtrichodermaharzianum.howevertrichodermaviridehasbeenassociatedwithhypersensitivities.volatileorganiccompoundswerefoundtopotentiatehistaminereleasefromhumanbronchoalveolarcells,suggestingthepossibleinvolvementoftrichodermavirideinallergenicreactions.nostudyhasbeenperformed.shouldmayhavethepotentialtoprovokesensitisingtoxicityafteracuteoralexposure:nomortalityoreffectsonbodyweightwereobserved,clinicalsigns(in1animal)hadresolvedbyday7,notreatment-relatednecropsyfindings'", "j.efsa.2013.3057.pdf": "1impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption87-89%basedonurineandbileexcretion,carcassandcagewashresidueswithin48htmaxvalue1-1.5hdistributionwidelydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidexcretionmainlyviafaecesurinary(11.8-17.2%within72h)faeces(72-83%within72h)bile(78-81%in48hours)t:22-24hmetabolisminanimalsextensivemetabolisminrat:demethylation,hydroxylation,oxidationandsubsequentconjugation.toxicologicallyrelevantcompounds(animalsandplants)sedaxanetoxicologicallyrelevantcompounds(environment)sedaxaneacutetoxicity(annexiia,point5.2)ratld50oralbetween2000-5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.25mg/lair(4h,nose-only)skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitizer(llna)short-termtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightandbodyweightgain(allspecies)rats:liver(increasedweight),reducedforegripstrength(females)mice:testisandliver(increaseadjustedweight)dogs:clinicalbiochemistryparameters,liver(increasedweight)relevantoralnoael90-dayrat:28mg/kgbwperday90-day&1-yeardog:50mg/kgbwperday90-daymice:567mg/kgbwperday'", "j.efsa.2013.3058.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnotavailable,notneededdistributionnotavailable,notneededpotentialforaccumulationnotavailable,notneededrateandextentofexcretionnotavailable,notneededmetabolisminanimalsnotavailable,notneededtoxicologicallyrelevantcompounds(animalsandplants)notavailable,notneededtoxicologicallyrelevantcompounds(environment)notavailable,notneededacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kdbwratld50dermal>2000mg/kdbwratlc50inhalation>3.26mg/l(themaximumattainableconcentration)skinirritationnotirritatingeyeirritationnotirritatingskinsensitisationnotsensitizingshorttermtoxicity(annexiia,point5.3)target/criticaleffectnotavailable,notneededrelevantoralnoaelnotavailable,notneededrelevantdermalnoaelnotavailable,notneededrelevantinhalationnoaelnotavailable,notneedednotavailable,notneededlongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnotavailable,notneededrelevantnoaelnotavailable,notneededcarcinogenicitynotavailable,notneeded'", "j.efsa.2013.3059.pdf": null, "j.efsa.2013.3060.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandcomplete,80%within6hdistributionwidelydistributedpotentialforaccumulationnonerateandextentofexcretionmainlyutilisedincellularprocessesinsteadofbeingexcretedmetabolisminanimalsformationofacetyl-coaandmetabolicintermediatestoxicologicallyrelevantcompounds(animalsandplants)aceticacidtoxicologicallyrelevantcompounds(environment)aceticacidacutetoxicity(annexiia,point5.2)ratld50oralinsufficientdataavailable,notrequiredratld50dermalnostudyavailable,notrequiredratlc50inhalationinsufficientdataavailable,notrequiredskinirritationirritating(10%solution),corrosiveathigherconcentrationsr38eyeirritationirritating(10%solution),corrosiveathigherconcentrationsr36skinsensitisationnodata;lowpotentialbasedonhumanexperienceshorttermtoxicity(annexiia,point5.3)target/criticaleffectinsufficientdataavailable,notrequiredrelevantoralnoael290mg/kgbwperday(8-wkrat,dietary,singledosetested)relevantdermalnoaelnostudyavailable,notrequiredrelevantinhalationnoaelnostudyavailablenotrequiredgenotoxicity(annexiia,point5.4)chromosomeaberrationtestinvitro:positivewithmetabolicactivationatcytotoxicdoses(unphysiologicallylowph),negativeinbufferedmediumsisterchromatidexchangesinvitro:slightlypositivewithoutmetabolicactivation,atcytotoxicdosesinducingalowerphinsufficientdataavailableinvivo,notrequiredconclusion:unlikelytobemutagenicinvivoforsufficientlybufferedsystems'", "j.efsa.2013.3061.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservationslimiteddata:noadverseeffectsobservedamongresearchers,productionworkersandfieldtechniciansexcepttwoinstancesofallergicreactioninunprotectedpersonnel.sensitisation(experienceinhumansandstudyresults:typeofstudy)twoinstancesofhumanrespiratoryallergicreaction.magnusson-kligmanmaximisationtestpositiveresult:moderatesensitisertoxicityafteracuteoralexposure:nomortality,slightandtransientclinicalsignsoftoxicity.ratld50>5000mgmycostop/kgbodyweight(>108cfu/kgbw)afteracuteinhalationexposure:intratrachealadministration:54%ofthemalesand48%ofthefemalesdiedwithin2days.clinicalsigns:hunchedposture,roughhaircoat,suppurativeinflammationinlungtissue.grosslesionsintherespiratorysystem,influxofreticulocytesattargetsite.ratlc50(male)=3.46x107cfu/animal<>25mgmycostop/animal(bodyweightrange96127g)<>197-260mgmycostop/kgbw<>2.7-3.6x108cfu/kgbwratlc50(female)=3.02x107cfu/animal=20mgmycostop/animal(bodyweightrange96127g)<>157-208mgmycostop/kgbw<>2.4-3.1x108cfu/kgbwafteracuteintraperitoneal/subcutaneousexposure:intraperitonealadministration:mortalityinbothheat-killedandviablemicroorganismwithin2daystreatment.adverseclinicalsignsreturnedtonormalwithin5daysinsurvivingmice,exceptcellularinfluxandenlargedspleens.mouseld50=1000mgmycostop/kgbodyweight<>1.0x108cfu/kgbwinfectivityafteracuteoralexposure:limiteddataafteracuteinhalationexposure:noindicationofinfectivityafteracuteintraperitoneal/subcutaneousexposure:limiteddatapathogenicityafteracuteoralexposure:limiteddataafteracuteinhalationexposure:noindicationofpathogenicity'", "j.efsa.2013.3062.pdf": null, "j.efsa.2013.3063.pdf": null, "j.efsa.2013.3090.pdf": "mammaliantoxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidandalmostcomplete(humanandanimal)oralabsorption:85%/poorlyabsorbedfromthebiliarysystem(human)rapidtodifferenttissuesinthebody,initiallyhighintheliver,kidneysandbloodnoevidenceofaccumulationwithin2-3days:75%-95%urine;lessthan10%faeces(humanandanimal)phaseimetabolisation(majormetabolicpathway=oxidationofthe1-methylgroupyieldingperillicacid)followedbyconjugationwithglucuronicacid.85%oftheurinarymetabolitesidentifiedasperillicacidormetaboliteofperillicacid.(animalandhuman)(animalsandplants)orangeoil(environment)orangeoilacutetoxicity(annexiia,point5.2)nodataratnodatanodatanodatanodatasensitising(m&kond-limonene)xir43h317shorttermtoxicity(annexiia,point5.3)rat(orangeoil):kidneysinmalerats:chronicnephrosis.notrelevantforhumans(2-globulin-associatedmechanism)liver:enzymes,weight,cholesterollevelsandbileflowdog(d-limonene):increasedserumalkalinephosphataseandcholesterol,increasedkidneyweights'", "j.efsa.2013.3131.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandrapidandalmostcompletelyto>93%(basedonurinaryandbiliaryexcretion)aftersingleorallowdose(ratstudy)widelydistributed(highestresiduesfoundinliverandkidneys)lowpotentialforaccumulationalmostcompletelyexcreted(>93%)within96hours;inmales20-35%ofradioactivityfoundinurinevs.59-73%infaeces;infemalesradioactivitywaspreferentiallyexcretedviaurine(74-84%vs.15-22%infaeces)extensivelymetabolizedmainlyviaoxidativemechanismswiththeformationofhydroxylgroupsoneitherorbothringsofthemolecule;somesex-relatedquantitativedifferencesinmetaboliteprofile(animalsandplants)parent(environment)parentacutetoxicity(annexiia,point5.2)ratld50>2500mg/kgbwratld50>2000mg/kgbwratlc50>4.58mg/l(4h,noseonly)noskinirritationslighteyeirritation;noclassificationrequiredskinsensitizer(m&ktest)r43shorttermtoxicity(annexiia,point5.3)rats,miceanddogs:eyes(cornealeffects),liver(organweight,clinicalchemistry,histologicalalterations)0.07mg/kgbwperday(90-dayrat)64mg/kgbwperday(90-daymouse)9mg/kgbwperday(1yeardog)<50mg/kgbwperday(28-dayrat)(loael)'", "j.efsa.2013.3136.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabsorptionprobablylow.roughestimationsfromlimitedexperiments:1.2-4.6%(average3%)fortheoralroute,0-5%forthedermalroutedistributionindicationthatsilveriswidelydistributed.potentialforaccumulationyesrateandextentofexcretionnotknownmetabolisminanimalssstwilldissociateintosilverionsandthiosulfateions.thelatterwillbemetabolisedinthephysiologicalpoolofthebody.silverisnotsubjecttometabolism.toxicologicallyrelevantcompounds(animalsandplants)silvertoxicologicallyrelevantcompounds(environment)silveracutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationnotavailableskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnonsensitiser(maximization)short-termtoxicity(annexiia,point5.3)target/criticaleffectaccumulationanddepositionofsilversaltsresultinginvisiblepigmentation.mostlyingastro-intestinaltract,liver,pancreas,andadrenals.relevantoralnoael13-weekrat:20mg/kgbwperday13-weekdog:<35mg/kgbwperdayrelevantdermalnoael28dayrat:systemiceffects:300mg/kgbwperdaylocaleffects:noael<100mg/kgbwperday(lowestdosetested)dermaleffectswereobservedafter2-3weeksofexposure.relevantinhalationnoaelnodata,notrequiredgenotoxicity(annexiia,point5.4)sstisconsideredtobenon-genotoxicinvivo.'", "j.efsa.2013.3143.pdf": "2impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption73-85%afterasinglelowdose(10mg/kgbw)and12-13%afterasinglehighdose(200mg/kgbw)basedonsuminbile,urine,andcarcass(exceptgicontents).distributionwidelydistributedpotentialforaccumulationlowpotentialforaccumulationrateandextentofexcretionrapidexcretionobservedviabile(49-53%)within48hours.extensiveexcretion(88-97%)within7daysaftersingleormultipledoseadministration.excretionmainlyviafaeces(62-92%forthelowandhighdoses)comparedwithurine(3.7-29%forthehighandlowdoses).metabolisminanimalsmetabolismoftheabsorbeddosewasextensiveandinvolvedsexdifferencesprimarilyininitialmethylphenylandn-methylcarbonhydroxylations.furthermetabolismofthehydroxylatedmetabolitesincludedn-demethylation,nitrogen-to-carboncyclisationwithlossofawatermolecule,oxidationofalcoholstocarboxylicacids,amidebridgecleavage,aminehydrolysis,ando-glucuronidation.toxicologicallyrelevantcompounds(animalsandplants)chlorantraniliproletoxicologicallyrelevantcompounds(environment)chlorantraniliproleacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalationlc50>5.1mg/lair/4h(nose-onlyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&kandllna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectdog:liver/increaseinliverweightrat&mouse:noadverseeffectsobservedrelevantoralnoael28-day,rat:584mg/kgbwperday*90-day,rat:1188mg/kgbwperday*90-day,mouse:1135mg/kgbwperday*90-day,dog:303mg/kgbwperday1-year,dog:278mg/kgbwperday'", "j.efsa.2013.3147.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidlyabsorbed(>80%)andextensivelymetabolisedatlowdoselevelswidespreadwiththehighestlevelsinliver,kidney,wholebloodandabdominalfatsomeevidenceofaccumulationmainlyinrbcfollowingrepeatdosingbutinconclusiverapidexcretiondemethylationofthemethoxygroupsatthe3-and/or4-positionsonthebenzeneringfollowedbyglucuronideconjugation(animalsandplants)pyriofenone(environment)pyriofenoneacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbwratld50>2000mg/kgbwratlc50>5.18mg/lairper4-hour(nose-only)non-irritantslightirritantnegativeinamousellnashorttermtoxicity(annexiia,point5.3)target/rat:increasedliverweightandreducedaltactivityinmales;prolongedapttandreducedbilirubininfemalesmouse:increasedliverweightdog:increasedalkalinephosphataseactivity,reducedapttandincreasedliverandkidneyweight90-day,rat:17.9mg/kgbwperday90-day,mouse:61mg/kgbwperday90-day,dog:15mg/kgbwperday1-year,dog:13.7mg/kgbwperday28-day,rat:300mg/kgbwperday,basedonprolongedaptt(alsoseeninoralstudies)'", "j.efsa.2013.3148.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rapidandextensiveabsorption,>80%within8hbasedonurinary(414%)andbiliary(6070%)excretion,benalaxylwidelydistributed,benalaxylandbenalaxyl-mnoevidenceofaccumulation,benalaxylandbenalaxyl-m>95%within72hoursmainlybyfaeces(about86%)withbothcompounds.t1/2=18h,benalaxyl-mextensivemetabolismmainlybyoxidationandhydroxylation.12metabolitesfoundinbothurineandfaeces;parentcompoundfoundonlyinfaeces.samepathwayswithbenalaxylandbenalaxyl-mtoxicologicallysignificantcompoundsbenalaxyl-macutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbw,benalaxyl-mratld50>2000mg/kgbw,benalaxyl-mratlc50nottechnicallyfeasible,benalaxyl-m>4.204mg/lair(4h,noseonly,highesttechnicallyachievableconcentration),benalaxylskinnonirritant,benalaxyl-mnonirritant,benalaxyl-mnonsensitising(m&ktest),benalaxyl-mshorttermtoxicity(annexiia,point5.3)liver,benalaxylandbenalaxyl-m6.2mg/kgbwperday(90drat),benalaxyl-mnodata-notrequirednodata-notrequiredgenotoxicitynogenotoxicpotential,benalaxylandbenalaxyl-mlongtermtoxicityandcarcinogenicity(annexiia,point5.5)heartweightandclinicalchemistry,benalaxyl4.42mg/kgbwperday(2-yearrat),benalaxylnocarcinogenicpotential,benalaxylreproductivetoxicity(annexiia,point5.6)noreproductiveeffects.decreasedpupbodyweightgainandincreasedliverweightatparentaltoxicdoselevels,benalaxyl(rat).parentalandoffspring:5.33mg/kgbwperday(rat),benalaxylreproductivetoxicity:275mg/kgbwperday,benalaxyl(rat,highestdosetested)developmentalnodevelopmentaleffects,benalaxyl-m(rat)delayedossification(rat)andreducedbodyweight,benalaxyl(rabbit).maternalanddevelopmental:50mg/kgbwperday,benalaxyl(rabbit)maternal:50mg/kgbwperday,benalaxyl-m(rat)'", "j.efsa.2013.3166.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)20%(basedonradioactivitydetectedinurine,organ/tissuesandcarcass168hourspost-dosing;singleorallowdoseratstudy).nobiliarydatawereavailable.widelydistributed:highestconcentrationinfat,bone,andthefemalegenitalorgans(singleloworhighdoselevelandrepeatedlowdosinggroups),lungs(repeatedlowdosegroup)andliverandspleen(singleoralhighdosegroup).noevidenceforaccumulation.rapidandextensive(>75%within48hours),mainlyviafaeces(72-89%)andminorinurine(16-21%).extensivelymetabolised,involvedoxidationandhydrolysisreactions.majoridentifiedmetabolitesweretheurinaryan-1(4.2-5.8%ofthedose)andthefaecalf-2(11.9-19.9%ofthedose),f-3(4.7-10.5%ofthedose),andf-1(3.5-8.4%ofthedose).theparentcompoundwasdetectedmostlyinfaeces(1.0-15.0%oftheadministereddose)andatminoramountsinurine(<0.5%ofthedose).(animalsandplants)fenazaquinandtbpe(environment)fenazaquinacutetoxicity(annexiia,point5.2)ratld50134mg/kgbwt;r25rabbitld50>5000mg/kgbwratlc50>1.9mg/lairxn;r20non-irritantnon-irritantnonsensitizer(m&k)'", "j.efsa.2013.3181.pdf": "comanuale4-rev.4(september2005))rapporteurmemberstatemonthandyearactivesubstance(name)unitedkingdomjanuary2013ipconazolemammaliantoxicologyefsajournal2013;11(4):31812828impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>90%basedmostlyonbiliaryexcretionwithin48h(oraldoseof2mg/kgbw)distributionat120h,widelydistributedwithhighestresiduesinliverpotentialforaccumulationlimitedaccumulationonrepeatdosingrateandextentofexcretion>70%excretedwithin24h(mostlyinfaeces)metabolisminanimalsextensivelymetabolised(maxof2%ofdoseexcretedunchanged)withlargenumberofmetabolitefractions(eachmostly<10%ofdose)toxicologicallyrelevantcompounds(animalsandplants)parentandthefollowingmetabolites:triazolealanine(plants)triazoleaceticacid(plants)toxicologicallyrelevantcompounds(environment)noneacutetoxicity(annexiia,point5.2)ratld50oral888mg/kgbw(females)r22h302ratld50dermal>2000mg/kgbwratlc50inhalation>3.53mg/lskinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitiser(magnussonandkligman)shorttermtoxicity(annexiia,point5.3)target/criticaleffectskinreddening,lensopacity,reducedthymusweight(dog)hepatocytevacuolation(mouse)renalmineralisation(rat)relevantoralnoael1.5mg/kgbwperday(1-yeardog)<2mg/kgbwperday(90-daydog)4.4mg/kgbwperday(90-daymouse)r48/22h373'", "j.efsa.2013.3182.pdf": "7impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrat:rapid(tmax<1h);about75%basedonurinary(57-61%)andbiliary(17%)excretionwithin48hat10mg/kgbwmouse:about60%basedonurinaryexcretionwithin72h(biliaryexcretionnotinvestigated)at10&100mg/kgbwdistributionrat:oflimitedtissuesinvestigated,highestsystemiclevels(atcmaxandcmax)inplasma,liverandkidney.mouse:oflimitedtissuesinvestigated,highestsystemiclevels(at72h)inliverpotentialforaccumulationrat:noevidenceforaccumulationbasedonadmestudy.mouse:noevidenceatrealisticexposurelevels,butsloweliminationfromtheliverat1000mg/kgbw(notmeasuredinrats)willfavouraccumulationonrepeatedextremeexposuresrateandextentofexcretionrat:rapidandextensive(atleast96%)within48h;at10mg/kgbw,urine(60%),faeces(c.50%),bile(17%)mouse:rapidandextensive(100%)within48h;at10mg/kgbw,urine(60%),faeces(40%)metabolisminanimalsrat:limitedmetabolism.parentwasmaincomponentinurineandfaeces.2-desmethyl-xde-742(ca15%ofadministereddoseof10mg/kgbw)onlymetaboliteidentifiedmouse:notinvestigatedtoxicologicallyrelevantcompounds(animalsandplants)rat:parentcompoundand2-desmethyl-xde-742mouse:parentcompoundandmetabolite(s)toxicologicallyrelevantcompounds(environment)furtherdataarerequired.acutetoxicity(annexiia,point5.2)ratld50oral>2,000mg/kgbwratld50dermal>2,000mg/kgbwratlc50inhalation>5.12mg/l4h(nose-only)skinirritationslightlyirritating(noclassificationproposed)eyeirritationslightlyirritating(noclassificationproposed)skinsensitisationsensitiser(mandkmaximisation)r43'", "j.efsa.2013.3183.pdf": null, "j.efsa.2013.3197.pdf": "3chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiondataavailableoflimitedvalidity.nofurtherdatarequired.distributiondataavailableoflimitedvalidity.nofurtherdatarequired.potentialforaccumulationdataavailableoflimitedvalidity.nofurtherdatarequired.rateandextentofexcretiondataavailableoflimitedvalidity.nofurtherdatarequired.metabolisminanimalsdataavailableoflimitedvalidity.nofurtherdatarequired.toxicologicallyrelevantcompounds(animalsandplants)dataavailableoflimitedvalidity.nofurtherdatarequired.toxicologicallyrelevantcompounds(environment)dataavailableoflimitedvalidity.nofurtherdatarequired.acutetoxicity(annexiia,point5.2)ratld50oralnodataavailable-notrequiredratld50dermalnodataavailable-notrequiredratlc50inhalationnodataavailable-notrequiredskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnodataavailable-notrequiredshorttermtoxicity(annexiia,point5.3)target/criticaleffectdataavailableoflimitedvalidity.nofurtherdatarequired.relevantoralnoaelrelevantdermalnoaelrelevantinhalationnoaelgenotoxicity(annexiia,point5.4)dataavailableoflimitedvalidity.nofurtherdatarequired.'", "j.efsa.2013.3212.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)atleast28%,afterlowdose,48hafteradministration,basedonradiolabelrecoveredfromurine,bile,cagewashandcarcass(rat).atleast4.8%,afterhighdose,48hafteradministration,basedonradiolabelrecoveredfromurine,bile,cagewashandcarcass(rat).24hoursaftersingleorallowdose(10mg/kgbw),highestconcentrationsgi-tractanditscontents;intermediateconcentrationswereinfat,kidneys,liver,lungs,lymphnodes,pancreas,pituitary,skin,uterusandwholeblood.noevidenceofaccumulation.within24hca.75%oflowdosewasexcretedandca.40%ofhighdose;within120hca.95%wasexcreted,afteroralhighandlowdose,mainlyviafaeces(ca.87%).extensivelymetabolised(noparentcompoundinurine,2%parentcompoundoftotalradiolabelinfaecesand2.5%oftotalradiolabelinbile).(animalsandplants)acequinocyl(environment)acequinocylacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>2000mg/kgbwratlc50>0.84mg/lair/4h(aerosol,noseonly)t;r39/23stotse1-h370non-irritatantnon-irritatantsensitising(maximisationtest)xi;r43skinsens.1-h317shorttermtoxicity(annexiia,point5.3)target/criticaleffectblood(prolongationofbloodclottingtime,increasedplateletlevels)inrats,miceanddogs;'", "j.efsa.2013.3213.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)morethan67-71%(sodiumphosphonate)widelydistributed.highestresiduesseeninspleen,liverandkidneys(sodiumphosphonate)noaccumulationpotentialrapid;essentiallycompleteexcretionwithin7daysaftermultipleapplicationmainlyexcretedunchanged.minoramountsofphosphateanioninfaeces(sodiumphosphonate)(animalsandplants)parenttoxicologicallyrelevant(environment)parentacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbw(disodiumphosphonate)/ratld50>2000mg/kgbw(disodiumphosphonate)/ratlc50>5.8mg/l/4h(disodiumphosphonate)/notirritant(disodiumphosphonate)/notirritant(disodiumphosphonate)/notsensitising(locallymphnodeassay)(disodiumphosphonate)/shorttermtoxicity(annexiia,point5.3)target/rat:softfaeces,increasedwaterintake,increasedsodiumandcalciumexcretion,reducebwandfoodconsumption(disodiumphosphonate)400mg/kgbwperday(phosphonicacid)/nodata(notrequired)/nodata(notrequired)/notgenotoxic/'", "j.efsa.2013.3220.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption26-29%(xde-175-j),39-57%(xde-175-l)basedoncomparisonofplasmaaucsfollowingoralandivdosing(measureofbioavailabilityforallorgansexceptliver).80-90%basedon%doseexcretedinurinefollowingoraldosingplus%doseexcretedinfaecesfollowingivdosing(measureofbioavailabilityforliver).distributionatplasmacmax,highestconcentrationsingitract,lymphnodes,liver,lungs,adrenals,spleen.at7dayspostdose,highestconcentrationswereconsistentlyinfatandkidneys(xde-175-j)andfatandlymphnodes(xde-175-l).potentialforaccumulationpotentialforslowaccumulationoflowamountsbasedonoccurrenceoflysosomalvacuoles(probablyconsistingoflipidboundxde-175/metabolites)inrepeatdosestudies.rateandextentofexcretion85%excretedinfaeces(evidenceforsignificantbiliaryexcretion);majorityexcretedinfirst24hmetabolisminanimalshighlymetabolised(atleast60%dosemetabolised).mainpathways:glutathioneconjugationofparentandofn-demethyland0-deethylmetabolites,hydroxylationofparentxde-175-j.toxicologicallyrelevantcompounds(animalsandplants)spinetoramandmetabolitestoxicologicallyrelevantcompounds(environment)spinetoramacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(75j:25land85j:15l)ratld50dermal>5000mg/kgbw(75j:25land85j:15l)ratlc50inhalation>5mg/l(75j:25land85j:15l)(nose-only)skinirritationnoirritation(75j:25l)slightreversibleirritation(85j:15l)eyeirritationslightreversibleirritation(75j:25land85j:15l)skinsensitisationsensitiser(weak)inllna(75j:25l)non-sensitiserinllna(85j:15l)(r43)h317'", "j.efsa.2013.3229.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensive,assumedtobe100%(basedonurineexcretionafteroralandfaecesexcretion,indicatingbileexcretionafteripadministrationandreadacrosstostructurallysimilarcompounds)distributionextensivelydistributedpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid,66%inurineand28%viafaeceswithin48hfollowingoraladministration57%inurineand41%viafaeceswithin72hfollowingi.p.administration(indicatingexcretioninbile).metabolisminanimalscompletelymetabolised(traceamountsofparentcompoundinurine).metabolizedmainlythroughsidechainoxidation,andtoalowerextentthroughringhydroxylation(rat,oral).toxicologicallyrelevantcompounds(animalsandplants)1,4-dimethylnaphthalenetoxicologicallyrelevantcompounds(environment)1,4-dimethylnaphthaleneacutetoxicity(annexiia,point5.2)ratld50oral2730mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.16mg/lskinirritationslightly/moderatelyirritatingeyeirritationirritatingr36skinsensitisationnon-sensitising(llna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectreducedbodyweightgainandfoodconsumptionandplasmatriglyceridelevels.increasedrelativeliverweight,plasmacholesterollevels.clinicalsigns.relevantoralnoael13weekrat:32mg/kgbwperdayrelevantdermalnoaelnodata,notrequiredrelevantinhalationnoaelnodata,notrequiredgenotoxicity(annexiia,point5.4)notgenotoxiclongtermtoxicityandcarcinogenicity(annexiia,point5.5)'", "j.efsa.2013.3240.pdf": "chapter2.3impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption65%,basedonradiolabelinurine,bile,tissuesandcarcass(48h).distributionradioactivityconcentrationsintissueswerelow(0.6-2.1%ar),highestresiduesa.o.infat,adrenal,ovary,skin/hair.potentialforaccumulationevidenceforaccumulationinfattytissues.rateandextentofexcretionrapidandextensivewithin48h:mainlyviafaeces(55-97%),2-18%viaurineand0-12%viaco2.metabolisminanimalsextensivelymetabolised.noparentinbileandurine.cleavageofthedichloropropenylgroupandofthemethylenebridgebetweenpyridylanddichlorophenylrings.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>2.01mg/l(studynotsuitableforc&l)-nofurtherdatarequiredskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitiser(magnusson&kligman)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffecthaematologicalsystem(changesinwhitebloodcellparametersinrats;reducedmchvaluesindogs),liver(increasedweight,clinicalbiochemistryandhistopathologychanges;ratsandmiceanddogs),adrenal(increasedweightandvacuolation;dogs),ovary(increasedweightandvacuolation;rats)andlung(increasedweightandhistopathologychanges;dogs).reducedbodyweightgain(ratanddogs)relevantoralnoael13-week,rat,5.6mg/kgbwperday13-week,dog,10mg/kgbwperday'", "j.efsa.2013.3243.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)95%absorbed(ratstudy,2mg/kgbw)highestlevelsfoundinplasma,liverandkidneynoevidenceforbioaccumulationrapid,mainlyviaurine(90%within24hours)cleavageofestergroupando-demethylationof8-methoxygroup(animalsandplants)spirotetramat(environment)spirotetramatacutetoxicity(annexiia,point5.2)ratld50ratld50>2000mg/kgbwratld50ratld50>2000mg/kgbwratlc50ratlc50>4.183mg/lair/4hnotirritantirritantxi,r36sensitiserxi,r43shorttermtoxicity(annexiia,point5.3)thymusinvolution,braindilatation,decreasedt3,t452-weekdog:5mg/kgbwperday28-dayrat:1000mg/kgbwperdaynodata,notrequirednogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)bodyweightdecrease,bodyweightgaindecrease,liverandkidneyweight,alveolarmacrophagesinlungs,spermatiddegenerationintestes,germcellexfoliateddebrisinepididymis'", "j.efsa.2013.3253.pdf": "2impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabout80%basedonurinary(12.84%inmales,30.79%infemales)andbiliary(64.55%inmales,48.68%infemales)excretionwithin48hoursdistributionwidelydistributed;highestresiduesinliverandkidneysatoneortwohoursafteradministrationpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(approx.99%)within48hours,mainlyviabile(64.55%inmales,48.68%infemales),urine(12.84%inmales,30.79%infemales)andfaeces(16.63%inmales,15.55%infemales)metabolisminanimalsextensivelymetabolised(>90%);mainmetabolitesr2(n-[(1-methylethoxy)carbonyl]-l-valyl-3-(4-chlorophenyl))andr5(3-amino-3-(4-chlorophenyl)propionicacid);oxidationreactionsandcleavagereactiontoxicologicallyrelevantcompounds(animalsandplants)valifenalatetoxicologicallyrelevantcompounds(environment)noneacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>3.118mg/l-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationnon-sensitising(magnussonandkligman)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver:increasedweight,hepatocytevacuolation(mouse);hepatocytehypertrophy,cytoplasmaticinclusion(dog)relevantoralnoael90-daymouse:15.3mg/kgbwperday(males)90-dayrat:150mg/kgbwperday90-daydog:<50mg/kgbwperday(nonoaelcanbeestablished)-'", "j.efsa.2013.3269.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandalmostcompletedistributionextensive,highestlevelsinliverandkidney.potentialforaccumulationnonerateandextentofexcretionrapidandcomplete.>90%excretedin72hoursmetabolisminanimalsextensive-majormetabolites:pivalicacid,m2andm4toxicologicallyrelevantcompounds(animalsandplants)m3(plants)toxicologicallyrelevantcompounds(environment)m2possiblym3,m11,m52,m54,m55andm56pendingconfirmation,inthecontextofregulation1272/2008,oftheproposedclassificationandabsenceoffurtherinformationtodemonstratethatthesemetabolitesdonotqualifyforthesameclassificationastheparent.acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mk/kgbwratlc50inhalation4.63mg/litre(males)acutetox4;h332r20skinirritationirritant(humanexperiencedata)skinirrit2;h315r38eyeirritationirritant(rabbit)r36eyeirrit2;h319skinsensitisationmaximisation(mandk)-negativellnapositiveskinsens1a;h317r43respiratorytractirritationhumandatastotse3;h335r37shorttermtoxicity(annexiia,point5.3)target/criticaleffectkidney(rat)-tubulardilatation/basophilia/atrophygitracteffects(dog)relevantoralnoael100mg/kgbwperday(rat)25mg/kgbwperday(dog)relevantdermalnoael>1000mg/kgbwperday'", "j.efsa.2013.3270.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidly(cmax<1hour)butmoderately(~48-55%)absorbedbasedonurineandbiliaryexcretion.distributionrapidlyandevenlydistributed;higherlevelsinthelungs&fat(thiophenelabel),adrenals,thyroid(dihydrotriazolelabel)andnasalmucosa(autoradiography).potentialforaccumulationnopotentialforaccumulation;<1%oftheadministereddoseremainsintissuesat48hours.rateandextentofexcretionrapidlyexcretedinurine(~50%)andfaeces(~50%)withnegligibleexcretioninbile(~1.5%).excretionoftheabsorbeddosewasessentiallycompletewithin48hours.metabolisminanimalslimitedmetabolismintherat:91-92%excretedunchanged.limitedcleavageofthemolecule.toxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50ld50>2000mg/kgbw-ratld50ld50>2000mg/kgbw-ratlc50lc50>2.018mg/l(4-hour,noseonly)-non-irritant-reversible,mildirritant-noevidence(maximisationstudy)-short-termtoxicity(annexiia,point5.3)urinarytract(kidney&bladder):irritation,inflammationandhyperplasiaassociatedwithurolithiasis(rat,mouse,dog).sulfonamide-crystalluriainrat.117mg/kgbwperday(4000ppm):12-monthdog24.7mg/kgbwperday(400ppm):90-dayrat-nostudysubmitted:nonerequired-nostudysubmitted:nonerequired-'", "j.efsa.2013.3298.pdf": "5impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapid,23.5%(radioactivityfoundinbile,urine,liver,gitractwithoutcontentandcarcass)widelydistributedtobloodandmostoftheorgans/tissues.inliver,adrenalglandandfathigherlevelsweredetectedmoderateaccumulationpotential-especiallyinfemales-afterrepeateddosing,butwithaplateaureachedatearlyphasethemainrouteofexcretionwasviafaeces(>91%ofpostlastdosing.inurineaminorpartofradioactivitywasdetected(0.15-1.67%ofthedose)relativeintensivemetabolisminvolvingoxidationofthemethylgroupsandresultinginthealcohol,aldehydeandbenzoicacidderivativesofflubendiamide(malesrats,mice,dogs)infemaleratsthemetabolismwaslessintensive(nocapabilityofoxidizingthemethylmoiety).mostrelevantanimal-model:malerattoxicological(animalsandplants)parentcompound.(environment)acutetoxicity(annexiia,point5.2)ratld50>2000mg/kgb.w.(males&females)rabbitld50>2000mg/kgb.w.(males&females)ratlc50>0.0685mg/lair(mac,males&females)noskinirritant(malejapanesewhiterabbits)noeyeirritant(malejapanesewhiterabbits)noskinsensitiser(m&k,females)'", "j.efsa.2013.3341.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption50%(basedoncomparativeweakacids)distributionnodatanotrequiredpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionnodatanotrequiredmetabolisminanimalsnodatanotrequiredtoxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>5.13mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectnoadverseeffectsrelevantoralnoael28-drat:>2171mg/kgbwperday90-drat:>1420mg/kgbwperday(males),1752mg/kgbwperday(females)relevantdermalnoael21-drat>1000mg/kgbwperdayrelevantinhalationnoaelnodatanotrequiredgenotoxicity(annexiia,point5.4)s-abscisicacidhasnogenotoxicpotentiallongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnolong-termtoxicityand/orcarcinogenicitystudiesweresubmittedbytheapplicant.relevantnoaelcarcinogenicitys-abscisicacidisunlikelytoposeariskofcarcinogenicitytohumans'", "j.efsa.2013.3346.pdf": null, "j.efsa.2013.3352.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rat:50%within7days(basedonurinaryexcretionandlevelsintissues/carcass)rabbit(non-pregnant):77%within3days(basedonurinaryexcretionandlevelsintissues)rabbit(pregnant):83%within3days(basedonurinaryexcretionandlevelsintissues)rat:rapidlydepletedfromthebodyafteroraladministration,lowlevelsinthelimitedtissuesinvestigated.at168h,highestconcentrationsinskin(0.45%ofhighdose,probablyduetocontaminationbyfaeces/urine)andcarcass(0.26%ofhighdose).rabbit:limitedtissuesinvestigated.at72h,detectablelevelsonlyingitractandspleen.ratandrabbit:noevidenceofaccumulationrat(singlelowdose):49%excretedinurinewithin24h,42%excretedinfaeceswithin24h,bilenotinvestigated.rabbit(singledose):72-77%excretedinurinewithin24h,15-20%excretedinfaeceswithin24h,bilenotinvestigated.ratandrabbit:notmetabolised(animalsandplants)aminopyralid(environment)aminopyralidacutetoxicity(annexiia,point5.2)>5000mg/kgbw>5000mg/kgbw>5.5mg/lair/4h(noseonly)non-irritantirritanth318r41non-sensitiser(m&k)shorttermtoxicity(annexiia,point5.3)dog:stomach(inflammation),liver(hypertrophy)noadverseeffectsinratsandmice.'", "j.efsa.2013.3354.pdf": null, "j.efsa.2013.3373.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)oralabsorptionishighlyvariable(<1-33%)andisinverselyrelatedtodoselevel.oralabsorptionfromthedietmaybegreaterthanfollowinggavageandisalsoinfluencedbythedosingvehicle.relevantoralabsorptionvalue=17%relativelyrapid,withhighestlevelsinfat,muscle,liver,kidneyandplasmaat/nearbloodtmax.clearpotentialforaccumulationinfat.relativelyrapid.primarilyfaecal(85-151%)withlowlevelsinbile(0.2-4.7%),urineandcagewash(0.3-0.5%).atalowdoselevel,alargeproportionoftheabsorbedradioactivityremainsinthecarcassat168hours.limited,initiallybyhydroxylationofanilineorbenzonitrileringofthecentralhydrazinecarboxamidegroups,followedbyconjugation(animalsandplants)metaflumizone(environment)metaflumizoneacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbw-ratld50>5000mg/kgbw-ratlc50>5.2mg/l(nose-only,4h)-notirritating-slightlyirritating-skinnon-sensitising(gpmk)-shorttermtoxicity(annexiia,point5.3)dog:spleen/redbloodcellsandliverprematuresacrificesat60/40/30and30mg/kgbwperdayduetoclinicalsignsoftoxicity.rat:bodyweightchanges(inhalation);increasedcholesterol,thymusandlymphnodes(dermalexposure)6mg/kgbwperday(dog,3-and12-month)stot-re,cat.2,h373rat,90-day:100mg/kgbwperday-rat,3-month(noseonly):0.03mg/l,i.e.8.1mg/kgbwperday.rat,3-month(wholebody):<0.03mg/l-'", "j.efsa.2013.3425.pdf": "impactonhumanandanimalhealtheffectsonhumanhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations(annexiim5.2)noreportsofmedicalsurveillancewereavailable.however,theexperimentalresearchfacilitiesandcommercialfieldswheretheproducthasbeentestedsofarhavenotreportedclinicalcasesorpoisoningincidentsduringhandlingofstreptomyceslydicuswyec108.sensitisation(experienceinhumansandstudyresults:typeofstudy)nohypersensitivityincidentsduringproductionandtestingofstreptomyceslydicuswyec108hasbeenreportedsincethebeginningofcommercialactivities.toxicity,infectivity,pathogenicityafteracuteoralexposurenomortality.clinicalsignsincludeddiarrheaandpiloerection,butanimalswereasymptomaticbyday2.clearancehasnotbeenstudied.ld50ofthetechnicalgradeactiveingredientwyec108-episgreaterthan5050mg/kgbwinratsafteracuteinhalationexposurenomortality.clinicalsignsincludedslightpiloerection,butanimalswereasymptomaticbyday2.completeclearancebyday28.theacuteintratracheallc50isgreaterthan9.1x108cfu/animalafteracuteintraperitoneal/subcutaneousexposurenomortality.clinicalsignswereabsentinallanimals.completeclearancebyday28.theacuteintraperitonealld50isgreaterthan9.33x108cfu/animalgenotoxicity(annexiim5.3.5)negativeinamestest(butoflimitedrelevanceasthetestconditionsdonotpermitthedevelopmentandgrowthofthefungusandthepotentialmutagenicityoftheeventuallyproducedtoxinsisnottested)cellculturestudies(annexiim,point5.3.6)noperformednorrequiredsincestreptomyceslydicuswyec108isafunguswithoutanyknownmechanismforintracellularreplication.shorttermtoxicity/pathogenicity(annexiim,point5.3.7)waivedfirstaidmeasures,medicaltreatment(annexiim,point5.2.5)asageneralhygienicmeasureincaseofdirectcontactwithstreptomyceslydicuswyec108theproducerlistedthefollowingfirstaidinstructions:-ifinhaled,flushnosewithwater.-incaseofskincontact,washwithsoapandwater.seekmedicalattentionifirritationpersists.-incaseofeyecontact,flushwithwater'", "j.efsa.2013.3461.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid,50%basedonurinaryandbiliaryexcretionwithin48hdistributionwidelydistributed,highestratiosintheliverat4,10and24hourspotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandextensive,>80%within48hours.mainlyviafaeces(83-94%),andurine(0.2-2.5%).excretionviabileatlowdose:42.7to51.3%.metabolisminanimalsapproximately75%metabolised,mainlybyoxidationandhydroxylation(atleast14metabolites)toxicologicallyrelevantcompounds(animalsandplants)chromafenozidetoxicologicallyrelevantcompounds(environment)chromafenozideacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-mouseld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-rabbitld50dermal>2000mg/kgbw-ratlc50inhalation>4.68mg/lair/4h(wholebody)-skinirritationnon-irritanteyeirritationslightirritant-skinsensitisationnon-sensitising-shorttermtoxicity(annexiia,point5.3)target/criticaleffectliverhypertrophy(rodentonly),slight,regeneratinganaemia(all)relevantoralnoael90-day,dog:52mg/kgbwperday90-day,rat:193mg/kgbwperday90daymouse:625mg/kgbwperday52-weekdog:27mg/kgbwperday-relevantdermalnoaelnodata-notrequired-relevantinhalationnoaelnodata-notrequired-'", "j.efsa.2013.3469.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)oralabsorptionofacrinathrinisrapid(tmaxof4-12h)andextensive(71%within48h)widelydistributed:higheraffinityforthyroidandkidneys(earlyafterdosingonly)andadrenals,fat,ovaries,pancreasandliver(stillafter7days).longerpersistenceoftheradioactivecompoundinfattissues,butnosignificantbioaccumulationpotentialasterminalresiduesarelow.rapidexcretionofmetabolitesinurineandbile(respectivetotalexcreteddoseover48h:39%inintactrats,50%inbileduct-cannulatedrats).urinaryexcretionlowerincannulatedrats(20%ofthedoseover48h),suggestingthatbilemayplayaroleinabsorption,and/orenterohepaticrecirculation.rapidlyandcompletelymetabolised.significantfirstpasseffectintheliver.biotransformationincludeshydrolysis,hydroxylation,carboxylation,oxidationandfinalconjugationofsomecompounds(glycine-orsulpho-conjugation).(animalsandplants)acrinathrin(environment)acrinathrinacutetoxicity(annexiia,point5.2)ratld50cd/sdrats:>5000mg/kgbwhanwistarrats:>2000mg/kgbw-ratld50cd/sdrats:>2000mg/kgbwhanwistarrats:>2000mg/kgbw-ratlc501.21mg/l(wholebody,4hexposure,aerosol)xnr20nonirritant-slightlyirritant-notasensitizer(magnusson&kligman)-shorttermtoxicity(annexiia,point5.3)neurovegetativesystem:diarrhoea,vomiting,salivation(dog);dyspnoea,loweractivity,salivation(rats,mice).skin:scabs,sores,alopecia,hyperkeratosis,ulcerativecellulitis,epidermalnecrosis,acanthosis(rat,mouse);(triggeringhumanekillingforsomeanimals;xnr48/22)kidney:acutetubularnecrosis,papillarynecrosis,corticaltubulardegeneration(malerats);blood:leukocyte,lymphocyteandneutrophilcounts'", "j.efsa.2013.3493.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)approximately60%,basedonexcretionviabile(47-55%)andurine(5-10%)within48hourswidelydistributed,thehighestamountsofradioactivitywerefoundinthegastrointestinaltract,liver,fatandkidney;168hafteradministrationtissueresiduesbelowlimitofdetectionnone168hafteradministrationof2mg/kgbwtheextentofexcretionamountedto70-85%viafaecesand12-18%viaurine,eliminationhalflive6.1-8.9h,delayedeliminationofhighdose(400mg/kgbw),alowdosewasexcretedmorerapidlyinmales,ahighdosemorerapidlyinfemales.intensivelymetabolised:cleavageofthebenzylmoietyfromthepyrazoleringwithfurtheroxidation,oximehydrolysis,esterhydrolysis,otherpathwaysofmetabolismwere4-hydroxylationofthe5-phenoxyringandoxidationofthet-butylmoietytoxicological(animalsandplants)fenpyroximateandmetabolitem1(environment)fenpyroximateandmetabolitem1acutetoxicity(annexiia,point5.2)ratld50oral245mg/kgbw(f),480mg/kgbw(m)xn,r22ratld50dermal>2000mg/kgbwratlc50inhalation0.21mg/lair(m),0.33mg/lair(f)(noseonly,4h)t+,r26skinirritationnotirritatingeyeirritationirritating(basedonhumanexperience)xi,r36skinsensitisationsensitising(m&ktest)r43shorttermtoxicity(annexiia,point5.3)reducedfoodintake,decreasedbwgainandindogsdiarrhoea,salivation,emesis,bradycardiadog,1-year:1.5mg/kgbwperdaydog,90-day:<2mg/kgbwperdayrat,90-day:1.3mg/kgbwperdayrat,21-day:300mg/kgbwperday(systemic'", "j.efsa.2014.3237.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed(cmax2-6hours)atalowdoselevelof10mg/kgbw;50%oralabsorptionbasedonbiliaryandurinaryexcretion.lessrapidly(cmax12-24hours)andlessextensively(5%)absorbedatahighdoselevelof1000mg/kgbw.distributionrapidlydistributed;highestlevelsofradioactivityfoundintheliverandkidneys.evidenceforthebindingofametabolitetoredbloodcells.potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionrapidexcretion,predominantlyinthefaeces(80-98%infaecesand10-15%inurine).almostcompleteexcretionwithin120hours.metabolisminanimalstotalmetabolismofabsorbedamisulbrom,involvingcleavageofthesulphonylaminosidechainonthetriazolering,oxidativedebrominationorhydroxylation.furtherdebromination,cleavageofthesulphonylaminosidechainopeningoftheindoleringandglucuronideconjugationaswellaslimitedcleavageofthesulphonylbridgewereobserved.toxicologicallyrelevantcompounds(animalsandplants)amisulbrom,it-4toxicologicallyrelevantcompounds(environment)amisulbrom,it-4acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation>2.85mg/lair(mac)/4-hour(noseonly)-skinirritationnon-irritant-eyeirritationmildbutpersistentirritationr41*(dsd)h318(clp)skinsensitisationnoevidence(m&kmaximisationtest)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat,mouseanddog:liverandunspecifictoxiceffects(onbodyweight,foodconsumptionand/orfoodconversion)relevantoralnoael1-year,dog:100mg/kgbwperday90-day,mouse:119mg/kgbwperday'", "j.efsa.2014.3353.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptiontheoralabsorptionisrapid(tmaxwithin1h)andequaltoabout73%(basedonurineandbileexcretionandresiduesinthecarcass72hposttreatment),independentlyontheradiolabelposition.nodifferenceswereobservedbetweengenders,lowtohighdoseandsingletorepeateddoseexperiments.distributionwidelydistributed,withthehighestconcentrationfoundingastrointestinaltract;concentrationsfoundinliverandkidneyweretheonlyoneshigherthanwholebloodconcentrations.potentialforaccumulationnoevidenceofbioaccumulation..rateandextentofexcretionradioactivityisalmostcompletelyexcreted(ca90%)viaurineby24hpostdoseandviafaecesby48h.nodifferencesbetweengenders,lowtohighdoseandsingletorepeateddoseexperiments.metabolisminanimalsextensivelymetabolisedmainlyby:o-demethylation,n-demethylation,hydrolyticcleavageofthesulfamoylurealinkage,conjugationwithsulphateandglucuronicacid.toxicologicallyrelevantcompounds(animalsandplants)orthosulfamurontoxicologicallyrelevantcompounds(environment)orthosulfamuronandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(rats,miceandrabbits)ratld50dermal>5000mg/kgbwratlc50inhalation>2.190mg/lair(4h,nose-only).skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitising(guineapigmaximisationtest)'", "j.efsa.2014.3473.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption50%basedonurinaryexcretion,cagewashandtissueresiduesinratsatthedoselevelofca.3mg/kgbwwidelydistributed(peakconcentrationsinliverandkidneynoevidenceforaccumulationraterapidandextensive(>90%excretedwithin24h,approx40-50%viaurineand5060%viafaeces)extensivelymetabolisedbyhydrolysisbyplasmaandhepaticmicrosomalesterasesto2,4-dinitro-6-(meptylheptyl)phenol(2,4-dnmhp),sequentialcytochromep-450,alcoholdehydrogenaseandaldehydedehydrogenasemetabolism,carboxylation,fattyacid-oxidationandconjugation.primarymetabolitefoundintheratandmouseurinewas2,4-dinitro-6-(1-methylpentanoate)phenol(pk13rat,pk16,mouse),thesecondwas2,4-dinitro-6-(1-methylbutanoate)phenol)(pk9,rat;pk11mouse)(animalsandplants)de-126and4-ppisomerstoxicologicallyrelevant(environment)de-126and4-ppisomersacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation1.24and1.63mg/lair/4h,formaleandfemale(nose-only,particulateexposure)cat4h332skinirritationslightirritant-eyeirritationslightirritant-skinsensitisationsensitiser(llna)h317'", "j.efsa.2014.3485.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>98%(basedonurinary(7.4%)andbiliary(90.9%)excretionwithin48hours)distributionwidelydistributed,highestconcentrationsinkidneyandliverpotentialforaccumulationnopotentialrateandextentofexcretionrapidandextensively.65-80%viafaecesand16-35%viaurinemetabolisminanimalsextensivelymetabolisedbyphase-1oxidationandphase-2conjugationtoxicologicallyrelevantcompounds(animalsandplants)tebuconazoleandtriazolemetabolitestoxicologicallyrelevantcompounds(environment)tebuconazoleandtriazolemetabolitesacutetoxicity(annexiia,point5.2)ratld50oral1700mg/kgbw(f)h302ratld50dermal>2000mg/kgbwratlc50inhalation>5.093mg/l(noseonly,4h)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&ktest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectadrenals/hypertrophyofzonafasciculatecells(dogs)liverbloodsystemandadrenals(rats)relevantoralnoael3mg/kgbwperday(1yeardog)9mg/kgbwperday(90dayrat)relevantdermalnoael1000mg/kgbwperday(3weekrabbit)relevantinhalationnoael0.0106mg/l(3weekrat)genotoxicity(annexiia,point5.4)noevidenceforgenotoxicpotential'", "j.efsa.2014.3508.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptio40-60%basedonurinaryexcretionwithin5daysapparentlywidelydistributednosignificantaccumulationexpected>80-90%excretedwithin2-3days(approximatelyequallyinurineandfaeces).biliaryexcretionnotmeasured.moderatelymetabolised.mainmetabolites:n-demethylmetabolite(in-n7468)o-deethylmetabolite(in-n7469)(animalsandplants)ethametsulfuron-methylandmetabolites(environment)ethametsulfuron(in-a8768)andmetabolitesin-d5119,in-n7468,in-n7469,in-rxr81,in-rym15andin-r7558.acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwrabbitld50>2000mg/kgbwratlc50>5.7mg/l(4hnoseonlyexposuretodust)nonenotirritant(directive67/548/eec)irritant(regulation(ec)no1272/2008)h319skinsensitisnon-sensitisershorttermtoxicity(annexiia,point5.3)reducedserumsodium,reducedbodyweightgainandfoodefficiency(dog)noadverseeffectsinratsandmicerat90d:365mg/kgbwperdaymouse90d:686mg/kgbwperdaydog1yr:87mg/kgbwperdaynodataavailablenotrequirednodataavailablenotrequirednotgenotoxic'", "j.efsa.2014.3524.pdf": "pactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataprovidednodataprovidednodataprovidednodataprovidednodataprovided(animalsandplants)i)(z)-8-dodecen-1-ylacetateii)dodecylacetate(environment)i)(z)-8-dodecen-1-ylacetateii)dodecylacetateacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwbasedonbridgingfromothersclpacetates:(e/z)-8-dodecen-1-ylacetate,(z)-9-dodecen-1-ylacetate,(e,z)-7,9-dodecadien-1-ylacetate,(z)-9-tetradecen-1-ylacetate,(z)-11-tetradecen-1-ylacetate,(z,z)-7,11-hexadecadien-1-ylacetate,(z,e)-7,11-hexadecadien-1-ylacetateratld50dermal>2000mg/kgbwbasedonbridgingfromothersclpacetates:(z)-9-tetradecen-1-ylacetate,(z)-11-tetradecen-1-ylacetate,(z,z)-7,11-hexadecadien-1-ylacetate,(z,e)-7,11-hexadecadien-1-ylacetateratlc50inhalation>5mg/lair/4hwholebodyexposurebasedonbridgingfromothersclpacetate:(z)-9-tetradecen-1-ylacetate,(z)-11-tetradecen-1-ylacetate,(z,z)-7,11-hexadecadien-1-ylacetate,(z,e)-7,11-hexadecadien-1-ylacetateskinirritationirritantbasedonbridgingfromothersclpacetate,andtakingintoconsiderationtheworstcaseresults:(e,z)-7,9-dodecadien-1-ylacetater38eyeirritationnon-irritantbasedonbridgingfromothersclpacetate:'", "j.efsa.2014.3525.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)nodataprovidednodataprovidedpotentialforaccumulatnodataprovidednodataprovidednodataprovided(animalsandplants)z,z,z,z-7,13,16,19-docosatetraen-1-ylisobutyratetoxicologicallyrelevantcompoun(environment)z,z,z,z-7,13,16,19-docosatetraen-1-ylisobutyrateacutetoxicity(annexiia,point5.2)ratld50oralnodataprovidedratld50dermalnodataprovidedratlc50inhalationnodataprovidedskinirritationnodataprovidedeyeirritationnodataprovidedskinsensitisationnodataprovidedshorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataprovidedrelevantoralnoaelnodataprovidedrelevantdermalnoaelnodataprovidedrelevantinhalationnoaelnodataprovidedgenotoxicity(annexiia,point5.4)nodataprovidedlongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataprovidedrelevantnoaelnodataprovidedcarcinogenicitynodataprovided'", "j.efsa.2014.3526.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabnodataprovidednodataprovidednodataprovidednodataprovidednodataprovided(animalsandplants)(z)-13-hexadecen-11-yn-1-ylacetate(environment)(z)-13-hexadecen-11-yn-1-ylacetateacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalationnodataprovidedskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnodataprovidedshorttermtoxicity(annexiia,point5.3)target/criticaleffectnodataprovidedrelevantoralnoaelnodataprovidedrelevantdermalnoaelnodataprovidedrelevantinhalationnoaelnodataprovidedgenotoxicity(annexiia,point5.4)nodataprovidedlongtermtoxicityandcarcinogenicity(annexiia,point5.5)target/criticaleffectnodataprovidedrelevantnoaelnodataprovidedcarcinogenicitynodataprovided'", "j.efsa.2014.3540.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rabbits:60%basedonurinaryexcretion.lowerabsorptionoccurredathighdoselevelwidelydistributed.highestresiduelevelinliver.nopotentialforaccumulation>95%oftheadministereddoseeliminatedatthelowestdose(10mg/kgbw)over168h.15-30%viaurineand80-73%viafaeces(male-femalerats);biliaryexcretionaccountedforapprox30-20%ofadministereddose(male-femalerats)limited;oxidationanddegradationoftheisoxazolineringoccurred(animalsandplants)topramezone(environment)topramezoneandmetabolitem670h05acutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbwratld50>2000mg/kgbwratlc50>5.05mg/lair/4h,head-noseexposuretodustaerosolnonirritanteyeirritationnonirritantnonsensitising(maximisationtestm&k)shorttermtoxicity(annexiia,point5.3)opacity,cornealcloudingvascularisationandchronickeratitis),pancreas(diffusedegeneration,necroticexocrinecells,lymphoidcellinfiltration)hypertrophy)90-dayrat:1.1mg/kgbwperday90-daymouse:2289mg/kgbwperday1-yeardog:2.9mg/kgbwperday28-dayrat:100mg/kgbwperdaynodatanotrequired'", "j.efsa.2014.3541.pdf": "pactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)>80%,basedonurinaryexcretion,cagewash,carcassandtissuesresidueswithin24hwidelydistributed,highestvalueinblood.metobromuronseemstoassociatewithbloodcellularcomponentnoevidenceforaccumulationrapidandextensive>90%within72h,mainlyviaurine(75%)within24h,10%viafaecesmetcompletedegradation,n-demethylation/n-demethoxylation,phenylringhydroxylationandconjugation(animalsandplants)metobromuron(environment)metobromuronacutetoxicity(annexiia,point5.2)ratld501000-2000mg/kgbw(femalerat)1290-2150mg/kgbw(malemice)acutetox4,h302ratld50>3000mg/kgbwratlc50>1.6mg/lair/4h,noseonlyexposure(highestattainableconcentration)non-irritantnon-irritantsensitiser(magnusson&kligman)skinsens,h317shorttermtoxicity(annexiia,point5.3)bloodsystem:regenerativehaemolyticanemia,bodyweighteffects(allspecies)rat:spleen,bonemarrowmouse:spleendog:liver,kidney,spleen,bonemarrow28-day,rat:<2.7mg/kgbwperday28-day,mouse:<13.8mg/kgbwperday1-year,dog:1.59mg/kgbwperdaystotre2,h37328-day,rat:40mg/kgbwperdaynodatanotrequired'", "j.efsa.2014.3560.pdf": "8impactonhumanandanimalhealthendpointsareforstudieswithgamma-cyhalothrinunlessstatedotherwise.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextent[lambda-cyhalothrin]relativelyrapidabsorption,variableresultsobtainedpendingonstudyconditions(radiolabel,vehicle,dose,etc.):inman5064%oralabsorptionbasedontheexcretionofametabolitedmcpa(tfmca)inurine;indog:50%absorptionbasedonplasmakineticscomparisonbetweenoralandintravenousroutes;inrat25%basedonurineexcretion.[lambda-cyhalothrinandcyhalothrin]rapidlyandextensivelydistributed,withhighestlevelsinfat.po[lambda-cyhalothrinandcyhalothrin]accumulationinfat:half-lifeof23-30.5daysforthedeclineofresiduesinadiposetissue.[lambda-cyhalothrin]rapidexcretioninurineandfaeces;90%within48hours.[lambda-cyhalothrinandcyhalothrin]extensivemetabolismviaestercleavageandconjugation.(animalsandplants)gamma-cyhalothrin(environment)gamma-cyhalothrinacutetoxicity(annexiia,point5.2)ratld5055mg/kgbwh301ratld501643mg/kgbwh312ratlc500.0282-0.0402mg/lair/4h(noseonlyaerosolexposure)h330mildirritant-irritant,severesystemictoxicityuponocularadministrationprecludesfullinvivoeyeirritationtestingopenstrongsensitiser(m&k)h317shorttermtoxicity(annexiia,point5.3)target/criticaleffclinicalsigns(neurologicaleffects)inratanddog,livertoxicityanddecreasedbodyweightgain(rat)90-day,rat:2.6mg/kgbwperday[gamma-h372'", "j.efsa.2014.3583.pdf": "mpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionnodata,considerednotnecessarydistributionnodata,considerednotnecessarypotentialforaccumulationnodata,considerednotnecessaryrateandextentofexcretionnodata,considerednotnecessarymetabolisminanimalsnodata,considerednotnecessarytoxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)noneacutetoxicity(annexiia,point5.2)ratld50oralnodata.nohumansafetyconcernsareknownorexpected.ratld50dermalnodata,considerednotnecessaryratlc50inhalationnodata,considerednotnecessaryskinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitizer(llna)inhalationsensitisationpositivecasesofrespiratorysensitisationreportedinhumansexposedtosaccharomycescerevisiae.resp.sens.1.h334shorttermtoxicity(annexiia,point5.3)target/criticaleffectnodata.nohumansafetyconcernsareknownorexpected.relevantoralnoaelnodata,considerednotnecessaryrelevantdermalnoaelnodata,considerednotnecessaryrelevantinhalationnoaelnodata,considerednotnecessarygenotoxicity(annexiia,point5.4)nodata.nohumansafetyconcernsareknownorexpected.'", "j.efsa.2014.3624.pdf": "243.impactonhumanandanimalhealthmedicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(oecddatapointiim5.1,5.2)noadversehealtheffectsobservedamongemployeesattheproductionsiteofbacillusamyloliquefacienssubsp.plantarumstraind747duringlasttwoyearssensitisation:(oecddatapointiim5.3.1&iiim7.1.6)sensitiser(nostudiesavailable,classificationbasedongeneralassumptionsformicro-organisms)acuteoralinfectivity,toxicityandpathogenicity(oecddatapointiim5.3.2&iiim7.1.1)ratld50oral:>5000mgproduct/kgbw(2.5x1011cfu/kgbw)ratld50oral:>7.7x108cfu/kgbw;noevidenceofadverseeffects,colonisationorinfectivity.acuteintratracheal/inhalationtoxicity,pathogenicityandinfectivity:(oecddatapointiim5.3.3&iiim7.1.3)ratld50intratracheal:>5.9x108cfu/kgbw;noevidenceofadverseeffects,colonisationorinfectivity.acuteintravenous/intraperitonealinfectivity:(oecddatapointiim5.3.4&iiim7.1.2)ratld50intravenous:>6.7x107cfu/kgbw;noevidenceofadverseeffects,colonisationorinfectivity.sporesstilldetectableinliverandspleenatendofstudyonday60,butclearlydeclining.genotoxicity:(oecddatapointiim5.3.5)nodata.furtherdatamayberequiredpendingontheidentification/quantificationoftoxins/secondarymetabolites.cellculturestudy:(oecddatapointiim5.3.6)nodatanotrequiredinformationonshort-termtoxicityandpathogenicity:(oecddatapointiim5.3.7)nodata,furtherdatamayberequiredpendingontheidentification/quantificationoftoxins/secondarymetabolitesdermaltoxicity:(oecddatapointiiia7.1.2)ratld50dermal:>5050mgpreparation/kgbwcorrespondingto>2.53x1011cfu/kgbw;noevidenceofadverseeffects,colonisationorinfectivity.specific-toxicity,pathogenicityandinfectivity:(oecddatapointiim5.5)nodatanotrequiredgenotoxicityinvivostudiesingermcells:(oecddatapointiim5.5.3)nodata.furtherdatamayberequiredpendingontheidentification/quantificationoftoxins/secondarymetabolitesreferencevaluesexposure(operator,workers,bystander,consumer):(oecddatapointiim6.1,iiim7.2,7.3and8.0)operator,worker,residentandbystanderexposureestimatestothemicroorganismarenotneededworkerriskassessmenttosecondarymetabolites/toxinscannotbefinalisedaoel:notnecessaryforthemicroorganism-notpossibletobederivedbasedontheavailabledataadi:notnecessaryforthemicroorganism-notpossibletobederivedbasedontheavailabledataarfd:notnecessaryforthemicroorganism-notpossibletobederivedbasedontheavailabledata'", "j.efsa.2014.3677.pdf": "efsajournal2014;12(5):367745impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrelativelyrapidabsorption,variableresultsobtainedpendingonstudyconditions(radiolabel,dose,etc.):inman:50-64%(basedonurineexcretionofthemetabolite(tfmca(metabolitexi).inrat:25%(basedonexcretioninurine).indog:50%(basedoncomparisonofplasmakineticsbetweenoralandintravenousroute).distributionrapidlyandextensivelydistributed,withhighestlevelsinfat.potentialforaccumulationaccumulationinfat:half-life:23-30.5daysforthedeclineinadiposetissue.rateandextentofexcretionrapidexcretioninurineandfaeces;90%within48hours.metabolisminanimalsextensivelymetabolised,mainlybycleavageofesterbondandfurthertransformationtoconjugatedmetabolitestoxicologicallyrelevantcompounds(animalsandplants)lambda-cyhalothrintoxicologicallyrelevantcompounds(environment)lambda-cyhalothrinacutetoxicity(annexiia,point5.2)ratld50oral56mg/kgbw(rat)19.9mg/kgbw(mouse)t;r25(rat)/t+;r28(mouse)h300(mouse)/h301(rat)ratld50dermal632mg/kgbwxn;r21h311ratlc50inhalation0.066mg/lair(4hoursexposure,nose-only)t+;r26h330skinirritationnon-irritanteyeirritationslightirritantskinsensitisationskinsensitiserbasedonreadacrossfromgamma-cyhalothrin(presentinlambda-cyhalothrin)andcyhalothrin(containinglambda-cyhalothrin)studiesxi;r43h317'", "j.efsa.2014.3679.pdf": "3.impactonhumanandanimalhealtheffectsonhumanhealth(annexiim5;iiim7)medicaldata,surveillanceandobservationsnotinfectiousallergicdiseaseswerereportedinopenliterature.sensitisation(experienceinhumansandstudyresults;typeofstudy):noincidenceduringproductionandtestinghasbeenreported.sensitiser(noreliablestudiesavailable,classificationbasedongeneralassumptionsformicroorganisms)acutetoxicity,pathogenicityandinfectivenessacuteoraltoxicity,pathogenicityandinfectivenessld50>1.7x106cfu/rat.noevidenceofadverseeffects,colonisationorinfectivity.acuteintratrachealtoxicity,pathogenicityandinfectiveness:ld50>106cfu/rat.noevidenceofadverseeffects,colonisationorinfectivity.intraperitonealsingledoseld50>1.6x107cfu/rat.noevidenceofadverseeffects,colonisationorinfectivity.genotoxicitynegativeamestest.furtherdatamayberequiredpendingontheidentification/quantificationoftoxins/secondarymetabolites.cellculturestudy:notestsperformed;notnecessary.informationonshorttermtoxicityandpathogenicitynodata.furtherdatamayberequiredpendingontheidentification/quantificationoftoxins/secondarymetabolites.specifictoxicity,pathogenicityandinfectivenessstudies(annexiim,point5.5)dermaltoxicity:transientirritationcompletelyreversiblebyapplicationof2gblastospores+mycelium/rabbiteyeirritationnotirritatingat0.1mlblastosporesandmycelium/rabbitreferencevaluesexposurescenarios(includingmethodofcalculation)applicationmethod:wg20%a.s.;2.109cfu/g;1-3kgformulation/hasprayconcentration:100gformulation/hl;1-3applications/season.operator:operatorexposureestimatestothemicroorganismarenotneeded.eachfermentationbrothshouldbecheckedtoensurethatnotoxins/secondarymetabolitesarepresentintheproducttoexcludetopotentialriskforoperatorstosecondarymetabolites/toxins.workers:workerexposureestimatestothemicroorganismarenotneededworkerriskassessmenttosecondarymetabolites/toxinscannotbefinalisedbystanders/residents:sincetheproductisintendedforuseonlyinglasshouses,thepossibilityofinadvertentpresenceofbystanders/residentscanbereasonablyexcluded.aoel:notnecessaryforthemicroorganism.openforthesecondarymetabolites/toxinsadi:notnecessaryforthemicroorganism.openforthesecondarymetabolites/toxinsarfd:notnecessaryforthemicroorganism.openforthesecondarymetabolites/toxins'", "j.efsa.2014.3691.pdf": "5impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidandextensive>90%widelydistributed.residuesmainlyfoundintheliver,andkidneys(lowdose,singleandrepeatedadministration)residuesalsofoundinthebloodandbloodrichtissues(lungs,musclesandspleen)forthehighdosenoevidenceforaccumulationalmosttotallyeliminatedwithin24hoursviaurine(90%)informoftheacidmetabolitecga210007>90%metabolisedtoacid,mainlyinliver.metabolismindependentfromsex,dose,pre-treatmentmechanisticstudy:hydrolysisratesoftheacibenzolar-s-methylthioestertoitscorrespondingacidcga210007(nmol/min/mgprotein):humanliver(409)>ratliver(64)>ratskin(41)>humanskin(11.2)>ratplasma(0.15)>humanplasma(0.04)(animalsandplants)acibenzolar-s-methyl(environment)acibenzolar-s-methylacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbw(rat)>1250<2000mg/kgbw(mousemicronucleustest)ratld50>2000mg/kgbwratlc50>5mg/lair/4h(nose-only)nonirritatingnonirritatingsensitizing(m&k)h317'", "j.efsa.2014.3692.pdf": "toxicologyimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabsorptionwas>95%.orallyadministeredsulfoxaflorwasrapidlyabsorbedwithoutanyapparentlagtimebasedoncmaxtimesof0.5-1hr(5mg/kg)and2hr(100mg/kg).distributionwidelydistributed.potentialforaccumulationremainingintissues7daysafterasingleoral/i.v.orrepeated(15-dailydoses)oraldosingregime.rateandextentofexcretionrapidandextensiveexcretionobservedviaurine(77-90%)within24hours,independentofdose.intotal,8699%ofthedoseiseliminatedwithin24hours.metabolisminanimalssulfoxaflorwaspoorlymetabolised.morethan93%oftheeliminatedradioactivityinurineandfaeceswasparentsulfoxaflor.onlyonemetaboliteexceeded1.0%,aurinaryglucuronideconjugateofthesulfoxaflormetabolitex11721061,whichaccountedfor24%oftheadministereddose.toxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50oral1000mg/kgbwacutetox.4;h302[xn;r22]ratld50dermal>5000mg/kgbwratlc50inhalation>2.09mg/lskinirritationnotaskinirritant.eyeirritationnotaneyeirritant.skinsensitisationnotaskinsensitiser(llna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat/mouse:liver(increasedweightwithhistopathologyincludingevidenceoftoxicity)relevantoralnoael100ppm(6.36mg/kgbwperday):rat90-daydietary.'", "j.efsa.2014.3717.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)relativelyrapid;tmax3-4hours;oralabsorption50%basedonurinaryexcretion(within24h)andtissueconcentrations.widelydistributed,mainlyinwellperfused(liver,kidney,heart)orlipophilic(ovaries,fat,skin)organs.nobioaccumulationafterrepeatedadministration.rateandextentofexcreti75%excretedin24hours,inurineandfaeceshydrolysisofesterbondtogivecyclopropanecarboxylicacidandphenoxybenzylmoieties;subsequentoxidationandorconjugation.(animalsandplants)beta-cypermethrin(environment)beta-cypermethrindatabridgedfromcypermethrinacutetoxicity(annexiia,point5.2)ratld5093mg/kgbwt;r25h301rabbitld50>5000mg/kgbwratlc501.06mg/lxn;r20,r37*h332;h335*notirritatingpersistentdiscolourationxi;r41h318notsensitising*consistentwithothercypermethrinsshort-termtoxicity(annexiia,point5.3)rat:clinicalsignsofneurotoxicity,decreasedbodyweightandserumglucosemouse:clinicalsignsofneurotoxicity,decreasedbodyweight,clinicalchemistrydog:consistentbodyweightgainreductionrrat(90-day):<10mg/kgbwperdaymouse(28-day):63.3mg/kgbwperdaydog(1-year):0.3mg/kgbwperdaynodatasubmittednodatasubmitted'", "j.efsa.2014.3736.pdf": "classificationandproposedlabellingwithregardtophysicalandchemicaldata(annexiia,point9andannexiiia,point11.3)activesubstance:noneformulation500g/kg:nonechapter3(impactonhumanandanimalhealth)absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption83%basedonurinaryandbiliaryexcretionsintheratdistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidlyexcreted,30-40%viaurineand60%viafaeceswithin7daysmetabolisminanimalsextensivelymetabolised;hydroxylationofcyclohexeneringandcleavageoftheimidelinkagetoxicologicallyrelevantcompounds(animalsandplants)parenttoxicologicallyrelevantcompounds(environment)parentacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>3.93mg/l(4-hours,wholebody)skinirritationnon-irritanteyeirritationminimallyirritating.notclassified.skinsensitisationnon-sensitising(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectanaemia(rats)hepatotoxicity(rats,miceanddogs)relevantoralnoael2.2mg/kgbwperd;90-drat10mg/kgbwperd,90-dand1y,dogrelevantdermalnoael300mg/kgbwperd(21-drat)relevantinhalationnoaelnodata,nostudyrequired'", "j.efsa.2014.3742.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyandalmostcompletelyabsorbeddistributionrapidlydistributedtoalltissues;highestlevelinliverpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretioneliminatedwithin2days;mainlyinurine(70-95%within24h)metabolisminanimalslimitedmetabolism(egthroughglutathione-s-transferase).minormetabolitesincludingmercapturicacidderivativesand1,2,4-triazolederivatives.toxicologicallyrelevantcompounds(animalsandplants)amitroletoxicologicallyrelevantcompounds(environment)amitroleand1,2,4-triazoleacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2500mg/kgbwratlc50inhalation>0.439mg/l(highestattainableconcentration,4hexposure)skinirritationnotirritanteyeirritationslightlyirritantskinsensitisationnotsensitiser(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectthyroid(rat,dog,monkey)stot-re2h373relevantoralnoael0.1mg/kgbwperday(90-drat)0.3mg/kgbwperday(1-ydog)relevantdermalnoael100mg/kgbwperday(28-drat)relevantinhalationnoael0.1mg/l(noec)(28-drat)genotoxicity(annexiia,point5.4)noevidenceofagenotoxicpotentialrelevanttohumans'", "j.efsa.2014.3744.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapid,>90%absorbedwidelydistributedintoorgansatlowlevels(highestresiduefoundinliverandkidneys)nopotentialforaccumulation(8995%eliminatedwithin48hours)rapidlyeliminatedmainlyinfaeces(56-79%infaeces,1633%inurineinrepeatedlowdosestudywithin48hours).extensiveenterohepaticrecirculationwith>90%excretionviabile.extensivelymetabolised,mainlyconjugationandhydroxylation(animalsandplants)fenhexamid(environment)fenhexamidacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>5000mg/kgbwratlc50>5mg/lair/4h(dustaerosol,noseonly)non-irritantnon-irritantskinsensitisnotaskinsensitiser(buehlerandm&k)shorttermtoxicity(annexiia,point5.3)dog:reductioninerythrocytesandpcv,increasedheinzbodies,clinicalchemistryindicatorsoflivertoxicity(ap)andlivereffectsathigherdosesrat:reductioninreticulocytes,kidneyeffectsathigherdosesmouse:reductioninreticulocytesandkidneyeffects;livereffectsathigherdoses1-year,dog:19.2mg/kgbwperday90-day,rat:38mg/kgbwperday90-day,mouse:52mg/kgbwperday21-day,rabbit:1000mg/kgbwperday28-day,rat(nose-only):0.07mg/lair(approximately20mg/kgbwperday,highdoseslimitedbyhighparticleoverload)'", "j.efsa.2014.3764.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)rateandextentoforalabsorption>90%oflowdose(10mg/kgbw);35-40%ofhighdose(1000mg/kgbw),basedonurinaryexcretionandcagewash,5daysafteradministrationdistributionalltissues;thelivercontainedthehighesttracesofradioactivity(<0.13%oftheadministereddose)potentialforaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid:>80%and>90%within24and48hourspost-dose,respectively.themajorroutewasurinaryatthelowdose(77-87%)andviathefaecesatthehighdose(55-63%).excretawerecollectedfor5daysbut>90%oftheadministereddosewasrecoveredwithin3days(72hours).therateofexcretioninurinerevealedabiexponentialeliminationprocess.themeanhalf-lifefortheinitialphasewasapproximately2.2-5.8hoursandfortheterminaleliminationphasewas21.4-56.7hoursforallgroups.metabolisminanimalsupto88%ofthedoseexcretedasparent.demethylationandpyrimidineringhydroxylationoccurtoalimitedextent(cleavageofthesulfuronylureabondisverylimited)toxicologicallyrelevantcompounds(animalsandplants)sulfosulfurontoxicologicallyrelevantcompounds(environment)sulfosulfuronacutetoxicityratld50>5000mg/kgbwratld50>5000mg/kgbwratlc50>3.0mg/lair/4h(head-noseonly)nonirritanttransient,slighttomoderatelyirritantnotsensitising(magnusson&kligman)short-termtoxicitytarget/criticaleffectmice:reducedbodyweightandreducedlevelsofalprats:reducedbodyweight,haematology/reducedlevelsofaptt,renalandbladderpathologyinconjunctionwithkidneyand/orbladdercalculidogs:clinicalchemistry/elevatedlevelsofastandalt,urinarytract(kidneys,bladder,ureters)pathologyinconjunctionwithsubstance-relatedcalculiformationrelevantoralnoael28-day,mice:186mg/kgbwperday'", "j.efsa.2014.3787.pdf": "6impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)40-60%basedonurinaryexcretionwithin5daysdistapparentlywidelydistributednosignificantaccumulationexpected>80-90%excretedwithin2-3days(approximatelyequallyinurineandfaeces).biliaryexcretionnotmeasured.moderatelymetabolised.mainmetabolites:n-demethylmetabolite(in-n7468)o-deethylmetabolite(in-n7469)(animalsandplants)ethametsulfuron-methylandmetabolitestoxicologicallyrelev(environment)ethametsulfuron(in-a8768)andmetabolitesin-d5119,in-n7468,in-n7469,in-rxr81,in-rym15andin-r7558.acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwrabbitld50>2000mg/kgbwratlc50>5.7mg/l(4hnoseonlyexposuretodust)nonenotirritant(directive67/548/eec)irritant(regulation(ec)no1272/2008)h319non-sensitisershorttermtoxicity(annexiia,point5.3)reducedserumsodium,reducedbodyweightgainandfoodefficiency(dog)noadverseeffectsinratsandmicerat90d:365mg/kgbwperdaymouse90d:686mg/kgbwperdaydog1yr:87mg/kgbwperdaynodataavailablenotrequirednodataavailablenotrequirednotgenotoxic'", "j.efsa.2014.3801.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionextensive(>80%),rapidlyandextensivelymetabolisedafteradministrationofsingleorallowandhighdosedistributionevenlydistributed,highestamountingi-tract,plasma,liverandkidneypotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion>90%within96hours,>80%viaurineinmalesandfemalesmetabolisminanimalsextensivelymetabolised,hydrolyzationtopyridafol(mainmetabolite);glucuronicandsulfateacidconjugationtoxicologicallyrelevantcompounds(animalsandplants)pyridateandpyridafoltoxicologicallyrelevantcompounds(environment)pyridateacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.37mg/l(maximumattainableconcentration),4hours,head/noseexposureskinirritationirritatingcat.2h315eyeirritationnotirritatingskinsensitisationsensitising(m&kandmodifiedbhlertest)cat.1bh317shorttermtoxicity(annexiia,point5.3)target/criticaleffectclinical(neurotoxic)signs,reducedbodyweight,liver(increasedweightandhistopathologicalchanges),kidney(increasedweight),haematologicalchangesrelevantoralnoael90dayrat:62.5mg/kg52weekdogs:30mg/kgbwperd90daydog:40mg/kgbwperdh370h373relevantdermalnoael21dayrat:1000mg/kgbwperdrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2014.3805.pdf": "pactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)poorbutmoderate-rapidlyabsorbed,approximately18%absorbedat10mg/kgbw(biliaryandurinaryexcretion),5%at250mg/kgbw(urinaryexcretion),2%at1000mg/kgbw,cmax27hoursat10mg/kgbwwidelydistributed;highestresiduesdetectedinliverafter5daysnosignificantaccumulation.approximately0.1%appliedradioactivityintotaltissueresiduesafter5daysrapidexcretion,approximately90%within24h:60-85%viafaeceswithin24h,213%viaurinewithin24h(lowdose).greaterurinaryexcretionformethoxyphenylringmetabolimitedmetabolism.6980%excretedunchanged,approximately20%(asyetmostlyunidentified)metabolites.widerrangeofurinarymetaboliteswithmethoxyphenyllabel(animalsandplants)flutianil(environment)flutianiloc56635,oc53276(basedonclassificationofparentsuggestedbytheefsapeerreview)acutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbw-ratld50>2000mg/kgbw-ratlc50>5.17mg/lair/4h(nose-only,aerosol)-non-irritant-non-irritant-notasensitiser(m&k)-shorttermtoxicity(annexiia,point5.3)target/criticalrat:liver:increasedweight,hypertrophy,decreasedprothrombintime&plasmabilirubin.adrenals:increasedweight.kidneys:-globulinnephropathy(maleratonly;irrelevanttohumans).mouse:atrophyofseminiferoustubules.dog:noadversefindingsin1-yeardogupto1000mg/kgbwperday,butatrophyofseminiferoustubulesandprostatecellinfiltratein90-daystudy.90-day,rat:122mg/kgbwperday90-day,mouse:138mg/kgbwperday-'", "j.efsa.2014.3812.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidandalmostcomplete(>90%within48h)higherconcentrationsinkidneyandliver;alsodetectedinbrainandcerebrospinalfluid(csf)lowpotentialforaccumulationrat:mainrouteofexcretionviaurine(>90%within48h),upto11%excretionviafaecesdog:speciesspecificlowcapacitytoexcreteweakorganicacids(suchas2,4-d)viaurine>97%excretedunchanged,twominormetabolites(2,4-dconjugates)(animalsandplants)2,4-d(environment)2,4-dacutetoxicity(annexiia,point5.2)ratld50>300&<2000mg/kgbwh302ratld50>2000mg/kgbw-ratlc50>1.79mg/lair/4h(wholebody,highestattainableairconcentration)-nonirritant-severeirritanth318nonsensitiser(buehler3-and9-inductions;llna)-short-termtoxicity(annexiia,point5.3)target/criticaleffectvacuolation,degenerationdescendingpctinflammation,kupffercell.at80mg/kgbwperday:moribundity.parenchymalcellpigmentation,liversinusoidectasia(1-year90-dayrat,2,4-d:5mg/kgbwperday90-daymouse,2,4-d:15mg/kgbwperday90-daydog,2,4-db:2.5mg/kgbwperday1-yeardog,2,4-db:2.04mg/kgbwperday21-day,rabbit,2,4-d:kidneyweight)euh066'", "j.efsa.2014.3814.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandtoahighdegree.cmax2h,70%oralabsorptionat10mg/kgbwdistributionextensive;attmax,highestlevelsinliver,gastro-intestinaltract,adrenals,thyroidandplasmapotentialforaccumulationnosignificantaccumulation.tissue:plasmaratios<1.0at168hours,highestresiduesinskin,gastro-intestinalcontent,liverandmuscle.rateandextentofexcretionrelativelyrapid,predominantlyviafaeces(ca.60%)andurine(ca.30%)within48hours.biliaryexcretionca15-30%metabolisminanimalsextensiveandcomparableinsingleandrepeatstudies,byhydroxylationandglucuronidation(withorwithoutringclosure).majormetabolitesin-n7b69,in-myx98,in-mla84bis-hydroxy-cyantraniliprole.toxicologicallyrelevantcompounds(animalsandplants)cyantraniliproletoxicologicallyrelevantcompounds(environment)cyantraniliproleacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>5000mg/kgbw-ratlc50inhalation>5.2mg/l(nose-only,4hexposure)-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationnotasensitiser(llna,buehlerandmaximisationtests)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver:increasedrelativeorganweight,centrilobularevidenceofarteritisindogsatdoselevelsaboveloaelforlivertoxicity.relevantoralnoaelrat7mg/kgbwperday(90-daystudy)mouse150mg/kgbwperday(90-daystudy)dog:1mg/kgbwperday(90-dayand1-yrstudies)-relevantdermalnoael>1000mg/kgbwperday(28-dayrat,no-'", "j.efsa.2014.3815.pdf": "8impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandcomplete(>90%)basedonurinaryexcretionafteroralandintravenousadministrationdistributionwidelydistributedpotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionabout90%within48h,mainlyviaurine(69-83%)metabolisminanimalsmoderatelytoextensivelymetabolisedinrats,upto30%excretedasunchangedparentcompoundpredominantmetabolicreactions:hydroxylationatthesidechainsandthephenylring,o-demethylationofthetriazinemethoxygroup,andgenerationofadoublebondonthetrifluoropropylgrouptoxicologicallyrelevantcompounds(animalsandplants)prosulfurontoxicologicallyrelevantcompounds(environment)prosulfuronacutetoxicity(annexiia,point5.2)ratld50oral546mg/kgbw(femalerat)r22/h302ratld50dermal>2000mg/kgbwratlc50inhalation>5.4mg/l,nose-onlyskinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitisinginexperimentaltests(buehlertestandmagnussonandkligman)xi,r43orh317**duetothepresenceofasensitisingimpurityshorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(hepatocytehypertrophy),heart(myocardialdegeneration),hematopoieticsystem(redbloodcellsdecreased)relevantoralnoael6mg/kgbwperday(90-day,dog)relevantdermalnoaelnovalidstudysubmitted,nofurtherstudyrequiredrelevantinhalationnoaelnotperformed-notrequired'", "j.efsa.2014.3817.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapid:bloodtcmax=15min-1habout90%within24h,basedonurinary(52-74%)andbiliary(12-30%)excretiondistributionwide,highestresiduesinliverandkidneyafter8hpotentialforaccumulationnoevidenceforaccumulationrateandextentofexcretion90%within48h(urine:52-74%within24h,faeces:10-37%within24h)metabolisminanimalsextensivelymetabolised(appr.90%);oxidationreactionsatthemethylgroupandthetriazine-methylenegroup,cleavagereactionsbetweenthetriazineandthepyridineringsystems;toxicologicallyrelevantcompounds(animalsandplants)pymetrozinetoxicologicallyrelevantcompounds(environment)pymetrozineacutetoxicity(annexiia,point5.2)ratld50oral5820mg/kgbwmouseld50oral2209mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1800mg/mskinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(optimisationtest,supplementary)non-sensitiser(m&k,maximisationtest)shorttermtoxicity(annexiia,point5.3)target/criticaleffectchemistrychanges),erythrocytes(anaemia;clinicalchemistrychanges).correlatedwithlowandrogenlevelsin28-daystudies)relevantoralnoael90-d,rat:33mg/kgbwperday1-yr,dog:0.57mg/kgbwperday90-d,mouse:<143mg/kgbwperdayreprocat2h361f9relevantdermalnoael28-d,rat:1000mg/kgbwperday9itshouldbenotedthatclassificationisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.proposalsforclassificationmadeinthecontextoftheevaluationprocedureunderregulation(ec)no1107/2009arenotformalproposals.'", "j.efsa.2014.3868.pdf": "impactonhumanandanimalhealthpreliminaryremarkregardingthewaivingoftoxicologicalstudies,referencevaluesandexposureriskassessment:cos(chito-oligosaccharides)-oga(oligo-galacturonicacid)isanoligosaccharidecomplex.-chito-oligosaccharides,derivedfromchitosan(3rdpolymermostpresentonearth)andcos,itsoligomer,whenreleasedintheenvironment,aredepolymerisedintoglucosamine.purifiedchitin,chitosan,chito-oligomersandglucosamine,besidetheirnaturaloccurrence,areusedinthebiomedicalfieldsuchastargeteddrugdelivery.chitinandchitosan(cos)areafamilyoflinearpolysaccharidesconsistingofvarying-4)linkedresiduesofn-acetyl-2amino-2-deoxy-d-glucoseand2amino-2-deoxy-d-glucoseresidues.chitinisthesecondmostabundantnaturalpolymerinnatureaftercelluloseandisfoundinthestructureofawidenumberofinvertebratesandthecellwallsoffungi,amongothers.-inthesameway,pectin(2ndpolymermostpresentonearth)andoga,itsoligomer,whenreleasedintheenvironment,aredepolymerisedintogalacturonicacid.pectinisoneofthemostimportantsourcesofdietaryfibre.pectin(oga)isafamilyofcomplexpolysaccharides(longline-1,4-glycoside-linkeddgalacturonicacid)presentinallplantprimarycellwalls.pectinoligosaccharidesrepresentadailyconsumptioninawesterndietbetween4and5g/day.pectinisusedasafoodadditive.ogaisobtainedfrompectinandcosisobtainedfromhydrolysisofchitosan.-variousreliablestudiesweresuppliedconcerningthetoxicologicalprofileofchitosan,cosandglucosamineaswellasoga.noneofthesestudiesreportedsignificantadverseeffects.-conclusion:boththestudiesconductedbytheapplicantandthosepublishedintheopenscientificliteratureareconsideredsufficientfortherisk-assessmentofcos-oga.takingintoaccount(i)theabsenceofadverseeffectsand(ii)thehighbackgroundlevelofabovementionedsubstances,thereisnoneedfortheestablishmentofreferencedoses.absorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)oga:lowbutrapidcos:important(>85%)andrapidwidelyandevenlydistributednopotentialforaccumulationnoaccumulationoga:requiresbacterialfermentationinlargeintestinegivingaspectrumofshortchainfattyacidsandgases.cos:isdegradedintoglucosaminefurthermetabolisedintoco2,waterandurea.(animalsandplants)nottoxicologicallyrelevant:ogaisobtainedfrompectinandcosisobtainedfromhydrolysisofchitosan.(environment)nottoxicologicallyrelevant:ogaisobtainedfrompectinandcosisobtainedfromhydrolysisofchitosan.acutetoxicity(annexiia,point5.2)ratld50female:>5000mg/kgbw-ratld50nostudy,notnecessary-ratlc50nostudy,notnecessary-non-irritant(invivoandinvitroepiskintest)-'", "j.efsa.2014.3873.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)64%(basedonurine+carcass)widelydistributednone94100%excretedafter7daysmorethan20metabolites,beingformedbyoxidationoftheacidandalcoholpartsofthemolecule,cleavageoftheesterlinkageandconversionofthecyanogroup.(animalsandplants)esfenvalerate(environment)esfenvalerateacutetoxicity(annexiia,point5.2)ratld50mouseld50oral88.5mg/kgbw250mg/kgbwacutetox.3(h301)9ratld50rabbitld50dermal>5000mg/kgbw>2000mg/kgbwratlc500.48mg/l(4h,wholebodyexposuretosubstanceincornoilmist)acutetox.2(h330)10non-irritantnon-irritantsensitising(m&kmethod)notsensitising(in2buehlertests)skinsens.1b(h317)19regulation(ec)no1272/2008oftheeuropeanparliamentandofthecouncilof16december2008onclassification,labellingandpackagingofsubstancesandmixtures,amendingandrepealingdirectives67/548/ec,andamendingregulation(ec)no1907/2006.ojl353,31.12.2008,1-1355.10itshouldbenotedthatclassificationisformallyproposedanddecidedinaccordancewithregulation(ec)no1272/2008.proposalsforclassificationmadeinthecontextoftheevaluationprocedureunderregulation(ec)no1107/2009arenotformalproposals.'", "j.efsa.2014.3880.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(oecddatapointiia5.1)rateandextentofabsorption:oralabsorptionis70%derivedfromametabolismstudyinrats,basedonurinaryexcretionwithin168h.distribution:widelypotentialforaccumulation:increaseofthyroidresiduelevelsafterrepeatedadministration(t1/2=117days)rateandextentofexcretion:85%-92%within24h,mainlyviaurinemetabolisminanimalsextensive,oxidationto5-hydroxythiabendazolefollowedbyconjugationwithglucuronideorsulfatetoxicologicallysignificantcompounds(animals,plantsandenvironment)parentcompoundandmetabolitesacutetoxicity(oecddatapointiia5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation>0.53mg/lskinirritationnotirritatingeyeirritationnotirritatingskinsensitization(testmethodusedandresult)nosensitisation(modifiedbuehlertest,nineinductions)shorttermtoxicity(oecddatapointiia5.3)target/criticaleffectredbloodcells,liverandthyroid(ratanddog)lowestrelevantoralnoael/noel10mg/kgbwperday(90d,rat)lowestrelevantdermalnoael/noel>1000mg/kgbwperday(23d,rabbit)lowestrelevantinhalationnoael/noelnotestablishedgenotoxicity(oecddatapointiia5.4)nogenotoxicpotentiallongtermtoxicityandcarcinogenicity(oecddatapointiia5.5)target/criticaleffectthyroidandliver.thyroidfollicularcellhyperplasiainratslowestrelevantnoael/noel10mg/kgbwperday(2yearstudy,rat)carcinogenicitythyroidadenomasandfollicularcellhyperplasiaduetoliverenzymeinductioninrats(basedonavailabledata)'", "j.efsa.2014.3881.pdf": "pactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)60%within120h,basedonurinaryexcretionwidelydistributedpotentiallowpotential~90%excretedinfaecesandurinewithin96hmetabolisationbycyclisation,hydroxylationandcleavageofthemolecule(animalsandplants)flupyrsulfuron-methyl-sodium(environment)flupyrsulfuron-methyl-sodiumgroundwatermetabolitesin-ky374,in-kc576andin-jv460(basedonclassificationoftheparentsuggestedbythepeerreview)acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbw-ratld50>2000mg/kgbw-ratlc50>5.8mg/lair/4h(nose-only)-non-irritant-non-irritant-notasensitiser(magnussonandkligman)-short-termtoxicity(annexiia,point5.3)reducedbodyweight/bodyweightgainandfoodefficiency,livertoxicity(rat,mouse,dog)rat:124mg/kgbwperday(90-day)mouse:171mg/kgbwperday(90-day)dog:13.6mg/kgbwperday(1-year)-nostudyrequired-nostudyrequired-negativeinvitroandinvivo-'", "j.efsa.2014.3912.pdf": "mentoftheactivesubstanceflumetralinefsajournal2014;12(12):391229impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption33%(basedonurinaryand/orbiliaryexcretionofthelowdose,within168h)distributionwidelydistributedat168h,highestratiosinthefatandfattytissuespotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapidandextensive,>87%within48hours,mainlyviafaeces(morethan65%),andurine(14-30%).excretionviabileathighdose:10to20%metabolisminanimalsabsorbedsubstancetotallymetabolized,mainlybycleavageofc-nbridge,reductionofnitro-groups,hydroxylation,oxidation,acetylationandglucuronidation(morethan30metabolites)toxicologicallyrelevantcompounds(animalsandplants)flumetralintoxicologicallyrelevantcompounds(environment)flumetralin,cga152604acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000mg/kgbw-ratlc50inhalation>2.41mg/lair/4h(noseonly)-skinirritationnon-irritant-eyeirritationnon-irritant-skinsensitisationnotsensitising(llna)-short-termtoxicity(annexiia,point5.3)target/criticaleffectrat:reducedbodyweight/bwgain,haematologicaleffectsandincreasedspleenweightdog:hepatotoxicity,rbcdeficiencyrelevantoralnoael90-day,rat:20.8mg/kgbwperdaynotdeterminedindogsduetolimitationsofthestudyavailable-relevantdermalnoael21-day,rabbit:2000mg/kgbwperday(highestdosetested)localloael:500mg/kgbwperday(basedondermatitis)-relevantinhalationnoael30-day,rat:cigarette-smokeinhalation:3.74g/lair(highestconcentrationtested)-'", "j.efsa.2014.3913.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionx11393729(halauxifen)(750mg/kgbw/day,10mg/kgbw/day)andhalauxifen-methyl(10mg/kgbw/day)arerapidly(<24hr)andcompletely(>80%)absorbed.distributionhalauxifen-methylandx11393729(halauxifen)undergowidespreadsystemiccirculation,althoughthereisnoevidenceofpreferentialdistributiontoanyparticulartissue.potentialforaccumulationnoevidenceofaccumulationofhalauxifen-methylorx11393729(halauxifen).rateandextentofexcretionhalauxifen-methylandx11393729(halauxifen)arerapidly(<24hrs)andextensively(~100%fororalexposure)eliminatedinurine(68-92%)andfaeces(11-99%).metabolisminanimalsthemainmetaboliteofhalauxifen-methylisthehydrolysisproductx11393729(halauxifen),accountingfor~80%ofdose).toxicologicallyrelevantcompounds(animalsandplants)halauxifen-methylandx11393729(halauxifen)toxicologicallyrelevantcompounds(environment)halauxifen-methylandx11393729(halauxifen)acutetoxicity(annexiia,point5.2)ratld50oralhalauxifen-methylandx11393729(halauxifen):>5000mg/kgbw(rat)ratld50dermalhalauxifen-methylandx11393729(halauxifen):>5000mg/kgbw(rat)ratlc50inhalationnotdetermined(thegenerationofarespirableatmosphereisnottechnicallypossible)skinirritationhalauxifen-methylandx11393729(halauxifen)arenotirritatingeyeirritationhalauxifen-methylandx11393729(halauxifen)arenotirritatingskinsensitisationhalauxifen-methylandx11393729(halauxifen)arenotskinsensitisers(negativeinllna)shorttermtoxicity(annexiia,point5.3)target/criticaleffecthalauxifen-methyl:liver:increasedliverweight,hypertrophy,fattyvacuolation,increasedcholesterol;x11393729(halauxifen):kidneytubuledegenerationandregeneration(ratsanddogs)andvacuolizationofcollectingduct(rats);bladderinflammation(malemice)relevantoralnoaelhalauxifen-methyl:'", "j.efsa.2014.3931.pdf": "impactonhumanandanimalhealthiia,point5.8)metabolitesthegroundwatermetabolitede-535-pyridinolwasnotdeemedrelevantbasedonhazardassessment(acuteoralld50=1030mg/kgbw;genotoxicitypackage:overallnegative).furtherdataarerequiredtosetconsumerreferencevalues.ld50oral(femalewistarrats)ofgroundwatermetabolitede-535pyridinone=123.7mg/kgbw.themetabolitede-535pyridinoneisdeemedrelevantbasedonhazardassessment.'", "j.efsa.2015.3056.pdf": "chapter3impactonhumanandanimalhealth(annexiim5;iiim7)medicaldata,surveillanceandobservations:trichodermaatrovirideimi-206040(formerlyt.harzianumimi-206040)hasbeenusedasaplantprotectionproductinseveralcountriesforupto30yearswithoutanyreportsofadverseeffects.theuseofbiosafetylevels(bsls)hasbeenproposedasameanstoclassifymicro-organismsaccordingtotheirpathogenicpotential.t.longibrachiatum,t.pseudokoningiiandt.viridewereopportunisticfungi).trichodermaatrovirideimi-206040(formerlyt.harzianumimi-206040)hasbeenshownnottogrowhumanbodytemperature,thuspreventingdeepinfectionsinmammals,eveninimmunocompromisedpersons.availableliteraturedataalsosuggestsaverylowrisktohumansandmammals,sincetherearenoknownhumanoranimalpathogensbelongingtothetrichodermagenusotherthanoccasionalincidentsinimmunocompromisedpersonsrecordedforsomespecies.sensitisation(experienceinhumansandstudyresults;typeofstudy):negativeinanindicativemagnusson&klingmanmaximisationtest.negativeinanindicativetestforanaphylacticreaction.negativeinanindicativetestforantibodiesagainsttrichodermainanexposedperson.howevertrichodermaviridehasbeenassociatedwithhypersensitivities.volatileorganiccompoundswerefoundtopotentiatehistaminereleasefromhumanbronchoalveolarcells,suggestingthepossibleinvolvementoftrichodermavirideinallergenicreactions.shouldbelabelledasfomayhavethepotentialtoprovokesensitizingtoxicityafteracuteoralexposure:ld50>2g/kgbw;accordingtonotifiercorrespondingto4.8x109spores/kgbwconductedwithanunidentifiedextractoftrichodermaviride.afteracuteinhalationexposure:nodataavailableafteracuteintraperitoneal/subcutaneousexposure:nodataavailableinfectivityafteracuteoralexposure:nodataavailableafteracuteinhalationexposure:nodataavailableafteracuteintraperitoneal/subcutaneousexposure:nodataavailable'", "j.efsa.2015.3932.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioninsufficientdataavailable(datagap)distributioninsufficientdataavailable(datagap)potentialforaccumulationinsufficientdataavailable(datagap)rateandextentofexcretioninsufficientdataavailable(datagap)metabolisminanimalsinsufficientdataavailable(datagap)toxicologicallyrelevantcompounds(animalsandplants)(3e)-3-decen-2-onetoxicologicallyrelevantcompounds(environment)(3e)-3-decen-2-oneacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>5000mg/kgbwratlc50inhalation0.52-2.04mg/l(>1mg/lair,inmales)(4hours,nose-only)h332skinirritationirritanth315eyeirritationnon-irritantskinsensitisationsensitising(buehler)h317short-termtoxicity(annexiia,point5.3)target/criticaleffecthistopathologicalfindingsinthelung.relevantoralnoaelnodata,furtherdatamaybeneededpendingconclusiononthegenotoxicpotentialrelevantdermalnoaelnodatarelevantinhalationnoaelnoaec139g/l(7-dayratstudy),equivalenttosystemicnoael0.38mg/kgbwperdaygenotoxicity(annexiia,point5.4)negativeinamestestpositiveingenemutationassayinvitrowithmammaliancellsnegativeinmicronucleustestinvivo,butnoevidencethatbonemarrowwasreachedbythecompoundnegativeinudsassayinliverinvivo,butlimitedsensitivitydatagapforinvivocometassayatthesiteofcontact'", "j.efsa.2015.3936.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)>80%through96hoursforalltreatmentgroupsbasedontheexcretioninurineandresiduesinorgansandtissues.widelydistributedinrats.highestresiduesfoundinhideandgitract.thedataindicatedasimilardistributionpatternfordose,sex,radiolabelused,orwithdietarypre-conditioning.noindicationofaccumulation.residuesinratcarcasseswerelow(0.2-1.7%)after3days.rapid(majorityofdoseexcretedwithin48h).extent:71-95%inurinein96hours,3.3-13%infaeces.eliminationhalf-livesfor14cresiduesfromurine:5-16hours.mostofmetsulfuron-methylinurineandfaeceswasexcretedasunchangedparentcompound.majormetabolicpathwayinvolveshydrolysisofureabridgeandformationofsulphonamideorphenylureaandtriazineaminederivative.demethylationofestergroupofsulphonamideresultsinformationofacidsulphonamidewhichcyclizestosaccharin.(animalsandplants)metsulfuron-methyl(environment)metsulfuron-methylacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbw(ratandmouse)ratld50>2000mg/kgbw(ratandrabbit)ratlc50>6.2mg/lair/4-h(nose-only)nonirritantnonirritantnotaskinsensitizer(buehlerandm&k)shorttermtoxicity(annexiia,point5.3)rat:reducedbwgainmouse:noeffectsobserveddog:noeffectsobserved90-dayrat:68mg/kgbwperday90-daymouse:813mg/kgbwperday(highestdosetested)90-day&1-yeardog:129mg/kgbwperday(highestdosetested)28-dayrat:localandsystemicnoael'", "j.efsa.2015.3943.pdf": "7impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolisminmammals(annexiia,point5.1)rateandextentoforalabsorption/systemicbioavailability:rat:rapidandvirtuallycomplete(>90%within24hbasedonurinaryexcretion)dog:43%basedonurinaryexcretionin168htoxicokinetics:tmax:0.5-2h,t1/2:3-4h(rat)distribution:uniformlydistributed;highestlevelsinliver,kidney,blood,skinmuscleandcarcasspotentialforbioaccumulation:noevidenceofaccumulationrateandextentofexcretion:rat:>90%within24h,mainlyviaurinemetabolisminanimals:majormetabolitecyhalofop,formedbyhydrolysis.minormetabolitedpformedbylossofthe2-propanoicsidechain.bothcanalsoundergoglucuronidation.toxicologicallyrelevantcompounds(animals,plantsandenvironment):cyhalofop-butyltoxicologicallyrelevantcompounds(environment):cyhalofop-butylacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwmouseld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.63mg/lair/4hr(dust;wholebodyexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitizationbuehler:non-sensitiserm&k:non-sensitisershorttermtoxicity(annexiia,point5.3)targetorgan/criticaleffectliverandkidney(rodents);gallbladder(dog)relevantoralnoael90-daystudies(mouse,rat,dog):3.0mg/kgbwperday52-weekdog:1.2mg/kgbwperday(loael7.6mg/kgbwperday)relevantdermalnoael28-day;rat:>1000mg/kgbwperday'", "j.efsa.2015.3958.pdf": "23impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapidlyandalmostcompletelyabsorbed>89%within24huniformlydistributedpotentialnopotential>90%inurine,10%infaeceswithin24h30%metabolisedbydemethylation,hydroxylationandoxidation(animalsandplants)parentcompound(environment)acutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>2000mg/kgbwratlc50>5.2mg/lnonirritanteyeirritatnonirritantnonsensitizer(maureroptimisationtests)shorttermtoxicity(annexiia,point5.3)kidney,blood14.5mg/kgbwperday(90dayoralrat)relevantdermalno100mg/kgbwperday(21dayrabbit)nodatarequiredclastogenicinvitro,genotoxicityinvivonotfullyaddressed.inconclusivelongtermtoxicityandcarcinogenicity(annexiia,point5.5)liver,blood'", "j.efsa.2015.3973.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionpoorbioavailability.approximately10%ofdietaryironabsorbed,influencedbydietaryandhost-relatedfactors,incaseofirondeficiencyupto60%absorptionofiron.distributionwidelydistributed,highestresiduesinliver,absorptiontospecifictransportproteins.potentialforaccumulationnopotentialforaccumulationundernormalphysiologicalconditions.excessiveironisstoredinliver,endocrineorgans(pancreas)andspleen.rateandextentofexcretionlowironexcretionundernormalphysiologicalconditions.metabolisminanimalsferricphosphatedissociatesintotrivalentiron-cationsandphosphate-anions,ironisseparatelyabsorbedasferrousions.toxicologicallyrelevantcompoundsironacutetoxicity(annexiia,point5.2)ratld50oralferricphosphate:>5000mg/kgbwratld50dermalferricphosphate:nodata;norelevantacutedermaltoxicityexpected;ferric-iii-sulphate:>2000mg/kgbw.ratlc50ferricphosphate:nodata(notvolatile)ferric-iii-sulphate>1.1mg/lferricphosphate:noskinirritation.ferricphosphate:minimaleffectsonirisandconjunctivae,noclassificationandlabellingrequired.ferricphosphate:noindicationofsensitisingpotential;naturalconstituentofhumandiet;ferric-iii-sulphate:noindicationofsensitisation.shorttermtoxicity(annexiia,point5.3)target/criticaleffectironsalts(acutesubchronic):gastrointestinaltract,liver,cns,cardiovascularsystem.52mgfepo4perday(18month,children)notapplicable,nostudiesrequired.relevantinhalationnoaelnotapplicable,nostudiesrequired.genotoxicity(annexiia,point5.4)nomutagenicpotential.'", "j.efsa.2015.3977.pdf": "chapter3:impactonhumanandanimalhealthimpactonhumanandanimalhealthmedicaldata:(includingmedicalsurveillanceonmanufacturingplantpersonnel)(oecddatapointiim5.1,5.2)routineexposureofpersonnel,laboratoryresearchers,aswellasconsumersoftomatoesaffectedwiththeubiquitousch2strainofpepinomosaicvirus,hasnotresultedinanyknownadverseeffectsoftoxicologicalsignificance.sensitisation:(oecddatapointiim5.3.1&iiim7.1.6)sensitiser(nostudiesavailable,classificationbasedongeneralassumptionsformicroorganisms)acuteoralinfectivity,toxicityandpathogenicity(oecddatapointiim5.3.2&iiim7.1.1)ld50oralrat>2000mg/kgbw=10108viralparticles/kgbw;noevidenceofadverseeffects.acuteintra-tracheal/inhalationtoxicity,pathogenicityandinfectivity:(oecddatapointiim5.3.3&iiim7.1.3)lc50(4h)>20mg/l=9.99106viralparticles/l;noevidenceofadverseeffects.acuteintravenous/intraperitonialinfectivity:(oecddatapointiim5.3.4&iiim7.1.2)nostudyprovided.genotoxicity:(oecddatapointiim5.3.5)negativeinvitroresultsusingtheamestest.cellculturestudy:(oecddatapointiim5.3.6)cellculturetestscouldprovideinformationontheabilityofviralpestcontrolagentstoinfect,replicatein,transformorcausetoxicityinmammaliancelllines.infectivityandreplicationoftheisolate1906wastestedinhumanepithelialcelllinea549.pepmvdidnotmultiplyandwasunabletoenterintothecellsinculture.informationonshort-termtoxicityandpathogenicity:(oecddatapointiim5.3.7)nodatanotrequired.plantvirusesdonotinfectmammals,sincetheydonotpossessreceptorsthatbindtohumancells.thusthepathogenicitypotentialofpepmv,ch2straincanbeconsideredirrelevant,asthevirushasnoabilitytoinfecthumans.dermaltoxicity:(oecddatapointiiia7.1.2)ld50dermal>2000mg/kg=9.99108viralparticles/kgbwnoevidenceofadverseeffects.specific-toxicity,pathogenicityandinfectivity:(oecddatapointiim5.5)nodatanotrequiredgenotoxicityinvivostudiesingermcells:(oecddatapointiim5.5.3)nodatanotrequiredexposure(operator,workers,bystander,consumer):(oecddatapointiim6.1,iiim7.2,7.3and8.0)notavailable;notrequiredchapter4:residues(normallynotrequired)notrequiredpepinomosaicvirusstrainch2isolate1906isacandidateforinclusioninannexivofregulation(ec)no396/2005(providingthatitcouldbeguaranteedthattheactivesubstancecanbeproducedfreeofpotentialmicrobialcontaminantsthatcouldbepathogenicforhumans).'", "j.efsa.2015.3984.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)highbioavailability(~90%)within24hextensivelyanduniformlydistributed;highestresiduesinskinandcarcassat168hnoevidenceforaccumulationrapidandextensive(approx.90%)within24h,mainlyviaurine(85%)limitedmetabolism,>70%ofdoseexcretedasparentcompoundhydroxylationofphenylmoietyandsubsequentconjugation(animalsandplants)florasulamtoxicologicallyrelevantcompounds(environment)florasulamacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwmouseld50oral>5000mg/kgbwratld50>2000mg/kgbwratlc50>5mg/lair(4hr;noseonly)notirritantnotirritantmaximisationtestandbuehlertest;notsensitizershorttermtoxicity(annexiia,point5.3)blood(anemia;ratsanddogs)liver(cholestasis,increasedapand/ororganweightandvacuolation;dogs)kidney(hypertrophyepithelialcellscollectingducts,allspecies;necrosisproximaltubules,papillarynecrosisand/ormineralization,rats)adrenals(vacuolation,dogs)rat:100mg/kgbwperday(90-day)mouse:100mg/kgbwperday(90-day)dog:5mg/kgbwperday(90-dand1-yr)28-drat:nosystemictoxicityupto1000mg/kgbwperdaynodata,notrequirednogenotoxiceffectsinvitroandinvivo'", "j.efsa.2015.3999.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)>80%within24hbasedoncomparisonofexcretionpatternsafteroralandi.v.administrationofmetalaxyl&bridgingurinaryexcretionbetweenmetalaxylandmetalaxyl-mwidelyandevenlydistributednopotentialforaccumulation(half-lifeinfat:2.59days)>94%excretedwithin-m);--mwithin24h)completemetabolismviaetherdemethylation,aromaticmethyloxidation,esterdemethylation,hydroxylationmetapositionofphenylringtoglucuronidesandsulphates(animalsandplants)metalaxyl-m(environment)metalaxyl-mandmetabolitescga62826andnoa409045acutetoxicity(annexiia,point5.2)ratld50rat:667mg/kgbw(malesandfemalescombined)male:953mg/kgbwfemale:375mg/kgbwmouse:male:>1000mg/kgbwfemale:500<ld50<1000mg/kgbwacutetox.4,h302ratld50>2000mg/kgbw-ratlc50>2.29mg/lair(4hoursexposure,nose-only)-non-irritant(rabbit)-severelyirritant(rabbit)eyedam.1,h318notsensitising(maximisationandbhlertest)-shorttermtoxicity(annexiia,point5.3)rat:liver(hepatocytehypertrophy,,reducedbwdog:liver(;blood(anaemia)'", "j.efsa.2015.4001.pdf": "6impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidlyabsorbed,withdose-dependence(andsaturationathighdose),andalimitedoralabsorptionof56%(basedonurinaryandbiliaryexcretionatlowdose).distributionlimitedtogastro-intestinaltract,liver,kidney,urinarybladder(excretoryorgans)potentialforaccumulationnoevidenceofaccumulationrateandextentofexcretionrapid(95-100%in24hrs),mainlyviathefaeces.metabolisminanimalsmainlythroughesterhydrolysis,n-demethylationofthepyrazoleringwhichmayundergohydrolysisofethertophenolandfurthermethylationtomethoxymoiety.toxicologicallyrelevantcompounds(animalsandplants)pyraflufen-ethyltoxicologicallyrelevantcompounds(environment)pyraflufen-ethylacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwmouseld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation5.03mg/l(4hours,noseonly)skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitiser(maximisation)shorttermtoxicity(annexiia,point5.3)target/criticaleffectrat:vacuolation,pigmentdepositionandmicrogranuloma);blood(mildhaemolyticanemia,increasedspleenweightwithextramedullaryhematopoiesis)mouse:liver(weight,clinicalchemistryandhistopathologicalchanges)dog:noadverseeffect'", "j.efsa.2015.4020.pdf": "2impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)>80%basedoncomparisonofpatternsofexcretionafteroralandivadministrations,almostcompletelyabsorbedwithin48hwidelydistributedwithhighestconcentrationsinliverandkidney.higherconcentrationalsodetectedingit,blood,myocardiumandseveralglands.maximumplasmaconcentrationwasreachedapprox.1hafteradministrationofasinglelowdosenoevidenceforaccumulation,supportedbythelowpowof1.2.afastdeclinewasobservedforallorgansandtissues(<loqsevendaysafteradministration)excretionwasfast,mainlyrenalandalmostcompletedafter24h(approx.7797%within24hand82100%within48h);7590%wasexcretedviaurinewithin48hand726%wasexcretedviafaecesmoderatelymetabolisedintherat.theparentcompoundrepresentsthepredominantpartoftheradioactivityinurine.mainmetabolitesdetectedinurine(accountingfor>10%ofthedoseadministered)werebyi02960-ohandbyi02960-hippuricacid(onlyhighdosemale).metabolites6-cnaanddfaweredetectedinurineatlevels>5%ofthedoseadministered.metabolicreactions:hydroxylationfollowedbyconjugationwithglucuronicacidorsulfate,cleavageofthedifluoroethylgroupformingbyi02960-des-difluoroethyl,anddifluoroaceticacid(dfa),cleavageofthemoleculeatthepyridinylmethylenebridgeforming6-cna,whichwasfurtherconjugatedwithglycinetobyi02960-hippuricacidandbyi02960-difluoroethyl-amino-furanone.6-cnaisconsideredamajormetaboliteinmaleratbutnotinfemales(animalsandplants)flupyradifurone(environment)flupyradifuroneacutetoxicity(annexiia,point5.2)>300<2000mg/kgbwh302>2000mg/kgbw>4.7mg/lair/4h(noseonly)nonirritatingslightrednessoftheconjunctivae,reversed'", "j.efsa.2015.4031.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(regulation(eu)n544/2011,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilitynodataavailable-notrequiredtoxicokineticsnodataavailable-notrequireddistributionnodataavailable-notrequiredpotentialforbioaccumulationnodataavailable-notrequiredrateandextentofexcretionnodataavailable-notrequiredmetabolisminanimalsnodataavailable-notrequiredtoxicologicallyrelevantcompounds(animalsandplants)rescaluretoxicologicallyrelevantcompounds(environment)rescalureacutetoxicity(regulation(eu)n544/2011,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbw(basedonqsar)ratlc50inhalation>5mg/lair(extrapolatedto4hourexposure;basedonqsar)skinirritationnon-irritanteyeirritationequivocal(basedon(q)sars);reliabilityofavailabledataisquestionablecat2h319skinsensitisationsensitising(llna)h317short-termtoxicity(regulation(eu)n544/2011,annexparta,point5.3)targetorgan/criticaleffectnodataavailable-notrequiredrelevantoralnoaelnodataavailable-notrequiredrelevantdermalnoaelnodataavailable-notrequiredrelevantinhalationnoaelnodataavailable-notrequiredgenotoxicity(regulation(eu)n544/2011,annexparta,point5.4)invitrostudiesnegativeinamestestinvivostudiesnodataavailable-notrequiredpotentialforgenotoxicitynegativeinamestest,noconcernsfrom(q)sars(oflimitedreliability)long-termtoxicityandcarcinogenicity(regulation(eu)n544/2011,annexparta,point5.5)long-termeffects(targetorgan/criticaleffect)nodataavailable-notrequired'", "j.efsa.2015.4032.pdf": "8impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidandextensiveabsorption(approximately>90%)distributionwidespreadwiththehighestresiduelevelsinbloodandliverpotentialforaccumulationnopotentialtoaccumulaterateandextentofexcretionrapideliminationpredominantlyinurineandbilemetabolisminanimalsabsorbedtricyclazoleisextensivelymetabolizedcharacterizedbyconjugationwithglutathione,with-lyasecleavagetothecorrespondingthiol,followedbyfurtherconjugationwithglucoronideormethylationtoxicologicallyrelevantcompounds(animalsandplants)tricyclazoletoxicologicallyrelevantcompounds(environment)tricyclazoleacutetoxicity(annexiia,point5.2)ratld50oral237mg/kgbwinfemaleratscat.3,h301ratld50dermal>5000mg/kgbwratlc50inhalation>0.52mg/l(4h,noseonly).cat.4,h332skinirritationnotaskinirritanteyeirritationnotaneyeirritantskinsensitisationnotaskinsensitizerinthemurinelocallymphnodeassayshorttermtoxicity(annexiia,point5.3)target/criticaleffectliver:increaseinliverweight(rat,mice,dog)kidney:increasedweight(dogs).ovary:increasedweight(mice)reducedbodyweightgain(rats,dogs).relevantoralnoael15mg/kgbwperday(1yeardog)20.5mg/kgbwperday(90-dayrat)84.8mg/kgbwperday(90-daymouse)relevantdermalnoael300mg/kgbwperday(28daydermalrat)relevantinhalationnoaelnotapplicable'", "j.efsa.2015.4043.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption60%(40mg/kgbw)-80%(1mg/kgbw)after48hours,basedonurineexcretion,bile,cagewashandcarcassresiduesdistributionwidelydistributedpotentialforaccumulationnoevidenceofaccumulationrateandextentofexcretion90%eliminatedin72hoursmainlyviafaeces(84-90%viafaecesand5-9%eliminatedviaurine)upto69%ofadministereddoseisexcretedinthebilewithin48hoursofdosingmetabolisminanimalsextensivemetabolisminrat:demethylation,hydroxylationandconjugationwithglucuronicacidorsulphate.themajormetaboliteidentifiedwassyn546041toxicologicallyrelevantcompounds(animalsandplants)benzovindiflupyrtoxicologicallyrelevantcompounds(environment)benzovindiflupyracutetoxicity(annexiia,point5.2)ratld50oral55mg/kgbwnoael17.5mg/kgbwh301ratld50dermal>2000mg/kgbwratlc50inhalation0.56mg/lair(4h,noseonly)h331skinirritationnonirritanteyeirritationnonirritantskinsensitisationnonsensitizer(llna)short-termtoxicity(annexiia,point5.3)target/criticaleffectrat&mouse:reducedbodyweight/bwgain,foodconsumptionandfoodutilisation,liver(increasedweight,alteredbiochemicalparametersandcentrilobularhypertrophy)mouse:colon/rectumhyperplasiadog:reducedbodyweightgainandlocaleffectsonthegastro-intestinaltractrelevantoralnoael90-day,rat:7.6mg/kgbwperday90-day,mice:17mg/kgbwperday1-year&90-day,dog:30mg/kgbwperdayrelevantdermalnoael28-day,rat:1000mg/kgbwperday(limitdose)relevantinhalationnoaelnodatanotrequired'", "j.efsa.2015.4060.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rapid,>91%within48h(lowdose,bile-fistulation);s,sdiastereoisomerabsorbedmorequicklythans,risomer.dwidelydistributed,highestresiduesinliverandgitract;evidencesuggestiveofenterohepaticcirculation.noevidenceforaccumulation.>98%recoveredradioactivityexcretedwithin48h(lowdose);majorroutefaecalformalesandaboutequallyfaecalandrenalforfemales.>90%metabolised(12metabolitesidentified);mainmetabolite:diastereoisomerpairofiprovalicarb-carboxylicacid(freeandconjugatedwithglycineormethylgroupandsubsequentoxidation.(animalsandplants)parentcompound(environment)parentcompoundandpmpaacutetoxicity(annexiia,point5.2)ratld50>5000mg/kgbwratld50>5000mg/kgbwratlc505.0mg/l(4hour,head/noseonly)non-irritantnon-irritantsknonsensitising(m&k)shorttermtoxicity(annexiia,point5.3)liver(increasedserumenzymeactivities,increasedweight,hepatocellularhypertrophy,fattychange,focalhepatocellularnecrosis,fibrosis;allspecies);gallbladder(dog);kidney(decreasedorganwt,increasedwaterintake,inmice).loael=3mg/kgbwperday(4,13,53wkdogstudy)373mg/kgbwperday(13wkrat)325mg/kgbwperday(13wkmouse)relevantderm'", "j.efsa.2015.4077.pdf": "72impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionhighbioavailability(about90%)distributiongenerallylowresidues;highestlevelsinkidneyspotentialforaccumulationnopotentialforaccumulationrateandextentofexcretionrapidexcretion(about90%viaurine;1-4%viafaeceswithin24h)metabolisminanimals10%metabolised;parentcompoundpredominantlyexcretedandsmallamountsofmetabolites6-hydroxy-bentazoneand8-hydroxy-bentazonetoxicologicallyrelevantcompounds(animalsandplants)bentazonetoxicologicallyrelevantcompounds(environment)bentazoneacutetoxicity(annexiia,point5.2)ratld5014001800mg/kgbw(rat)10001100mg/kgbw(guineapig)7501139mg/kgbw(rabbit)500mg/kgbw(cat)>500mg/kgbw(dog)h302ratld50>5000mg/kgbwratlc50>5.1mg/lair/4h(head-noseonly)nonirritanteyeirritanth319sensitizer(m&k)h317phototoxicitynophototoxicpotential(invitro3t3nrutest)short-termtoxicity(annexiia,point5.3)target/criticaleffectmouse:prolongedbloodcoagulationtimerat:retardedbwgain,clinicalchemistryandhaematologicalchanges,increasedkidneyandliverweights.dog:blood(prolongedbloodcoagulationtime,diminishedhaematocrit,reducedhaemoglobin);liverandkidney(increasedorganweightandclinico-chemicalchanges)relevantoralnoael28-daymouseloael:407mg/kgbwperday90-dayrat:77.8mg/kgbwperday1-yeardog:13mg/kgbwperdayrelevantdermalnoael21-dayrabbit:1000mgkgbwperday'", "j.efsa.2015.4092.pdf": null, "j.efsa.2015.4100.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)>95%basedonurinaryandbiliaryexcretionwithin24hextensivelydistributedthroughoutthebody(mainlyingastro-intestinaltract,liverandkidneys)noevidenceforaccumulationfaecalelimination,viathebile,wastheprimaryrouteofelimination(~80%),urinaryexcretionupto~15%)extensivelymetabolisedtonumerousmetabolites(unchangedparentinfaeces<0.2%oflowdose).theprimaryroutesofmetabolismwerebyoxidationandsubsequentconjugationwithglucuronicacid,demethylationwithsubsequentoxidation,oroxidationwithsubsequentdemethylation.(animalsandplants)mandestrobin(environment)mandestrobinacutetoxicity(annexiia,point5.2)ratld50>2000mg/kgbwratld50>2000mg/kgbwratlc50>4.96mg/l(maximumattainableconcentration,noseonly)notirritatingmildtransientirritation(nottriggeringclassification)notsensitizing(m&ktest)shorttermtoxicity(annexiia,point5.3)hepatotoxicity(increasedliverweightandhepatocellularhypertrophyinratsanddogs,liverpigmentationandcentrilobulardegenerationindogs,increasedalkalinephosphataselevelsindogs)noadverseeffectinmiceatthehighestdosetested90-dayrat:54mg/kgbwperday90-daymouse:807.3mg/kgbwperday90-daydog:90.9mg/kgbwperday1-yeardog:19mg/kgbwperday28-dayrat:1000mg/kgbwperday(highestdosetested)nodata-notrequired'", "j.efsa.2015.4123.pdf": null, "j.efsa.2015.4194.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptioninitialrapidabsorptionof40%,basedonbiliarycannulationandurinaryexcretiondataafter48h.distributionverylowtissueresiduelevelsat120hours(mainlyinliverandfat);thephenylaminomoietyoffamoxadonewasshowntobindtorbc.potentialforaccumulationlowduetorapideliminationandmetabolism.however,itshouldbenotedthatverylowresiduelevelsarestillpresentintheeyesofdogsattermination(36hours).rateandextentofexcretionrapidclearancewithin120hoursinrats(urine10%&faeces90%)metabolisminanimalsunmetabolisedfamoxadonewasthemajorcomponentrecoveredinthefaeces(50-60%),withhydroxylatedmetabolites(upto13%oftheadministereddose).inurine,onlyhydrolyticandhydrolysiscleavageproductssuchasin-by759(4-acetoxyaniline)weredetectedupto7%oftheadministereddose.toxicologicallyrelevantcompounds(animalsandplants)famoxadonetoxicologicallyrelevantcompounds(environment)famoxadoneacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw(ratandmouse)rabbitld50dermal>2000mg/kgbwratlc50inhalation>5.3mg/lair(4hourexposure,nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotasensitiser(m&k)short-termtoxicity(annexiia,point5.3)target/criticaleffectdog:ocularlesions,andblood(haemolytic)effectsathigherdoselevelsrat:blood(haemolytic)effectsmouse:liver,bloodandspleniceffectsprimates:spleniceffects'", "j.efsa.2015.4201.pdf": "0monitoring/enforcementmethodsfood/feedofplantorigin(analyticaltechniqueandloqformethodsformonitoringpurposes)dupont:lc-ms/msloq=0.01mg/kgforsoybeanseed,olives,corngrain,orangesandlettuce.taskforce:lc-ms/msloq=0.01mg/kgforcerealgrainandcornkernels.food/feedofanimalorigin(analyticaltechniqueandloqformethodsformonitoringpurposes)notrequiredasnomrlsareproposedsoil(analyticaltechniqueandloq)dupont:lc-ms/msloq=0.05g/kgforsoiltaskforce:lc-ms/msloq=0.005mg/kgforsoilwater(analyticaltechniqueandloq)dupont:lc-ms/msloq=0.05g/lforbothdrinkingandsurfacewatertaskforce:lc-ms/msloq=0.1g/lforbothdrinkingandsurfacewater.air(analyticaltechniqueandloq)dupont:lc-ms/msloq=2.8g/m3forairtaskforce:lc-ms/msloq=21g/m3forair.bodyfluidsandtissues(analyticaltechniqueandloq)notrequired.classificationandproposedlabellingwithregardtophysicalandchemicaldata(annexiia,point10)rms/peerreviewproposalactivesubstancenoneimpactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption>80%oralabsorptionat20mg/kgbw(basedonurineexcretionwithin96h).lowerabsorptionat2000mg/kgbw.distributionwidelydistributedpotentialforaccumulationnoevidenceforaccumulation.'1rateandextentofexcretionrapidandextensive(app.completeby72h);mainlyviaurine(60to80%;10to30%viafaeces).notextensivelymetabolised(majorityofparentthifensulfuron-methyl(upto95%)wasnotmetabolised)themajorbiotransformationpathwayinvolveddemethylationtoo-demethylthifensulfuronmethyl(in-l9226),whichwassubsequentlyhydrolysedto2-ester-3-sulfonamide(in-a5546)(furtherconvertedto2-acid-3-sulfonamidein-l9223)andtriazineamine(in-a4098).thifensulfuronmethylwasalsode-esterifiedbyanon-specificesterasetoyieldthifensulfuronacid(in-l9225).toxicologicallyrelevantcompounds(animalsandplants)nonetoxicologicallyrelevantcompounds(environment)groundwatermetabolites(in-l9225,in-l9223,in-a4098,in-w8268,in-jz789,2-acid-3-triuret)acutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbw-ratld50dermal>2000-5050mg/kgbw-ratlc50inhalation>5.03-7.9mg/l(nose-only;4-hr)-skinirritationnotaskinirritant-eyeirritationnotaneyeirritant-skinsensitisationnotaskinsensitiser(m&kandllna)-shorttermtoxicity(annexiia,point5.3)target/criticaleffectdecreasesinbodyweights,bodyweightgainsandfoodefficiency(rat,dog)none(mouse)relevantoralnoael7mg/kgbwperday(rat90-daystudy)>1427mg/kgbwperday(mouse90-daystudy)19.7mg/kgbwperday(dog1-yearstudy)-relevantdermalnoaelnotavailablerelevantinhalationnoaelnotavailable'", "j.efsa.2015.4206.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorption90%basedonurinaryexcretionin24hdistributionwidelyandevenlydistributedpotentialforaccumulationnoaccumulationrateandextentofexcretioncompletelywithin3days,mainlyviaurine(>85%)metabolisminanimalscompletelymetabolisedoxidationoftheisopropylgroup,n-demethylationnoanilinederivativesdetectedinurineandfaecestoxicologicallyrelevantcompounds(animalsandplants)parentcompoundandmetabolitestoxicologicallyrelevantcompounds(environment)parentcompoundandmetabolitesacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>1.95mg/l(4h,wholebodyexposure,aerosol)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k;lna)shorttermtoxicity(annexiia,point5.3)target/criticaleffectredbloodcells(haemolyticeffects,methaemoglobinformation,haemosiderindeposition,dog,rat,monkey).liver(degenerationofhepatocytes,dog,rat,monkey,mouse).reducedbodyweightgain(rats,dogs,monkeys)relevantoralnoael3.2mg/kgbwperday(dogstudies)10mg/kgbwperday(forpotentialacutetoxicityeffectsindogstudies).5.6mg/kgbwperday(13-weekrat).50mg/kgbwperday(13-weekmonkey).307mg/kgbwperday(4-weekmouse).h373relevantdermalnoael1000mg/kgbwperday(90-dayrabbit)relevantinhalationnoael>0.25mg/l(14-dayrat)genotoxicity(annexiia,point5.4)negative(whenisoproturonfromcurrentmanufacturingprocesswastested)'", "j.efsa.2015.4221.pdf": "viewofthepesticideriskassessmentoftheactivesubstancereynoutriasachalinensisextractwww.efsa.europa.eu/efsajournal34efsajournal2015;13(9):4221impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandemodin:tmax40mininmice,2to9hrinrats.56%oralabsorption(biliaryandurinaryexcretioninrats)physcion:tmax6hrinrats.56%oralabsorption(fromemodin)resveratrol:tmax30minto4hrinhumanvolunteers,1hrinrats.20%oralabsorption(urinaryexcretioninhumanvolunteers).evidenceofstrongfirstpassmetabolismandenterohepaticrecirculationofemodinandresveratrolemodin:primarilyliverandkidneys,alsomesenteriumandadiposetissue(rats)physcion:liver,kidney,brain,lungandheart(rats)resveratrol:primarilyliver,kidney,andgitract.(ratsandmice)emodin:inratsradioactivitylevelsincreasedinmesenteriumandadiposetissueat120hrcomparedto72hr;aslogkowopen(datagap),thepotentialforaccumulationcouldnotberuledout.physcion:aslogkowopen(datagap),apotentialforaccumulationcouldnotberuledout.resveratrol:inratsradioactivityintissuesaccountedfor0.2%ofadministereddoseat72hrcomparedto1%at24hr,indicatinglowpotentialforaccumulation.emodin:90%excretedwithin120hr(rats),68%faeces,22%urine.extensivebiliaryexcretion(49%in30hr)physcion:limitedinformationresveratrol:plasmahalf-lifeinhumanvolunteers3to9hr.emodin:extensivelymetabolisedtoglucuronideandsulphideconjugates(somehydroxylatedmetabolitesalsoidentified)physcion:metabolisedtoemodinandotheranthraquinonederivatives(noinformationonconjugationreactions)resveratrol:extensivelymetabolisedmainlytoglucuronideandsulphideconjugates.(animalsandplants)open'", "j.efsa.2015.4222.pdf": ".efsa.europa.eu/efsajournal21efsajournal2015;13(12):4222impactonhumanandanimalhealthothertoxicologicalstudies(annexiia,point5.8)studiesperformedonmetabolitesorimpurities4-chlorophenylurea(cpu),2,6-difluorobenzamide(dfbam)and2,6-difluorobenzoicacid(dfba)toxicitycouldbecoveredbythediflubenzurondatapackage.4-chloroaniline(pca)invivogenotoxicandcarcinogenicagent.4-chloroacetanilide(pcaa)limitedinformationavailable,noconclusionofthetoxicitycouldbedrawn.summary(annexiia,point5.10)pcavaluestudyuncertaintyfactoradi,aoel,arfdcannotbesetbecauseathresholdforagenotoxiccarcinogencannotbeassumed.bmdlbmdl10=0.56mg/kgbw(ratadrenalglandpheochromocytomasendpoint,log-probitmodel).bmdl5=0.16mg/kgbw(ratadrenalglandpheochromocytomasendpoint,log-probitmodel).exposurescenarios(annexiiia,point7.2)pcaasaresidueworkersexposurefromresiduesonapples=0.0135g/kgbwequalstoamoeof11,852and41,481(foranextra5and10%riskcomparedtothebackground)exposurefromworkingwithpears=0.0249g/kgbwequalstoamoeof6,426and22,490(foranextra5and10%riskcomparedtothebackground).bystanders/residentsnobystander/residentestimates.'", "j.efsa.2015.4250.pdf": "chapter2.3impactonhumanandanimalhealthmedicaldata,surveillanceandobservations(annexiib,point5.1)limiteddata:noadverseeffectsobservedamongresearchers,productionworkersandfieldtechnicians.acutetoxicity(annexiib,point5.2.1and5.2.2)pathogenicity:noevidenceofadverseeffectsfromacuteintraperitonealstudy.inconclusiveresultsinintratrachealstudy;reliableinformationmissing.infectivity:noevidenceofadverseeffectsfromacuteintraperitonealstudy.inconclusiveresultsinintratrachealstudy;reliableinformationmissing.toxicity:ratld50oral:ratld50intratracheal:ratld50i.p.:>108cfu/animalinconclusive;reliableinformationmissing>3.5x107cfu/animalirritation,sensitisationrabbit:noirritatingeffectsontheeyeskinirritant.genotoxicity(annexiib,point5.2.3,5.4and5.5)limitedinformationtoconcludeonthetoxicologicalprofileofsecondarymetabolites/toxins.cellculturestudies(annexiib,point5.2.4)waiveraccepted.shorttermtoxicity(annexiib,point5.2.5)pendingonthefinalconclusiononacuterespiratorytoxicity.firstaidmeasures,medicaltreatment(annexiib,point5.2.6)sufficientdatasubmitted.specifictoxicity,pathogenicityandinfectivenessstudies(annexiib,point5.5)dependingontheresultsoftherequestedinformationonshort-termtoxicity,moreinformationonchronictoxicity,pathogenicityandinfectiveness,carcinogenicityand/orreproductivetoxicitymayberequired.acceptableexposurescenarios(includingmethodofcalculation)operatorbasedonthesubmitteddatariskevaluationwasnotpossible.workersbasedonthesubmitteddatariskevaluationwasnotpossible.bystandersexposureconsiderednegligible.'", "j.efsa.2015.4261.pdf": null, "j.efsa.2015.4264.pdf": null, "j.efsa.2015.4265.pdf": "w.efsa.europa.eu/efsajournal34efsajournal2015;13(10):4265impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(regulation(eu)n544/2011,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>80%(basedonthesumofurinaryandbiliaryexcretion,andcarcassradioactivitywithin48h)toxicokinetics(plasma)low-dose:cmax=0.7-1.3g/g,tmax=1.8-5.5h,t1/2=31-43h.high-dose:cmax=13-28g/g,tmax=5.5-8.5h,t1/2=36-45h.distributionwidelydistributed;highestlevelsingit+contentandliverpotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(completeeliminationwithin48h),mainlyviabile.within24h:85%viabile,6%viafaeces,9%viaurine.metabolisminanimalsextensivelymetabolised(>80%);mainmetabolites4-hpandppa;o-dealkylation,oxidation,phenyl-andthiopheneringhydroxylation,glucuronidation,sulphation.toxicologicallyrelevantcompounds(animalsandplants)isofetamid(ikf-5411)toxicologicallyrelevantcompounds(environment)isofetamid(ikf-5411)acutetoxicity(regulation(eu)n544/2011,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.8mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(llna)short-termtoxicity(regulation(eu)n544/2011,annexparta,point5.3)targetorgan/criticaleffectrat:liverliverweight,adrenalweight,hepatocellularandthyroidfollicularcellhypertrophydog:bodyweightrelevantoralnoael90-dayrat:6.65mg/kgbwperday90-dayevaluationinthe1-yeardog:5.34mg/kgbwperday1-yrdog:1.57mg/kgbw/dperdayrelevantdermalnoael28-dayrat:>1000mg/kgbwperdayrelevantinhalationnoaelnodatanotrequired'", "j.efsa.2015.4279.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionabout60%(observedrange:51-84%)wereabsorbedwithin48h,basedonurinary(16-70%)andbiliary(8-34%)excretionwithconsiderabledifferencesbetweensexesandpositionofthelabelinthemolecule.onlylowamountsofcompoundwereexhaledviaair.administrationofhigherdosesleadstohighertissueconcentrationsintheevaluatedtissues.distributionwidedistributionbetweentissueswasreported,highestconcentrationsofresidueswereobservedinblood,liver,andkidney.potentialforaccumulationnoevidenceforaccumulation.rateandextentofexcretionexcretionwas90%within168h(urine:21-65%,faeces:69-25%)withconsiderabledifferencesbetweensexesandpositionofthelabelinthemolecule;morethan75%wereexcretedwithin24h.metabolisminanimalspicolinafenwasmoderatelymetabolisedinrats(cleavageofamidebond,oxidationandconjugation).metabolitecl153815wasidentifiedasamajorratmetabolite.toxicologicallyrelevantcompounds(animalsandplants)picolinafentoxicologicallyrelevantcompounds(environment)picolinafenacutetoxicity(annexiia,point5.2)ratld50oral>5000mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>5.9mg/l(4-h,nose-only)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitiser(m&k)shorttermtoxicity(annexiia,point5.3)target/criticaleffectoralstudies:anaemia(rats,dogsandmice)dermalstudy:anaemia(haematologicalchanges)at75mg/kgbwperdayandaboverelevantoralnoael90-day,rat:6.3mg/kgbwperday(80ppm)90-day,mouse:10.2mg/kgbwperday(50ppm)90-dayevaluationin1-yrstudy:5.2mg/kgbwperday(150ppm)1-yr,dog:1.4mg/kgbwperday(50ppm)stot-re2,h373(bloodsystem)'", "j.efsa.2015.4302.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidbutlimited,about20%,basedonurinaryexcretionandcomparisonofkineticbehaviourafteroralandivadministrationsdistributionwide,highestresiduesafter7dinbone,liverandkidney;cmaxinplasma:0,7-1,8g/ml(after3-4h),auc:18.6-23.1gh/ml,t1/2:6-12hpotentialforaccumulation1%oftheadministereddose)rateandextentofexcretionvirtuallycompletewithin7dwithmajorportionexcretedwithin48h;absorbedamounteliminatedviaurine,unabsorbedviafaeces;biliaryexcretionandexhalationnegligiblemetabolisminanimalspoorlymetabolisedwiththeonlybiotransformationproductaminomethylphosphonicacid(ampa)accountingforupto1%ofthetotalexcretedamount(probablyresultingfrombacterialmetabolisminthegut)toxicologicallyrelevantcompounds(animalsandplants)glyphosatetoxicologicallyrelevantcompounds(environment)glyphosateacutetoxicity(annexiia,point5.2)ratld50oral>2000mg/kgbw(glyphosateacid&salts)ratld50dermal>2000mg/kgbw(glyphosateacid&salts)ratlc50inhalation>5mg/lair(4-hnoseonlyexposure)(glyphosateacid&salts)skinirritationevidenceofveryslightirritation;classificationandlabellingnotrequired(glyphosateacid&salts)eyeirritationirritant,classificationneededforglyphosateacidbutnotforitssaltscat.1,h318skinsensitisationnegative(m&ktest,llna,buehler)(glyphosateacid)negative(m&ktest)(ipasalt)'", "j.efsa.2015.4308.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)oral,3-4%,rat(urine;15%bile)highestlevelsinkidneys,gastro-intestinaltract,lungandliver,certainaffinitiestoeyelenshalflifeinblood4h.someevidenceforaccumulationintheeyelensabsorbeddoseextensivelyexcreted(>90%)inurineandbilewithin96h.metabolismwaslimited,with<20%oftheurinaryresidues(<1%oftheadministereddose)consistingofmetabolites.(animalsandplants)diquation(environment)diquationacutetoxicity(annexiia,point5.2)214-222mgdiquation/kgbw1000mgdiquatdibromide/kgbw.h302>2000mgdiquatdibromide/kgbw-0.50.6mgdiquatdibromide/l.(respiratoryirritant)h330h335irritant(diquatdibromide)h315irritant(diquatdibromide)h319magnussonandkligman-positive(diquatdibromide)h317shorttermtoxicity(annexiia,point5.3)rat:eye(cataract),bodyweigth(decrease).dog:eye(cataract),bodyweigth(decrease),epididymis(decreasedweight).1-year,dog:0.5mg/kgbwperday(female)90-day,rat:4.7mg/kgbwperday(3studies)h3723-week,rat:5mg/kgbwperday20-day,rabbit:20mg/kgbwperday3-week,rat:0.1g/l(0.02mg/kgbwperday)'", "j.efsa.2015.4322.pdf": null, "j.efsa.2016.4359.pdf": null, "j.efsa.2016.4374.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability>80%(basedonurinaryexcretionafterrepeatedlowdoseadministration)correctionofaoelfororalabsorptionnotconsiderednecessarytoxicokineticscmax,tmax,plasmatnotreportedforethofumesateplasmatapproximately1.6hoursformetaboliteethofumesate-carboxylicaciddistributionwidelydistributed(highestlevelinliver,kidneyandfat)potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidandextensive(app.93-100%within24h),mainlyviaurine(singleoraldose:66-90%,repeatedoraldose:8192%);tolessextentviafaeces(singleoraldose:7-13%,repeatedoraldose:6-16%)metabolisminanimalsextensivelymetabolised(>95%);majormetaboliteethofumesate-carboxylicacid,minormetabolitesethofumesate-lactoneandethofumesate-2-hydroxy;dealkylationandringopeninginvitrometabolismnouniquehumanmetabolitesexpected.toxicologicallyrelevantcompounds(animalsandplants)ethofumesate;metabolitesethofumesate-carboxylicacidandethofumesate-lactone,bothidentifiedinratmetabolismstudiestoxicologicallyrelevantcompounds(environment)ethofumesateacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>0.16mg/lair/4h(wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(m&k,buehler)phototoxicitynoappropriatephotoxicitytest.notphototoxicin3t3nru-pttest**the3t3nru-pttestisnotappropriatetestforuvbabsorberasethofumesate.'", "j.efsa.2016.4406.pdf": "6impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidly,>80%inratsbasedonurineandbileexcretions.toxicokineticsoraldose300mg/kg(c-phenyllabel):cmax=12.2/17.7,tmax=14.6/25.7,t1/2=72.0/83.5(m/f)auc0-168hg.hour/g776/1675oraldose3mg/kg(c-phenyllabel):cmax=0.29/0.31,tmax=4.3/2.7,t1/2=61.5/72.8(m/f)auc0-168hg.hour/g13.8/16.6distributionwidelydistributed,maximumconcentrationinthyroidpotentialforbioaccumulationnopotentialforaccumulationinorgans.somepersistenceinplasmaandthyroidsrateandextentofexcretionalmostcompletelyin7days,mainlyviabileandfaeces(5080%),lessinurine(1146%)metabolisminanimalsintensivemetabolisation,oxidation,reduction,hydrolysisandconjugation.invitrometabolismnotavailable(datagap).toxicologicallyrelevantcompounds(animalsandplants)parentcompound.furtherconsiderationsonplantmetabolitespendingonthesettingofreferencevaluesoftheparent.toxicologicallyrelevantcompounds(environment)parentcompoundrpa412708(relevantforgroundwater;acutelytoxicbytheoralroute)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>2028mg/kgratld50dermal>2000mg/kgbwratlc50inhalation>2.1mg/l(4hours,nose-only).skinirritationnon-irritanteyeirritationslightlyirritating,notclassifiedskinsensitisationnonsensitizer(magnussonetkligman).phototoxicityunlikelytobephototoxic'", "j.efsa.2016.4416.pdf": "6impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability60%(basedonurinaryexcretion,within24h)toxicokineticssinglelowdose(1mg/kgbw)cmax:0.5males;0.27females(gequiv/g)tmax:1.0h(males);0.5h(females)plasmat1/2:61.0h(males);59.5h(females)singlehighdose(100mg/kgbw)cmax:48.1males;25.2females(gequiv/g)tmax:0.98h(males);0.67h(females)plasmat1/2:59.2h(males);60.0h(females)distributionhighestlevelsinliverandkidneys(rat)potentialforbioaccumulationlowrateandextentofexcretion>85%inurineandfaeces,rat;mainlywithin24hmetabolisminanimalsextensive,saturatedathighdosemajorratmetabolite:rpa202248invitrometabolisminvitrolivermicrosomesmetabolicprofilebetweenhumanandratwascomparabletoxicologicallyrelevantcompounds(animalsandplants)isoxaflutoleandrpa202248toxicologicallyrelevantcompounds(environment)rpa202248acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.23mg/lair/4h(wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(modifiedbuehlerandmagnusson-kligman)phototoxicitynotphototoxictobalb/c3t3cellsshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(hypertrophy),eye(cornealopacity)mice:liver(hypertrophy,clinicalchemistrychangesandincreaseda/rweight)dog:liver(hepatocyteswelling,clinical'", "j.efsa.2016.4419.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability~70%basedoncomparisonofexcretionpatternsafteroralvs.intravenousadministrationsinratstreatedwith1mg/kgbw50%basedonradioactivityexcretedinurineandcage-washinmicetreatedwith1mg/kgbwviatheoralroutetoxicokineticslowdose-cmax0.25,tmax0.5h,plasmat1/21.6highdose-cmax40,tmax1.5h,plasmat1/21.8distributionwidelydistributed(andkidneyshavethehighestdistribution)potentialforbioaccumulationnoevidenceofbioaccumulation.rateandextentofexcretionrat:>80%within72h,mainlyviaurine(43-67%,23-37%viafaeces,2-14%viabileinrats)mouse:~80%within72h(36-59%viaurine,21-46%viafaeceswithin72hmetabolisminanimalsnotextensivelymetabolised(~90%inurineunchanged,upto5%hydroxylatedmetabolites,mnbaandamba);mnbaandambageneratedbygutmicrofloracanbereabsorbedandcontributetothehydroxylatedmetabolitesinurineorexcretedinfaeces.invitrometabolismdatagapforinterspeciescomparativeinvitrometabolismstudyincludinghumanmetabolismnoinvitrodatabutahumanvolunteerstudyconfirmsabsorptionandexcretionsimilartorodents.toxicologicallyrelevantcompounds(animalsandplants)mesotrioneambatoxicologicallyrelevantcompounds(environment)mesotrioneacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.75mg/lair/4h(noseonly)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnoevidenceofskinsensitisation(m&k)phototoxicitynotphototoxic'", "j.efsa.2016.4420.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability57%(basedonurinaryandbiliaryexcretion48hafteradministration)toxicokineticsmetabolitereg.no.4108077(femalerats):cmax:27.2ng/ml(lowdose),135ng/ml(highdose)tmax:8hourst1/2init.:3.14(lowdose),2.69(highdose)t1/2term:8.35(highdose)metabolitereg.no.4108474(femalerats):cmax:61.2ng/ml(lowdose),393.6ng/ml(highdose)tmax:8hourst1/2init.:2.63(lowdose),2.63(highdose)distributionwidedistributionindifferenttissues,firstpassmetabolismintheliverwithcompletebiotransformationduringtheresorptionisobserved.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapidlyexcreted;excretionsviaurinebetween21and29%andviafaecesbetween57to60%within96hours.excretionpatternsimilarforbothsexes.metabolisminanimalsextensivelymetabolized:oxidationofthemethyland/or1-ethylpropylgroupfollowedbyglucuronicacidorglucoseconjugationinsomecases;reductionofone/orbothnitrogroupstoaminesandformationofbenzimidazoleringwithcarbonunitincorporation.metabolicpatternsinurinedifferbetweensexeswithmetabolitem445h050(reg.no4108077)asthemostabundantinfemalesandmetabolitem455h047/m455h048inmales.metabolitesm455h001(reg.no.4108474),m455h017(iso)andm455h019wereonlyidentifiedinfemales,whereasm455h056wasonlyidentifiedinmalesinvitrometabolismnouniquehumanmetabolitedetectedtoxicologicallyrelevantcompounds(animalsandplants)pendimethalintoxicologicallyrelevantcompounds(environment)pendimethalinacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral4665mg/kgbw'ratld50dermal>5000mg/kgbwratlc50inhalation>6.73mg/lair/4h(nose-only,liquidaerosolexposure)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationsensitising(m&k)h317(cat1b)phototoxicityprobablyphototoxicshort-termtoxicity(regulation(eu)n283/2013,annexparta,point5.3)targetorgan/criticaleffectrat:liver(increasedweight,hypertrophy,cytoplasmicvesiculation)andthyroiddog:noadverseeffectupto90-dayexposurerelevantoralnoael90-day,dog:1000mg/kgbwperday,thehighestdosetested90-dayrat:41.3mg/kgbwperdayrelevantdermalnoaelnodatanotrequiredrelevantinhalationnoaelnodata-notrequiredgenotoxicity(regulation(eu)n283/2013,annexparta,point5.4)invitrostudiesnegativegenemutationinbacterianegativegenemutationtestinmammaliancells(cho/hgprt)threenegativechromosomeaberrationassays(choandhumanlymphocytes)onepositivechromosomeaberrationassayinchinesehamsterv79cellsnegativeudstest(limitedvalidity)positivecometassay(limitedvalidity)negativesisterchromatidexchangeassay(limitedvalidity)invivostudiestwonegativemicronucleustestsinbonemarrowoficrandnmrimicenegativealkalineelutiondnaeffectsinrattesticularcellsphotomutagenicitynotrequiredpotentialforgenotoxicitypendimethalinisunlikelytobegenotoxic'", "j.efsa.2016.4421.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailability20%oralabsorption(basedon12.7%inurine,4.2%inbileand2.3%inthecagewashwithin48h)toxicokineticsplasmacmax:0.690.90g/g(lowdose),11.5714.81g/g(highdose)plasmatmax:0.51.0h(lowdose),4.0h(highdose)plasmat1/2:5.418.5h(lowdose),2.42.9h(highdose)distributioninitiallywidelydistributed;highestresiduesat30hpostapplicationinliverandkidney(lowdose),andinthyroid,adrenals,liver,femalegonadsandeyes(highdose);levelsgenerallylowat72h.potentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretion%within48h(5.6%viaurine,89.6%viafaeces,lowdose)metabolisminanimalslimited,>75%excretedasparent;n-deformylationtoaef130619orcleavageofsulfonylureabridgetoaef153745+minorpolarunidentifiedmetabolites(<4%ofdose)invitrometabolismphaseimetabolismisnotinvolvedinthebiotransformationofforamsulfuroninratandhumanlivermicrosomes;nospeciesdifferenceobserved.toxicologicallyrelevantcompounds(animalsandplants)foramsulfurontoxicologicallyrelevantcompounds(environment)foramsulfuronacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>5.04mg/l(4h,noseonly,aerosol)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitising(magnusson-kligmantest)phototoxicitynotphototoxic'", "j.efsa.2016.4432.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapid.imazamoxhasanoralabsorptionvalueof75%.toxicokineticsboththeabsorptionandeliminationof14c-residuesinbloodwasrapid.dosetoratswasreadilyabsorbedandefficientlyclearedthroughtheexcreta(withoutpassingthroughthebile)within24hoursfollowingadministration.nosignificantsex-relateddifferences.distributionwidelydistributed.verylowlevelsintissuespotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid(approx.74%inurineand24%infaeceswithin24h)metabolisminanimalslimited(>95%unchangedparentinexcretaandtissues)viao-demethylationandoxidation.invitrometabolismnometabolisationofparentcompoundbylivermicrosomesofdogs,rabbits,mice,ratsandhumans.nouniquehumanmetabolitewasdetected.toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompound,groundwatermetabolitesacutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral>5000mg/kgbwratld50dermal>4000mg/kgbwratlc50inhalation>6.3mg/lair(analytical)/4h(wholebody)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnon-sensitizer(m&kandbuehler)phototoxicitynoappropriatephototoxicitytest.notphototoxicin3t3nru-pttest**the3t3nru-pttestisnotappropriatetestforuvbabsorberasimazamox.'", "j.efsa.2016.4452.pdf": "w.efsa.europa.eu/efsajournal41efsajournal2016;14(4):4452impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(regulation(eu)n544/2011,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrat:2.39-4.79%(400mg/kgbw)8.99-10.73%(10mg/kgbw)dog:30.6-48.9%(1mg/kgbw)basedonthesumoftotalradioactivityexcretedinbile,urine,liver,cagewashandcarcasswithin48hours(asthedogturnedouttobethemostsensitivespecies,acorrectionof30%forlimitedbioavailabilitywasconsideredappropriateforaoelderivation)toxicokineticsrat(single10mg/kgbw),[14c-ph]and[14c-pz]:cmax(plasmag/g):2.47and2.70();1.82and1.51()tmax(plasma,h):24and24();48and72()auc,t1/2andkcouldnotbedeterminedasradioactivitydidnotdeclinesignificantlyduringtheperiodofthestudyupto168hourspost-dosing.rat(repeated10mg/kgbw),[14c-ph]:cmax(plasmag/g):54.3();39.6()tmax(plasma,h):2();12()auc,t1/2andkcouldnotbedeterminedasradioactivitydidnotdeclinesignificantlyduringtheperiodofthestudyupto168hourspost-dosing.dog(single1mg/kgbw),[14c-ph]and[14c-pz]:cmax(plasmageq/g):1.36();0.399and0.903()tmax(plasma,h):48();6and24()auc,t1/2andkcouldnotbedeterminedasradioactivitydidnotdeclinesignificantlyduringtheperiodofthestudyupto48hourspost-dosing.distributionrat:highestconcentrationsinplasma/wholebloodthewholebloodtoplasmaratioswereca.0.5-0.6forbothsexesandbothlabelsatbothdoselevels,suggestinglittledistributionintoredbloodcells.dog::highestconcentrationsinplasma/fat:highestconcentrationsinplasma/wholebloodpotentialforbioaccumulationpotentialforaccumulationsuggestedbythedivergingpharmacokineticparametersafterrepeatedadministration(highcarcass,tissueandplasma/wholebloodconcentrationsandabsenceofdeclineinradioactivity)ascomparedtosingledoseadministration.'w.efsa.europa.eu/efsajournal42efsajournal2016;14(4):4452rateandextentofexcretionrat(10mg/kgbw):rapidandextensive(>97%()and>91%()within48hours)faeces:91.58%(),88.34%()bile:3.55%(),2.77%()urine:2.02%(),0.69%()dog(1mg/kgbw):excretionwasnotcompleterangingbetween26.2%and46.9%within48hoursfaeces:23.4-43.1%bile:2.17-3.29%urine:<1%metabolisminanimalsrat:infaeces,unchangedcyclaniliprolerepresentedamaximumof97.1%dose.themajormetaboliteinplasmawasnsy-28.toxicologicallyrelevantcompounds(animalsandplants)cyclaniliproletoxicologicallyrelevantcompounds(environment)cyclaniliproleacutetoxicity(regulation(eu)n544/2011,annexparta,point5.2)ratld50oral>2000mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>4.62mg/lair/4h(maximumattainableconcentration)skinirritationnon-irritanteyeirritationveryslightirritationskinsensitisationnonsensitizing(llna,m&k)short-termtoxicity(regulation(eu)n544/2011,annexparta,point5.3)targetorgan/criticaleffectdog:hepatotoxicity(liverweight,alp,albumin)rat,mouse:notreatmentrelatedeffectsuptothehighestdosetestedrelevantoralnoaels1-year,dog:loael:1.29mg/kgbwperday90-day,rat:1331mg/kgbwperday(highestdosetested)90-day,mouse:1023mg/kgperday(highestdosetested)relevantdermalnoael28-day,rat:300mg/kgperday(bodyweightgain)relevantinhalationnoaelnodatanotrequired'", "j.efsa.2016.4453.pdf": "impactonhumanandanimalhealthabsorption,distribution,metabolismandexcretion(toxicokinetics)(regulation(eu)n283/2013,annexparta,point5.1)rateandextentoforalabsorption/systemicbioavailabilityrapidlyabsorbed(rat:maxconcentrationsinblood2-8hrsafteradministration;dog:>90%ofadministeredradioactivityexcretedwithin24hrs)extent:rat:95%(basedonurinaryexcretionincludingcagewash,singlelowdoseadministration)dog:70%(basedonurinaryexcretion,singlehighandlowdoseadministration)toxicokineticscmax:2-8hrsafteradministration,singlelowdoseinratbiphasiceliminationwithfastinitialelimination(t:2-5hrs)andsecondslowelimination(t:35-47hrs),singlelowdoseinratdistributionwidelydistributed.residuesinorgansandtissueswerelow(0.5%).highestlevelsinbloodandplasmapotentialforbioaccumulationnoevidenceforaccumulationrateandextentofexcretionrapid(nearlycompletewithin72hrs)andextensivemainlyviaurine:between95%(lowdose)and70%(highdose).faecalexcretion:about5%(lowdose)and14-26%(highdose)metabolisminanimals<20%metabolisedbyhydrolysisando-demethylation:oxidativehydroxylationandbreakdownofthesulfonylureabridgeinvitrometabolismcomparativeinvitrometabolismstudy:nometabolismobservedinratmicrosomes.thehumanmicrosomalincubationsproducedasinglemetaboliteaccountedfor52%oftheappliedradioactivityandidentifiedasiodosulfuron-methyl-benzoicacid(aef145740)toxicologicallyrelevantcompounds(animalsandplants)parentcompoundtoxicologicallyrelevantcompounds(environment)parentcompoundandmetaboliteaef075736(metsulfuron-methyl)acutetoxicity(regulation(eu)n283/2013,annexparta,point5.2)ratld50oral2448mg/kgbwratld50dermal>2000mg/kgbwratlc50inhalation>2.81mg/lair/4h(noseonly,aerosol)skinirritationnon-irritanteyeirritationnon-irritantskinsensitisationnotsensitising(m&k)phototoxicitynotphototoxic'", "j.efsa.2017.4833.pdf": "impactonhumanandanimalhealthabsorption,distribution,excretionandmetabolism(toxicokinetics)(annexiia,point5.1)rateandextentoforalabsorptionrapidabsorption(tmax48h);extensivelyabsorbed(8595%basedonurinaryandbiliaryexcretiondistributionrapidlyandextensivelydistributed;highestlevelsassociatedwithredbloodcellsduetobindingpotentialforaccumulationlimitedevidence(bloodcells)rateandextentofexcretionrapidlyexcreted(~80%within24h),inurine(~3040%)andbile(~5060%)metabolisminanimalsextensivemetabolismbyanumberofroutes;theinitialstepinthemajorrouteisformationofglutathioneconjugation.noevidenceofcleavagetoxicologicallyrelevantcompounds(animalsandplants)metazachlortoxicologicallyrelevantcompounds(environment)metazachlormetabolites479m09(bh479-9)and479m11(bh479-11)toxicologicallynon-relevantcompounds(environment)metabolites479m04(bh479-4),479m08(bh479-8)and479m12(bh479-12)acutetoxicity(annexiia,point5.2)ratld50oral>2,000mg/kgbw-ratld50dermal>2,000mg/kgbw-ratlc50inhalation>34.5mg/l(noseonly/4h)-skinirritationsomeevidenceofirritation(basf)non-irritant(fsg)-eyeirritationminimaltoslightirritation-skinsensitisationstrongsensitiser(m&k;basf)noevidenceofsensitisation(oet/buehler;fsg)r43shorttermtoxicity(annexiia,point5.3)target/criticaleffectliver(adaptivechangesatlowdoselevels);redbloodcell(mildanaemia)intherat.increasedliverandkidneyweightsinthemouse.liverandkidney(increasedweights)andredbloodcellinthedog.relevantoralnoael90-dayrat:110mg/kgbwperday(basf)90-dayrat:21mg/kgbwperday(fgs)90-daydog(gav):90mg/kgbwperday(basf)90-daydog:48mg/kgbwperday(fgs)1-yeardog:29mg/kgbwperday(basf)relevantdermalnoael1000mg/kgbwperday(28-dayrat);basfrelevantinhalationnoaelnotrequired"}